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SU M M A R Y 
 
 
The regeneration of bone tissue depends on the concerted actions of a plethora of signals 
that recruit mesenchymal stem cells for lineage-specific differentiation. The signals are 
conveyed in hormones, growth factors and transcription factors. These molecules are 
crucial for the osteoblast commitment, differentiation, functions and, consequently, ensure 
the proper bone modelling and remodelling. Among these factors, Wnt proteins have a 
critical role in bone development and homeostasis. Accumulated evidences have shown 
that lymphocyte enhancer binding factor 1/T cell factor (Lef1/Tcf) transcription factors, the 
???????? ?????????? ??? ???? ?????-catenin signaling pathway, influence osteoblast 
proliferation, function, and regeneration. Nevertheless, most downstream bone-specific 
target genes of this pathway are only partially known. Among these, Slug has been recently 
implicated in osteosarcoma progression as a Wnt-responsive molecule strongly correlated 
with a loss of tumor suppressors such as E-cadherin. Slug, also named Snail2, belongs to 
the Snail family of genes encoding zinc-finger transcription factors. It is expressed at 
different stages of development in different tissues, mediates epithelial?mesenchymal 
transition and directs cell motility during embriogenesis. Slug is also expressed in most 
normal adult human tissues, but little is known about its potential functions. 
 In order to identify new potential osteoblast-specific proteins, in this study we analysed 
the expression, regulation and role of Slug in human normal primary osteoblasts (hOBs) 
and in their mesenchymal precursors (hMSCs), in relation to the expression of Wnt/?-
catenin signalling mediators and genes which are required in the control of 
osteochondroprogenitors differentiation. The experiments were performed on hOBs and 
????????????????????????????????????????????????????????????????????????????? ?????????
jelly umbilical cord. Using several molecular analysis including siRNA strategy and 
Chromatin Immunoprecipitation (ChIP) assay, we demonstrated that: 
 
- Slug is expressed in hOBs as well as their mesenchymal precursors; 
- ???????????????????????????????-catenin and Lef1 that, together with Tcf-1, Tcf-4 and 
Runx2 are recruited to the Slug gene promoter in vivo; 
- In hOBs, Slug is positively correlated with osteoblastic markers, such as Runx2, 
??????????????????????????????????? ????? ????????????????-catenin signalling and mineral 
deposition. At the same time, it negatively correlated with Sox9, a factor indispensable for 
chondrogenic development; 
- In hMSCs, Slug acts as a negative regulator of Sox9 and Sox5 expression and a 
positive regulator of Sox6 and STAT1 genes. Regarding Runx2, the role of Slug seems 
influenced by cell type; 
- Slug interacts in vivo with Runx2 and Sox9 promoters in hOBs and hMSCs. 
 
Our results support the hypothesis that Slug functions as a novel regulator of osteoblast 
activity, even if with a different role in mature committed osteoblasts and in their 
undifferentiated progenitors. Furthermore, these findings suggest Slug as a new potential 
therapeutic target for bone tissue repair and regeneration. 
 
 
K ey words: 
Slug, Human osteoblasts, Osteogenic differentiation, Human mesenchymal stem cells, Wnt 
signalling, Osteoblast regulators. 
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C hapter 1 
The Snail/Slug family members: character ization and functions. 
 
Snail/Slug family members encode transcription factors of zinc-finger type which play a 
key role in various differentiation processes in vertebrate and invertebrate organisms 
(Nieto., 2002; Hemavathy et al., 2000). At first described in Drosophila melanogaster 
(Grau et al., 1994; Nusslein-Volhard et al., 1984), subsequently, Snail/Slug transcription 
factors have been found in many species including humans, other vertebrates, non-
vertebrates chordate (protochordates), insects, nematodes, annelids and mollusks (Nieto., 
2002). To date, about 50 members of this family have been isolated, showing significant 
differences between them even if a phylogenetic analysis indicates having a common 
ancestral precursor. Several studies suggested that numerous genes coding for Snail/Slug 
factors of all Metazoa derived from a common ancestor, snail, which, after gene 
duplication, gave rise to the Snail and Scratch genes, which one inter-related but 
independent (Ohno., 1999; Manzanares et al., 2001; Barrallo-Gimeno et al., 2005). In 
particular, in this thesis I will delve into the role of transcription factors encoded by Snail 
genes. These proteins have overall an homology, in terms of the sequence, which varies 
between 50% and 70% (Metzstein et al., 1999). In particular, three Snail/Slug proteins 
have been identified in vertebrates: Snail (Snail1), Slug (Snail2 or Snai2), and Smuc 
(Snail3 or Snai3) (Nieto., 2002; Barrallo-Gimeno et al., 2005; Katoh and Katoh., 2005). 
They all share a similar organization, being composed of a highly conserved carboxy-
terminal region, which contains zinc fingers, and a much more divergent amino-terminal 
region. While many of the zinc fingers are employed in nucleic acid binding, an increasing 
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numbers of reports have demonstrated that zinc fingers in some proteins are also utilized 
for protein-protein interaction (Mackay and Crossley., 1998). The fingers are structurally 
?????????????????-????????????????????????-helix, the amino-terminal part of which binds 
to the major groove of the DNA. The two conserved cysteines and histidines (C2H2) 
coordinate the zinc ion. The number of zinc fingers in the family varies from four to six. 
Probably a minimum of four fingers are required for functioning (Fuse et al., 1994; Grimes 
et al., 1996; Nakayama et al., 1998). Both random selection and transfection experiments 
with different promoters have shown that the consensus binding site for Snail-related genes 
????????????????????????????????-CANNTG-?????????????????????????????????????-called E-box, 
the consensus of the core binding site of basic helix-loop-helix (bHLH) transcription 
factors. Under some circumstances, the Snail family proteins compete directly with bHLH 
proteins for the same binding sequences (Fuse et al., 1994; Nakayama et al., 1998; 
Kataoka et al., 2000). Moreover, Snail/Slug family members show different affinity toward 
the E-box flanking sequences. This will decide whether they can regulate similar or 
different target genes when multiple members are expressed in the same cell (Hemavathy 
et al., 2000). Binding of Slug/Snail proteins to their target promoters leads to repression of 
gene activity (Hemavathy et al., 2000). The repressor activity depends not only on the 
finger region, but also on at least two different motifs that are found in the amino-terminal 
region. In Drosophila, Snail (dSnail) contains two conserved motifs that allow interaction 
with the corepressor dCtBP (Drosophila C-terminal Binding Protein) (Nibu et al., 1998). 
These motifs allow the binding of dCtBP with dSnail in vitro and are essential for 
transcriptional repression in vivo. ????????? ????????? ????? ??? ??????????? ????????????? ???
mostly dependent on the amino-terminal transcription regulatory domain with the two 
dCtBP interaction motifs, and not on the carboxy-terminal DNA-binding domain 
(Hemavathy et al., 2004); but there is evidence that dSnail would also be able to repress 
target genes in the absence of dCtBP.  
Vertebrate members have an amino-terminal SNAG (Snail/Gfi-1) domain that has been 
found in three diverged types of families: vertebrate Snail/Slug proteins, Gfi proteins and 
IA-1 proteins (Tateno et al., 2001). The SNAG domain was originally characterized in the 
The Snail/Slug family members: characterization and functions 
 
 
3 
 
growth factor independence-1 (Gfi-1) oncoprotein, where it forms part of the first 20 
amino acids that suffice for transcriptional repression (Grimes et al., 1996). For the 
vertebrate Snail members, the maximal repressive effect is dependent on both the zinc 
finger DNA-binding domain and the amino-terminal SNAG domain. The SNAG domain is 
of particular interest because it is indispensable to the recruitment of histone deacetylase 
(HDACs) for the formation of a multimolecular complex that drives remodeling and 
compaction of chromatin mediating gene silencing (Tripathi et al., 2005). 
 
From data reported in the literature, it appears that many of the Snail/Slug protein 
functions have been preserved during evolution from invertebrates to vertebrates, although 
the knowledge of the different roles that they mediate in the embryonic and adult life of 
many organisms is still limited. At the cellular level, Snail/Slug factors regulate cell 
differentiation, cell adhesion, cell movement, cell cycle regulation, and apoptosis 
(Hemavanthy et al., 2000). The main experimental evidences regarding the functions that 
these proteins play, are described below. 
 
Snail /Slug and embryonic development 
The first evidence about the functions of the Snail family members have been found in 
Drosophila, where these proteins are involved in embryonic development (Ashraf et al., 
1999). Both Snail RNA and protein expression have been detected precisely in the ventral 
region of the blastoderm stage embryos where mesoderm arises (Alberga et al., 1991; 
Kosman et al., 1991; Leptin., 1991). The expression persists during gastrulation in the 
invaginated mesoderm and disappears during late gastrulation. Expression reappears in the 
neuroectoderm and persists as neuroblasts delaminate from the neuroectoderm. Later, 
during mid-embryogenesis, expression can be detected in precursor cells of some imaginal 
tissues, including the wing discs. At mesoderm specification stage, Snail acts as a repressor 
to restrict lateral genes from being expressed in the ventral region to establish mesodermal 
cell fate (Kosman et al., 1991; Leptin, 1991; Ip et al., 1992). The expression is also 
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required to control ventral cell invagination to form the mesoderm layer. Indeed, in Snail 
mutants, it was found that no mesoderm derivative is formed and that the ventral cell 
invagination does not occur (Boulay et al., 1987; Grau et al., 1984; Nusslein-Volhard et 
al., 1984). Although the Snail-related proteins Escargot and Worniu have redundant 
functions during asymmetric division of neuroblasts later in development (Ashraf et al., 
1999; Cai et al., 2001), these proteins cannot substitute ???? ??????? normal role in 
mesoderm invagination (Hemavathy et al., 2004). The elucidation of the significant role of 
Snail genes family in Drosophila embryogenesis, prompted the search for similar functions 
of their homologs in other organisms. Several authors have analyzed the involvement of 
Snail/Slug proteins in the embryonic development of amphibians.  
Numerous studies in Xenopus have shown an interest of  the Snail/Slug family members in 
gastrulation, and especially in the development of neural crest (Carl et al., 1999).  
Neural crest cells are proliferative, migratory, tissue-invasive stem cells that originate in 
the ectoderm of vertebrate embryos (LaBonne and Bronner-Fraser., 1998a). The precursors 
of these cells arise at the lateral edges of the neural plate during mid-gastrulation. 
Following neural tube closure, these cells undergo an epithelial to mesenchymal transition 
(EMT), a process that involves the modification of the transcriptional activity, cell 
adhesion, cytoskeleton assembly, and cell-matrix interaction of prospective neural crest 
cells (Savagner., 2001). Cells then delaminate from the dorsal aspect of the neural tube, 
and migrate extensively to populate distant sites throughout the embryo. The neural crest 
contributes to a large and diverse set of derivatives that include most of the neurons and 
glia of the peripheral nervous system, melanocytes and elements of the craniofacial 
skeleton, such as cells of upper and lower jaw bone, dermis, and adipose tissue of 
epidermis, and connective tissue cells (Bronner-Fraser., 1995) (see F igure 1). 
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Figure 1. Successive stages of neural crest formation. The neural crest consists of  bilateral bands of cells 
near the margins of the embryonic folds that form the neural tube. After neural tube closure, the cells 
originally located at the crests of the neural folds, known as neural crest cells, come to lie on top of the neural 
tube, from where they migrate to different locations, giving rise to some of the anatomical structures unique 
to vertebrates, including some of the bones and cartilage of the skull. (font: 
http://bio1152.nicerweb.com/Locked/media/ch34/craniate.html). 
 
The induction and regulation of this process are extremely complex and, to date, only 
partially understood. The involvement of different signaling pathways mediated by Wnt, 
fibroblast growth factor (FGF), bone morphogenic proteins (BMPs) has been amply 
demonstrated by several studies in Xenopus, zebrafish and mice (Ikeya et al., 1997; Dorsky 
et al., 1997; LaBonne and Bronner-Fraser., 1998b; Marchant et al., 1998; Vallin et al., 
2001). In addition, a lot of transcriptional regulatory proteins have been implicated in one 
or more aspects of neural crest formation. Among these, some Snail/Slug family members 
have been identified as targets of the signaling pathways mentioned above. In Xenopus 
both Snail (xSnail) and Slug (xSlug), can be detected in neural crest?forming regions of 
the neural plate border by late gastrula stages, and both factors are expressed at the lateral 
edges of the open neural plate in midbrain, hindbrain and spinal cord regions. Snail, is also 
transiently expressed in the transverse neural fold, from which neural crest does not arise 
(Essex et al., 1993; Mayor et al., 1995). xSnail expression is the earliest marker for the 
neural crest. At the early gastrula stage, the coordinated action of Xiro1 as a positive 
regulator and xSnail as a repressor restricts the expression of Delta1 at the border of the 
neural crest territory, which will later on lead to proper formation of the neural folds 
(Glavic et al., 2004). xSnail is upstream of xSlug in the specification of neural crest cells, 
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as it is able to trigger the expression of a series of early and late neural crest markers, such 
as products of the Zic5, FoxD3, Twist, E ts1 and Sox10 genes (Aybar et al., 2003; Honore et 
al., 2003). xSlug overexpression alone is insufficient to direct neural crest formation in 
ectodermal explants, but it can do so in cooperation with a Wnt or FGF signal. Similarly, 
xSlug overexpression causes an expansion of the neural crest domain and an increase in 
melanocyte formation in whole embryos, where all inductive signals are present (LaBonne 
and Bronner-Fraser., 1998a). In avian embryos, both Slug and Snail overexpression have 
also been shown to result in excess neural crest production, although in these experiments 
the effects were confined to cranial regions (del Barrio and Nieto., 2002). Treatment of 
chick (Nieto et al., 1994) or Xenopus (Carl et al., 1999) embryos with antisense 
oligonucleotides to Slug mRNA results in an inhibition of cranial neural crest cell 
migration. By testing the effects of expressing fusions with transcriptional repressor or 
activator domains, it was shown that Xenopus Slug protein normally acts as a repressor 
(LaBonne and Bronner-Fraser., 2000). In an analogous manner to Drosophila Snail, Slug 
may down-regulate genes whose expression needs to be excluded from neural crest and 
have an indirect role in the upregulation of genes in the neural crest. Studies performed 
using a fusion protein acting as a hormone-inducible dominant negative inhibitor of Slug 
and Snail protein function, demonstrate that these factors are required for the expression of 
Twist, which encodes a specific marker of neural crest (LaBonne and Bronner-Fraser., 
2000).  
Interestingly, whereas Slug and/or Snail clearly play essential roles in neural crest 
formation in both Xenopus and avian embryos, a recent double knockout of their orthologs 
in the mouse epiblast displays no defects in neural crest development, at least in cranial 
regions before E9.5 (Murray and Gridley., 2006). These mutant mice do have defects in 
left?right asymmetry, however, further highlighting the essential role of Snail family 
proteins in patterning and regulatory events beyond cell survival and EMT. Neural crest 
specific Snail1 deletion on a Slug -/- background does lead to later craniofacial and palate 
defects (Murray and Gridley., 2006; Murray et al., 2007). Nevertheless, the surprising 
finding that neural crest cells form and migrate normally in the double mutant mice 
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suggests that murine neural crest cells express one or more factors that can carry out the 
essential functions that Snail family proteins mediate in frog and chick. 
Multiple levels of regulation, including transcriptional, post-transcriptional and post-
translational modification, are employed to ensure tight control of the activity of these key 
regulatory proteins. 
The characterization of regulatory regions of Slug gene in Xenopus laevis and in Xenopus 
tropicalis has allowed the identification of preserved sequences, which seem to be 
necessary and sufficient for the Slug expression in neural crest cells. These sequences 
contain, binding sites for the Lef/Tcf transcription factors, which are effectors of the Wnt 
signaling pathway. This supports a direct role for this signaling pathway in Slug induction 
in Xenopus (Vallin et al., 2001). Further confirmation of the importance of Wnt signaling 
in Slug regulation comes from the identification of binding sites for Lef/Tcf transcription 
factors also in chicken Slug (cSlug) promoter (Liem et al., 1995; Sakai et al., 2005). In 
addition, the presence of Smad1 binding sites in the proximal sequence of cSlug, suggests 
that BMP signaling is a further important regulator for Slug expression in neural crest 
formation (Sakai et al., 2005). Moreover, it has been demonstrated that, in avian neural 
crest cells, Sox9 together with Slug directly activates the Slug promoter through a direct 
binding to E-box site, promoting crest formation and EMT (Sakai et al., 2006). The xSlug 
promoter also contains binding sites for YY1 (Ying Yang). The YY1 protein is expressed 
in the ectoderm at about the time of Slug induction and knockdown of YY1 with 
morpholino oligos specifically represses Slug but not Snail or AP2. Disrupting the YY1 
cis-regulatory element also affected Slug promoter-mediated transcription (Morgan et al., 
2004). Finally, recent work in Xenopus has shown that the stability of Slug and Snail is 
dynamically regulated during neural crest development via the ubiquitin-proteasome 
system, and that the F-box protein Ppa is essential for directing their degradation (Vernon 
et al., 2006). Point mutations that abrogate Ppa targeting were found to stabilize the Slug 
protein and allow it to elicit premature migration. Work in mammalian cell culture has 
suggested that GSK-mediated phosphorlyation directs ?-Trcp mediated degradation of 
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Snail (Yook et al., 2006; Yook et al., 2005; Zhou et al., 2004); however, this mechanism 
does not appear to function in the neural crest, at least in Xenopus (Vernon et al., 2006). 
Indeed, Slug and many other Snail factors lack the ?-Trcp destruction box present in 
mammalian Snail, suggesting that this is unlikely to be an evolutionarily conserved means 
of targeting Snail proteins for degradation. Snail is also regulated at the level of nuclear 
translocation (Zhou et al., 2004; Dominguez et al., 2003) and it will be important to 
determine the role that this mechanism plays in neural crest development. 
 
Snail /Slug and EMT 
The study of neural crest cells is particularly interesting for understanding the mechanisms 
of migration, differentiation and cell survival. During embryonic development, in fact, this 
population undergoes a process that occurs in many physiological and pathological events: 
the ephitelial-mesenchymal transition (EMT) (Kang and Svoboda., 2005). This process 
involves the acquisition of the proper mesenchymal phenotype by the epithelial cells of 
different embryonic and adult tissues. The normal epithelial tissue is characterized, in fact, 
by the presence of cell-cell interactions crucial for the development of tissues during 
embryogenesis, and for the maintenance of homeostasis and architecture of epithelial 
structures. Through epithelial-mesenchymal transition, cells acquire the ability to migrate 
into tissues, acting on the regulation of specific genes. The EMT process involves, 
therefore, the activation of genes encoding proteolytic enzymes for extracellular matrix 
degradation the inactivation of genes coding for epithelial markers and adhesion 
molecules, including E-cadherin and ?- ?????-catenin (Yang et al., 2004). During the EMT 
process, epithelial cells lose the expression of E-cadherin and other components of 
epithelial cell junctions, adopt a mesenchymal cell phenotype, and acquire motility as well 
as invasive properties (Acloque et al., 2009; Kalluri et al., 2009). The lack of adhesion 
proteins expression by epithelial cells, mean the loss of apical-basal polarity, which is 
characterized, also, by an extensive cytoskeleton remodeling and a redistribution of 
organelles (Boyer et al., 2000; Shook and Keller., 2003; Kang and Massagué., 2004). The 
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cells that undergo epithelial-mesenchymal transition acquire, therefore, the expression of 
mesenchymal characteristic markers, such as, fibronectin, vimentin and N-cadherin (Yang 
et al., 2004). Several studies also showed that as this is a reversible process, mesenchymal 
cells may, in some cases, restore the differentiated epithelial phenotype, through the so-
called mesenchymal-epithelial transformation (MET) (Thiery., 2003; Kang and Svoboda., 
2005). In particular, this event has been demonstrated in the development of somites, 
kidney and neural tube (Griffith et al., 1992). 
EMT is triggered by several extracellular induction signals such as extracellular matrix 
(ECM) components and growth factors. Furthermore, EMT is mediated by several 
signaling pathways, including epidermal growth factor (EGF), fibroblast growth factor 
??????? ??????????? ??????? ??????? ??????? ????????????? ??????? ??????? ?? ???????? ?????
morphogenic proteins (BMPs) and Wnt signaling pathway. The involvement of  these 
signaling pathways in modulating the expression of Snail/Slug family factors has been 
widely demonstrated in several animal models, and has led to attribute to these proteins a 
major role in the EMT activation (Barrallo-Gimeno et al., 2005; De Craene et al., 2005) 
(see F igure 2). 
 
Figure 2. Role of Snail/Slug transcription factors in epithelial-mesenchymal transition (EMT). The 
diagram shows general signaling pathways regulating Snail/Slug and some of the molecules known to be 
affected by Snail/Slug activity. (modified from: Alves C.C., Carneiro F., Hoefler H., et al. (2009). Role of 
the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci., 14:3035-
3050). 
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For example Snail is expressed during the early stages in chick development and its 
induction is promoted by FGF-2 and FGF-8 (Isaac et al., 2000; Montero et al., 2001). Slug, 
instead, is required for the initial steps of the EMT, which occur during endocardial 
cushion formation in chicken heart (Romano and Runyan., 1999). Slug appears to be an 
essential target of TGF?? signalling during the initial steps of EMT in the heart, as Slug is 
sufficient to rescue the inhibitory effect of an anti-TGF??? ????????? ??? ???? (Romano., 
2000). Slug also plays an important role in the palate fusion, which require a combination 
of EMT and apoptosis. In fact, in some pathological conditions, Slug acts as anti-apoptotic 
factor causing a pathological cleft palate and the consequent differentiation of surviving 
cells in keratinized stratified epithelium (Martinez-Alvarez et al., 2004). In humans, TGF??
factors represent the main candidates for EMT induction that occurs during the 
development of lens cataracts. It has been shown that TGF???????????????????????????????
which negatively regulates the expression of E-cadherin in epithelial cells of the lens, thus 
promoting the migration (Choi et al., 2007).  
Studies performed in adult keratinocytes have highlighted that the presence of Slug is also 
required during cutaneous wound reepithelialization after skin injury. The phenotypic 
plasticity observed at margins of healing wounds during the reepithelialization process 
resembles certain aspects of the epithelial?mesenchymal transition (EMT) that occurs 
during embryonic development (Arnoux et al., 2008; Savagner et al., 2005). It has been 
observed that adult mouse and human keratinocytes taken from the wound  margins, show 
high Slug expression levels. In mice, Slug knockout experiments leads to a reduced cell 
migration from skin explants (Coulombe., 2003; Chandler et al., 2007; Hudson et al., 
2009), while overexpression of this protein reduces cell adhesion in human keratinocytes 
(Savagner et al., 2005) and this is related to a reduced presence of adhesion molecules such 
as E-cadherin and integrins, which result in decreased interaction with the extracellular 
matrix (Turner et al., 2006). 
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Snail /Slug and cancer 
The transformation from epithelial to mesenchymal cell requires the acquisition of an 
invasive cell phenotype, able to break free from cell-cell interactions and to migrate 
extensively. This means that this event is not only involved in embryonic development, but 
also in neoplastic transformation. In particular, cells acquire this feature in the later stages 
of tumor progression, when they reach the ability to penetrate the basal lamina and give 
rise to metastases in other areas of the body. Aberrant expression of Slug protein has been 
found in many types of cancer: esophageal cancer, gastric and colon cancers, liver, 
pancreas and lung cancers, ovarian and breast cancer (Barrallo-Gimeno et al., 2005; Shih 
et al., 2005). The involvement of Slug in neoplastic transformation is primarily related to 
its ability to induce epithelial-mesenchymal transition, with particular reference to the 
regulation of adhesion and cell migration. Several experimental evidences have shown that 
this factor can regulate the expression of cell adhesion molecules, particularly E-cadherin. 
It is known that Snail/Slug factors possess binding sites within the promoter region of the 
gene encoding E-cadherin (Cano et al., 2000; Perez-Moreno et al., 2001). For instance, in 
esophageal squamous cell carcinomas (SCC), Slug overexpression is correlated with 
reduced E-cadherin expression and with depth of tumor invasion, lymph node metastasis, 
stage and lymphatic invasion (Jethwa et al., 2008). Slug and E-cadherin expression levels 
are also inversely related in melanoma cells, breast cancer, hepatocellular carcinoma, 
gastric and colon cancers (Poser et al., 2001; Jiao et al., 2002; Sugimaschi et al., 2003; 
Hajra et al., 2002). In the latter has been demonstrated that Slug expression is regulated by 
the proto-oncogene c-Myb and the down-regulation of Slug and/or c-Myb led to increased 
E-cadherin, desmoplakin, and occluding expression, and decreased vimentin expression 
and reduced invasion capability (Tanno et al., 2010). Furthermore, Larriba et al., 
demonstrated that Slug inhibits vitamin D receptor (VDR) gene promoter activity and 
decreases VDR mRNA and protein levels by binding to the three E-boxes present in the 
VDR promoter, in colon adenocarcinoma cell lines (Larriba et al., 2009). Similar finding 
was reported by Mittal and co-workers. They demonstrated that Slug binds in vivo to the 
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VDR gene promoter in human breast cell nucleus and inhibits VDR gene expression by 
chromatin remodeling, thus leading to an alteration of mammary epithelial cells 
proliferation, differentiation and survival (Mittal et al., 2008). In breast cancer, also, it has 
been observed a correlation between the expression of estrogen receptor ????????????????
loss of E-cadherin induced by Snail/Slug proteins. In this tissue ??? and its ligand, 
estradiol, play an important role in the regulation of cell differentiation and proliferation. 
???, however, is a positive prognostic marker of breast cancer progression. This can be 
partly explained by the fact that ER activates transcription of MTA3 (metastasis-associated 
protein 3) in an indirect way. This involved the formation of the transcriptional repression 
complex Mi-2/NuRD, together with other several factors, including ATPase and histone 
deacetylases for chromatin remodeling (Wade et al., 1999; Xue et al., 1998; Dhasarathy et 
al., 2007). Most of the genes modulated by this mechanism are not yet known, but some 
experimental evidences indicate their involvement in the development of invasive tumors 
and metastases (Toh et al., 1997). Slug is one of the targets of the negative modulation 
performed by Mi-2/NuRD transcriptional complex (Dhasarathy et al., 2007). Therefore, 
the presence of ER indirectly maintains the expression of E-cadherin. In contrast, in the 
absence of estrogen receptor, MTA3 activity is inhibited, and the loss of Slug repression 
induces, consequentely, the loss of E-cadherin expression. ER-negative breast cancer cells 
are, thus, more predisposed to the acquisition of an invasive phenotype (Fujita et al., 
2003). Regarding invasive ductal carcinoma of breast, recent studies substantiate the role 
?????????? ????-????????????????????????????????????????????????????? ?????????????-catenin 
partners with Lef/Tcf transcription factors to activate target genes, such as Slug, which in 
turn, promote EMT inhibiting E-cadherin expression (Prasad et al., 2009). Further 
confirmation of the correlation between Slug and Wnt signaling derives from studies 
performed by Medici and co-workers in DLD1 colon carcinoma, MDCKII, and A375 
????????? ??????? ??? ?????? ??????????????????????????? ??????? ??-regulation in Slug and 
Snail expression levels, which reduce E-cadherin expression. Both Slug and Snail, also, 
?????????-catenin-Tcf4-induced up-regula????????????????????? ????????? ??????????????? ????
?????????? ??? ????? ???????????? ?????? ?-catenin-Lef1 transcription complex then cause 
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increased expression of target genes (vimentin, fibronectin etc.) that drive formation of the 
mesenchymal phenotype (Medici et al., 2008). Furthermore, Slug has been recently 
implicated in osteosarcoma progression as a Wnt-responsive molecule strongly correlated 
with a loss of tumor suppressors such as E-cadherin (Nieto., 2002; Conacci-Sorrell et al., 
2003; Guo et al., 2007).  
In addition to E-cadherin, other Slug target genes have been identified, which support the 
role of this transcription factor in cell motility regulation. Slug negatively modulates the 
expression of various molecules involved in the formation of tight junctions, adherent 
junctions and desmosomes. These include: claudine, occludin, integrins, cytokeratins, 
desmoplakins, mucins, aggrecan, matrix metalloproteinases, collagen type II (Martinez-
Estrada et al., 2006; Wang et al., 2007; Seki et al., 2003). 
 
Snail /Slug and apoptosis 
Several evidences indicate the existence of a correlation between the expression of 
Snail/Slug proteins and apoptosis regulation, highlighting the central role of these 
transcription factors in neoplastic transformation. It is known that apoptosis is an essential 
process during embryonic development as well as in the adult, because it is able to remodel 
or remove any structures, controls cell number of a specific organ and eliminates damaged 
or non-functional cells. Apoptosis is a finely regulated event that, in vertebrates and 
invertebrates, involves a large number of molecules and intracellular signaling pathways. 
Alterations in apoptosis regulation are involved in tumors development, as they promote 
cell survival in combination of adverse environmental conditions and severe DNA 
damages. 
Several Snail/Slug family members are known regulators of this process. First evidence 
were observed in Caenorhabditis elegans, where CES-1 (a protein homologous to 
Drosophila Scratch), was able to prevent the physiological death of a particular neuronal 
cell type (Metzstein and Horvitz., 1999). CES-1 has the ability to ensure survival of mouse 
pro-lymphocytes B, cultured without growth factors. Moreover, Slug showed anti-
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apoptotic activity in mice (Inukai et al., 1999). Even in fetal rat hepatocytes Snail has been 
observed to promote cell survival, despite apoptosis induction mediated by TGF???????????
et al., 1996). A further example of Slug involvement in preventing apoptosis was observed 
during neural crest development. Experiments performed in Xenopus embryos led to 
demonstrate a correlation between Slug expression and the acquisition of resistance to 
apoptosis. In this experimental model, Slug seems to be directly involved in the regulation 
of apoptosis molecules cascade: indeed, it is able to activate the expression of Bax and Bcl-
2, known anti-apoptotic factors, and to repress the transcription of genes coding for various 
caspases, apoptosis effector proteins. 
Apoptosis is also involved in limb embryonic development in chicken. This process is 
regulated by the action of fibroblast growth factor (FGF) and bone morphogenic (BMPs), 
which cooperate in inducing Snail/Slug expression, in order to hamper apoptosis (Ros et 
al., 1997; Montero et al., 2001). 
 
The involvement of Snail/Slug transcription factors in cell survival has also been found in 
the onset of leukemia. The fusion protein E2A-HLF (E2A-hepatic leukemic factor), which 
has transforming activity in several cell types, is able to lead an aberrant increase of Slug 
expression in precursor B lymphocytes. Slug confers protection from apoptosis to these 
cells, allowing them to acquire additional mutations that free them from control 
proliferation, thus promoting the development of leukemia (Inukai et al., 1999). The ability 
of Snail/Slug proteins to promote migration and cell survival was also found in 
hematopoietic stem cells. In this cell population Slug expression is induced by the 
interaction between the stem cell growth factor, SCF, and c-kit receptor (a specific marker 
of stem cells, constitutively activated in many types of cancer). The biological relevance of 
Slug in these processes has been described: mice knocked out for Slug have a complex 
phenotype, including gonadal, haematopoietic and pigmentation defects, which are similar 
to the defects of SC F and c-kit deficient mice. The pigmentation defects suggest a role for 
Slug in the development of melanocytes from the neural crest. It was demonstrated that 
SCF/c-Kit signaling specifically induces the expression of Slug gene (Perez-Losada et al., 
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2002). As to its role in haematopoiesis, Slug expression can be detected in diverse subsets 
of haematopoietic progenitors, and irradiated Slug deficient mice have significantly more 
apoptotic bone marrow progenitor cells than wild-type controls. This indicates that Slug 
can act as a radioprotection agent, and normally functions to promote the survival of bone 
marrow progenitors that have undergone DNA damage (Inoue et al., 2002). In addition, in 
hematopoietic progenitors, Slug has shown an antagonistic activity against p53 and 
PUMA, two factors involved in the apoptosis induction (Wu et al., 2005). 
 
Analysis of the role of Snail/Slug proteins in cell proliferation control have provided 
controversial results. In Drosophila gastrulation, changes in cell morphology produced by 
the cytoskeleton reorganization during cell migration, are related to an inhibition Snail-
dependent of mitosis and cell division (Grosshans and Wieschaus., 2000). In Drosophila, 
also other Snail/Slug transcription factors are involved in mitosis suppression, inhibiting 
the transcription of genes involved in this process. These observations are consistent with 
the reduced replication rate of epithelial cells expressing Snail (Nieto., 2002). The 
inhibition of proliferation by Snail/Slug family members occurs in cells induced to make 
the epithelial-mesenchymal transition (Peinado et al., 2003), including keratinocytes 
(Turner et al., 2006). Despite a lot of evidences confirm the ability of these proteins to 
promote tumor progression, it was observed that Snail inhibits cell cycle and proliferation, 
promoting the acquisition of an invasive phenotype rather that cell growth (Vega et al., 
2004). On the contrary, during hair follicles formation in mice, the expression of Snail has 
revealed a proportional reduction of E-cadherin expression and an increased in 
proliferative activity. A direct correlation between Slug expression and cell proliferation 
was also found during the development of renal fibrosis (Thiery., 2003). 
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C hapter 2 
H uman Slug gene. 
 
 
Human Slug gene is mapped to chromosome 8q11. Analysis of the coding region, which 
has a size of about 4 kb, revealed that the gene is composed of three exons and two introns. 
A single transcription start site has been identified and no evidence for alternative splicing 
have been detected. The human Slug transcript is 2.2 kb in size, and it codes for a putative 
protein of 268 amino acids and about 30 kDa, with five zinc fingers in its carboxy-terminal 
portion (Cohen et al., 1998). The amino-terminal portion of the human Slug protein 
contains regions shared with mouse (Savagner et al., 1997), chicken (Nieto et al., 1994), 
and Xenopus (Mayor et al., 1995) Slug with 89, 87 and 77% identity, respectively, but 
bears significantly less homology to Snail proteins with 23% identity to the mouse (Smith 
et al., 1992). When the Slug zinc finger region in human is compared with that of mouse, 
chicken, and Xenopus, their identity is 100, 99, and 98%, respectively. The mouse Snail 
zinc finger region is only 68% identical to that of human or mouse Slug. The structural 
differences in this region between Slug and Snail suggest that they possess distinct 
affinities and specificities in DNA binding as the basis for their functional differences. The 
identity over the entire protein sequence between human and each of the mouse, chicken, 
and Xenopus Slug protein is 95, 93, and 88%, respectively (Cohen et al., 1998).  
As mentioned before, Slug respressor activity, is localized in the amino-terminal domain, 
mainly at the level of the first 32 amino acids (see F igure 1)???????? ?????????? ???? ??????
????????????????????????????????tion, leads to loss of protein function. Slug has a domain 
with seven amino acid residues at its ??????????????????????????????????????????????
(Snail/Gfi-1). Through SNAG domain, Slug may recruit other co-repressor proteins, 
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interacting with them directly or through adapter proteins, including Sin3A (Bailey et al., 
2007) and HDAC1 and 2 (Tripathi et al., 2005). Following deletion analysis, it has been 
shown that the 30 amino acid residues of the central amino-terminal domain can activate 
transcription, although this ability is hidden by the presence of the "core repression 
domain". The possibility that the Snail/Slug proteins, as well as other transcription factors, 
are able, in certain situations, to act as activators of transcription, has been considered by 
some authors, because various members of that family (including Drosophila Snail and 
human Slug) possess a domain able to regulate positively the transcription process, 
although to date, examples in favor of this hypothesis have not yet been reported in the 
literature (Han and Manley., 1993; Hemavathy et al., 2000; Hemavathy et al., 1997). On 
the contrary, the last 30 amino-????????? ????????? ???? ??? ????????? ??????? ???? ????
transcriptional repression (Hemavathy et al., 2000).  
 
 
 
Figure 1. a. hSlug gene organization. hSlug gene is composed of three exons and two introns. The coding 
sequence produces a transcript of 807 bp, which codes for a protein of about 30 Kda. b. Schematic 
representation of functional domains in hSlug protein. Slug protein has five zinc fingers in its carboxy-
terminal portion, which are involved in DNA binding, and an amino-terminal domain responsible for Slug 
repressor activity.  
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mRNA coding for hSlug has been found in placenta and embryonic stem cells and in most 
adult tissues, such as spleen, thymus, testis, prostate, ovary, intestine, colon, heart, liver, 
skeletal muscle, kidney and pancreas and, at lower levels in brain and lung. Its expression 
is particularly high in the prostate and ovary. Otherwise, the hSlug mRNA is almost 
undetectable in peripheral blood leukocytes (Cohen et al., 1998; Hemavathy et al., 2000; 
Katoh et al., 2005). 
Although the regulation of Snail/Slug expression and their role have been investigated 
extensively in many animal species, as shown in the previous chapter, mechanisms 
governing Snail/Slug expression in humans are largely unknown. Indeed, most of the data 
relating to the Snail/Slug characterization and functions in humans derived from analysis 
conducted especially on cancer cells. Studies performed in human breast carcinoma cell 
lines demonstrated that ligand-?????????????????????????Slug transcription through direct 
interaction with the Slug promoter. More specifically, ligand-?????????? ???? ???????
together with HDAC1 and N-CoR, a transcriptional inhibitory complex which binds to the 
Slug promoter in a region containing three half-site estrogen response elements (EREs), 
localized at -?????????????????????????????????????????????????????????-responsive gene. 
Human breast cancers which lack ligand-???????????????????????????????????????????????
may down-regulate E-cadherin and lead to EMT (Ye et al., 2008). According to Elloul et 
al. (Elloul et al., 2006), it has been suggested that Snail is regulated at the post-
transcriptional level in ovarian carcinoma, whereas Slug is probably regulated 
transcriptionally. The authors found that the up-regulation of both Snail and Slug by ???-
estradiol (E2) was predominantly mediated through activation of their promoter activities. 
The ERs elicit gene transcription by interacting with the classical ERE or non-ERE 
elements that bind heterologous transcription factors, including activator protein 1 sites 
(Webb et al., 1995), Sp1 sites (Porter et al., 1997) and cAMP-response elements (Sabbah 
et al., 1999). Of particular note, putative ERE sites can be found in the Snail promoter 
region (Moggs et al., 2005), but not in the Slug promoter. By sequence homology search, 
they found several potential Sp-1, activator protein 1, and cAMP-response element sites 
within the 5?-flanking regions of Snail and Slug (Park et al., 2008). In addition, ER might 
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also be recruited to the 3?enhancer downstream of the coding region, constituting a 
combinatorial network for transcription regulation (Eeckhoute et al., 2006).  
Slug transactivation was observed also in human uterine carcinosarcomasas (UCSs), where 
Slug up-regulation caused repression of E-cadherin, with subtle changes in cell 
morphology. In this cellular context, activation of the Slug promoter is mediated by ?-
catenin, through the proximal region (-361 to  -257 bp). Although most ?-catenin targeted 
genes require Tcf/Lef factors for their activation (Roose and Clevers., 1999; Tetsu and 
McCormick., 1999) the observed activation did not require binding sites in the promoter, 
as evidenced by the failure of deletion or dominant-negative Tcf4, in contrast to Xenopus 
and mouse Slug promoters activated by ?-catenin/Tcf complexes through the binding sites 
(Vallin et al., 2001; Conacci-Sorrell et al., 2003). A direct involvement of Wnt signaling 
pathway in Slug regulation was demonstrated also in colorectal carcinogenesis (Jin et al., 
??????? ??????? ??????-catenin complex binds on a Tcf consensus binding sequence 
(TACAAAGC), identified within one kilobase upstream of the human Slug promoter 
(Sakai et al., 2005), transactivating Slug expression. This leads to suppression of E-
cadherin transcription and induces EMT. Interaction of Tcf4 with MAD2B (a key mitotic 
checkpoint protein) inhibits the DNA binding ability of Tcf4, which attenuates 
transactivation of Slug, thus realizing the suppression of E-cadherin and leading to 
mesenchymal-epithelial transdifferentiation (MET) (Hong et al., 2009). 
While several evidence have been described the role of Snail/Slug transcription factors in 
cancer, more limited indications are available about the physiological role of these 
proteins, as well as their involvement in the development of non-neoplastic diseases.  
Studies performed in human lens epithelial cells obtained from patients with anterior polar 
cataracts, revealed an up-regulation of Slug levels. Analysis of the human Slug promoter 
???????????????????????????????????????????????Slug through an Sp1 binding site localized 
between positions -179 and -??????????????????????????????????????????????????????????????
in the repression of E-cadherin production through binding to the E-box element of its 
promoter and subsequently, in the EMT induction of lens ephitelial cells and in formation 
of anterior polar cataracts (Choi et al., 2007). Ikuta and Kawajiri demonstrated that Slug 
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expression is regulated by the aryl hydrocarbon receptor (AhR) in human keratinocyte. 
AhR is a ligand-activated transcription factor involved in xenobiotic metabolism, in 
teratogenesis (Mimura et al., 1997) and thymic atrophy (Fernandez-Salguero et al., 1996). 
It binds to the xenobiotic responsive elements (X??????????????????????-flanking region of 
the target genes, controlling their expression levels (Fujisawa-Sehara et al., 1986). In 
particular, five XREs are located in 3.4 kb upstream of the initiation codon of the human 
Slug gene (Stegmann et al., 1999), but only XRE5 is involved in the binding with 
AhR/ligand complex, as shown by ChIP assay in HaCaT cells. This observation indicates 
that AhR participates in Slug induction, which regulates cellular physiology such as cell 
adhesion and tumor cell invasion (Ikuta and Kawajiri., 2006). 
Mutations in the coding region for hSlug were detected in patients with Waardenburg 
syndrome, a congenital disorder that involves many genes. The disease has an 
heterogeneous phenotype, and is characterized by a rare form of hereditary deafness, 
coupled with abnormalities in pigmentation (Sanchez-Martin et al., 2002). The 
Waardenburg syndrome involves defects of various cell lines derived from the neural crest, 
including melanocytes. Defects in the development of pigmented cells thereby cause an 
abnormal distribution of melanin, as demonstrated by patches of white pigmentation on the 
skin and white hair. Alterations in the development of this structure are indeed implicated 
in the pathogenesis of piebaldism (or hypochromia), a rare disorder inherited in an 
autosomal dominant pattern, which leads to a heterogeneous distribution of pigmentation 
(Spritz et al., 1997). Large deletions in hSlug gene have been reported in patients with this 
pathology (Murakami et al., 2004). 
Furthermore, some studies have identified hSlug mutations in patients with neural tube 
defects. They have an incomplete closure of the neural tube, which causes the development 
of serious and highly debilitating diseases, such as spina bifida (Stegmann et al., 1999). 
 
As previously mentioned, Slug plays a critical role during neural crest formation, that 
under the control of this transcription factor, can give rise to different cell types including 
neurons, glia,  facial  chondrocytes, osteoblasts, and melanocytes (Nieto., 2002; Basch and 
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Bronner-Fraser., 2006; Le Douarin et al., 1994). In addition, craniofacial abnormalities 
have been observed  in  association  with  cerebral  malformations and cutaneous lesions in 
some neurocutaneous syndromes, emphasizing an important inductive role of the neural 
tube in the development of non-neural tissues mediated  through neural crest and 
differentiating genes such as Slug and Sox10 (Sarnat and Flores-Sarnat., 2005; Sakai et al., 
2006). Overall, these observations encourage investigation on Slug expression and 
functions in adult cells, including osteoblasts. This study is further supported by recent 
evidences that demonstrated the role of Snail1 during osteoblast differentiation and on 
adult bones. Indeed, its deregulated expression in the developing bone leads to 
achondroplasia in transgenic mice, the most common form of dwarfism in humans (de 
Frutos et al, 2007). Achondroplasias are associated with activating mutations in FGFR3, 
which signal in a ligand-independent manner to impair chondrocyte proliferation and 
differentiation (Ornitz and Marie, 2002). Snail1 is the transcriptional effector of FGFR3 
signaling during bone development and disease, and its activity can be inversely correlated 
with the length of the long bones (de Frutos et al, 2007). As in other tissues, Snail1 
expression is very tightly regulated in the bone, and thus, its aberrant activation in the adult 
had any impact on bone homeostasis. de Fructos and co-workers highlighted the 
fundamental role of Snail1 in controlling bone mass by acting as a repressor of both Runx2 
and vitamin D receptor (VDR) transcription during osteoblast differentiation. They 
observed that, sustained activation of Snail1 in transgenic mice provoked deficient 
osteoblast differentiation, which, together with the loss of vitamin D signaling in the bone, 
impaired osteoclastogenesis (de Fructos et al., 2009). Therefore, these indications shows 
that the impact of Snail1 activity on the osteoblast population regulates the course of bone 
cells differentiation and ensures normal bone remodeling.  
 
 
 
 
 
Human Slug gene 
23 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human Slug gene 
 
24 
 
 
 
 
 
 
 
Bone tissue and osteogenesis 
25 
 
 
 
 
 
 
C hapter 3 
Bone tissue and osteogenesis. 
 
 
Bone is a specialised connective tissue hardened by mineralization with calcium phosphate 
in the form of hydroxyapatite. Bone has well recognised important functions, such as 
structural functions that provide mobility, support for and protection of the body. It also 
has an important function as a reservoir for calcium and phosphorus. Morphologically, 
bone is characterized either as cancellous (spongy, trabecular) or as a cortical (compact). 
Functionally, cancellous bone is more closely associated with metabolic capabilities than 
cortical bone, whereas cortical bone generally provides greater mechanical strength 
(Downey and Siegel., 2006).  
Regarding cellular composition, bone tissue consists of specialized cells including 
osteoblasts, osteocytes, bone lining cells, and osteoclasts, and the extracellular matrix 
containing an organic and an inorganic component. Osteoblasts, which mature in ostecytes, 
are responsible for depositing the proteinaceous and calcified matrix and secreting the 
growth factors necessary for osteogenesis. Osteoclasts, derived from the monocyte-
macrophage lineage, participate in the critical function of bone remodelling. The 
extracellular matrix is composed of collagenous proteins (predominantly collagen type I), 
non-collagenous proteins (osteocalcin, osteopontin and bone sialoprotein) and mineralized 
matrix (hydroxyapatite) (Kwan et al., 2008). 
 
Bone Formation and Remodeling 
Several lines of evidence from classical embryology have established that two different 
embryonic lineages, neural crest and mesoderm, form early skeleton (Aubin and Liu., 
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1996; Erlebacher et al., 1995). The branchial arch derivates of the craniofacial skeleton 
originate from neural crest, whereas the axial skeleton, ribs, appendicular skeletons, and 
the skull base arise from mesoderm. Among the skeletal tissues formed by the mesoderm, 
the axial skeleton originates from the sclerotome, and the appendicular skeleton arise from 
the lateral plate mesoderm.  
During skeletogenesis, bone is formed in two different manners, intramembranous 
ossification and endochondral ossification, regardless of the embryonic lineage (see F igure 
1).  
Intramembranous ossification is characterized by invasion of capillaries into the 
mesenchymal zone and the emergence and differentiation of mesenchymal cells into 
osteoblasts. These osteoblasts costitutively deposit bone matrix, leading to the formation of 
bone spicules. These spicules grow and develop, eventually fusing with other spicules to 
form trabeculae. As the trabeculae increase in size and number they become 
interconnected, forming woven bone (a disorganized weak structure with a high proportion 
of osteocytes), which eventually is replaced by more organized, stronger lamellar bone. 
This type of ossification is involved in the development of flat bones in the cranium, 
various facial bones, parts of the mandible and clavicle and the addition of new bone to the 
shafts of most other bones (El Tamer and Reis., 2009). 
Endochondral ossification forms most of the bones including the axial and appendicular 
skeletons. It has simplistically been referred to as replacement of cartilage by bone, but this 
process is very complex in both its molecular and cellular transitions (Caplan and Boyan., 
1994). The beginning of the cartilage differentiation process is signalled by cellular 
condensation of the mesenchyme prior to cartilage matrix secretion. The mesenchymal 
cells differentiate into chondroblasts, which proliferate and produce a matrix that forms 
both the shape and position of the eventual bone. The embryonic model for long bones 
consists of hyaline cartilage, which undergoes appositional growth resulting in a dumbbell-
like shape. The shaft of the cartilaginous mass becomes the diaphysis, with the epiphyses 
located at both ends, and completely surrounded by the perichondrium (Sandberg., 1991). 
In the central aspect of the forming bone, long linear columns of chondrocytes 
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progressively hypertrophy, resorb the surrounding cartilage, and leave behind trabeculae of 
cartilage matrix, which then becomes mineralized. The chondrocytes degenerate, leaving 
behind interconnected spaces (Marks and Hermey., 1996; Sandberg., 1991). 
Along the circumference of the developing endochondral bone, the perichondrium 
develops osteogenic potential and lays down a thin layer of bone around the shaft, known 
as the periosteum. Primitive mesenchymal cells and blood vessels then invade the spaces 
within the shaft of the bone that are left after the chondrocytes degenerate. This 
mesenchyme differentiates into osteoblasts and bone marrow cells (Marks and Hermey., 
1996; Sandberg., 1991). Irregular woven bone is then formed as the osteoblasts layer along 
the surface of the calcified cartilage remnants. The ends of the original cartilaginous model 
are now separated through this process known as primary ossification. 
Secondary ossification also is occurring within the epiphysis, while a thin layer of hyaline 
cartilage is retained along the articular surface. The border between the diaphysis and 
epiphysis of developing long bones is the epiphyseal or growth plate. This is the area of 
continued longitudinal bone growth until physical maturity, when cartilage is replace by 
bone, bringing together the diaphysis and the epiphysis (Sandberg., 1991). 
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Figure 1. Schematic representation of the two modes of bone formation. (a) Endochondral bone formation 
as it takes place in long bones, starting with the condensation of skeletal precursors, proceeding to the 
formation of a cartilaginous template. Next prehypertrophic cells differentiate in the center of the 
cartilaginous template. At the subsequent steps hypertrophic chondrocytes appear, which continue to 
differentiate into mature hypertrophic chondrocytes producing a mineralized matrix and eventually are 
removed by chondroclasts leaving behind the mineralized matrix. Concurrently, blood vessels invade and 
together with those osteoblasts will enter and start to make trabecular bone utilize the mineralized matrix.  
(b) Membranous bone formation as it occurs in the flat bones of the skull: osteoblast progenitors differentiate 
directly from condensed mesenchyme and eventually differentiate into osteoid producing mature osteoblasts. 
Osteoblasts that get entrapped into the compact bone, reside in lacuna and differentiate into osteocytes. (Font: 
Hartmann C. (2009). Transcriptional networks controlling skeletal development. Current Opinion in Genetics 
& Development., 19:437?443). 
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Bone tissue is not static, and healthy bones require continuous remodeling in order to 
maintain bone mass, to repair microdamage of the skeleton, to prevent accumulation of too 
much old bone, and for mineral homeostasis. Remodeling is a lifelong coordinated and 
dominant process in the adult skeleton, whereby cortical and trabecular bone is rebuilt, a 
process initiated by osteoclastic bone resorption and followed by osteoblastic bone 
formation at the same site where the resorption process occurs, known as bone multi-
cellular units (BMU) (Lerner., 2006). 
????? ???????????? ???? ????? ?????????? ??? ?? ?????? ???????????? ??????? ??????????? ??? ??????
phases: initiation, transition, and termination of remodelling (Matsuo and Irie., 2008).  
The initiation phase starts with osteoblastic activation of osteoclast differentiation, fusion, 
and activation. This process involves upregulation of the expression of macrophage 
colony-stimulating factor (M-????? ???? ????????? ?????????? ??? ???????? ??????? ??? ???????
(RANKL) by osteoblastic and other cells (Boyce and Xing., 2007). By cell-to-cell contact, 
RANKL and M-CSF will activate their cognate receptors, RANK and c-Fms, respectively, 
on osteoclast progenitor cells. This will lead to an expansion of the osteoclast progenitor 
pool, increased survival of these cells, and the initiation of a differentiation program that 
terminates in fusion of the mononucleated progenitor cells and the development of latent 
multinucleated osteoclasts. Finally, these osteoclasts become activated to bone-resorbing 
osteoclasts and create resorption lacunae (Lerner., 2006). Osteoclastic bone resorption lasts 
about three weeks in human bone.  
During transition phase, bone-resorbing osteoclasts stimulate differentiation of osteoblast 
precursors, activating bone formation in bone resorption lacunae. While bone formation is 
being activated, osteoclastic bone resorption stops and osteoclasts undergo apoptosis in a 
Bim/caspase-3-dependent manner (Wakeyama et al., 2007) or through estrogen-induced 
Fas ligand (Nakamura et al., 2007). High extracellular calcium released from bone during 
resorption induces osteoclast apoptosis (Lorget et al., 2000; Nielsen et al., 2007). 
The termination phase includes new bone formation, mineralization and entry into 
quiescence. This phase proceeds slowly and lasts much longer (about three months) than 
resorption. Osteoblasts become quiescent presumably with the help of sclerostin, a factor 
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produced by osteocytes (van Bezooijen et al., 2004). During bone formation in the 
termination phase, osteoclast differentiation is suppressed, most likely through 
osteoprotegerin (OPG) produced by osteoblasts (Matsuo and Irie., 2008). 
The balance of these three phases, the rate of bone remodelling and the number of 
remodelling sites are altered in a variety of pathologic conditions affecting the skeleton, 
leading to loss of bone, as in osteoporosis, hyperparathyroidism, and rheumatoid arthritis, 
or, more rarely, to gain of bone as in osteopetrosis (Lerner., 2006; Boyce and Xing., 2008). 
 
Bone tissue regeneration 
Many pathological conditions (e.g. osteoporosis, osteoarthritis, and cancer metastases to 
the bone) as well as high-impact bone fractures present with a problem of tissue 
regeneration and/or replacement due to the extent of the injury and/or the lack of 
proliferating and tissue-regenerating cells in bone. Regarding this aspect, the currently 
used therapeutical strategies are based mainly on autografts, allografts, demineralised bone 
matrix and bone substitutes (Salgado et al., 2006). Autografts and allografts are the most 
popular methodologies in the field, presenting, however, several disadvantages. 
Autografts require a second surgical procedure that can lead to infection and chronic pain 
in the harvest site. Furthermore, it can also cause donor site morbidity, and the amount of 
biological material available for grafting is not high, limiting in this sense, the type of 
injuries in which it can be used (Heary et al., 2002; Perry., 1999). 
Allografts are especially attractive when a larger segment of bone needs to be replaced. It 
introduces however, the possibility of immune rejection and of pathogen transmission from 
donor to host, and, although infre??????????????????????????????????????????????????????????
to the transplantation (Salgado et al., 2004). 
Taking into account these evidences, the need to improve upon the failings with which 
current interventions remain beset is very important. As such, a shift in focus towards the 
development of cell-based bone tissue engineering strategies is transpiring, as their 
potential to provide novel solutions to the persistent inadequacies of current skeletal 
Bone tissue and osteogenesis 
31 
 
reconstructive modalities is being increasingly realized. Recent investigations, probing 
multiple progenitor cell populations, have produced a compelling body of evidence to 
support the clinical viability of cell-based bone tissue engineering. 
First and foremost, multipotent cells must be able to differentiate toward osteogenic 
lineage in an efficient manner, thanks to the concerted actions of a plethora of signals (e.g. 
hormones, growth factors, mechanical forces, transcription factors) important for 
osteoblastogenesis. However, this alone is insufficient to make a cell source a viable 
candidate for use clinically. In order for a particular cell population to be successfully 
utilized in clinical bone tissue engineering applications, it must not only possess the 
capacity to regenerate mature, functionally competent, bone tissue de novo. Furthermore, 
the cells must maintain an adequate proliferative capacity post-harvest, be accessible in 
sufficient numbers, and be able to be obtained without imparting undo donor morbidity. 
Undoubtedly, human mesenchymal stem cells (MSCs) have shown a clear capacity to fulfil 
these criteria (Panetta et al., 2009). 
 
????????????????????????????????????????osteogenesis process:  
mesenchymal stem cells (MSCs) and osteoblasts (OBs) 
 
? Mesenchymal stem cells (MSCs) 
The use of living cells as therapeutic agents for the maintenance, regeneration, or 
replacement of malfunctioning tissues has been proposed in last decades (Kirouac and 
Zandstra., 2008). Stem cells are the basis for cell therapy. They are functionally 
undifferentiated cells that retain the ability to differentiate in one or more mature cell types 
under appropriate conditions, and to self-renew, representing a potentially inexhaustible 
cell source (Alberts et al., 2002). There are two main sources of stem cells: embryonic and 
non-embrionic stem cells. 
Embryonic stem cells (ESCs) are harvested from the inner cell mass of the blastocyst and 
are acclaimed for their unlimited capacity for self-renewal (Allison et al., 2002; Preston et 
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al., 2003). They were primarily isolated during early 1980s from mouse embryos (Evans 
and Kaufman., 1981; Martin., 1981), then later from human embryos (Thomson et al., 
1998; Reubinoff et al., 2000). Human ESCs are pluripotent, as they can give rise to 
essentially all cell types in the body (Buckwalter and Mankin., 1998; Hentthorn, 2002). In 
vitro and in vivo experiments have demonstrated the ability of ESCs for osteogenic 
differentiation (Whang and Lieberman., 2003). In spite of this broad differentiation 
capability and potential to be used in regenerative medicine, the predisposition of these 
cells for teratoma formation and the political and ethical debate currently surrounding their 
use pose substantial challenges for forward progress on these cells (Lauffenburger and 
Schaffer., 1999; Montjovent et al., 2004). 
Non-embrionic stem cells or mesenchymal stem cells (MSCs) are a group of clonogenic 
cells present in different adult human tissues. These cells are able to self-renew and 
possess a high proliferative capacity (Minguell et al., 2001; Uccelli et al., 2008).  Many 
studies suggest that MSCs can give rise to different mesenchymal cell type such as 
osteoblasts (Pittenger et al., 1999; Donald et al., 1996; Jaiswal et al., 1997; Kadiyala et al., 
1997; Nilsson et al., 1999), chondrocytes (Kadiyala et al., 1997; Pittenger et al., 1999; 
Johnstone et al., 1998; Mackay et al., 1998), adipocytes (Young et al., 1998; Pittenger et 
al., 1999; Endres et al., 2003), tenocytes (Awad et al., 1999) and myocytes (Pereira et al., 
1995; Horwitz et al., 1999; Jiang et al., 2002; Bhabavati et al., 2004; Smith et al., 2004; 
Beyer and da Silva, 2006; Sethe et al., 2006). MSCs can also differentiate into cells of 
ectodermal origin, such as neurons (Woodbury et al., 2000), and of endodermal origin, 
such as hepatocytes (Petersen et al., 1999) (see F igure 2). 
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Figure 2. Multi-lineage potential of mesenchymal stem cells (MSCs). MSCs can differentiate into multiple 
lineages as osteocytes, chondrocytes, fibroblasts, adipocytes, astrocytes, myocytes and bone marrow stromal 
cells. (font: Grassel S and Ahmed N. (2007). Influence of cellular microenvironment and paracrine signals on 
chondrogenic differentiation. Front Biosci., 12:4946-4956). 
 
Several ideas have been put forward to explain stem cell lineage determination. One 
current line of research is focused on the stem cells microenvironment or niche. A niche 
consists of signalling molecules, intercellular communication and the interaction between 
stem cells and their neighbouring extracellular matrix. This three-dimensional 
microenvironment is thought to influence/control genes and properties that define 
??????????????????????????????????????-renewal or development to committed cells (Watt and 
Hogan., 2000). An interesting theory put forward is that stem cells might be terminal 
differentiation cells with the potential to display diverse cell types, depending on the host 
niche. Adult stem cells that are implanted into a totally different niche (different germ 
layer) can potentially differentiate into cell types similar to those found in the new 
environment. For example, human neural stem cells were found to produce muscle cells 
when they were implanted into skeletal muscle (Galli et al., 2000). Bone marrow cells 
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were found to differentiate into neural cells when they were transplanted into a neural 
tissue (Zhao et al., 2002; Mezek et al., 2000). In addition, trans-differentiation of liver 
cells to islet cells was achieved (Alam and Sollinger., 2000). These findings showed the 
?????????????????????????????? ?????????? ????????????????????m cells plasticity (the ability to 
dedifferentiate into cells from other lineages) (Bajada et al., 2008).  
Historically, research involving the cells currently referred to as MSCs dates back to the 
60s and 70s, when Dr. Alexander J. Friedenstein and colleagues started researching 
fibroblastic cells from bone marrow (BM) of rodents and rabbits (Phinney., 2002). At first, 
these cells were not called MSCs, not even were termed stem cells, but were considered to 
be fibroblastic precursors derived from an entity with unknown anatomical location in BM 
termed the colony-forming unit-fibroblast (CFU-F). Experiments involving transplantation 
of BM cells into ectopic sites including the renal capsule resulted in ectopic bone 
formation, and brought up the notion that BM housed osteogenic precursors (Phinney., 
2002). Later, the fibroblastic colonies derived from BM cells were found to be able to 
differentiate into cells with characteristics of osteoblasts, chondrocytes, and adipocytes 
(Phinney., 2002). By that time, Dr. T. M. Dexter and colleagues developed a cultured 
system to study hematopoiesis in vitro (Dexter et al., 1977). In this system, cells bearing 
hematopoietic stem cell (HSC) characteristics were found to be non-adherent to the culture 
vessels, and to be dependent on the establishment of a layer of adherent cells that were 
viewed as representative of the BM stromal environment. The notion that CFU-F was 
derived from the stromal compartment of BM became established, and the term bone 
marrow stromal cell used in reference to these culture-adherent BM cells (Lanotte et al., 
1981). 
 
Source of MSCs 
Adult MSCs have been identified in the vast majority of tissues and organs. They have 
been isolated from muscles (Deasy et al., 2001), peripheral blood (Kuznetsov et al., 2001; 
Roufosse et al., 2004), adipose tissue (Lee et al., 2004), tendon (Salingcarnboriboon  et al., 
2003), synovial membrane (De Bari et al., 2001), hair follicles and scalp subcutaneous 
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tissue (Shih et al., 2005), periodontal ligament (Trubiani et al., 2005), fetal bone marrow, 
blood, lung, liver and spleen (???? Anker et al., 2003), as well as pre-natal tissues such as 
cord blood (Erices et al., 2000) and placenta (Fukuchi et al????????????????????et al., 2004). 
As a result, significant efforts have been directed at identifying postnatal sources for 
multipotent cells. Multipotent cells have been identified in bone marrow, adipose tissue, 
placenta, umbilical cord, human amniotic fluid, dental pulp and skeletal muscle among 
others (Freeman, 1997; Clarkson, 2001; Mitka, 2001; Kadner et al., 2002; Kaviani et al., 
2002, 2003; Rosser and Dunnett, 2003; Savitz et al., 2004). 
Bone marrow-derived mesenchymal stem cells (B M-MSCs) were the first adult stem 
cells identified (Friedenstein., 1976). BM-MSCs represent the most characterized type of 
adult stem cells (Bianco et al., 2001; Owen and Friedenstein., 1988) and remain the most 
commonly used cell source for bone regeneration and repair in the studies using different 
animal models (El Tamer and Reis., 2009). 
It has since been shown that in the bone marrow, there exists approximately one stem cell 
for every 100000 bone marrow cells (Polak and Bishop., 2006). Stem cells population 
derived from the bone marrow are usually a heterogeneous mix of different 
subpopulations, including bone marrow-derived hematopoietic stem cells (BM-HSCs), 
mesenchymal stem cells (BM-MSCs) (Friedenstein., 1976) and endothelial progenitor cells 
(Hristov and Weber., 2003). 
 
Isolation and characterization of MSCs 
Currently, the culture of MSCs from human BM most invariably starts with the 
centrifugation of BM aspirates on a density gradient formed by Ficoll-Paque or Percoll to 
separate the nucleated cells from the red blood cells (Phinney et al., 1999; Lennon and 
Caplan., 2006). In rodents, BM is obtained by flushing the BM out of the long bones, and 
the tissue obtained is usually disaggregated by flushing it in and out a syringe with needle 
(da Silva Meirelles and Nardi., 2003; Lennon and Caplan., 2006). MSCs obtained from 
solid tissues can be obtained by digestion using collagenase type I with or without the use 
of other proteolytic enzymes ( da Silva Meirelles et al., 2006; Krampera et al., 2007). The 
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cells are then counted and placed in plastic culture vessels with culture-treated surface in 
culture medium. MSCs can be expanded in vitro to hundreds of millions of cells from a 10-
to-20-mL BM aspirate (Di Girolamo et al., 1999; Sekiya et al., 2002). The cell yield after 
expansion varies with the age and condition of the donor and with the harvesting 
technique. Therefore, differences in isolation methods, culture conditions, and media 
additives greatly affect cell yield and possibly also the phenotype of the expanded cell 
product (Sekiya et al., 2002; Caterson et al., 2002; Sotiropoulou et al., 2006). For these 
reasons, efforts have been made within the European Group for Blood and Marrow 
Transplantation (EBMT) MSC expansion consortium for the standardization of MSC 
isolation and expansion procedures. This organization, including European centers 
interested in the biology and clinical application of MSCs, has defined common protocols 
in order to facilitate comparisons between cell products generated at different sites and to 
run large-scale clinical studies (Bernardo et al., 2009). In this regard, MSCs are currently 
expanded in vitro, either under experimental or clinical grade conditions, in the presence of 
10% fetal calf serum (FCS) (Caterson et al., 2002; Sotiropoulou et al., 2006), and serum 
batches are routinely prescreened to guarantee both the optimal growth of MSCs and the 
biosafety of the cellular product. Despite this, the use of FCS has raised some concerns 
when utilized in clinical-grade preparations, because it might theoretically be responsible 
for the transmission of prions and still unidentified zoonoses or cause immune reactions in 
the host, especially if repeated infusions are needed, with consequent rejection of the 
transplanted cells (Horwitz et al., 2002). In view of these considerations, serum-free 
media, appropriate for extensive expansion and devoid of the risks connected with the use 
of animal products, are under investigation. The possibility of using autologous or 
allogeneic human serum for in vitro expansion of MSCs has been tested, and autologous 
serum has proved to be superior to both FCS and allogeneic serum in terms of proliferative 
capacity of the expanded MSCs (Shahdadfar et al., 2005).  
 
MSCs characterization consists of the analysis of their adherent properties, proliferation, 
differentiation potential and surface molecule profile. In detail, ex vivo expanded MSCs 
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have been phenotipically characterized on the basis of the expression of some markers, 
including CD105 (SH2 or endoglin), CD73 (SH3 or SH4), CD90 (Thy-1), CD166, CD44, 
and CD29. In addition, culture-expanded cells lack the expression of some hematopoietic 
and endothelial markers, such as CD14, CD31, CD34, and CD45 (Caplan., 1994; Pittenger 
et al., 1999). Little is known about the characteristics of the primary precursor cells in vivo, 
since it has not yet been possible to isolate the most primitive mesenchymal cell from bulk 
cultures. One of the hurdles has been the inability to prospectively isolate MSCs because 
of their low frequency and the lack of specific markers. Recently, the identification and 
prospective isolation of the most primitive mesenchymal progenitors, both in murine and 
human adult BM, have been reported, based on the expression of some markers (Anjos-
Afonso and Bonnet., 2007; Gang et al., 2007; Simmons and Torok-Storb., 1991; Quirici et 
al., 2002; Buhring et al., 2007; Battula et al., 2009; Gentry et al., 2007). One group has 
reported the identification, isolation, and characterization of a novel multipotent cell 
population in murine BM, based on the expression of the stage-specific embryonic antigen-
1 (SSEA-1). This primitive subset, found both directly in the BM and in mesenchymal cell 
cultures, can give rise to SSEA-1+ MSCs and is proposed to be placed at the apex of the 
hierarchical organization of the mesenchymal compartment (Anjos-Afonso and Bonnet., 
2007). In human cells, surface markers such as SSEA-4, STRO-1, and the low-affinity 
nerve growth factor receptor (CD271) (Gang et al., 2007; Simmons and Torok-Storb., 
1991; Quirici et al., 2002; Buhring et al., 2007), which enrich for MSCs, have been 
employed with the aim to prospectively isolate MSCs. Moreover, Battula and colleagues 
have recently isolated by flow cytometry MSCs from human BM using antibodies directed 
against the surface antigens CD271, mesenchymal stem cell antigen-1 (MSCA-1), and 
CD56, and identified novel MSC subsets with distinct phenotypic and functional properties 
(Battula et al., 2009). Platelet-derived growth factor receptor-beta (PDGF-RB; CD140b) 
has also been identified as a selective marker for the isolation of clonogenic MSCs 
(Buhring et al., 2007), and other reports have demonstrated a 9.5-fold enrichment of MSCs 
in human BM cells with prominent aldehyde dehydrogenase activity (Gentry et al., 2007). 
The relevance and usefulness of these markers for the prospective isolation and consequent 
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expansion of MSCs from BM and/or other sources is being evaluated and will possibly 
allow a more precise definition of the cell products employed both in the experimental and 
clinical setting. 
However, due to the lack of specific markers that define the multipotent MSC, coupled 
with the lost of certain markers during MSCs in vitro expansion, these cells are usually 
defined in functional terms based on in vitro and in vivo functional assay.  The 
International Society for Cellular Therapy has provided the following minimum criteria for 
defining multipotent human MSCs (Dominici et al., 2006): 
? Plastic-adherent under standard culture conditions; 
? Positive for expression of CD105, CD73, and CD90, and absent for expression of 
hematopoietic cell surface markers CD34, CD45, CD11a, CD19, and HLA-DR; 
? Under specific stimulus, cells should differentiate into osteoblasts, adipocytes and 
chondroblasts in vitro. 
 
??? ?????????? ????? ????? ?????????? ?????? ????????? ????????? ??? ?????? ??? ???? ???????? ??? ????
cells to form ectopic bone and bone marrow microenvironment supporting hematopoiesis 
upon implantation in an open system (subcutaneous implantation) in immune deficient 
severe combined immunodeficiency disease mice. This assay has also been employed to 
demonstrate the ability of the multipotential MSC cells to exhibit self-renewal and 
maintenance of stemness capacity during serial implantations (Piersanti et al.,  2006). 
 
???????????????? ?????????????????????????????? 
As mentioned above, different adult human tissue have been considered as MSCs sources, 
including bone marrow, trabecular bone, adipose tissue, peripheral blood, synovium, 
skeletal muscle, dental pulp and periodontal ligament (Dennis et al., 1999; Kern et al. 
2006; Peng et al., 2008). Although bone marrow still represent the main and most 
investigated source of adult MSCs, the isolation and use of these cells still present some 
drawbacks. For instance, the number of MSCs found in bone marrow, decrease 
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progressively starting at age 17 and the harvesting techniques are invasive, often causing 
severe infections, bleeding and chronic pain for donors (Bajada et al., 2008). Looking for 
alternative MSCs sources, fetal tissue (Hu et al., 2003; Guillot et al., 2008) and exta-
embryonic tissues (Yen et al., 2005; De Coppi et al., 2007; Lee et al., 2004; Parekkadan et 
al., 2007; Sarugaser et al., 2005; Can and Karahuseyinoglu., 2007), have recently been 
considered.  
In particular, in this thesis I will focus the attention on umbilical cord stroma. 
Umbilical cord, due to the unique morphological properties, represents an interesting 
alternative source for MSCs, especially if compared with umbilical cord blood (Secco et 
al., 2008; Troyer and Weiss., 2008). The human umbilical cord weighs approximately 40 
g, its length reaches to approximately 60?65 cm, and it has a mean diameter of 1.5 cm at 
term (Raio et al., 1999; Di Naro et al., 2001). The inner tissue architecture is composed of 
a set of two arteries and one vein and a surrounding matrix of mucous connective tissue 
??????? ???????????????????????????????ibed by Thomas Wharton in 1956 (see F igure 3). 
 
 
Figure 3. Umbilical cord in cross-section. 
(modified from: http://embryology.med.unsw.edu.au/Science/ANAT2341lab04_4.htm) 
 
 
This jelly acts as a protective tissue for vessels and contains into its stromal compartment, 
?????? ????? ????????? ???????????? ????????????????? ??????? ?????????? ?????? ????????????
Stem Cells (WJMSCs) (Wang et al??? ???????????????????????????? ?????? ???? ??? ??? ???????
unique, easily accessible and uncontroversial source for early MSCs, due to the simple 
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collection procedure once umbilical cord is routinely discharged at parturition (Penolazzi 
et al., 2010).  
???????????????????????????????of specialized fibroblast-like cells and occasional mast cells 
embedded in high amounts of extracellular matrix (ECM) components, mainly collagen, 
hyaluronic acid and several sulphated proteoglycans (Sobolewski et al., 1997; Franc et al., 
1998). The accumulation of peptide growth factors, such as insulin-like growth factor 
(IGF) (Edmondson et al., 2003), fibroblast growth factor (FGF) (Yu et al., 2003), and 
transforming growth factor ? (TGF-?) (Shalitin et al., 2003), followed their release and 
activation, may strongly promote the biosynthesis of these ECM components. This 
amorphous ground substance would provide a strong mechanical resistance, elasticity and 
high degree of hydration to prevent the umbilical cord vessels from occlusion, such as that 
induced by bending, torsion or scretch evoked by uterine contraction or fetal movement 
(Pennati 2001). ??????? ???????????????? ???????????????????????????????????????????????
indistinct regions: the perivascular zone, the intervascular zone, and the subamnion (Troyer 
and Weiss., 2008). 
WJMSCs have some genetic and surface markers that are also common in MSCs. Among 
these, CD105, CD73, and CD90, which are known to characterize MSCs (Dominici et al., 
2006), were consistently found to be positive in WJMSCs. They do not express 
hematopoietic stem cell markers such as CD45, CD34, and human leukocyte antigen 
(HLA)-DR, which are also lacking in MSCs (Dominici et al., 2006). 
WJMSCs principally display a fibroblast-like appearance, are plastic-adherent and 
multipotent, so they can be differentiated into bone, cartilage, fat and neural cells 
(Karahuseyinoglu et al., 2007; Wang et al., 2004; Lund et al., 2007). Many reports have 
demonstrated that WJMSCs have faster proliferation and greater ex vivo expansion 
capabilities than BM-MSCs. First, the isolation frequency of colony forming units (CFU-
F) from bone marrow is estimated to be in the range of 1-10 CFU-F per 106 mononuclear 
cells (MNCs), while in WJMSCs is reported to have a higher frequency of CFU-F 
(Karahuseyinoglu et al., 2007; Sarugaser et al., 2005). Second, coupled with the greater 
CFU-F frequency, the doubling time of WJMSCs is shorter than BM-MSCs 
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(Karahuseyinoglu et al., 2007; Baksh et al., 2007; Lund et al., 2007). This may be due to 
the expression of telomerase by WJMSCs (Mitchell et al., 2003). 
Telomerase activity (TA) in proliferating cells is an active area of research since, unlike 
embryonic stem cells and tumorigenic cells, somatic cells display low levels of TA 
(Greider., 1998). Few studies dealing with the TA of human WJMSCs revealed that TA in 
those cells is higher than in somatic cells of the body. Mitchell et al. (Mitchell et al., 2003) 
showed that TA in isolated porcine WJMSCs was about 10% of that expressed by 
carcinoma cell lines, whereas Weiss et al. (Weiss et al., 2006) found that telomerase 
reverse transcriptase gene expression is elevated in cultured human WJMSCs. 
Karahuseyinoglu et al. (Karahuseyinoglu et al., 2007) demonstrated a stable but higher 
than normal TA in those cells during early passages, which then decreased and reached a 
level below control HeLa cell lines. Since the transplanted WJMSCs did not develop any 
tumorigenic formation (Conconi et al., 2006), it is possible to conclude that WJMSCs have 
a certain limit of TA that provide cells with the ability to proliferate up to 30?60 divisions 
but never to a level of tumorigenic state. 
WJMSCs have, also, stromal support properties. For example, extra-embryonic 
????????????????? ??????????????????????????????????????????????????????????????????????
island cells during their migration to the aorta-gonad mesonephros from the yolk sac 
region prior to day E10.5 (Sadler., 2004). WJMSCs retain this property as demonstrated by 
their role in ex vivo hematopoietic expansion (Lu et al., 2006) and in vivo engraftment of 
HSCs. In fact, Friedman and co-workers (Friedman et al., 2007) shown that in a 
NOD/SCID mouse model, human WJMSCs, when co-injected with human umbilical cord 
blood cells (UCB), can accelerate human hematopoietic stem cell recovery when limited 
numbers of UCB cells or CD34 cells are injected. 
Regarding immune properties, many results indicate that WJMSCs are immunosuppressive 
and have reduced immunogenicity (Troyer and Weiss., 2008). Indeed, WJMSCs exert 
immunosuppression by inhibiting T-cell responses to polyclonal stimuli (Di Nicola et al., 
2002; Glennie et al., 2005) and suppress lymphocyte proliferation in vitro (Bartholomew et 
al., 2002). In addition, WJMSCs express HLA-G, do not express co-stimulatory molecules, 
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such as CD80, CD86 or CD40 and express cytokines which may modulate immune 
function, like interleukin (IL)-6 and vascular endothelial growth factor (VEGF) (Weiss et 
al., 2006). 
 
Differentiation potency of culture-expanded MSCs 
One of the criteria to define MSCs is their ability to differentiate into the adipogenic, 
chondrogenic and osteogenic lineages (Dominici et al., 2006).  
For adipogenic differentiation, MSCs are treated with dexamethasone, insulin, isobutyl 
metyl xanthine, and indomethcin (added to medium containing FBS), and the 
differentiation is revealed by the detection of lipid vacuoles with oil red O staining (da 
Silva Meirelles et al., 2006; Mackay et al., 2006). The chondrogenic differentiation is 
performed using a high cell-density pellet or micromass culture treated with transforming 
growth factor-??????-????????????????????????-glycerophosphate; this results in production 
of cartilage-specific highly sulphated proteoglycans and type II collagen (Johnstone et al., 
1998). Classically, osteogenic differentiation of human MSCs requires incubation in FBS-
containing medium supplemented with as??????? ?????? ?-glycerophosphate, and 
dexametasone, resulting in an increase in alkaline phosphatase activity and calcium 
deposition. However, other supplements, such as 1,25-dihydroxyvitamin D3 and members 
of the bone morphogenic protein (BMP) family are also routinely used for osteoinduction 
(Tuan et al., 2003). Indeed, BMP-2 together with the aforementioned agents, successfully 
mediates the osteogenic differentiation of human WJMSCs and BM-MSCs inducing the 
expression of osteoblast-specific markers such as alkaline phosphatise (ALP), Runx2, 
osteocalcin (OC), collagen type I (COL I) and osteopontin (OPN) (Hou et al., 2009). In 
addition, BMP-2 alone appears to increase bone nodule formation and the calcium content 
of osteogenic cultures in vitro, while concomitant application of BMP-2 and basic 
fibroblast growth factor increases MSCs osteogenesis both in vivo and in vitro (Hanada et 
al., 1997). 
Increasing evidence, supports that MSC populations are heterogeneous with coexisting 
subsets having varying potency; this applies to bone marrow as well as to MSCs from 
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other tissues. As an example, Karystinou and co-workers, recently reported that human 
synovium-derived clonal MSCs were capable of osteogenic and chondrogenic 
differentiation though with varying potency, but only 30% of the clonal populations tested 
were able to differentiate into adipocytes (Karystinou et al., 2009).  
 
Osteogenic differentiation potency of MSCs 
The osteogenic potential of culture-expanded MSCs (Friedenstein et al., 1976; Ashton et 
al., 1985) has been studied extensively in vitro and in vivo. The first in vivo experiments 
with MSCs were performed using diffusion chambers loaded with culture-expanded cells 
(Ashton et al., 1980). Later, the adoption of bioscaffolds such as hydroxyapatite (HA) 
implanted in immunocompromised mice proved useful to help studying MSC osteogenic 
differentiation in vivo (Ohgushi and Okumura., 1990). It was possible to obtain donor 
MSC-derived bone by subcutaneous implantation of HA scaffolds seeded with human 
MSCs (De Bari et al., 2008; Muraglia et al., 1998; De Bari and ?????????????????; Bluteau 
et al????????????????????et al., 2008). Using HA-based bioscaffolds, it became than possible 
to repair segmental bone defects in vivo by using autologous MSCs, in loaded conditions, 
both in large animals (Kon et al., 2000) as well as in humans in proof-of-concept studies 
(Quarto et al., 2001).  
The use of MSCs in bone tissue engineering remains challenging for issues such as the 
plethora of tissues sources and culture conditions, with resulting biological variability. For 
instance, human periosteum contains cells that upon enzymatic release and culture 
expansion display MSCs phenotype and capacity at the single-cell level to differentiate 
into multiple skeletal lineages including bone (De Bari et al., 2006). Notably, in a proof-
of-concept study, De Bari and co-workers quantified the bone-forming potency of matched 
human MSCs from synovium and periosteum and analyzed the sources of variability in 
osteogenic outcome. They identified the tissue of origin of MSCs as the main source of 
variability, since MSCs from periosteum had significantly greater osteogenic potency than 
MSCs from synovium. The different origin of MSCs may influence also the beginning and 
the achievement of osteogenesis. Indeed, Baksh and co-workers demonstrated that 
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WJMSCs undergo osteogenesis at a faster rate than BM-MSCs, based on the increase in 
ALP positive cells, and after 5 weeks of culture under osteogenic conditions, WJMSCs 
generated a greater extend of mineralization than BM-MSCs, including bone nodule 
generation (Baksh et al., 2007). A second source of variability is related to the individual 
????????????????????????????????????????????????????????????????????????????????????????????????
capacity of MSCs, has been well documented in both human and animal models (Zhang et 
al??????????????????? et al., 1999). For instance, the BM-MSCs/progenitor cell number and 
differentiation ability decrease in an age-dependent manner (Bajada et al., 2008; Hamrick 
et al., 2006).   
 
?  Osteoblasts (OBs) 
Osteoblasts, bone producing cells, originate from multipotent mesenchymal stem cells and 
are responsible for the secretion of the organic extracellular matrix of bone (ECM), both 
during development and later during the remodeling of mature bone (Karsenty and 
Wagner., 2002). These cells also express genes that are necessary and sufficient to induce 
mineralization of this ECM and deposit osteoid on the pre-existing mineralized matrix only 
(Huang et al., 2007). 
Despite that, osteoblasts are required for bone resorption: indirectly, because they produce 
some factors, including RANKL (Theoleyre et al., 2004) and interleukin (IL)-6 (Ishimi et 
al., 1990), necessary to induce osteoclast differentiation; directly, because they release 
metalloproteinases, enzymes involved in the extracellular matrix digestion (Filanti et al., 
2000). 
To date, some specific osteoblast differentiation markers have been defined, which allow 
to discriminate between osteoblasts and other cells (Gundberg., 2000; Titorencu et al., 
2007): 
? Runx2 (Runt-related transcription factor 2) or Cbfa1 (Core binding factor 1): is the 
master gene regulator of osteoblast differentiation; 
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? Collagen type I (Col1a1): is a significant component of bone matrix, which is involved 
in the mineralization process; 
? Osteopontin (OPN): is an extracellular structural phosphoprotein which is rich in sialic 
acid;   
? Osteocalcin (OC) or Bone gamma-carboxyglutamic acid-containing protein (BGLAP): 
is a noncollagenous protein, vitamin K-dependent, which binds bone mineral calcium 
and hydroxyapatite; 
? Osteonectin: is a glycoprotein secreted by osteoblasts during bone formation, initiating 
mineralization and promoting mineral crystal formation. It is also shows affinity for 
collagen type I in addition to bone mineral calcium. 
? Bone Sialoprotein (BSP): is a component of bone extracellular matrix; 
? Alkaline phosphatise (ALP): is implicated in mineralization mechanisms. 
 
Recently, also collagen type XV (COL15A1), previously described as being expressed in 
the basement membrane in other cell types, was identified as a matrix protein released by 
osteoblasts. It was demonstrated that, the expression of collagen XV significantly increases 
during the osteogenic differentiation in vitro. On the contrary, the presence of free ionised 
extracellular calcium in the medium, significantly down-modulates its expression 
(Lisignoli et al., 2009). 
Besides the estrogen receptor ???? is a key regulator of bone and its mRNA is actively 
regulated throughout development of the osteoblastic phenotype. The activation of this 
receptor has a direct effect on the expression of genes coding for enzymes, bone matrix 
proteins, hormone receptors, transcription factors, cytokines and growth factors of 
osteoblasts and osteoclasts (Zallone., 2006). 
With regard to the precise effect of estrogen on osteoblastic differentiation and 
proliferation of mature osteoclasts, the data reported in the literature are partly conflicting 
and in some cases seem to vary depending on the experimental model adopted. 
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It is possible to outline osteoblastogenesis in three major stages: proliferation, matrix 
maturation, and mineralization, which are characterized by sequentially expressed 
distinctive osteoblast markers. Proliferation is characterized by increased expression of 
genes related to cell cycle; at the end of this phase and during the matrix deposition, it is 
possible to detect mRNA for collagen I, osteonectin  and ALP. Indeed, ALP is an early 
marker of osteoblast differentiation. The production of OPN, OC and BSP occurs between 
the end of matrix deposition and the beginning of mineralization; these proteins are 
therefore classified as late markers of differentiation (Olsen et al., 2000; Zur Nieden et al., 
2003). This is associated with the deposition of calcium and phosphate salts, which can be 
detected by specific assays. 
The implementation of osteoblast differentiation process is controlled by several factors, 
some of which have been characterized and are currently successfully used to induce 
specific differentiation of mesenchymal progenitor cells. As mentioned before, the main 
agents reported in the literature capable of inducing osteogenesis are: ascorbic acid, 
vitamin D3, ?-glycerophosphate and dexamethasone (Zur Nieden et al., 2003; Kawaguchi., 
2006). 
 
Runx2 (which will be discussed more fully in the following paragraphs) is certainly the 
most studied transcription factor and was indicated as the main regulator of the "osteogenic 
commitment"; indeed, it is always expressed in the three phases, even if its role is decisive, 
especially during stem cell-preosteoblast and preosteoblast-osteoblast transition (Komori., 
2008). 
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C hapter 4 
Osteogenic differentiation: molecular signaling pathways. 
 
 
Progenitor cells will likely form the cornerstone of future skeletal tissue engineering 
modalities. Yet, gaining an understanding of the intra and intercellular processes which 
transpire on a molecular level to guide the osteogenic differentiation of skeletal progenitors 
will be pivotal in optimizing their potential to enhance osseous healing. Multiple signaling 
pathways, including those involvi????????????? ?????????????????????????????????????
are now known to be intimately involved in skeletal development, homeostatic bone 
turnover, and skeletal regeneration after injury (see F igure 1).  
More importantly, many have been found to in part regulate the osteogenic differentiation 
of MSCs. Though not an exhaustive list, these factors represent excellent targets for MSCs 
manipulation on a molecular level with the goal of augmenting the osteogenic potential of 
MSCs implemented in skeletal reconstruction, as well as enhancing the endogenous 
regenerative capacity of native tissues. 
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Figure 1. Schematic representation of the major signalling pathways that play an important role in 
regulating skeletal development. ?????????????? ????-?????????????????????????????, and FGF signalling 
pathways. (font: Deng Z.L., Sharff K.A., Tang N., et al. (2008). Regulation of osteogenic differentiation 
during skeletal development.  Front Biosci., 13:2001-2021). 
 
 
 ????????? ?ignaling?? ????? ???????????? ????????? ??? ????? ??? ????????? ????????
polypeptide factors that play critical roles in regulating a diverse set of cellular functions 
including proliferation, differentiation and embryonic development (Luu et al., 2007; Shi 
and Massague.????????????????????? ?????????????????????????????????????????????????????
???????????????????? which are highly conserved in mammals. BMPs belongs to the 
????????????????????????????????????????????????????????????????????????????????????????
and were initially identified by their capacity to induce endochondral bone formation 
(Canalis., 2003; Cao and Chen., 2005). Many of these proteins, mostly notably BMP-2,-4,-
6,-7,-9 initiate their signalling cascade by binding to the dimeric complex of two 
transmembrane serine-threonine kinase receptors, termed Type I and Type II (Hogan., 
1996; Cheng et al., 2003). The activated receptors, transmit signals through Smad-
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dependent and Smad-indipendent pathways, including ERK, JNK, and p38 MAP kinase 
(MAPK) pathways (Derynck et al., 2001). There are three classes of Smads: 1) receptor-
regulated Smads (BR-???????????????????????????????????????????????????????-Smads); 
?????????????????????????????????????????????????-Smads); 3) inhibitrory Smads (I-
Smads). The BR-Smads/Co-Smads complexes then traslocate into the nucleus and regulate 
transcription of target genes by interacting with various transcription factors and 
transcriptional co-activators or co-repressors. The BR-Smads activates expression of 
Distal-less homeobox 5 (Dlx5), that induces expression of Runx2 and Osterix in 
osteoprogenitors cells (Miyama et al., 1999; Lee et al., 2003). Although the Smads are 
??????????????????????????????????????????????????????-2 can activate ERK, JNK and p38 
in osteoblastic cells and provide evidences that these MAP kinases have dinstinct roles in 
regulating alkaline phosphatise and osteocalcin expression (Guicheux et al., 2003; Lai and 
Cheng., 2002). 
 Hedgehog (Hh) signalling: The Hedgehog family of secreted proteins consists of 
three mammalian orthologs, Sonic  Hedgehog (Shh), Indian Hedgehog (Ihh) and Desert 
Hedgehog (Dhh). Ihh is produced by prehypertrophic chondrocytes and appears to act 
directly on perichondrially located osteoblast progenitors to specify the osteoblast 
precursors (St-Jacques et al., 1999; Long et al., 2004). The failure of activation of Runx2, 
indicates that hedgehog (Hh) signalling acts to initiate an osteogenic program (Razzaque et 
al., 2005). Ihh, is essential for skeletal development as demonstrated by knockout of Ihh in 
transgenic mice. Ihh-knockout mice demonstrate reduced chondrocyte proliferation, 
inappropriate chondrocyte maturation and an absence of osteoblast differentiation in 
endochondral bones, suggesting the importance of Ihh in endochondral bone development 
(St-Jacques et al., 1999). 
 F G F signalling: The fibroblast growth factors (FGFs) are a family of secreted 
polypeptides that acts through four related tyrosine kinase receptors (Fgfr1-Fgfr4) to 
regulate a plethora of developmental processes, and they are critical for the control of 
endochondral and intramembranous ossification (Ornitz and Marie., 2002). Both FGF 
ligands and FGF receptors have a demonstrated role in osteogenic differentiation (Chen 
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and Deng., 2005; Ornitz., 2005; Jackson et al., 2006). For example, FGF-2 has been shown 
to induce alkaline phosphatase activity in rat bone marrow precursor cells, and FGF-2,-4 
and -8 have been shown to induce Runx2 (Woei et al., 2007). Furthermore, FGF-9 can 
induce osteocalcin expression, and FGF-2, -9 and -18 are important in subsequent matrix 
mineralization. Regarding FGF receptors, FGFR1 plays a dominant role during osteogenic 
differentiation, and FGFR2 appears to function during both osteogenic proliferation and 
differentiation. Although FGFR3 has been shown to function primarily during 
endochondral ossification to control chondrocyte proliferation, recent evidence suggests it 
may also play a critical role in osteogenesis. FGFR4 is expressed in rudimentary 
membranous bone and localized to the osteoblasts, suggesting that it may also be an 
important regulator of osteogenesis and play a critical role in intramembranous ossification 
(Cool et al., 2002). 
Notch signalling: The Notch gene encodes a single pass transmembrane receptor 
that is activated by a membrane bound ligand. In mammals, four Notch receptors (Notch 1-
4) and five ligands (Delta-like1, Delta-like3, Delta-like4, Jagged 1 and Jagged 2) have 
been identified (Ehebauer et al., 2006; Chiba., 2006; Hurlbut et al., 2007). Notch 1 and 
Notch 2 are expressed by osteoblasts, while Notch 3 and Notch 4 have been identified in 
subgroups of the osteogenic lineage (Chau et al., 2009). Notch signalling regulates 
osteogenesis, although the mechanisms involved in this pathway are poorly understood 
(Tezuka et al., 2002; Sciaudone et al., 2003; Schnabel et al., 2002). Notch/TGF?????????????
???????????????????????????? ??????????-2 promotes osteogenic differentiation (Nobta 
et al., 2005), although a recent study demonstrated that Notch1 overexpression inhibits 
????????????? ??? ??????????? ?????-catenin but not BMP signalling (Deregowski et al., 
2006). 
Ephrin signaling: Ephrins have the capacity for bidirectional signalling. That is, 
when a cell expressing an ephrin receptor contacts a cell expressing an ephrin ligand, 
signals are transduced into both the ephrin receptor-expressing cell (forward signalling) 
and the ephrin ligand-expressing cell (reverse signalling). There are two classes of ephrins, 
the B class (ephrin B1 to B3) are ligands for EphB tyrosine kinase receptors (B1 to B6), 
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whereas class A ephrins (A1 to A5) are ligands for GPI-anchored EphA receptors (A1 to 
A10) (Mundy and Elefteriou., 2006). In bone biology, ephrinB and EphB receptors control 
patterning of the developing skeleton (Compagni et al., 2003). Zhao et al. suggested that 
ephrin signalling is critical to the two-way communication between osteoclasts and 
osteoblasts (Zhao et al., 2006). This bidirectional signalling is mediated by transmembrane 
ephrinB2 ligand in osteoclasts and EphB4, a tyrosine kinase receptor, in osteoblasts. 
EphB4 expression is constitutive and the forward signalling through EphB4 induces 
osteogenic regulatory factors, such as Dlx5, Osterix, and Runx2, in calvarial osteoblasts, 
suggesting that EphB4 ia at the top of the regulatory cascade during osteoblast 
differentiation (Huang et al., 2007). 
Wnt signalling: The Wnt family consists of a large number of secreted 
glycoproteins (Cadigan and Nusse., 1997; Woderz and Nusse., 1998; Logan and Nusse., 
2004). The Wnt pathway plays an important role in embryonic development, tissue 
induction and axis polarity (Cadigan and Nusse., 1997; Croce and McClay., 2006; Luo et 
al., 2007).  As described in detail below, Wnt plays an important role in skeletal 
development and osteoblast differentiation (Fischer et al., 2002; Wang and Wynshaw-
Boris., 2004; Gregory et al., 2005). 
 
Wnt signaling: a critical pathway for bone differentiation 
Discovered in 1980s, the Wnt (Wingless and int-1) signaling cascade is involved in 
embryonic development and homeostasis, through regulation of cell proliferation, 
differentiation, and apoptosis (Rubinfeld et al., 1993; Su et al., 1993). Besides, it has been 
well established that Wnt signaling plays an integral role in many physiologic and 
pathologic processes, such as various types of cancer (Polakis., 2000; Reya and Clevers., 
2005), Al????????????????????????????????????????????????????????????????????????????????
and bone disorders (Wagner et al., 2011). 
Wnt genes encode a family of approximate 20 cysteine-rich secreted glycoproteins, which 
interact with cell surface receptors and trigger a cascade of intracellular events. Cell 
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signaling cascades provoked by Wnt proteins have been highly conserved across species, 
including Caenorhabditis elegans, Drosophila melanogaster, Zebrafish, Xenopus laevis, 
chicken, mouse, and human (Behrens., 2000). There are three distinct pathways through 
which Wnt signaling can be transduced???????????-catenin or canonical pathway, a planar 
cell polarity pathway and a Ca2+/Protein kinase A pathway (see F igure 2). The best studied 
of the pathways is the so-called canonical Wnt payhway. Activation of the canonical 
pathway is initiated when Wnt proteins, such as Wnt 1, Wnt 3a, or Wnt 8, bind to the 
Frizzled (Frz) receptors, seven-span transmembrane receptor proteins, and co-receptor 
LRP5/6 (low-density lipoprotein-receptor-related protein 5/6), activating the associated 
kinases, which in turn phosporylates the intracellular protein disheveled (Dvl). Activation 
of Dvl inhibits glycogen synthase kinase 3 ? (GSK3?), resulting in subsequent 
stabilization of ?-catenin (Chen and Alman., 2009). Stabilized ?-catenin then translocates 
to nucleus and forms a transcriptional complex with lymphoid-enhancer binding factor 
(Lef)/T-cell specific transcription factors (Tcfs) to regulate target gene expression 
(Westendorf et al., 2004). Examples of the ? catenin/Tcf target genes include c-Myc, cyclin 
D1 and ????? (Clevers., 2006; He et al., 1999; Tetsu and McCormick., 1999). 
In the absence of Wnt ligands, a complex consisting of GSK3?, Axin and adenomatous 
polyposis coli (APC), phosphorylates the N-terminal of ?-catenin and initiates its 
proteosomal degradation (Kubota et al., 2009; Piters et al., 2008). 
The non-canonical Wnt pathways, which occur independently of ?-catenin, include the 
calcium dependent and cell polarity pathways. Well characterized non-canonical Wnts 
include Wnt 5a and Wnt 11 (Rao and Kuhl., 2010). The calcium-dependent Wnt pathway 
plays important roles in embryonic development, cell migration and motility, and possibly 
tumor suppression (Piters et al., 2008; Torres et al., 1996). In the calcium-dependent Wnt 
pathway, the Wnt ligands bind to Frz receptor and trigger intracellular calcium release by 
heterotrimeric G protein stimulation. The released intracellular calcium activates protein 
kinase C (PKC) or calcineurin (CaCN), which then turns on transcription factors Elk-1 and 
NFAT (Kuhl., 2004). The cell polarity pathway functions through Frz receptors, activating 
Rho and Rac, which lead to c-jun NH2 terminal kinase (JNK) activation (Davis., 2000). 
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This pathway may modify the actin cytoskeleton, while also plays a role in cell 
proliferation, differentiation, and apoptosis (Chen and Alman., 2009; Habas et al., 2003). 
 
 
 
Figure 2. Schematic representation of Wnt signaling pathways. Wnt ligands can activate either the 
canonical pathway (through ?-catenin) or the non-canonical pathway (through Ca++ signaling or Rac/Rho 
pathway) to achieve distinct biological functions. (font: Wagner E.R., Zhu G., Zhang B.Q., et al. (2011). The 
therapeutic potential of the Wnt signaling pathway in bone disorders. Curr Mol Pharmacol., 4(1):14-25). 
 
 
Wnt signaling is tightly controlled by several groups of negative regulators that interfere 
acting either outside and within the cell. Extracellular inhibitors of the Wnt proteins 
include Wnt Inhibitory Factors (WIFs), Dickkopfs (Dkks), secreted frizzled-related 
proteins (SFRPs), Kremen1 and 2 (Krm 1/2), and Sclerostin (Sost). These regulatory 
molecules act by either binding the Frz (SFRPs) or LRP 5/6 (Sclerostin, Dkks, Krm) 
receptors to prevent Wnt association, or by directly binding the Wnt proteins (WIFs) 
(Piters et al., 2008). Dkk 1 and Dkk 2 are secreted proteins that bind to the LRPs, leading 
to a cross-linking and internalization of receptor (Clevers., 2006). Intracellular inhibitors 
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include the GSK3?-Axin-APC complex and Chibby (Cby). Cby competes with Tcf/Lef-1 
to block ?-catenin signaling (Takemaru et al., 2003). This nuclear control involves 
modifying the Tcf and Lef transcription factors in the Wnt signaling cascade (Cavallo et 
al., 1998; Semenov et al., 2005). The activity of Wnts is not only regulated by the 
components in signaling pathways, but also regulated by extracellular factors, specifically 
heparin sulfate proteoglycans. By binding to Wnt ligands at different affinity, heparin 
sulfates fine-tune the access of Wnts to Frz receptors and regulate various processes, like 
proliferation and differentiation of MSCs as well as progenitors in certain lineage such as 
osteoprogenitors (Manton et al., 2007a; Cool and Nurcombe., 2006; Dombrowski et al., 
2009). The antagonist regulation of the Wnt cascade is critical in a variety of disease 
processes, and therefore, has tremendous potential in therapeutic regimens. 
 
Wnt signaling in MSCs 
Wnt signaling plays a vital role in the regulation of proliferation and differentiation of 
MSCs. Etheridge et al. demonstrated that MSCs express a number of Wnt ligands, 
including Wnt2, Wnt4, Wnt5a, Wnt11 and Wnt16 and several Wnt receptors, including 
FZD2, 3, 4, 5 and 6 as well as various co-receptor and Wnt inhibitors (Etheridge et al., 
2004). Studies have suggested canonical Wnt signaling  keeps stem cells in a self-renewing 
and undifferentiated state. Exogenous application of Wnt3a to cell cultures expands the 
multipotential population of MSCs as well as human adipose-derived stem cells as a result 
of both increased self-renewal and decreased apoptosis.  (Boland et al., 2004; Cho et al., 
2006; Ling et al., 2009). Moreover, the overexpression of LRP5, has been reported to 
increase proliferation of MSCs (Baksh et al., 2007). Conversely, Wnt5a, by activating the 
non-canonical ??????????????????????????????-catenin/Tcf signaling, leading to a decline of 
both the level of cyclin D1 and the proliferation rate of MSCs (Baksh et al., 2007; Baksh 
and Tuan, 2007). However, canonical Wnt signaling has also been reported to inhibit 
human MSCs proliferation in an autocrine or paracrine fashion (Qiu et al., 2007). 
Supportively, Dkk1, is required for the arrested human MSCs to re-enter into cell cycle 
and subsequent proliferation through antagonizing canonical Wnt signaling (Gregory et al., 
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2003). Interestingly, one study has revealed that canonical Wnt signaling stimulates human 
MSCs proliferation at low dose while inhibits it at high dose (De Boer et al., 2004b). This 
dual effect of Wnt signaling suggests the intensity of Wnt signals can lead to different or 
even opposite biological functions. Furthermore, these controversial findings about the role 
of canonical Wnt signaling in MSCs self-renewal may also come from the difference in 
culture conditions and manipulation of the cells. 
Recently, Quarto et al. (Quarto et al., 2010) reported that Wnt3a has differential effects 
when using different in vitro models and an in vivo model of bone regeneration; the effects 
were dependent on the dose as well as the differentiation state of the recipient cell. When 
added to undifferentiated MSCs, Wnt3a inhibited osteogenic differentiation. By contrast, 
when added to calvarial osteoblasts, Wnt3a at high doses had an inhibitory effect in cells 
from juvenile mice but induced bone production in cells from adult animals, as assessed by 
alkaline phosphatase activity and Alizarin red mineralization assay. The defect repair was 
influenced once again both by Wnt3a dose and by the age of the animal, mimicking the in 
vitro results. These findings are in accordance with previous investigations (Kahler and 
Westendorf., 2003; Kahler et al., 2006; Eijken et al., 2008; Kahler et al., 2008), showing 
that the effect of canonical Wnt signaling on osteogenesis is influenced by the 
differentiation stage of target cells. Overall, the canonical Wnt signaling appears to 
stimulate the differentiation of MSCs committed to osteogenic lineage, while it inhibits the 
terminal differentiation of mature osteoblasts. 
 
Wnt signaling in bone 
The canonical and non-canonical Wnt signaling pathways play an important role in bone 
metabolism and osteogenesis, and contribute to osteogenic pathologies, as shown in both 
animal studies and genetic disorders in humans. The first indication that Wnt signaling 
play a critical role in bone formation came from human studies performed in the Wnt co-
receptor LRP5. 
Loss-of-function mutations in LRP5 was found to associate with osteoporosis-
pseudoglioma syndrome (OPPG), an autosomal recessive disorder, characterized by 
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blindess, low bone mineral density and skeletal fragility (Gong et al., 2002). Similar results 
have been seen in LRP5 knockout mice, where, a significant reduction in bone matrix 
deposition was observed, although expression of Runx2 and osteocalcin was not affected, 
suggesting that LRP5 deletion affects osteoblast function not osteoblast differentiation 
(Kato et al., 2002). In contrast, mutations in the N terminus of human LRP5 (e.g. G171V) 
that reduce affinity of LRP5 for Dkk1, was found to associate with high bone mass (Ai et 
al., 2005; Boyden et al., 2002). Also mice that overexpress the G171VLRP5 mutant in 
osteoblast have enhanced osteoblast activity, reduced osteoblast apoptosis, and a high bone 
mass phonotype reminiscent of that observed in human with this mutation (Babij et al., 
2003). 
The role of LRP6 is analogous to that of LRP5 in initiating the Wnt signaling pathway. A 
mutation in the LRP6 gene in humans leads to osteoporosis and other metabolic 
abnormalities (Mani et al., 2007). In mice, a spontaneous missense mutation in the LRP6 
gene leads to defects in somitogenesis and reduced bone mass in adults (Kokubu et al., 
2004). Null mutations in the LRP6 gene lead to prenatal lethality secondary to truncated 
distal limb and axial skeletal structures (Williams and Insdogna., 2009; Pinson et al., 
2000).  
Although a few attentions have been paid to the Wnt ligands, there appears to be some 
associations of the extracellular Wnt agonists with metabolic abnormalities. Some Wnts 
including Wnt7b, Wnt10b, and Wnt5a are shown to function in bone homeostasis mice. 
Wnt7b is expressed in osteoblasts, and its expression is elevated along with osteoblast 
differentiation (Hu et al., 2005; Li et al., 2005). Removal of Wnt7b in skeletal progenitor 
cells using Dermo1-Cre mice results in defects in chondrogenesis and osteoblastogenesis 
(Tu et al., 2007). Wnt10b promotes osteoblast differentiation by induction of the 
osteoblastogenic transcription factors Runx2, Dlx5 and Osterix and suppression of the 
adipogenic transcription factors CCAAT/enhancer-binding protein-a (C/EBPa) and 
peroxisome proliferator-activated receptor-c (PPARc) (Bennett et al., 2005; Kang et al., 
2007). Overexpression of Wnt10b using the osteocalcin promoter in mice increases bone 
mass by stimulating osteoblastogenesis (Bennett et al., 2007). Wnt10b-/- mice have 
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decreased trabecular bone with reduced bone formation rate (Bennett et al., 2005; Bennett 
et al., 2007). Wnt5a+/- mice have low bone mass with enhanced adipogenesis and reduced 
osteoblastogenesis in bone marrow mesenchymal progenitors (Takada et al., 2007). 
As an important mediator of the canonical Wnt signaling pathway, ?-catenin is crucial in 
bone formation and regeneration (Krishnan et al., 2006). Deletion of ?-catenin in 
mesenchymal precursors of chondrocytes and osteoblasts, using Dermo1-Cre mice and 
Prx1-Cre mice, blocks osteoblast differentiation and causes ectopic formation of 
chondrocytes during both intramembranous and endochondral ossification. In the absence 
of ?-catenin, the expression of collagen I, osterix, and osteocalcin is greatly diminished, 
??????????? ????? ??-catenin is required for osteoblast differentiation in early stages (Hu et 
al., 2005; Day et al., 2005; Hill et al., 2005). In mature osteoblasts, ?-catenin plays another 
important function. Inactivation of ?-catenin in osteoblasts using a1 (I) collage-Cre mice 
leads to low bone mass caused by increased bone resorption through decreased expression 
of osteoprotegerin (Opg) (Glass et al., 2005). In addition, loss of ?-catenin using 
osteocalcin-Cre mice severe osteopenia with increases in osteoclasts (Holmen et al., 
2005). In vitro, osteoblasts lacking ?-catenin exhibited elevated expression of Rankl and 
diminished expression of Opg. These findings suggest that ?-catenin in mature osteoblasts 
regulates osteoclastogenesis and osteoclast function. 
Some extracellular proteins which function as antagonist of Wnt signaling, such as 
sclerostin, Dkks, SFRPs and axin are involved in the development of skeletal tissues. 
Sclerostin (Sost) is a protein secreted by osteocytes that binds to and blocks Wnt binding to 
co-receptors LRP5/6, leading to inhibiting osteogenic differentiation (ten Dijke et al., 
2008). During bone remodeling, osteocytes regulate bone formation by expressing 
sclerostin to complete a negative feedback cycle of Wnt signaling in mature osteoblasts 
(van Bezooijen et al., 2005). Furthermore, mechanical stimulation of long bones reduces 
the expression of sclerostin and enhances bone formation, while mechanical unloading 
increases the sclerostin antagonistic effects and diminishes bone strength (Lin et al., 2009; 
Moustafa et al., 2009). In addition, sclerostin represents one of the best documented 
examples that offer a link between Wnt antagonists and specific pathologies. The 
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autosomal recessive diseases Sclerostosis and Van Buchen disease form secondary to 
homozygous mutations of Sost encoding the secreted protein sclerostin (Balemans et al., 
2001; Brunkow et al., 2001). These disorders are associated with a progressive increase in 
bone mass, hyperostotic skeleton and increased bone mineral density (Li et al., 2008). 
Sclerostin is directly involved in the regulation of osteoblastic differentiation through the 
antagonism of the Wnt signaling pathway (Li et al., 2008). Furthermore, specific 
polymorphisms of the Sost promoter have been implicated in osteoporosis (Huang et al., 
2009).  
Another group of extracellular regulators are the Dkk proteins, which play an important 
role in regulating bone matrix mineralization through the Wnt pathway. Dkk1-/- mice die 
because of failure of head induction (Mukhopadhyay et al., 2001). Dkk1-/- mice are viable 
and exhibit an high bone mass (HBM) caused by an increase in bone formation without 
any changes in bone resorption (Morvan et al., 2006). Mice overexpressing Dkk1 in 
osteoblasts develop osteopenia because of reduced osteoblast number and bone formation 
(Li et al., 2006). Unexpectedly, Dkk2-/- mice are osteopenic with increased osteoid and 
impaired mineralization. They display enhanced osteoclastogenesis with the upregulation 
of Rankl expression (Li et al., 2005), indicating that Dkk2 affects both bone formation and 
bone resorption. 
Although the antagonists to LRP 5/6 co-receptors are well established in their osteogenic 
regulatory roles, the Frizzled receptor antagonists play a key function in osteogenesis and 
osteogenic pathologies. Osteogenic abnormalities are associated with SFRPs, as increased 
incidence of hip osteoarthritis has been associated with alterations of the Sfrp gene 
(Loughlin et al., 2004). Sfrp1 knockout mice exhibit increased trabecular bone volume. 
The deletion of Sfrp1 inhibits osteoblast lineage cell apoptosis in vivo and increases 
osteoclastogenesis in vitro (Bodine et al., 2004). Furthermore, deficiencies in both 
sclerostin and Sfrp1 result in increased bone mass (Hartmann., 2006; Li et al., 2005). 
Also the Axin-?????-APC complex has been shown to play a role in osteogenesis. Axin 
mutations lead to both osteogenic and chondrogenic abnormalities as familial tooth 
agenesis has been linked to Axin2 mutations (Lammi et al., 2004). Through the activation 
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of the ?-catenin signaling pathway, Axin2 knockout mice present with increased osteoblast 
proliferation, craniosynostosis, increased chondrocyte differentiation, reduced limb length, 
and increased bone mass phenotypes (Dao et al., 2010; Yan et al., 2009; Yu et al., 2005). 
GSK3? also regulates osteogenesis, as GSK3?  inhibitors, such as lithium, are able to 
increase bone density and enhance osteoblast differentiation (Clement-Lacroix et al., 2005; 
Kulkami et al., 2006). Mice heterozygous for Gsk3? alleles exhibit increased bone mass 
(Kugimiya et al., 2007). 
 
Cross-talk between Wnt signaling and other pathways 
The differentiation of osteoblasts from the mesenchymal progenitors is a complex process, 
which remains to a great extent an unknown cascade of complex biological events, 
particularly at the interactions between various intracellular and extracellular molecular 
signaling pathways. Many signaling pathways are involved in osteoblast differentiation, 
such as the Wnt/?-catenin pathway, BMP/Smad pathway, Hedgehog pathway, and Notch 
????????????? ????????? ??????? ??????????? ??? ???????????? ???? formation, the crosstalk 
between Wnt and BMP pathway during chondrogenic or osteogenic differentiation has 
received increasing attentions. 
??????????????????????????????????????????????????????????????-catenin and BMP-2 synergize 
to promote osteoblastic differentiation such induction of ALP activity (Mbalaviele et al., 
2005). In addition, BMP-2 enhances ?-catenin-induced transcriptional activation of the 
osteoprotegerin (OPG) promoter, while the OPG gene promoter functionally interacts with 
?-catenin/Tcf-1 in cooperation with Smad1/4, and these complexes then cooperate to 
regulate graded expression of OPG (Sato et al., 2009). Chen et al. recently demonstrated 
that in cultured osteoblasts that had been treated with BMP-2, several Wnt ligands (e.g., 
Wnt-7a, Wnt-10b) and their receptors (e.g., Fz-1, LRP-10) were upregulated at their 
mRNA level, together with an increased ?-catenin-mediated Tcf-dependent transcription 
(Chen et al., 2007b). Intramuscular implantation of BMP-2 in mice caused a highly 
expressed ?-catenin and resulted in ectopic endochondral ossification. In another study, 
Fischer et al. demonstrated that BMP-2 treatment upregulates expression of Wnt- 3a and ?-
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catenin in C3H10T1/2 cells, whereas overexpression of Wnt-3a in this cell lines not only 
increases total and nuclear levels of both ?-catenin and Lef-1, but also leads to enhanced 
BMP-2-mediated chondrogenesis, an early stage during endochondral ossification and 
fracture healing. Interestingly, in response to BMP-2, both nuclear levels of Smad-4 as 
well as the interaction between Smad-4 and ?-catenin are enhanced upon BMP-2 
treatment, thus providing a direct mechanism for a crosstalk between Wnt and BMP-2 
pathway (Fischer et al., 2002a). 
Hedgehog (Hh) signal is another pathway that is crucial to embryonic skeletogenesis (Day 
and Yang., 2008). It has been shown that Wnt signaling controls Hh signal transduction 
through its regulation of Gli2 and Gli3, the key mediators to transduce Hh signals (Ogden 
et al., 2004), and provides a synergistic effect on surface ectoderm/neural tube and 
notochord signaling in somite cell specification (Borycki et al., 2000). 
Notch pathway is also involved in embryonic skeletogenesis. Among Notch ligands genes, 
JAG-1 gene is predicted as an evolutionarily conserved target of the canonical Wnt 
signaling pathway based on the conservation of double Tcf/Lef-????????????????????????????
promoter region of mammalian JAG-1 orthologues (Katoh., 2006). Additionally, when 
expressed in osteoblast cell line (MC3T3), the notch intracellular domain (NICD) impaired 
differentiation and blocked expression of Tcf/Lef-1 target promoter, thus resulting in 
inhibition of the canonical Wnt pathway (Sciaudone et al., 2003). 
 
Transcriptional factors involved in bone differentiation 
Osteoblast commitment, differentiation, and functional activity are all governed by several 
regulatory signalling pathway, as mentioned above, and specific transcription factors that 
promote expression of phenotypic genes and establishment of the osteoblast phenotype 
(see F igure 3). Regulatory factors that influence various aspects of osteoblast biology can 
be divided into five major categories (Javed et al., 2010). These include (1) cis-acting 
DNA binding transcription factors such as Runx2, Osterix, Sox9, Lef/Tcf transcription 
factors, C/EBPs, ATF4, NFATc, AP-1, Dlx5, Smads and Twist (Javed et al., 2010; Javed 
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et al., 2008; Yang et al., 2004) ; (2) signal transducers and non-DNA binding coregulatory 
proteins, such as Satb2, Cbf???????????????????????? et al., 2002; Dobreva et al., 2006; 
Javed et al., 2000; Kim et al., 2003); (3) posttranslational regulatory proteins, such as 
Shn3, WWP1, Smurf1, CHIP and Schnurri-3 (Jones et al., 2006, Li et al., 2008); (4) 
chromatin-modifying enzymes, such as p300 acetyltransferase and histone deacetylase 
(Vega et al., 2004; Lian et al., 2004); (5) chemokines such as such as MCP-4/CCL13, 
PARC/CCL18, Mig/CXCL9, SDF-1/CXCL12, and MCP-1/CCL2 (Iwamoto et al., 2008). 
Only some of the osteoblastic regulatory factors just mentioned, will be taken into account 
in this thesis. 
 
Figure 3. Control of osteoblast differentiation by transcription factors. Osteoblast differentiation starts with 
the commitment of osteoprogenitor cells from mesenchymal cells, their differentiation into immature and 
more mature functional osteoblasts expressing osteoblast phenotypic genes, and ends by becoming 
osteocytes within the bone matrix, or cell death for a fraction of osteoblasts. The indicated transcription 
factors control osteoblastogenesis in a time and space coordinated way. Transcription factors themselves are 
tightly regulated by the indicated multiple proteins acting positively or negatively on their expression or 
transcriptional activity to modulate osteoblast gene expression. (font: Marie P.J. (2008). Transcription factor 
controlling osteoblastogenesis. Archives of Biochemistry and Biophysics 473:98?105). 
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Runx2 
Runx2 (CBFA1, AML3), an essential factor for bone and hypertrophic cartilage formation, 
is a member of the Runt family of transcription factors that is expressed by mesenchymal 
cells at the onset of skeletal development and is present in osteoblasts throughout their 
differentiation. Although Runx2 is the most abundant factor in mature osteoblasts, Runx2 
and Runx3 are also present in osteoblast lineage cells (Lian et al., 2004). Runx2 was found 
to control bone formation during both skeletal development and post-natal life (Karsenty 
and Wagner., 2002). Molecular studies and genetic manipulation of Runx2 in vivo 
indicated that the expression of Runx2 is both necessary and sufficient for mesenchymal 
cell differentiation towards the osteoblast lineage (Karsenty and Wagner., 2002; Komori., 
2006). Runx2 invalidation inhibits the differentiation of mesenchymal cells into osteoblasts 
(Ducy et al., 1997; Komori et al., 1997). Consistently, Runx2 haploinsufficiency in 
humans results in cleidocranial dysplasia, a disease characterized by defective bone 
formation (Lee et al., 1997; Otto et al., 1997). 
As a member of the Runx family of transcription factors, Runx2 operates in bone lineage 
cells by binding to the Runx consensus sequence (PuACCPuCA), first named the 
osteoblast specific element (OSE2). The Runx regulatory element can be found in the 
promoter of all major osteoblast genes controlling their expression, including type I 
collagen alpha 1 chain, osteopontin, bone sialoprotein and osteocalcin, resulting in the 
establishment of an osteoblast phenotype. In addition to control osteoblast differentiation, 
Runx2 was found to negatively control osteoblast proliferation by acting on the cell cycle 
(Pratap et al., 2003). Recent studies indicate that Runx2 interacts with several regulatory 
proteins within the nuclear architecture, resulting in activation or repression of genes 
which control the program of osteoblast proliferation and differentiation (Stein et al., 
2004). Despite its important role in osteoblast commitment, Runx2 is not essential for the 
maintenance of the expression of the major bone matrix protein genes in mature 
osteoblasts (Maruyama et al., 2007). Mice overexpressing Runx2 exhibit osteopenia, as a 
result of reduced number of mature osteoblasts, indicating that Runx2 negatively controls 
osteoblast terminal differentiation and maintain osteoblastic cells in an immature stage 
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(Liu et al., 2001). Thus, Runx2 can act differently at multiple levels to control osteoblast 
differentiation and bone formation. As expected from the important role of Runx2 in 
osteoblastogenesis, both expression and activity of Runx2 are tightly controlled by 
transcription factors, protein?DNA or protein?protein interactions. Notably, Runx2 is 
controlled by Hoax2, a member of the Hox homeodomain family of transcription factors 
that regulate skeletal patterning, inhibiting Runx2 expression and thereby bone formation 
(Dobreva et al., 2006). SATB2, a nuclear matrix protein, represses Hoxa2 expression and 
thereby activate Runx2-dependent osteoblast differentiation (Dobreva et al., 2006). Other 
complex mechanisms can negatively regulate Runx2 expression. The transcription factors 
Stat1 and Sox9 interact with Runx2 and blunt its transcriptional activity (Kim et al., 2003; 
Zhou et al., 2006). In particular, Stat1 exerts its inhibitory effect mainly, if not exclusively, 
in the cytoplasm. In addition, it has been demonstrated that the loss of inhibition of Runx2 
activity by Stat1 results in increased bone mass in the adult Stat1-/- mice without affecting 
bone formation during the developmental period, suggesting that Stat1 is selectively 
involved in the Runx2 regulation in bone remodeling at the postnatal stage (Kim et al., 
2003). Runx2 activity is also positively controlled by transcriptional activators such as Rb, 
TAZ, HOXA10 or BAPX-1 (Tribioli and Lufkin., 1999; Hassan et al., 2007; Luan et al., 
2007; Hong et al., 2005). It can be phosphorylated and activated by the mitogen-activated 
protein kinase (MAPK) pathway by binding of type I collagen to alpha2beta1 integrins on 
the osteoblast surface (Xiao et al., 2000). CBFb1 is the most important co-activator of 
Runx2 which is required for Runx2-dependent bone formation (Miller et al., 2002; 
Kanatani et al., 2006). Runx2 directly interacts ????? ????????? ????????? ?? ?????? ??? ???
estrogen-dependent manner, and the interaction enhances Runx2 activity (McCarthy et al., 
2003); but Runx2 seems to suppress ???????? promoter activity in osteoblasts (Lambertini 
et al., 2007). Another important regulator of Runx2 activity is its interaction with signal 
transducers of transforming growth factor beta superfamily receptors, Smads. Runx2 
functions synergistically with Smad1 and Smad5 to regulate bone-specific genes (Lee et 
al., 2000; Zhang et al., 2000). The importance of the Runx2-Smad complex in driving 
osteoblastogenesis has been demonstrated both in vitro and in vivo (Phimphilai et al., 
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2006; Javed et al., 2008). In addition to these important mechanisms controlling Runx2, 
other transcriptional coactivators of Runx2, such as C/EBPb, C/EBPd and Menin have 
been identified (Westendorf., 2006). Interestingly, recent studies showed that Runx2 
interacts with factors with histone acetyl transferase activity such as p300, allowing a tight 
control of transcriptional activity by a balance between acetylation and deacetylation of the 
chromatin (Westendorf., 2006). Finally, Runx2 regulation also occurs at the level of 
protein stability. Smurf1 and Schnurri-3 interacts with the Runx2 protein promoting its 
degradation (Zhao et al., 2004; Jones et al., 2006). 
 
Lef/Tcf t ranscription factors 
Human and mouse Lef1/Tcf family members are encoded by four genes: Tcf1 (Tcf7), Lef1 
(Tcf1a), Tcf3 (Tcf7L1), and Tcf4 (Tcf7L2). As mentioned above, Lef1/Tcf transcription 
factors are nuclear high mobility group (HMG) proteins that mediates gene transcription in 
???????????????????????????-catenin signalling pathway (Westendorf et al., 2004; Barker., 
2008; Leucht et al., 2008). These factors are involved in many processes occurring both in 
embryonic and adult tissues. In particular, experiments performed in mutant mice have 
allowed to demonstrate the involvement of these factors in the regulation of skeletal 
development and bone homeostasis. Tcf1 null mice exhibit a low bone mass with an 
increased in Osteoprotegerin expression and in osteoclast number, while osteoblast 
number and function are not altered. These findings are similar to those in osteoblast-
specific ?-catenin-deficient mice (Glass et al., 2005). Lef1-deficient mice are smaller than 
wild type mice and die shortly after birth (van Genderen et al., 1994). A mouse model 
expressing a mutant form of Lef1 lacking the HMG domain (Lef1-?????????????? several 
skeletal abnormalities, mostly associated with skeletal patterning (Galceran et al., 2004). In 
addition, an age- and gender-dependent role for Lef1 in regulating bone mass phenotype 
and  turnover  in vivo, has recently been described (Noh et al., 2009). 
Controlling the development and homeostasis of bone tissue, the Wnt signaling pathway, 
and in particular their effectors Lef1/Tcf proteins, directly interact with other proteins 
involved in the regulation of osteoblastogenesis. It was demonstrated that osteoblast-like 
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cell lines treated with differentiation-inducing factor-1 (DIF-1), show a significant 
reduction of alkaline phosphatase (ALP) reporter gene activity through a specific Lef/Tcf 
?????????????????????????????? ????-catenin signaling affects ALP expression (Matsuzaki et 
al., 2006). Furthermore Lef1 is reported to up-regulate the expression of Col11a1 (Kahler 
et al., 2008) and Runx2 (Gaur et al., 2005). On the contrary, Kahler and Westendorf found 
that Lef1 binding to Runx2 through the Lef1 HMG domain, represses Runx2-induced 
transcription of the osteocalcin promoter. (Kahler and Westendorf, 2003). Lef1, 
suppressing the activity of Runx2, prevents the expression of this gene in the early stages 
of osteoblast maturation. In addition, it has been showed that osteoblasts with reduced Lef1 
expression mineralize at an accelerated rate while osteoblasts over expressing Lef1 do not 
mineralize (Kahler et al., 2006).  
 
Sox9 
Sox9 is a member of the Sox gene family characterized by high?mobility-group-box DNA 
binding motif related to that of the sex determining factor SRY. Normally, Sox9 is 
expressed predominantly in mesesnchymal progenitor cells and in proliferating 
chondrocytes, but not in hypertrophic chondrocytes and osteoblasts (Zhao et al., 1997). 
The malfunction of Sox9 results in campomelic dysplasia (CMD1), which is a semilethal 
osteochondrodysplasia, characterized by skeletal anomalies that include bending of the 
long bones and XY sex reversal (Sock et al., 2003; Giordano et al., 2001). Sox9 is a potent 
transcriptional activator for chondrocyte-specific genes such as ???????????? ???????? 
(Lefebvre et al., 1997), ?????? (Bridgewater et al., 1998), or aggrecan (Sekiya et al., 
2000) genes by binding to their enhancer sequences. Nevertheless, it requires the activity 
of two other Sox family members, L-Sox5, the large Sox5 isoform and Sox6 in order to 
transform cells into early chondrocytes the so-called chondroblasts (Hartmann., 2009). 
Sox5 and Sox6 are present after cell condensation (Smits et al., 2001; Akiyama et al., 
2002), are highly related, coexpressed with and regulated by Sox9, but belong to a 
different Sox family subgroup (Lefebvre and Smits., 2005). In addition to its well 
established role as transcriptional activator for chondrogenesis, Sox9 also acts as a 
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transcriptional repressor for osteoblast differentiation and chondrocyte hypertrophy in part 
via inhibition of Runx2 transactivation of its target genes. (Zhou et al., 2006). The precise 
mechanisms involved in this process are unclear; however, some evidences have shown 
that Sox9 promoted the degradation of Runx2, directing it toward lysosomal degradation 
(Zhou et al., 2006). Sox9 can repress the expression of Runx2 in chondrocytes also 
indirectly, through the transcription factor Nkx3.2/Baxp1 (Yamashita et al., 2009). This 
indicates that Sox9 regulated Runx2 through a variety of mechanisms both 
transcriptionally and posttranscriptionally. Moreover, Eames et al, demonstrated by 
retroviral injection experiments in chicken embryos that Sox9 misexpression repressed 
Runx2 function and diverted cell fate from bone to cartilage in the craniofacial region 
(Eames et al., 2004). In a Sox9 knockin mouse model in which Sox9 was overexpressed in 
proliferating chondrocytes during endochondral ossification, osteoblast differentiation was 
also delayed (Akiyama et al., 2004). Interestingly, mouse genetic studies showed that 
Sox9-expressing precursor cells could eventually differentiate into tendons and osteoblasts 
(Akiyama et al., 2005). Cheng and Genever, found that Runx2 inhibited the transactivity of 
Sox9, which is consistent with the findings that Sox9 is expressed in mature osteoblasts 
(Akiyama et al., 2005) and provides a mechanism whereby the expression level of Sox9 
may be maintained but its transactivity repressed by Runx2 during the process of 
osteogenic differentiation in MSCs (Cheng and Genever., 2010). 
 
C X C L12 
CXCL12, also known as stromal cell-derived factor-1 (SDF-1), is a member of the CXC 
chemokine family (Shirozu et al., 1995; Zlotnik and Yoshie., 2000), wirh several isoforms 
that vary in the number of amino acid extensions at the carboxyl (C) terminus (Yu et al., 
2006). CXCL12 signals through its G-protein-coupled transmembrane receptor CXC 
chemokine receptor-4 (CXCR4) ??????????et al., 1997; Zlotnik and Yoshie., 2000); and a 
second receptor, CXCR7, was identified in several types of cells (Hartmann et al., 2008; 
Levoye et al., 2009). CXCL12 is constitutively expressed in various cell types (Baggiolini 
et al., 1997), including immature osteoblasts lining the bone endosteum, MSCs and 
 Osteogenic differentiation: molecular signaling pathways 
69 
 
endothelial cells (Ponomaryov et al., 2000; Lisignoli et al., 2006). Accumulated evidence 
suggests that constitutive and induced expression of CXCL12 is tightly regulated in 
different cells. Nevertheless, the molecular mechanisms involved in directing the correct 
levels of this chemokine remain unclear. Recently, a functional characterization of the 
CXCL12 gene promoter has been performed (Garcia-Moruja et al., 2005; Calonge et al., 
2010), and potential binding sites for transcriptional regulators including Sp1, AP2, HNF-
3, NF-X3, glucocorticoid receptor, NFAT, c-myb, c/EPB? and bHLH have been identified. 
CXCL12/CXCR4 signaling plays pleiotropic functions in organogenesis, developmental or 
pathologic angiogenesis, hematopoietic myeloid and lymphoid cell homing and 
differentiation, and  in tumorigenesis process (Rossi and Zlotnik., 2000; Kim et al., 2007; 
Chen et al., 2008). The important role of CXCL12/CXCR4 signaling in tumorigenesis was 
recently confirmed in pancreatic cancer, in which the abrogation of CXCR4 inhibited 
invasion-related genes and the invasive ability of cancer cells (Wang et al., 2008). 
Moreover this CXCL12/CXCR4 orientated chemotaxis regulates the homing into and 
retention of hematopoietic stem cells and MSCs within marrow microenvironments, as 
well as the metastatic colonization of bone and bone marrow by breast and prostate cancer 
cells (Lataillade et al., 2000; Majka et al., 2000). It has been highlighted that 
CXCL12/CXCR4 signaling finely modulates craniofacial development and both their 
knockdown and over-expression result in cranial neural crest cell migration defects and 
ectopic craniofacial cartilage formation (Olesnicky Killian et al., 2009). Concerning bone 
tissue, it has recently been suggested that this signaling is involved in the remodeling 
process (Ponomaryov et al., 2000; Dominici et al., 2009; Otsuru et al., 2008), has a critical 
role in the recruitment of MSCs to the fracture site during skeletal repair (Kitaori et al., 
2009), and is highly expressed and secreted by regenerating/proliferating osteoblasts after 
irradiation in mouse models (Dominici et al., 2009). Furthermore, CXCL12 has also been 
found to have a regulatory role in the osteogenic differentiation of murine MSCs. Zhu et 
al, (Zhu et al., 2007) reported that blocking of the CXCL12 signaling inhibited the 
progression of C2C12 cells towards osteoblastic cells in response to BMP-2 stimulation. 
Hosogane and co-workers (Hosogane et al., 2010) demonstrated that the perturbation of 
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CXCL12/CXCR4 signal in primary MSCs derived from human and mouse bone marrow, 
significantly reduced Runx2 and Osterix expression, affecting the differentiation of  MSCs 
towards osteoblastic cells in response to BMP-2 stimulation. Finally, Kitaori et al, (Kitaori 
et al., 2009) using mouse segmental bone graft models, found that CXCL12 recruits MSCs 
to bone repair sites during the early phase of bone endochondral repair, suggesting the 
importance that this chemokine may have to promote successful bone healing. 
 
As can be deduced from the evidences reported above, bone tissue homeostasis depends on 
the concerted actions of a plethora of signals that control osteoblast commitment, 
differentiation, and functions. Therefore, a better understanding of molecular mechanisms 
behind osteogenic differentiation and bone remodeling may help to identify the role of a 
specific transcription factor in mediating these processes and consequently, may help to 
discover new molecular targets to use in bone repair regenerative medicine and in the 
treatment of bone and skeletal diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Osteogenic differentiation: molecular signaling pathways 
71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Osteogenic differentiation: molecular signaling pathways 
 
72 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
AIM 
73 
 
A I M 
 
 
In recent years much attention has been paid to strategies enhancing bone regeneration in 
severe osteogenic abnormalities, such as critical sized defects, non-union fractures, and 
vertebral interventions, as well as in many pathological conditions (e.g. osteoporosis, 
osteoarthritis, and cancer metastases to the bone). The regeneration of bone is a 
multidisciplinary approach consisting of stem and progenitors cells, various types of 
scaffolds and different signaling pathways involved in the commitment of mesenchymal 
stem cells towards osteogenic lineage. These signals, that conveys in hormones, growth 
factors and transcription factors, are crucial for osteoblast differentiation, proliferation, 
functions and, consequently, ensure the proper bone modelling and remodeling.  
Among these factors, Wnt proteins have a critical role in bone development and 
homeostasis. 
Most downstream bone-specific target genes of this pathway are only partially known. 
Among these, Slug has been recently implicated in osteosarcoma progression as a Wnt-
responsive molecule strongly correlated with a loss of tumor suppressors such as E-
cadherin (Nieto., 2002; Conacci-Sorrell., 2003). To date, for what concerns bone tissue, 
Slug is considered exclusively a marker of malignancy, and there are no data about its 
expression and regulation in human normal osteoblasts. 
 
In order to identify new potential osteoblast-specific proteins, the aim of this thesis is 
addressed to explore a possible function of Slug in normal bone tissue by: 
 
- analyse Slug expression in human normal osteoblasts (hOBs) and in their 
mesenchymal precursors (hMSCs), obtained from bone marrow iliac crest, bone 
?????????????????????????? ???????????????????????????????Despite the difficulties of 
experimental set up, indeed, the use of a model obtained from human primary cells, 
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represents the chosen system for a detailed study of processes related to bone 
tissue, as it allows to mimic the physiological conditions that occur in vivo;  
- analyse Slug gene regulation in hOBs in relation to ?????-catenin signaling 
mediators and osteoblast regulators such as Runx2 transcription factor; 
- evaluate the role of Slug in hMSCs and hOBs in relation t?? ????-catenin signaling 
mediators and genes involved in the control of osteoprogenitors differentiation; 
- use experimental targeted strategies, such as siRNA approach or chemical 
compound (e.g. SB216763) administration, to identify the role of specific 
transcription factors, by modifying their expression levels. 
On the whole this study aims to investigate the role of Slug in the context of bone tissue, in 
order to identify a new potential therapeutic target for bone tissue repair and regeneration. 
In addition, and more generally, the work of this thesis aims to underline the concept that 
the appropriate manipulation of gene expression might affect cell behaviour leading to 
significant improvement in the efficiency of tissue engineering and enhancing the 
therapeutic value of stem cells/osteoprogenitors for the restoration of bone defects. 
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M A T E RI A LS A ND M E T H O DS 
 
 
 
Cell cultures 
Human cell lines 
Osteosarcoma cell line SaOS-2, osteoblast-like cells CAL72 and Hobit, and breast cancer 
cell lines MCF-7 and MDA-MB-231 were maintained in ????????????????????????????
St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (CELBIO EuroClone, 
??????? ???????? ???????????????? ????????????? ???????????? ?????????? ?????????????? ???? ???
???????????????????????????????midified atmosphere of 5% CO2. 
 
 
Human osteoblasts (hOBs) 
Craniofacial osteoblasts 
Human craniofacial osteoblast cells were obtained from bone samples collected during 
nasal septum surgery. Recruitment of subjects donating osteoblasts was in accordance with 
approved procedures, and informed consent was obtained from each patient. Bone samples 
were collected from patients that underwent septoplasty surgery, FESS or both procedures 
from June 2006 to February 2010 at the ENT Department of the University Hospital of 
Ferrara. This type of surgery consists in the exeresis of the lower part of the osseous nasal 
septum (this portion has been used in this study). This sampling is very handily and 
costless. 
Briefly, the bone samples, about 1 cm2 in size, were cut into small fragments that were 
washed several times in phosphate-buffered saline (PBS) (136 mM NaCl, 2.68 mM KCl, 
1.76 mM KH2PO4) to remove blood cells and debris with a final wash in culture medium. 
Fragments were then collected in culture flasks containing 6 ml of 1:1 mixture of 
??????????????? ?????? Aldrich, St. Louis, MO, USA) supplemented with 20% fetal 
bovine serum (FBS) (CELBIO EuroClone, Milan, Italy), 2 mM glutamine, 100 units/ml 
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penicillin, 100 mg/ml streptomycin, and 50 mg/ml ascorbate at 37°C in a humidified 
atmosphere of 5% CO2. After about 5-7 days, outgrowth of bone cells from the bone chips 
commenced, and confluency in 25 cm2 dishes was usually reached after 3-4 weeks. For the 
data here presented, only first and second passage cells were used. 
 
Tibial plateau osteoblasts 
Human osteoblasts were obtained from trabecular bone located in the inner portion of the 
tibial plateau of patients undergoing total knee replacement. The study was approved by 
the Istituto Ortopedico Rizzoli (Bologna, Italy) ethical committee and informed consent 
was obtained from each patient. Briefly, bone chips were removed from the tibial plateau, 
collected in a V-glass tube containing 1.5 ?????? ??????????????????????????????????
calcium (Gibco, Invitrogen Corporation, Paisley, Scotland, UK) and supplemented with 
15% FBS, antibiotics (100 U/ml penicillin and 100?g/ml streptomycin), 25 ?g/ml ascorbic 
acid, 4mM glutamine (Sigma-Aldrich, St Louis, MO, USA), and 2 mM calcium chloride 
(referred to as enzyme medium) according to the methods previously described  by Robey 
and Termine (Robey and Termine., 1985).  
 
 
Human mesenchymal stem cells (MSCs) 
Tibial plateau MSCs 
Human tibial plateau mesenchymal stem cells (hTP-MSCs) were isolated from bone 
marrow tibial plateau aspirates using Ficoll-Hypaque density gradient (d=1.077 g/ml) 
(Sigma, St Louis, MO, USA). Briefly, nucleated cells were collected at the interface, 
washed twice, suspended in ?-MEM supplemented with 15% FBS and penicillin G 
(Sigma), counted and plated at a concentration of 2X106 cells/T150 flask. After 48h non-
adherent cells were removed and the adherent MSCs expanded in vitro. 
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Iliac crest MSCs: Human bone-marrow mesenchymal stem cells were isolated from 
bone-marrow aspirates of the iliac crest (hIC-MSCs) and cultured as described for hTP-
MSCs. 
 
????????????????????? ??????????????????????????????????????????????hWJ-MSCs) 
????? ????????? ????? ?????????? ?????? ??? ?????? ?????????? ??rds collected from full-term 
???????? ?????? ????????? c??????? ???? ????????? ??? ???? ????????? ????????? ??? ??????????? ???
????????????????????????????, as previously described (Penolazzi et al., 2010). Harvesting 
procedures of ?????????? ?????? ????? ?????? ????????? cords were conducted in full 
??????????? ????? ???? ????????????? ??? ?????????? ??? ???????? ??? ???? ??th World Medical 
Assembly in 1964 successively revised in Edinburgh (2000) and the Good Clinical 
Practice guidelines. 
Cords were processed within 4 hours, and until that moment had been stored at 4°C in 
sterile saline. Typically, the cord was rinsed several times with sterile PBS before 
processing and was cut into pieces, 2-4 cm in length. Blood and clots were drained from 
vessels with PBS, to avoid any contamination. Single pieces were dissected, first 
separating the epithelium of each section along its length, to expose the underlying 
?????????? ??????? ?????? ????? ???????? ????? ???? ????????? ???? ???? ?????? ????? ??????? ?????
without opening them. The soft gel tissue was then finely chopped. The same tissue (2-3 
mm2 pieces) were place directly into 25-cm2 flask culture expansion in DMEM low 
glucose media (Euroclone S.p.a., Milan, Italy), supplemented with 10% FCS, penicillin 
100 mg/ml and streptomycin 10 mg/ml at 37°C in a humidified atmosphere of 5% CO2. 
After 5-7 days, the culture medium was removed and changed twice a week. 
 
 
Human chondrocytes 
Human primary chondrocytes were obtained from patients with osteoarthritis undergoing 
knee arthroplasty. The chondrocytes were isolated from minced tissue by sequential 
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enzymatic digestion with 0.25% trypsin (Biochrom KG, Seromeds, Berlin, Germany) at 
37°C for 15 min and with 300 U/ml collagenase II (Worthington, Lakewood, NJ, USA) at 
37°?? ???????? ?????????????? ?????????????? Digested material was centrifuged at 1000 
rpm for 10 min, and pellets were resuspended and expanded in monolayer cultures in 
complete ???????? ?????s F12 supplemented with 10% fetal calf serum (FCS), 1% 
pennicillin?streptomycin, 1% L-glutamine and 50 mg/ml L-ascorbic acid (Sigma, St. 
Louis, MO, USA). 
 
 
F low cytometr ic analysis 
hMSCs and hOBs (at passage 2) were fixed in 4% paraformaldehyde. hMSCs were then 
incubated at 4°C for 30 min with 5?????? ??? ???? ?????????????????nal antibodies: anti-
human-CD3, -CD34, -CD45, (DAKO Cytomation, Glostrup, Denmark), -CD31 (Chemicon 
International, temecula, CA), -CD73, -CD90, -CD146 (Becton Dickinson, Mountaine 
View, CA), -CD105 (produced from the hybridoma cell line, clone SH2, ATCC, 
Rochville, MD). Instead, hOBs were incubated at 4°C for 30 min ????? ??????? ?? 
monoclonal antibodies anti human -CD45, -STRO-1 (DakoCytomation; Glostrup, 
Denmark), and ?CD90 (Becton Dickinson, Mountaine View, CA). The cells were washed 
?????? ???? ?????????? ????? ???? ?????? ??? ?? ??????????? ??????? ????-mouse 
????????????????????? ?????????? ??? ????? ?? ?????? ??? ?? ??????????? ??????? ????-rat 
????????????????????? ?????????? ??? ????? ??????? ??? ?? ??????????? ????? anti-rabbit 
immunoglobulins/FITC conjugate (DAKO Cytomation) at 4°C for 30 min. After two final 
washes, the cells were analysed using a FACStar plus Cytometer (Becton Dickinson). For 
isotype control, FITC-coupled non-specific mouse IgG was substituted for the primary 
antibody. 
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Viability analysis (Calcein-A M uptake assay) of MSCs populations 
The viability of the cells was analyzed by double staining with propidium iodide (PI) and 
Calcein-AM according to the manufacturer?s instructions and as previously described 
(Penolazzi et al., 2010). For propidium iodide and calcein analysis the cells were 
visualized under a fluorescence microscope (Nikon, Optiphot-2, Nikon corporation, Japan) 
using the filter block for fluorescein. Dead cells were stained in red, while viable ones 
appeared in green.  
 
 
A nalysis of the osteoblast phenotype 
Alkaline phosphatase staining and activity 
For alkaline phosphatase staining, the Alkaline phosphatase (ALP) Leukocyte kit (Sigma) 
was used, as previously described (Penolazzi et al., 2008). To perform the test, prefixed 
mono-layered cells were incubated at room temperature in a solution containing naphthol 
AS-BI phosphate and freshly prepared fast blue BB salt buffered at pH 9.5 with 2-amino-
2-methyl-1,3-propanediol (AMPD). The presence of sites of ALP activity appeared as blue 
cytoplasmatic staining. 
ALP activity was evaluated in hOBs and hMSCs by the hydrolysis of p- 
nitrophenylphosphate (PNPP), as indicated by Ibbotson et al. (Ibbotson et al., 1986). The 
cells were washed in cold PBS 1X pH 7.4, were mechanically detached and centrifuged at 
1200 rpm for 30 min at room temperature. The pellet was then resuspended in 500 µl of 
Triton X-100 (0.1%) and subjected to rapid freezing and thawing in liquid nitrogen for 
three times, in order to facilitate the breakdown of cell membranes; the lysate was then 
recovered after a quick spin at 1200 rpm. Different amounts of lysate (25, 50 and 100 µl) 
are added to a fixed quantity (100 µl) of substrate represented by 10 mM p-
nitrophenylphosphate solution in a diethanolamine buffer 100 nM (pH 10.5, 0.5 mM 
MgCl2). After 30 min at 37 ° C, the reaction was stopped with 100 µl of 0.2 M NaOH each 
well; the enzyme activity was expressed as µmol of substrate hydrolyzed for time unit 
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(minutes) for mg cellular protein. The total quantity of protein was determined by the 
"Bradford method? (Bradford Reagent for Protein Determination, Sigma) The enzyme 
activity, expressed as µmol/min/µg of protein, was evaluated 6 days after siRNA/Slug 
treatment in hOBs and in MSCs before and after osteogenic induction. 
 
 
Osteogenic induction  
Osteogenesis of hMSCs and hOBs was induced 24 h after seeding (in 12 well), by 
incubating hMSCs in ?-MEM medium supplemented with 10% FBS, ???? ??? ?????????
acid, 10 ????-glycerophosphate and 100 nM dexamethasone (all purchased from Sigma) 
and by incubating hOBs in DMEM high-glucose (Euroclone S.p.a., Milan, Italy), 
supplemented with 10% FBS, ????????????bic acid, 10 m???-glycerophosphate and 100 
nM dexamethasone for 3/4 weeks. In the committed cells, the osteogenic medium was 
changed every three days. The cells were analysed after 24h (day 0) and at days 7, 14, 21 
and 28.  
 
 
Mineralization assay 
The extent of mineralized matrix in the plates was determined by Alizarin Red S staining 
(Sigma). The cells were then fixed in 70% ethanol for 15 min at room temperature, washed 
with deionized water, stained with 40 mM ARS (pH 4.2) for 20 min at room temperature, 
and washed five times with deionized water to eliminate non-specific staining. The stained 
matrix was observed at different magnifications using a Leitz microscope. Concerning 
osteogenic induction of hOBs, matrix mineralization was quantified by measuring the 
number and surface of mineralized ???????? ?????? ?? ???????? ?????? ????????? ????????????
?????? software, Biorad). The surface and the number of all mineralized nodules were 
quantified in 2 wells per condition at day 14 and 21 of culture. With regard to hMSCs 
osteogenesis, mineralized matrix positive to Alizarin Red S was quantified analyzing 10 
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different RGB images, that were acquired under white transmitted light from each well by 
a linear (gamma=1) CCD camera mounted on an inverted microscope (DS Camera Control 
Unit DS-L2, Nikon Instruments Europe BV, Amstelveen, Netherlands), using an objective 
at 10X magnification and maintaining the sampling area fixed. Photometric analysis were 
conducted on the monochrome red channel of the RGB stack. Images were calibrated by 
adjusting the brightest gray level to 255 and then analyzed using the public domain ImageJ 
software (rsbweb.nih.gov/ij). The data were expressed as integrated optical density (O.D.).  
 
 
Immunocytochemistry 
A sample of 104 human osteoblasts obtained from tibial plateau (at passage 2) were seeded 
in 8-well chamber slide and allowed to adhere for 96 h. Human osteoblasts were fixed in 
4% PFA for 20 min at room temperature and then hydrated with TBS 1% BSA for 5 min at 
room temperature. The slides were incubated with monoclonal antibodies anti-human -
CD146 (Nocastra, Newcastle, UK), -CD105 (produced from the hybridoma cell line, clone 
SH2; ATCC, Rockville, MD), -Runx-2, -osteocalcin (OC), anti-human-CXCL12 (all 
purchased from R&D Systems, Minneapolis, MN), -alkaline phosphatase (ALP), -collagen 
type 1 (Col1a1) (both obtained from DSHB, Department of Biological Sciences, Iowa city, 
IA), -bone sialoprotein (BSP), (Fisher Scientific,Pittsburg, PA, USA), and -estrogen 
receptor alpha ????? (Upstate Biotechnology, Lake Placid, NY), for 1 h at room 
temperature. The slides were washed three times with TBS 1% BSA and then sequentially 
incubated with multilinker biotinilated secondary antibody and alkaline phosphatase-
conjugated streptavidin (Kit BioGenex, San Ramon, CA, USA) at room temperature for 20 
min. The slides were developed using fast red as substrate, counterstained with 
haematoxylin, mounted with glycerol jelly, and evaluated in a brightfield microscope. 
Negative and isotype matched controls were performed. Positive cells were manually 
counted by two evaluators blinded to marker evaluated. For each well, we randomly 
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selected 20 fields at high magnification (X40). Results were expressed as the percentage of 
positive cells on the total number of cells counted. 
For immunocytochemical analysis of human craniofacial osteoblasts and osteogenic -
induced hWJMSCs (at days 0, 7, 14, 21 and 28) the cells were fixed in 4% 
paraformaldheide (PFA) for 20 min at room temperature, washed twice in PBS, treated 
with 3% H2O2 (in PBS) and incubated in 2% normal horse serum (S-2000, Vector labs, 
CA, USA) for 15 min at room temperature. After the incubation in blocking serum, the 
slides were incubated with monoclonal antibodies anti-human-Slug and ?Runx2 (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) at room temperature for 1hour. The slides 
were washed three times with PBS 1X and then were visualized under a brightfield 
microscope fluorescence. 
 
 
Construction of reporter plasmid 
Promoter region (+1 to -982 bp) of the human Slug promoter was amplified by PCR from 
human genomic DNA using Slug F genomic primer (5?-
gaagatctTGTCAAAAGTGTGAGAGAAT-3?) as sense primer and Slug R genomic primer 
(??-cgacgcgtCTTGCCAGCGGGTCTGGC-???? ??? ?????????? ??????? ?in lower font are 
shown the recognition sequences for MluI and BglII restriction enzymes). The PCR 
product was subcloned upstream of a firefly luciferase (LUC) gene in the promoter-less 
pGL3-Basic vector (Promega, Madison, WI) using MluI and BglII restriction sites, and the 
presence of the insert was confirmed by restriction digestion. 
 
 
Plasmids and transient transfection 
The expression vector  for  full-length Lef-1 (K14-myc-hLEF1) was a gift from Elaine 
Fuchs and Rebecca C. Lancefield (Howard Hughes Medical Institute, The Rockfeller 
University, Lab. of Mammalian Cell Biology & Development, New York U.S.A.).  
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The TCF reporter plasmid TOP FLASH was kindly provided by Rolf Kemler (Max Planck 
Institute, Heidelberg, Germany). TCF reporter plasmid containing two sets (with the 
second set in the reverse orientation) of three copies of the TCF binding site  upstream of 
the Thymidine Kinase (TK) minimal promoter and Luciferase open reading frame. 
 
 
Luciferase reporter gene assays 
The cells were cultured in 9.4 cm2  wells, to a confluence of 60-70% and maintained in D-
MEM supplemented with 10% FCS for 24 hours. The cells were transfected with 1 µg of 
reporter plasmid pGL3-Basic or the reporter plasmid containing the insert (+1 to -982 bp) 
of the human Slug promoter, or TOPflash plasmid,  previously complexed with a 1 µg of 
Lipofectamine reagent (Invitrogen, Carlsbad, CA), by incubation at room temperature for 
20 min. The cells were cotransfected with ??????g of pCMV-Sport-?gal (Invitrogen)  to 
evaluate transfection efficiency and ???? ??? ??? ??????????? ?????rs for Lef1 (K14-myc-
hLEF1). Where indicated, the cells were treated with 10 ?? SB216763 (purchased from 
Sigma, and dissolved in DMSO), for 24 h prior to harvest. The cells were lysed 48h after 
transfection using the reporter lysis buffer (Promega, Madison, WI). As previously 
described, Luciferase and ?-galactosidase activities were determined with luciferase and 
Beta-Glo assay systems respectively (Promega, Madison, WI). Their activities were 
normalized with respect to total protein amount (Lambertini et al., 2008). 
 
 
Small interfer ing RN A (siRN A) transfection 
Three sets of Stealth RNAi duplexes and corresponding Stealth control were synthesized 
by Invitrogen Life Technologies (Carlsbad, CA, USA). Stealth RNAi compounds are 25 
mer dsRNA containing proprietary chemical modifications that enhance nuclease stability 
and reduce off-target effects. The following Stealth RNAi sequences were used:  
siRNA/Slug1  sense: 5?-CCGUAUCUCUAUGAGAGUUACUCCA-3??? 
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antisense: 5?-UGGAGUAACUCUCAUAGAGAUACGG-3?;  
siRNA/Slug2  sense: 5?-CCCUGGUUGCUUCAAGGACACAUUA-3?,  
antisense: 5?-UAAUGUGUCCUUGAAGCAACCAGGG-3?;  
siRNA/Slug3  sense: 5?-GGCUCAUCUGCAGACCCAUUCUGAU-3?,  
antisense: 5?-A UCAGAAUGGGUCUGCAGAUGAGCC-3?.  
The most effective fragments used for targeting human Slug were siRNA/Slug2. 
Twenty-four hours before siRNA transfection, hOBs and hMSCs were seeded in triplicate 
at density of 16 X 103/cm2 and 12 X 103/cm2, respectively, in DMEM with 10% FCS. Cells 
were transfected with 30 nM siRNA using Lipofectamine RNAiMAX (Invitrogen Life 
Technol??????? ?????????? ??? ???? ??????????????? ????????????? Transfected cells were 
incubated for 6 days at 37°C before gene silencing analysis. As a negative control for the 
siRNA treatment, Medium GC Stealth RNAi Negative Control Duplex (Invitrogen) was 
used. Knockdown of Slug expression was verified by Real-Time RT-PCR. 
 
 
Real-time quantitative R T-PC R 
Cells from three wells were harvested and total RNA was extracted using an RNeasy Mini 
????????????????????????????????????????????????????????????????????????. One microgram 
of the total RNA was reverse transcribed with the ?????? ????????? ????? ????????
??????????????? ???? ????????? ??????????? Foster City, CA, USA) according to the 
??????????????? ???????????. Real-time PCR was carried out using the ABI PRISM 7700 
Sequence Detection System (Applied Biosystems, Foster City, CA, USA). TaqMan 
technology, the Assays-On-Demand kit for human Slug, Lef1, Snail1, Snail3, Runx2, BSP, 
Sox9, Sox5, Sox6, STAT1,OPN, OC, Col1a1, Rankl, c-myc, and CXCL12 were used. The 
mRNA levels of target genes were corrected for GAPDH mRNA levels (endogenous 
control). ????? ??????? ???? ????? ??? ?????? ???? ????? ??????????, as previously described 
(Lambertini et al., 2008). Ct was calculated as the difference between the Ct of the target 
gene and that of GAPDH. Then a calibrator sample (which is the value of ??? of the 
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sample with the lowest levels of the target cDNA) was chosen. Then ???? was calculated 
as the difference between the ?Ct of each sample and ?Ct of calibrator. According to a 
process validated by the custodian of the technology, the expression levels of samples are 
expressed as 2-????, named "fold induction", which estimates the times of increase of each 
sample compared to the sample chosen as calibrator. All PCR reactions were performed in 
triplicate for each sample. All experimental data were expressed as the mean ± SEM. 
 
 
Cell lysates 
As previously reported (Penolazzi et al., 2007), the cells were washed twice with ice-cold 
PBS, containing protease inhibitors (AESBF 104 mM, Aprotina 0.08 mM, Leupeptina 2 
mM, Bestatina 4 mM, Pepstatina A 1.5 mM, E-64 1.4 mM; protease inhibitor cocktail, 
Sigma) and PMSF (Phenylmethanesulfonyl fluoride), harvested and centrifuged for 5 min 
at 1200 rpm at 4°C. The cell pellet corresponding approximately to 5 x 107 cells, was 
resuspended in 200 ?l of a lysing solution (50 mM Tris-HCl pH 8, 150 mM NaCl, 0.02% 
sodium azide, 1% Triton X-100, water) to which was added protease inhibitors. The cells 
were kept on ice for about 30  min and then centrifuged for 2 min at 14,000 rpm at 4°C. 
Then the supernatant was collected and 5 ?l were removed for spectrophotometric 
determination of protein concentration. The rest was stored at -80°C before use. 
 
 
Western blotting 
For western blot analysis, the cells were washed twice with ice-cold PBS and cell lysates 
were prepared as above mentioned. Then, 10 µg of each sample was electrophoresed on a 
12% SDS-polyacrylamide gel. The proteins were then transferred onto an Immobilon-P 
PVDF membrane (Millipore, Billerica, USA). After blocking with PBS-0.05% Tween 20 
and 5% dried milk, the membrane was probed with the following antibodies: Slug (L40C6) 
from Cells Signaling Technology (Danvers, CA, USA), Runx2 (sc-10758), Sox9 (sc-
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20095), Tcf-1 (sc-13025), and Tcf-4 (sc-13027), from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA), Lef1 (L7901) from Sigma Aldrich, IP3K (06-195), and Active ?-Catenin 
(05-665) from Upstate Biotechnology (Lake Placid, NY). After washing with PBS-Tween, 
the membranes were incubated with peroxidase-conjugated anti-rabbit antibody (1:50000) 
or anti-mouse (1:2000) (Dako, Glostrup, Denmark) in 5% non-fat milk. Immunocomplexes 
were detected using Supersignal West Femto Substrate (Pierce, Rockford, IL, USA). Anti-
IP 3K was used to confirm equal protein loading. 
 
 
Osteocalcin assay 
Osteocalcin secretion was measured in cell culture supernatants collected from osteoblasts 
plated in 24-well dishes and cultured with D-MEM, 10% FCS in presence or in absence of 
30 nM siRNA/Slug for 6 days. Prior to measurements, the media were collected, 
centrifuged at 1,300g for 5 min, and tested by using a human osteocalcin enzyme-linked 
immunosorbent assay (ELISA) kit, according to ??????????????? ????????????? ?????
Diagnostics, Germany). Osteocalcin levels were corrected with total protein content and 
expressed as nanograms per micrograms of cell protein and each treatment was performed 
in duplicate. 
 
 
Secretion of C X C L12 chemokine 
Supernatants from both control and silenced-hOBs were collected. CXCL12 production 
was evaluated by a specific immunoassay standardized in our laboratory using antibody 
pairs matched for CXCL12 (R&D Systems, Minneapolis, MN, USA). Sensitivity of the 
assay was 15 pg/ml. Data were expressed as measured pg/mlCXCL12/µg of total proteins 
± s.e.m. 
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Scratch wound assay 
hMSCs were seeded at density of 12X103/cm2, grown to 90% confluency, transfected with 
siRNA/Slug or scramble RNAs. 72h later the cells were wounded by scratching with a 
sterile 200 µl pipette tip. 24 and 48 hours after wounding, the cells were incubated with 
Calce????????????????????????????????????????????????????????Images were taken at 0, 24  
and 48 hours. 
 
 
C hromatin immunoprecipitation (C hIP) assay 
The ChIP assay was carried out as previously described (Brugnoli et al., 2010) using the 
ChIP kit from Upstate Biotechnology, Inc. (Lake Placid, NY). The cells were cross-linked 
with 1% formaldehyde for 10 minutes at 37°C, washed in ice-cold PBS, and resuspended 
in SDS lysis buffer for 10 minutes on ice. Samples were sonicated, diluted 10-fold in 
dilution buffer supplemented with protease inhibitors, and precleared with 80 µl of DNA-
coated protein A-agarose; the supernatant was used directly for immunoprecipitation with 
5 µg of anti-Lef1 (sc-8591), Tcf-1 (sc-13025), Tcf-4 (sc-13027), Runx-2 (sc-10758) and 
Slug (sc-10436) (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. 
Immunocomplexes were mixed with 80 µl of DNA-coated protein A-agarose followed by 
incubation for 1 h at 4°C. Beads were collected and sequentially washed five times with 1 
ml each of the following buffers: low-salt wash buffer (0.1% SDS,1% Triton X-100, 2 mM 
EDTA, 20 mM Tris-HCl, pH 8.1, and 150 mM NaCl), high-salt wash buffer (0.1% 
SDS,1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, and 500 mM NaCl), LiCl 
wash buffer (0.25 mM LiCl, 1% IGEPAL-CA630, 1% deoxycholic acid, 1 mM EDTA, 
and 10 mM Tris, pH 8.1) and TE buffer. The immunocomplexes were eluted two times by 
adding a 250-µl aliquot of a freshly prepared solution of 1% SDS and 0.1 M NaHCO3, and 
the cross-linking reactions were reversed by incubation at 65°C for 4 h. Furthermore, the 
samples were digested with proteinase K (10 mg/ml) at 42°C for 1 h, DNA was recovered 
by phenol/chloroform extractions, ethanol was precipitated using 1 µl of 20 mg/ml 
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glycogen as carrier and resuspended in sterile water. For PCR analysis, aliquots of 
chromatin before immunoprecipitation were saved (Input). PCR was performed to analyze 
the presence of DNA precipitated by specific antibodies and by using specific primers 
(Table 1) to amplify fragment of Slug, Runx2, Sox-9 and CXCL12 gene promoters.  
Each PCR reaction was performed with 5 µl of the bound DNA fraction or 2 µl of the 
input. The PCR was performed as follows: preincubation at 95°C for 5 minutes, 30 cycles 
of 1 minute denaturation at 95°C, 1 minute annealing at 62°C, and 1 minute at 72°C, with 
one final incubation at 72°C for 5 minutes. No-antibody control was included in each 
experiment. 
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Statistical analysis 
Statistical analysis was performed using the non-parametric tests (Wilcoxon matched pair 
???????????????????????????????????????????????? ???-parametric test) to evaluate if 
there was any tendency to increase or decrease along the time points analyzed and to 
compare basal versus treated cells. The Kruskal-Wallis ANOVA and Mann-Whitney U test 
were also used for comparing non-matched group of data. All values were expressed as the 
mean ? s.e.m. of at least three different experiments. The analyses were performed using 
CSS Statistica Statistical Software (Statsoft Inc., Tulsa, OK, USA). Values of p<0.05 were 
considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
92 
 
RESULTS 
 
93 
 
R ESU L TS 
 
 
 
C hapter 1 
Slug expression in human normal osteoblasts and the i r mesenchymal 
precursors. 
 
 
In this chapter it will be considered: 1. the cellular models on which it based the analysis of 
the expression and regulation of Slug, and 2. Slug expression in relation with other 
transcription factors involved in OB lineage cells.  
 
Isolation and characterization of human primary osteoblasts (hOBs) 
Human primary osteoblast cultures (hOBs) were generated from bone chips removed from 
nasal septum, and were subjected to the experimental procedure schematized in F igure 1. 
Briefly, the bone samples, about 1 cm2 in size, were cut into small fragments and collected 
in culture 25-cm2 flasks. The appearance of isolated human osteoblastic cells was 
examined and cell morphology was found to be consistent with what has been reported in 
the literature (Robey and Termine., 1985) (see F igure 1). It was observed that immediately 
following isolation, there was limited cellular migration from the trabecular bone chips at 
day 1. After about 7 days, outgrowth of bone cells from the bone chips commenced, and 
confluency in 25-cm2 flask was usually reached after 3-4 weeks. The cellular morphology 
was spindle-shape as well as circular for some osteoblastic cells. On examination of the 
cells at day 21, there was a substantial increase in the number of primary cells that had 
migrated from the bone chips, increasingly further away from the bone chips. 
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      Figure 1. Isolation and use of human primary osteoblasts (hOBs). Human primary osteoblasts were 
obtained from bone chips removed from nasal septum. Bone was cut in small pieces which were 
rinsed and then cultured in 25-cm2 flask. About 7 days after isolation, outgrowth of bone cells from 
bone chips began. As shown in this figure, cells present a spindle-shape morphology. Once hOBs 
reached confluency, they were used for cellular and molecular analysis. 
 
 
To characterize hOBs, the immunophenotypical profile of the cells obtained from bone 
chips was determined by testing three specific surface markers using flow cytometric 
analysis. The results indicate that most of the cells (98.12%) expressed cell surface marker 
CD90 (Thy-1) (see F igure 2A) that is detected in the early stage of osteoblast 
differentiation and declines as osteoblasts differentiate into osteocytes (Chen et al., 1999). 
The hematopoietic marker CD45 was not detectable on these cells (see F igure 2A), 
indicating that cells were not contaminated with cells of hematopoietic origin. In addition, 
flow cytometry showed that the cells did not express STRO1 (a marker that recognizes 
osteoprogenitor stem cells of the colony-forming unit-fibroblastic) (see F igure 2A), 
suggesting that they are mostly mature osteoblasts (Byers et al., 1999).  
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At the same time hOBs phenotypic characterization was analysed by 
immunocytochemistry staining for Runx2, a typical osteogenic protein. As shown in 
F igure 2B, the cells were highly positive for this marker and this result was further 
confirmed by data from gene expression analysis based on RT-PCR (see F igure 2B). In 
addition, a significant component of the bone extracellular matrix, the bone sialoprotein 
(BSP), was detected at mRNA level by real time RT-PCR. These data confirm the level of 
maturation of the cells giving a definite indication of their commitment. 
 
Osteogenic ability of hOBs 
Next, the cells were characterized for their osteogenic capacity in terms of alkaline 
phosphatase (ALP) activity and mineral deposition (see F igure 2C). Alkaline phosphatase 
is an early osteogenic marker whose activity tends to increase with increasing in 
osteoblastic differentiation. The presence of blue staining, indicating an intense ALP 
activity, was detected in the cells analysed (see F igure 2C). In addition, Alizarin Red 
staining showed an evident extracellular matrix mineralization deposition after 14 days of 
culture under osteogenic conditions (see F igure 2C). 
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Figure 2. Phenotypical characterization of human primary osteoblasts (hOBs). A . The characterization of 
hOBs has been performed by flow cytometric analysis of CD45, CD90 and STRO-1 phenotypical markers. 
X-axis, mean fluorescent channel; Y-axis, number of events. B . hOBs samples were subjected to 
immunocytochemical analysis for Runx2 osteoblastic marker. A representative sample is shown (X10 
magnification). The level of Runx2 and BSP expression was examined by quantitative RT-PCR in five hOB 
samples. The experiments were carried out in triplicate, the expression levels were normalized on the basis of 
GAPDH expression and results of the experiments are reported as relative mRNA expression levels. ??Ct 
method was used to value the gene expression; SEM was calculated. C . The cells were treated with ?-
glycerophosphate, ascorbic acid, and dexamethasone. The authentic osteoblast phenotype was confirmed in 
hOBs by staining for alkaline phosphatase (ALP) activity. Deposition of extracellular matrix was 
evaluated.Mineral formation was examined by Alizarin Red-S staining after 14 days of osteogenic induction. 
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Isolation and characterization of human mesenchymal stem cells (hMSCs) 
As sources of human MSCs, adult hMSCs from tibial plateau (TP) trabecular bone, iliac 
???????????????????????????????????????????????????????????????????????????????????????
examine these three populations in order to analyze their different characteristics in terms 
of isolation, proliferation and differentiation potential.  
???? ??? ???? ??????? ??????????? ????????????????????? ?????? ???????????? ?????? ???? ??????? ????
easiest accessible source for MSCs. The choice to use solely ???????????????????????????????
whole cord was made with the aim of isolating a relatively homogeneous cell population, 
possibly avoiding any epithelial cell contamination. Contrary to the majority of groups 
working on WJ-????????????????????????????????????????????????????????????????????????
capacity of MSCs to adhere to a plastic surface, without enzymatic digestion treatment. As 
??????????? ?????????? ??? ??????????? ????????????? ????????? ?????????? ??????????? ????????
and scraped to obtain only the jelly mucoid connective tissue from each sample. Then, the 
small pieces (2-3 mm2) were placed directly into 25-cm2 flasks in D-MEM Low Glucose 
medium supplemented of 10% FCS. After 3 to 5 days of culture, the WJ-MSCs form 
adherent colonies reaching confluence after 10-14 days, while hTP-MSCs and hIC-MSCs 
usually reach the confluence after 2-3 weeks from seeding. However, the cells isolated 
from the three sources, display both a monocyte-like and a spindle-shape morphology (see 
F igure 3 and 4).  
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Figure 3. Isolation and use of human ???????????? ????? ?????? ????? ?????????? ???ly (WJ-MSCs). 
MSCs were obtained from ????????????????????????????????????????????????????????????????????????????
subjected to longitudinal incisions to obtain only the jelly mucoid tissue. WJ pieces were then rinsed and 
cultured in 25-cm2 flask. About 3-5 days after isolation, WJ-MSCs form adherent colonies. As shown in 
this figure, cells present a spindle-shape morphology. Once WJ-MSCs reached confluency, they were 
used for cellular and molecular analysis. 
 
 
 
 
Figure 4. Morphological analysis of hMSCs from different sources. Optical micrographs of hMSCs 
isolated from tibial plateau (TP) trabecular bone, iliac crest (IC) bone marrow and ?????????????????????
umbilical cord. After one passage (P1), cells show a fibroblast-like morphology (original magnification: 
10X). 
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To evaluate the characteristics of each MSC sample, the immunophenotypic profile of 
adherent cells obtained from the different sources was determined by testing a panel of 
surface markers using flow cytometry (see F igure 5). MSC from all samples were positive 
for CD90, CD73, CD105, CD146 (mesenchymal cell markers), but negative for CD31 
(endothelial cell marker), CD3, CD14, CD34, CD45 (hematopoietic cell markers). In 
particular, we observed that the expression of CD90, CD73 and CD105 was not 
significantly different in all the three types of MSC analysed (total mean±SD 97±3), while 
the percentage of positive cells for CD146 was significantly lower in hTP-MSC (mean±SD 
25.77±17.82) and in hWJ-MSC (mean±SD 23.4±19.09) compared to hIC-MSC (mean±SD 
53.12 ± 23.01, P=0.000007 and P=0.01 respectively). 
 
 
 
 
Figure 5. Phenotypical characterization of hMSCs. Flow cytometric analysis of a representative case of 
hTP-MSC, hIC-MSC and hWJ-MSC. Open histograms represent the isotype control antibody, dotted 
histograms represent anti-CD3, -CD14, -CD31, -CD34, -CD45, -CD73, -CD90, -CD105, -CD146 antibodies. 
X-axis, mean fluorescent channel; Y-axis, number of events. 
 
 
Osteogenic potential of MSCs 
We then investigated the osteogenic potential of hMSCs from the three sources. The 
experiments were performed after the 3rd to 4th passage at least, and then the cell 
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populations were differentiated. The osteogenic differentiation of expanded hMSCs was 
induced for 3 weeks by the addition of 100 nM dexamethasone, 10 mM ?-
glicerophosphate and 100 µM ascorbic acid to the culture medium. During this lapse of 
time, the cells lost their typical spindle-shape morphology turning into wider polygonal 
cells. At 21 days of differentiation, the cultures showed the presence of mineralized 
nodules following Alizarin red staining analysis (see F igure 6A). These data support 
the ability of hMSCs to differentiate towards osteogenic lineage when appropriately 
stimulated in vitro. Interestingly, mineralization occurred at day 7 only for hWJ-MSC 
while for hTP- and hIC-MSC started from day 14. In addition, we noticed that, both at 
day 14 and 21, mineralization was significantly increased in hTP- (p=0.003 and 
p=0.006, respectively) and hIC-MSC (p=0.00001 and p=0.006, respectively) compared 
to hWJ-MSC. Comparing hTP- and hIC-MSC we observed that, while at day 14 
mineralization was significantly higher in hIC-MSC than in hTP-MSC (p=0.008), at day 
21 it reached approximately the same values in both cell sources. The effectiveness of 
osteogenic differentiation was then assessed analysing Runx2 mRNA expression levels 
in all three hMSC populations (see F igure 6B). After 21 days in osteogenic medium, 
Runx2 expression showed a decrease in hTP-MSCs, an increase in hWJ-.MSCs, but 
remained constant in hIC-MSCs, suggesting that hMSCs from the three different 
sources are at different stage of maturation.   
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Figure 6. Osteogenic differentiation of hMSCs. A . Differentiation potential of hMSCs from the three 
sources was assessed by evaluating the mineralization of the cell cultures in the presence of osteogenic 
induction medium, up to 21 days. Data were expressed as integrated optical density (O.D.) ± SE. Statistical 
analysis was performed hTP-MSC versus hWJ-MSC *, hTP-MSC versus hIC-MSC §  and hIC-MSC versus 
hWJ-MSC o???????????????????????????????????? B . Runx2 gene expression was evaluated in hMSCs isolated 
????? ??????????????? ?????????????????????? ???????????? ??????????????????????????????? ?????? ???????????????
cord and cultured up to 21 days in osteogenic medium (OS medium). mRNA level was revealed by 
quantitative RT-PCR analysis. RT-PCR results, were calculated using the ??Ct method. Data were 
expressed as fold difference value between the calibrator (Runx2 expression level in uninduced hWJ-MSCs) 
and the other samples. Data were expressed as median, box: 25-75 percentiles and whisker: minimum and 
maximum of non-outliers. It was not possible to apply statistical tests since the N was equal to 4 samples for 
each group analysed. 
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Osteogenic potential of WJ-MSCs and variabily between samples 
Nevertheless the majority of WJ-MSC samples examined has shown the ability to 
differentiate into osteoblasts beginning from day 7 (see F igure 6A), however a very high 
heterogeneity in response to treatment with osteogenic medium was observed. This 
evidence, in agreement with the data obtained by other researchers (Markov et al., 2007; 
Zhang et al., 2009), prompted us to search a possible correlation between the osteogenic 
potential of WJ-MSCs and five different obstetric parameters, including baby's gender and 
birth weight, mother's age at delivery, gestational stage at parturition and mode of delivery. 
With the collaboration of Section of Obstetric and Gynaecological Clinic, Azienda 
Ospedaliero-Universitaria S, Anna, it was possible to obtain 60 fresh samples of human 
umbilical cords. Among the collected samples, we selected the 20 most homogeneous ones 
considering the percentage of CD90 presence and CD??? ???????? ??? ?????? ??? we 
analyzed for each one the different obstetric parameters aforementioned (see F igure 7 
table A). 
We conducted analyses adjusting for two specific markers of osteoblast differentiation: the 
activity of alkaline phosphatase (ALP) and the expression levels of  Runx2. As shown in 
F igure 7C , focusing on basal levels of ALP and Runx2, it has been possible to 
demonstrate that these parameters can be predictive of osteoblastic potential of WJ-MSCs. 
In fact, the samples with high basal levels of Runx2 and ALP are more prone to deposit 
mineral matrix if compared to WJ-MSC with low levels of these two proteins. 
Next, we analyzed whether the basal levels of Runx2 and ALP correlate with the examined 
obstetrics factors (see F igure 8). We found that the infant gender and mode of delivery 
didn't significantly correlate (P > 0.05) with basal Runx2 expression and ALP activity. On 
the other hand, the age of the mother at delivery, has a significant impact on the basal ALP 
activity but doesn't affect Runx2 expression level. Samples collected from mothers which 
were <32 years old give origin to WJ-MSCs with high ALP activity (see F igure 8 upper 
graph). Interestingly, birth weight of the infant was shown to significatively impact on 
Runx2 basal expression level which, decreases with the decreasing of the baby's weight 
(see F igure 8 lower graph). The same relationship was found for the duration of 
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pregnancy. In fact, it was found that WJMSCs from babies born before the 37 weeks of 
gestation express lower basal level of Runx2 than the full term born (see F igure 8 middle 
graph). 
As a whole, these findings led us to focus on two parameters, weeks of pregnancy and 
consequently birth weight of the baby, and Runx2 basal levels, subdividing the collected 
samples in the two subgroups reported in F igure 7 table A: subgroup I, premature birth 
with low levels of Runx2, and subgroup II, full term birth with high levels of Runx2. The 
ability of the samples belonging to these two subgroups to complete the event of cellular 
maturation, that is the deposition of mineralized matrix, was then compared. Two 
representative samples of the two subgroups demonstrate that, samples from subgroup I 
showed a null mineralization status also after 21 day of cell culture in osteogenic medium, 
whereas samples from subgroup II showed a high level of mineralization beginning from 
day 14 (see F igure 7B). These findings suggest that maximal WJ-MSCs osteoblastic 
potential can be obtained by primary cultures with Runx2 high basal levels, selected from 
the heaviest term babies. 
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Figure 7. Osteogenic potential of WJMSCs and variabily between samples. In the table (A) clinical 
parameters, Runx2 expression and alkaline phosphatase activity (ALP) basal level are reported. As indicated, 
the samples were divided in two subgroups: subgroup I, premature birth; subgroup II, full term birth. F 
(female), M (male), CS (Caesarian delivery), SP (spontaneous delivery). B . The ability to deposit mineralized 
matrix was evaluated at the indicated times (0d, 14d, 21d) in two representative samples of each subgroup, 
by Alizarin red staining. C . The mineralization status  (+, positive or -, negative) was correlated with the 
basal level ???????????) of Runx2 expression (on the left) and ALP activity (on the right). * = p < 0.05. 
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Figure 8. Relationship between molecular and obstetric parameters in WJMSCs. Basal levels of Runx2 
expression and ALP activity were related to mother's age (upper graph), weeks of pregnancy (middle graph) 
and birth weight (lower graph) in 20 WJMSC samples. 
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Slug expression  in human  osteoblasts and their mesenchymal precursors 
Slug expression levels were first assessed in osteoblastic cells by real-time RT-PCR 
analysis. To this aim the following cellular models were used: human craniofacial 
osteoblasts obtained from bone sample collected during nasal septum surgery, 
osteosarcoma cell lines (SaOS-2 and U2OS), osteoblast-like cell lines (CAL72 and Hobit), 
characterized by a different stage of differentiation. As negative control breast cancer cell 
line MCF7 was employed.  
As shown in F igure 9, Slug mRNA level was expressed at a significant level in all types of 
osteoblastic cells analyzed, both in cell lines and in normal primary cells. In particular, the 
highest expression was observed in CAL72 cells and human primary osteoblasts. On the 
contrary, as expected (Hajra et al., 2002), no Slug mRNA expression was detected in 
MCF7 cells. 
 
Figure 9. Analysis of Slug expression by quantitative RT-PCR in different osteoblastic cells. The level of 
Slug mRNA was examined by quantitative RT-PCR in four osteoblast-like cell lines (U2OS, SaOS-2, Hobit 
and CAL72), in MCF7 breast cancer cell line and in five human primary  hOB samples. The cDNA obtained 
from total RNA was subjected to quantitative TaqMan RT-PCR for Slug transcript analysis. The experiments 
were carried out in triplicate, the expression levels were normalized on the basis of GAPDH expression and 
results of the experiments are reported as relative mRNA expression levels. ??Ct method was used to value 
the gene expression; standard error of the mean (SEM) was calculated.  
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The experiments have then carried on the investigation of Slug function and its expression 
??????????? ??????????????????????????????????????????in vivo???onditions, in human primary 
cells. Starting from evidence present in the literature, describing the role of Lef1 in 
osteoblast differentiation and the existence of a relationship between Lef-????-catenin and 
Slug in some epithelial-mesenchymal transition cellular models (Saegusa et al., 2009; 
Hong et al., 2009), we hypothesized a correlation between Lef-1 and Slug may in mature 
osteoblasts and their mesenchymal progenitors. To test this idea Slug and Lef1 expression 
were examined, at first, in hOBs obtained from five bone specimens (hOBs). All these 
samples were positive for ALP activity and were able to form mineralized nodules after 14 
days in osteogenic condition (see F igure 2C).  
As shown in F igure 10A , Slug was detected at mRNA and protein level in all hOBs 
analyzed by RT-PCR and immunocytochemical analysis, respectively. Also Lef1 was 
observed in the same samples as well as Runx2, the master regulator in osteoblast 
development and bone formation (Marie., 2008).  
Slug expression was then evaluated in uninduced hTP-MSCs, hIC-MSCs and WJ-MSCs 
by quantitative RT-PCR analysis. As shown in F igure 10B, basal Slug expression level 
was higher in hTP- and hIC-MSCs than in hWJ-MSCs. Furthermore, Slug expression trend 
was  investigated during osteoblast differentiation. To this aim Slug mRNA levels were 
measured in hWJ-MSCs induced towards osteogenesis (see F igure 10C). We chose this 
source of hMSCs for its ability to anticipate the deposit of mineralized compared to hTP- 
and hIC-MSCs, as reported in F igure 6. As shown in F igure 10C , RNA was collected 
after 0, 7, 14, 21, and 28 days in culture and evaluated by quantitative RT-PCR. WJ-MSCs 
differentiate along the osteoblast lineage in osteogenic medium as confirmed by the 
positive staining for extracellular calcium deposition. Abundant Slug mRNA was detected 
in the cells at all times tested, and was induced as the cultures progressed. This was 
confirmed also at protein level by immunocytochemical analysis, thus showing that the 
positive signal increased during osteogenic differentiation of WJ-MSCs, both in the single 
cells and in the mineralized nodules (see F igure 10D). Lef-1 was less abundant, but 
significantly increased during the osteogenesis. Runx2 was also expressed at all stages, and 
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was induced as the cultures progressed, confirming that each time point represented 
increasingly mature osteoprogenitors. 
To further characterize the potential involvement of Snail family members in osteogenesis, 
the expression of Snail1 and Snail3 was examined in the same set of experiments. Snail1 
has been recently reported to act on the osteoblast population regulating bone cells 
differentiation and contributing to bone remodeling in mice (de Fructos et al., 2009). In 
agreement with this previous study, we found that Snail1 was expressed at early stages of 
osteoblast differentiation and then downregulated for differentiation to proceed (see 
F igure 10C). In hOB Snail1 was expressed at substantial levels (see F igure 10A). The 
expression of Snail3 (Katoh et al., 2003) was detectable at low levels in hOBs (see F igure 
10A) and at very low levels in the hMSCs induced towards osteogenesis (see F igure 10C). 
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Figure 10. Detection of Slug expression in hOBs and hMSCs. The level of Slug, Lef1, Runx2, Snail1 and 
Snail3 expression was examined by quantitative RT-PCR in five hOB samples (A) and in three hMSC 
samples cultured up to 28 days in osteogenic medium (C). Slug expression level was also evaluated in 
uninduced hTP-MSCs, hIC-MSCs and WJ-MSCs (B). The cDNA obtained from total RNA was subjected to 
quantitative TaqMan RT-PCR for Slug, Lef1, Runx2, Snail1 and Snail3 transcript analysis. The experiments 
were carried out in triplicate, the expression levels were normalized on the basis of GAPDH expression and 
results of the experiments are reported as relative mRNA expression levels. ??Ct method was used to value 
the gene expression; standard error of the mean (SEM) was calculated. Slug expression was also examined 
by immunocytochemical analysis both in hOBs (A) and in osteogenic-induced WJMSCs at day 0, 7, 14, 21, 
and 28 days (D). Magnification 4X and 10X. The commitment to osteoblastic lineage of hMSCs was 
evaluated by Alizarin Red staining (AR) for extracellular calcium deposition (B). * = p < 0.05 (respect to day 
0). 
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C hapter 2 
Slug gene regulation in human osteoblasts. 
 
 
Human Slug promoter characterization 
As previously mentioned in the introduction, although the regulation of Slug expression 
and its role have been investigated extensively in many animal species, mechanisms 
governing Slug expression in humans are largely unknown. Indeed, there is little 
information regarding the characterization of Slug promoter and the role that specific 
proteins play in regulating its expression in normal adult human tissues. 
In order to identify potential binding sites for transcription factors involved in Slug gene 
expression regulation, at first, we analyzed a region of approximately 2 Kb upstream of the 
transcription start site in the human Slug gene. This region was initially subjected to 
bioinformatic analysis based on the search for E-box sites for Slug protein and for binding 
sites for Runx2 and Lef1/Tcf transcription factors, which potentially can interact with Slug 
and modify its expression. 
By using the programs Transcription Element Search Software TESS for transcription 
factor search and MatInspector 7.4 program, we identified ten E-box sites, four Runx2 
binding sites and another seven potential consensus binding sites for the Lef/Tcf family, in 
addition to the previously identified Tcf binding site at -859/-855 position (Saegusa et al., 
2009; Hong et al., 2009) (see F igure 1A). 
Since most of the binding sites for the factors of our interest are located in the first 
thousand base pairs upstream of the transcription start site, we have focused on the analysis 
of this region. In addition to putative binding sites for Lef/Tcf, Runx2 and Slug (see 
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F igure 1B and Table 1), some other binding sites for transcription factors that play an 
important role ????????????????????????????????????????????????????????????????????????????et 
al., 2000 and AP-1 (activator protein-1) (McCabe et al., 1996) have been identified in the 
same sequence. 
 
 
 
Figure 1. Schematic representation of Slug promoter region under investigation. A , B . Putative binding sites for 
Lef/Tcf, Runx2 and Slug transcription factors, identified by using bioinformatic analysis, are indicated. B . Each 
?????????????????????????????????????????????????????????????????????????????-982/+1, are reporter in the table below. 
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Table 1. Positions and putative binding site sequences for Lef/Tcf, Runx2 and Slug transcription factors, 
identfied in the Slug promoter region represented in Figure 1B. 
 
 
Furthermore, the same region of about 1 Kb was analyzed to search for sequence 
homology between the different Slug gene promoters of different animal species so far 
characterized. The alignment revealed a degree of identity, corresponding to 8.3%, 46.3% 
and 54.5% of hology compared with Xenopus, chicken and mouse. 
This first computing approach, together with the consideration that Snail/Slug genes 
regulation by Lef1/Tcf and Runx2 factors has been highlighted in other animal species 
(Vallin et al., 2001; de Fructos et al., 2009), led us to analyze the binding sites for these 
transcription factors in the human Slug promoter, in order to understand their possible role 
in modulating the expression of Slug in human osteoblasts. 
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Effect of Lef1 on Slug promoter activity 
To understand the role of Lef1/Tcf in the regulation of Slug promoter activity, we chose to 
focus on an approximately 1 Kb fragment upstream of the transcription start site in the 
Slug gene since it contains six binding sites for the Lef/Tcf family, as aforementioned.  
The sequence was cloned upstream of the Luc reporter gene in the pGL3-basic vector (see 
F igure 2), and the construct, (named 982 bp luc-construct), was assayed in five hOBs in 
presence of Lef1 expression plasmid (K14-myc-hLef1). 
 
 
 
Figure 2. Representation of the plasmid construct used for cloning the sequence under investigation.The 
vector has an origin for replication in bacteria (ori), an origin for phage reliplication (f1 ori), a selection 
marker, represented by a gene conferring resistance to ampicillin, and a luciferase reporter gene. It also has a 
multiple cloning site, which was digested using restriction enzymes MluI and BglII and, in which  the region 
to be analyzed was cloned. 
 
 
As shown in F igure 3, transient transfection with the luciferase reporter 982 bp luc-
construct (pGL3-Slug) resulted in an increase in luciferase activity relative to the empty, 
promoterless pGL3-basic vector, demonstrating that this DNA fragment contains 
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significant promoter activity in hOBs and in SaOS-2 cells. On the contrary, the same 
experiments performed in the non-osseous Slug-negative MCF7 breast cancer cell line 
revealed no promoter activity.  
 
 
 
 
Figure 3. Analysis of human Slug promoter activity. The DNA construct containing the human Slug 
promoter region was cloned into upstream of the firefly luciferase (Luc) reporter gene. hOBs and SaOS-2 
osteoblast-like cells were transfected with the pGL3-Slug Luc reporter vector containing the sequence from 
+1 to -982 of the human Slug promoter (pGL3-Slug 982 bp), and with the promoterless pGL3-basic vector. 
The results of reporter gene assays were normalized with protein concentration and ?-gal activity for 
transfection efficiency and the data are represented as ratios of luciferase units to ?-galactosidase units. 
MCF7 breast cancer cell line was used as negative control. All experiments were performed in triplicate and 
the average of the ratio of the reporter activity + SEM is shown. * = p < 0.05. 
 
 
Cotransfection with plasmid encoding Lef1 produced a significant increase in Luc activity 
in hOBs as compared with cells containing the 982 bp luc-construct reporter plasmid. As 
expected, this increase was dramatic in Lef1 overexpressing SaOS-2 cells, because of a 
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higher intrinsic transfection facility of this cell line (see F igure 4). As a whole, these data 
indicate that Lef1 positively affects activity of Slug gene promoter in normal human 
osteoblasts. 
 
 
 
F igure 4. Lef1 affects the activity of human Slug promoter. The DNA construct containing the human Slug 
promoter region was cloned into upstream of the firefly luciferase (Luc) reporter gene. hOBs and SaOS-2 
osteoblast-like cells were transfected with the pGL3-Slug Luc reporter vector containing the sequence from 
+1 to -982 of the human Slug promoter (pGL3-Slug 982 bp), in the absence (-) or presence (+) of 2.5 ?g of 
hLef1 expression plasmid. The results of reporter gene assays were normalized with protein concentration 
and ?-gal activity for transfection efficiency and the data are represented as ratios of luciferase units to ?-
galactosidase units. MCF7 breast cancer cell line was used as negative control. All experiments were 
performed in triplicate and the average of the ratio of the reporter activity + SEM is shown. * = p < 0.05. 
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Effect of Lef1 overexpression on Slug gene expression 
hLef1 cDNA-transfected hOBs were then subjected to analysis of Slug gene expression. 
As shown in F igure 5, Slug expression significantly increased in Lef1 overexpressing 
cells, both at mRNA and protein level, as demonstrated by RT-PCR (see F igure 5A) and 
western blot analysis (see F igure 5B), respectively. As expected, forced expression of 
Lef1 increased Slug expression to higher levels in SaOS-2 cell line, in agreement with data 
obtained by luciferase assay. 
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Figure 5. Effect of Lef1 overexpression on Slug expression in hOBs. The effect of Lef1 overexpression was 
examined at mRNA (A) and protein (B) level. A . Slug mRNA was evaluated by quantitative RT-PCR in 
hOBs and SaOS-2 osteoblast-like cells transfected with 2.5 ?g of hLef11 (K14-myc-hLef1) expression 
plasmid. The cDNA obtained from total RNA was subjected to quantitative TaqMan RT-PCR for Slug 
transcript analysis. The expression levels were normalized on the basis of GAPDH expression and results of 
the experiments are reported as relative mRNA expression levels. Results are representative of three 
independent experiments carried out in triplicate. ??Ct method was used to compare gene expression data; 
standard error of the mean (SEM) was calculated. * = p < 0.05. B . Slug protein levels were examined by 
Western blot analysis in hOBs and SaOS-2 osteoblast-like cells transfected with 2.5 ?g of hLef1 expression 
plasmid. Whole cell lysates were prepared and 10 ?g of protein run on a 12% SDS-polyacrylamide gel. The 
proteins were visualized using Supersignal West Femto Substrate (Pierce). The quantitative presentation of 
the protein levels were performed by densitometric analysis using Anti-IP3K as control. D.U. = 
densitometric units. This experiment was repeated three times with similar results. A representative Slug 
Western blot analysis with size markers (KDa) is reported. * = p < 0.05. 
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?In vivo??????????????????????????????????????????? 
???????????????????????????????????????????in vivo?, physically bind with the human Slug 
promoter. Western blot analysis reveald that all analyzed hOBs and SaOS-2 cells 
expressed remarkable levels of Lef1 and other Tcf family members, including Tcf-1 and 
Tcf-4. All three transcription factors were investigated in the experiments described below 
(see F igure 6). 
 
 
Figure 6. Western blot analysis of Lef1, Tcf-1 and Tcf-4 expression levels in hOBs and SaOS-2 osteoblast-
like cells. 10 ?g of  whole cell lysates were assayed on a 12% SDS-polyacrylamide gel. The proteins were 
visualized using Supersignal West Femto Substrate (Pierce). Size markers are reported (KDa). IP3K was 
used as a loading control. 
 
 
The ?in vivo?? transcription factors to the Slug promoter was studied by chromatin 
immunoprecipitation (ChIP) assays (see F igure 7B). To this aim, hOBs were exposed to 
formaldehyde to cross-link proteins and DNA, and were sonicated to fragment the 
chromatin. Specific antibody against Lef1, Tcf-1 and Tcf-4 were used to 
immunoprecipitate the protein-DNA complexes. After immunoprecipitation DNA was 
extracted from the beads and used as a template to generate specific PCR products. The 
presence of the promoter specific DNA region before immunoprecipitation was confirmed 
by PCR (input). In the Slug promoter fragment used for the reporter assay, three different 
regions were identified, and analyzed by a set of primers (see F igure 7A and Table 1 in 
??????????? ???? ????????? ????????? spanning the six consensus binding sites for the 
RESULTS 
 
122 
 
Lef1/Tcf family. The amplified product sizes (bp) were 178 for region 1, 164 for region 2, 
and 165 for region 3. The results showed that all transcription factors analyzed were 
recruited to the Slug promoter even if at different levels (see F igure 7B). In particular: a) 
the promoter region 3, containing the previously identified Tcf binding site at -859/-855 
position (Saegusa et al., 2009; Hong et al., 2009), was immunoprecipitated by Lef1 and 
Tcf-4 antibodies; b) Lef1 was mostly associated with the promoter region 1 and not at all 
with the promoter region 2; c) region 2 was occupied by Tcf-1 and Tcf-4 but not by Lef1; 
??????????????????????????????????in vivo?????????.  
Therefore, the observation that the endogenous Slug gene expression may be increased by 
Lef1 was validated by the ?in viv?? occupancy of the Lef/Tcf regulatory sites in the Slug 
gene promoter. 
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Figure 7. ???? ?????? ???????????? ??? ????? ??? ????? ????? ????????? A . The Slug promoter region under 
investigation is reported. The positions of putative Lef/Tcf binding sites are enclosed by rectangles and are 
compared with those recently investigated by others. Positions of PCR primers used in ChIP experiments are 
also reported. B . Recruitment of Lef1/Tcf  transcription factors to the human Slug  promoter is demonstrated 
??? ?in vivo???????????? ???????????????????? ??????????????????????????????? ??????????????????????? ?????
hOBs and immunoprecipitated with the indicated specific antibodies against Lef1, Tcf-1, and Tcf-4. The 
associations of the transcription factors to bound precipitated DNA were monitored on the human Slug 
promoter regions 1, 2 and 3 by PCR with the primers indicated in the scheme. Input represents a positive 
control using the starting material (0.2%) prior to immunoprecipitation. Representative agarose gels are 
shown. 
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Regulation of Slug promoter activity through Wnt signaling activation by 
GSK-???????????? 
It has been demonstrated that ?-catenin may act as co-factor promoting Lef/Tcf interaction 
with target DNA sequences in many cellular contexts (Shimizu et al., 2008). In order to 
support the role of Lef/Tcf transcription factors in Slug expression regulation, we next 
investigated whether ?-catenin activation was involved in Slug expression regulation. We 
used a treatment with a maleimide compound named SB216763, which was previously 
?????????????????????????????????-catenin activation (see F igure 8A). This compound binds 
and specifically inhibits glycogen synthase kinase GSK-3?? a serine/threonine kinase, 
originally identified as a kinase that is involved in glucose metabolism. Recent research 
has determined that GSK-3????????????????? ??????????? substrates, including transcription 
factors, and is a key regulator in many signaling pathways (Cohen and Frame., 2001).  
In particular and for what concerns our interests, this enzyme is known to be a key 
negative regulator of canonical Wnt/?-catenin and PI3K/Akt signalings (Patel et al., 2004); 
hence, its inhibition activates Wnt signaling selectively via the ?-catenin/Tcf pathway and 
resu???? ?????????????????????????????-catenin to the nucleus. We transfected hOBs with a ?-
catenin/Tcf transcription reporter construct named TOPflash reporter system to investigate 
the efficancy of SB216763 treatment. 
As shown in F igure 8B an increase in TOPflash activity up to 4-fold was observed after 
SB216763 treatment, demonstrating the sensitivity of our experimental model to this 
approach. Therefore, as TOPflash has three Tcf-binding sites, it could be applied to 
represent the activation of the Wnt pathway in hOBs. 
The efficancy of SB216763 treatment was confirmed at protein expression level. In fact, 
Western blot analysis showed an increase in ?-catenin expression after SB216763 
treatment (see F igure 8C). The same analysis demonstrated that the increase in ?-catenin 
mediated by SB216763 was correlated with a significative increase in Slug and Runx2 
protein expression level (see F igure 8C). Therefore, on the whole, this suggests that the 
canonical Wnt signaling positively affects Slug expression in normal human osteoblasts 
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via the ?-catenin/Tcf p??????? ????????? ??? ????????????? ?-catenin, Slug expression 
increases. 
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Figure 8. Treatment of hOBs with the glycogen synthase kinase (GSK-3b) inhibitor, SB216763. A . A 
scheme of SB216763 action mechanism is reported (see the text for details). B . Effect of SB216763 on the 
TOPflash reporter system. 24 h after transient transfection with the TOPflash plasmid, the cells were treated 
(+) or not (-) with SB216763 (10 ?M) for 24 h prior to harvest. Luciferase activity was normalized to ?-
galactosidase activity in the same sample. The bars represent mean ± SEM. * = p < 0.05. On the right, 
schematic representation of TOPflash reporter plasmid containing two sets (with the second set in the reverse 
orientation) of three copies of the TCF binding site (in red) upstream of the Thymidine Kinase (TK) minimal 
promoter and Luciferase open reading frame. C . ???????????????-catenin expression, Slug and Runx2 were 
examined by Western blot in hOBs treated with SB216763 (10 ?M) or with the only vehicle (-). The 
quantitative presentation of the protein levels was performed by densitometric analysis using Anti-IP3K as 
control. D.U. = densitometric units. A representative Western blot analysis with size markers (KDa) is 
reported. * = p < 0.05. 
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?????????????????in vivo????????????????????????? 
The results described above prompted us to investigate whether also Runx2 transcription 
factor may be directly involved in the control of Slug transcription in hOBs. To this aim, 
hOBs were exposed to formaldehyde to cross-link proteins and DNA, and sonicated to 
fragment the chromatin. Specific antibody against Runx2 was used to immunoprecipitate 
the protein?DNA complexes. The presence of the promoter-specific DNA region before 
immunoprecipitation was confirmed by PCR (input). After immunoprecipitation, DNA 
was extracted from the beads and used as a template to generate specific PCR products 
spanning the putative Runx2 binding sites localized at -537 and -476 from the transcription 
start site +1 in the Slug promoter, as indicated in F igure 1 and 9. Runx2 recruitment was 
assessed at the promoter region under investigation, as indicated in F igure 9, by using 
specific sets of primers (see Table 1 ??? ??????????? ???? ????????? ???????). Runx2 
occupancy was detected only at the region 4. As expected,  no recruitment of this bone-
specific transcription factor was observed in a sequence of Slug promoter, (region 5), 
lacking of Runx2 binding sites (see F igure 9). 
These ChIP experiments demonstrated that Slug is also a Runx2 target gene in human  
osteoblasts.  
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Figure 9. ???? ?????? ???????????? ??? ?????? ?????????????? ??????? ??? ?????? ????? ????????? The Slug 
promoter region under investigation is reported (+1/-1900). The positions of the putative Runx2 consensus 
binding sites are enclosed by black circle. Recruitment of Runx2 transcription factor to the human Slug 
promoter is demonstrated by ?in vivo? ChIP binding assays. Protein-DNA complexes were formaldehyde-
cross-linked in hOBs in vivo. Chromatin fragments from these cells were subjected to immunoprecipitation 
with antibody against Runx2. After cross-link reversal, the coimmunoprecipitated DNA was amplified by 
PCR using the reported primers, which positions are indicated with arrows. Region 5, lacking Runx2 binding 
sites, represents a negative control of ChIP experiments. PCR fragments were resolved through 1.5% agarose 
gels. No Ab represents a negative control. Input represents a positive control using the starting material 
(0.2%) prior to immunoprecipitation. The molecular weights of PCR fragments are shown in parentheses. M: 
molecular weight marker. 
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C hapter 3 
Slug and osteogenesis. 
 
 
Phenotypical characterization and osteogenic potential of human osteoblasts 
Human primary osteoblast cultures (hOBs) were generated from bone chips removed from 
???? ??????? ???????? ??? ????????? ??? ??Materials and methods?? section. We first analyzed a 
panel of nine phenotypic markers in cells at the second passage in culture. All osteoblasts 
were highly positive for the typical osteogenic markers, including Runx2, collagen type 1 
(Col1a1), bone sialoprotein (BSP), and osteocalcin (OC), and weakly positive to alkaline 
phosphatase (ALP). In addition, the cells were positive for estrogen receptor alpha (ER?), 
a protein that is known to be associated to osteoblast differentiation. The samples were 
negative for a typical hematopoietic marker (CD45), only partially positive for a 
mesenchymal marker such as CD146, and positive for CD105. After this analysis, the cells 
that we used may be considered mature osteoblasts because they express low levels of 
CD146 and ALP, and high levels of CD105, as previously reported (Tonnarelli et al., 
2008). The percentage of positive cells for the markers analyzed by immunocytochemistry 
in five hOB samples is shown in Table 1, and the immunocytochemical staining of a 
representative sample is reported in F igure 1A . Next, the cells were characterized for their 
osteogenic capacity. All hOBs exhibited an evident extracellular matrix mineralization 
after 21 days of culture under osteogenic conditions (a representative sample is shown in 
F igure 1B). 
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Table 1. Immunocytochemical analysis of human primary osteoblasts (hOBs). 
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Figure 1. Phenotypical characterization of hOBs. Five hOB samples were subjected to 
immunocytochemical analysis for ALP, CD146, BSP, OC, CD105, Col1a1, Runx2, and ER-? phenotypical 
markers. A . The staining showed the local expression of the markers analyzed in a representative sample 
(X20 magnification). B . The deposition of extracellular matrix by cells treated with osteogenic medium. 
Mineral formation was examined by Alizarin Red S staining. The deposition of calcium salts was observed in 
osteogenic cultures at day 21. 
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Silencing of Slug gene expression by siRNA in hOBs 
We firstly evaluated Slug expression in the five hOBs under investigation. As shown by  
western blot analysis performed on whole cell extracts (see F igure 2), all hOB samples 
express Slug protein at comparable levels, approximately the same that were found in 
Slug-positive MDA-MB-231 breast cancer cells (Tripathi et al., 2005). 
 
 
Figure 2.  Western blot analysis of endogenous Slug expression in hOBs. 10 µg of whole cell lysates from 
five hOBs samples were assayed on a 12% SDS-polyacrylamide gel. The proteins were visualized using 
Supersignal Femto Substrate (Pierce). Size markers are reported (KDa). IP3K was used as a loading control. 
Positive and negative controls for Slug signal (Slug-positive MDA-MB-231 breast cancer cells, and Slug-
negative MCF7 breast cancer cells, respectively) are shown. 
 
 
 
In order, to test how Slug expression may be correlated with osteoblast phenotype, we used 
an indirect approach represented by a Slug knockdown through transient using siRNA. For 
this purpose, three siRNAs against Slug were designed, siRNA/Slug1, siRNA/Slug2, and 
siRNA/Slug3. Transfection of hOBs and osteosarcoma SaOS2 cell line with these siRNAs 
resulted in the down-regulation of Slug transcript by 30% (siRNA/Slug1 and 
siRNA/Slug3) or 80% (siRNA/Slug2) (see F igure 3). 
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Figure 3. Evaluation of Slug knockdown using three different siRNAs. hOBs and SaOS-2 cells were 
transfected with three sets of Stealth siRNA duplexes against Slug (siRNA/Slug1, siRNA/Slug2, 
siRNA/Slug3) or a non relevant siRNA (scramble). Slug expression was determined after 6 days of treatment 
by quantitative RT-PCR. RT-PCR results, after correction to GAPDH content, are expressed as siRNA/Slug 
over control ratio. Results represent means ± SEM of six hOBs samples, and in SaOS-2 cell line rhe 
experiments were repeated three times. 
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Therefore, we chose to perform knockdown experiments treating the cells for 6 days with 
siRNA/Slug2 30 nM. As shown in F igure 4, western blot analysis confirmed the efficancy 
of siRNA/Slug2 that was able to inhibit protein expression by 80%. 
 
 
 
Figure 4. Silencing of Slug gene expression by siRNA/Slug2 in hO Bs. hOBs were transfected with 
siRNA/Slug2 or a non-relevant siRNA (scr). Slug expression was determined at protein level as revealed by 
western blot analysis. Representative western blot of siRNA/Slug treated cells shows a specific decrease of 
endogenous Slug protein level. 
 
 
 
 
Effect of Slug siRNA on Wnt signaling target genes in hOBs 
In order to establish a role of Slug in osteoblasts, we firstly analyzed the effects of Slug 
silencing on the expression of mediators of a central pathway in bone metabolism, such as 
Wnt signaling. 
As shown in F igure 5, Slug knockdown significantly reduced the protein levels of two 
important Wnt mediators, Lef1 and ?-catenin, in all the analyzed samples. This evidence 
suggests that the levels of Slug may interfere with Wnt signaling modulating the levels of 
Lef1 and ?-catenin transcription factors, and that Slug may consequently act by controlling 
the expression of specific genes in osteoblasts. 
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Figure 5. Effect of Slug interference on Wnt protein mediators. Western blot analysis of Lef1 and active ?-
catenin protein levels, after siRNA/Slug treatment in five hOB samples. Size markers are reported (KDa). 
IP3K was used as a loading control. 
 
 
In order to strengthen this hypothesis, the expression of downstream target genes of 
canonical Wnt signaling such as Runx2, Sox9, osteocalcin, Rankl and c-myc were 
examined in Slug silenced cells. In F igure 6A the evaluation of Runx2 and Sox9 
expression by RT-PCR and western blot is reported. Interestingly, the expression of 
Runx2, the master transcription regulator of osteoblasts previously identified as a Lef1/?-
catenin target gene (Gaur et al., 2005), was markedly decreased in Slug silenced cells 
compared to untreated osteoblasts. On the contrary, Slug knockdown induced expression 
of Sox9, a factor indispensable for chondrogenic development (Akiyama et al., 2004), both 
at mRNA and protein level in four out five samples (see F igure 6A). 
Accordingly, in four out five samples, the amount of secreted osteocalcin, which is a 
marker of late osteoblast differentiation positively modulated by Wnt signaling (Zhu et al., 
2008), was significantly reduced by Slug knockdown (see F igure 6B), as well as the 
expression of c-myc which is induced in response of activation of Wnt signaling (Katoh., 
2008) (see F igure 6C). On the contrary, mRNA levels of the receptor activator of NFkB 
ligand (Rankl), the expression of which is repressed by Wnt signaling (Spencer et al., 
2006), was significantly increased in the siRNA/Slug hOBs treated samples (see F igure 
6D). As a whole, these results suggest that Slug knockdown affects Wnt signaling and 
consequently its downstream target genes in human osteoblasts. 
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Figure 6. Effect of Slug interference on Wnt signaling target genes in hOBs. After 6 days of  siRNA/Slug 
treatment the expression of bone-related Wnt target genes was analyzed in five hOB samples. A . Runx2 and 
Sox9 expression analysis in siRNA/Slug treated cells. mRNA and protein levels were determined by 
quantitative RT-PCR and western blot analysis, respectively. Osteocalcin (B), c-myc (C), and Rankl (D) 
expression analysis in siRNA/Slug treated cells. B. Osteocalcin protein was measured in cell culture 
supernatants by ELISA. The level of c-myc (C) and Rankl (D) expression was determined by quantitative 
RT-PCR. In all quantitative RT-PCR experiments the results, after correction to GAPDH content, are 
expressed as siRNA/Slug over control ratio. Results represent means ± SEM of triplicate determinations (*p 
< 0.05, **p < 0.01) 
 
 
 
Effect of Slug siRNA on CXCL12 expression 
In order to further delineate the function of Slug transcription factor in hOBs, we also 
evaluated the effect of Slug silencing on the expression of CXCL12, a chemokine which, 
together with its receptor CXCR4, has recently been found to play an important role in 
bone tissue remodeling and repair (Dominici et al., 2009; Kitaori et al., 2009).  
We blocked the endogenous production of Slug by treating hOBs for 6 days with 
siRNA/Slug and obtained a strong inhibition of Slug mRNA, as revealed by quantitative 
RT-PCR (see F igure 7A). At the same time, we found an increase in CXCL12 mRNA (see 
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F igure 7A), but a significant decrease in CXCL12 protein in Slug-silenced cells, as seen 
by immunocytochemical (F igure 7B) and ELISA analysis (F igure 7C) by measuring 
CXCL12 intracellular expression and secretion, respectively. The absence of correlation 
between mRNA and protein levels of CXCL12 in Slug-silenced cells suggests that Slug is 
differently involved in determining CXCL12 expression at mRNA and protein level. 
 
 
Figure 7. Evaluation of Slug knockdown effect on CXC L12 expression. A . Evaluation of Slug and 
CXCL12 mRNA expression both in control (-) and in siRNA/Slug silenced (+) hOBs. Data were expressed 
as relative mRNA expression levels (% of untreated sample) ± s.e.m. * p< 0.05. B . Immunocytochemical 
analysis of CXCL12 in control (-) and in siRNA/Slug silenced (+) hOBs. Scale bar = 25?m. C . CXCL12 
protein secreted levels in control (-) and in siRNA/Slug silenced (+) hOBs. Data were expressed as pg/ml 
CXCL12/?g protein ± s.e.m. 
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????????? recruitment of Slug on Runx2, Sox9 and CXCL12 gene promoters 
In order to correlate the effect of Slug silencing on gene expression of specific genes with 
molecular events directly controlled by Slug, chromatin immunoprecipitation (ChIP) 
experiments were then performed. The promoters of Runx2, Sox9 and CXCL12 were 
chosen for this analysis. TFSEARCH program 
(www.cbrc.jp/research/db/TFSEARCH.html) revealed the presence of many putative Slug 
binding sites (E boxes) in the promoter of all three genes (see F igure 8). In order to 
determine the in vivo association between Slug and the promoter sequences, hOBs were 
exposed to formaldehyde to cross-link proteins and DNA, and sonicated to fragment the 
chromatin. Specific antibody against Slug was used to immunoprecipitate the protein?
DNA complexes and verify the functionality of these sites. The presence of the promoter-
specific DNA region before immunoprecipitation was confirmed by PCR (input). After 
immunoprecipitation, DNA was extracted from the beads and used as a template to 
generate specific PCR products spanning the putative Slug binding sites from -3000 bp to 
+1 bp in the promoter of Runx2 and Sox9 genes and from -2000 bp to +1 bp in the 
CXCL12 gene promoter. Slug recruitment was assessed at the different promoter regions, 
as indicated in F igure 8, by using specific sets of primers (see Table 1 ??????????????????
????????????????). These experiments allowed us to determine specific Slug occupancy: 
Slug was recruited at the region 2 and 3 of Runx2 gene (see F igure 8A), at the region 2 of 
Sox9 gene (see F igure 8B), and at the region 1 and 2 of CXCL12 gene. This was 
confirmed reapiting these ChIP experiments four times: this demonstrated that Runx2, 
Sox9 and CXCL12 are Slug target genes in human osteoblasts. 
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Figure 8. ???? ?????? ???????????? ??? ????? ?????????? ???-9 and CXCL12 gene promoters. Protein?DNA 
complexes were formaldehyde-cross-linked in hOBs ?in vivo?. Chromatin fragments from these cells were 
subjected to immunoprecipitation with antibody against Slug. After cross-link reversal, the 
coimmunoprecipitated DNA was amplified by PCR using the primers reported in Table 1???????????????????
????????? ???????, and specific for the indicated promoter regions. PCR fragments were resolved in 1.5% 
agarose gels. Aliquots of chromatin taken before immunoprecipitation were used as Input positive controls 
whereas chromatin eluted from immunoprecipitations lacking antibody were used as no antibody (NoAb) 
controls. The immunoprecipitates were subjected to PCR analysis using primer pairs spanning the reported 
regions of Runx2 (A), Sox9 (B), CXCL12 (C)  promoters. Representative agarose gels are shown. The 
specific molecular weights of PCR fragments are shown in parentheses. The relative positions of Slug 
putative binding sites (striped boxes) are indicated. *Sites showing 100% homology with consensus-binding 
site (CAGGTG). M: molecular weight marker. 
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Slug knockdown inhibits maturation of osteoblasts and supports 
differentiation of chondrocytes 
 
The effect of Slug silencing was then examined at cellular functional level investigating 
the osteoblast maturation in terms of ALP activity and mineralized matrix deposition. As 
shown in F igure 9A , there was a significative decrease of ALP activity after 6 days of 
siRNA/Slug treatment. Accordingly, Slug silenced cells showed a reduced mineralization 
ability; in fact, 14 days after the initiation of osteoblast induction in osteogenic medium, a 
reduction up to 86% of mineral deposition was observed in Slug silenced cells in 
comparison with non-silenced cells (see F igure 9B). This decrease in osteoblast 
maturation was accompanied by a significative decrease of other correlated markers 
including Col1a1 and classical Runx2 target genes such as osteopontin and osteocalcin, all 
analyzed by quantitative RT-PCR (see F igure 9C). 
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Figure 9. Effect of Slug depletion on osteoblast maturation. After siRNA/Slug treatment the cells were 
analyzed for the presence of alkaline phosphatase activity (ALP), formation of mineralized matrix and 
expression of osteoblast maturation markers. A . Alkaline phosphatase activity was evaluated by PNPP 
hydrolysis and ALP Leukocyte kit. The presence of sites of ALP activity appeared as blue cytoplasmic 
staining as shown in the reported representative sample (X20 magnification). B . Mineral formation was 
examined by Alizarin Red S staining in the cells cultured with ?-glycerophosphate, ascorbic acid, and 
dexamethasone (osteogenic medium). The deposition of calcium salts was observed in osteogenic cultures at 
day 14, but not in control cells (not cultured in osteogenic medium), and was quantified by measuring the 
number and surface of mineralized nodules using a digital ?????? ????????? ???????????? ????? software, 
Biorad). The ratio of the surface to the number of nodules in a representative hOB sample is reported. C . The 
expression of Col1a1, osteopontin (OPN) and osteocalcin (OC) was determined by quantitative RT-PCR in 
the cells cultured in osteogenic medium. The results, after correction to GAPDH content, are expressed as 
siRNA/Slug over control ratio. Results represent means ± SEM of triplicate determinations (*p< 0.05, **p< 
0.01). 
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Since we have here demonstrated that Slug knockdown induced expression of Sox9 in 
hOBs, investigations were then performed to evaluate the potential pro-chondrogenic 
effect of Slug knockdown in human undifferentiated chondrocytes at passage 6?8. In these 
conditions, the cells express very low level of Collagen type 2 (Okazaki et al., 2002). Slug 
mRNA expression was blocked in these cells with the same approach and effectiveness as 
in hOBs (see F igure 10). Runx2 and Sox9 expression was then tested by quantitative RT-
PCR analysis. As shown in F igure 11A , a significative upregulation of both these genes, 
required for chondrocyte maturation (Komori., 2009), was found in all analyzed samples 
after Slug silencing. This effect was accompanied by a significant increase of Collagen 
type 2 evaluated by immunocytochemistry (see F igure 11B). 
These preliminary findings demonstrate that when endogenous Slug levels are suppressed, 
chondrocytes are inclined to differentiate, supporting the idea that Slug may play a critical 
role as pro-chondrogenic factor. 
 
 
 
Figure 10. Silencing of Slug gene expression by siRNA/Slug in undifferentiated chondrocytes. 
Undifferentiated chondrocytes were transfected with siRNA/Slug or a non-relevant siRNA (scr). Slug 
expression was determined at mRNA, and revealed by quantitative RT-PCR. RT-PCR results, after 
correction to GAPDH content, are expressed as siRNA/Slug over control ratio. Results represent means ± 
SEM of three chondrocytes samples (*p< 0.05). 
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Figure 11. Effect of Slug silencing on factors involved in chondrocytes differentiation. A . Runx2 and Sox9 
expression analysis in siRNA/Slug treated cells. mRNA levels of these samples were determined by 
quantitative RT-PCR analysis. Results means ± SEM of triplicate determinations (*p< 0.05). B . Collagen 
type 2 expression analysis in siRNA/Slug treated cells. The presence of Col2a1 protein was determined by 
immunocytochemistry and appeared as violet cytoplasmic staining, as shown in the reported representative 
sample (X20 magnification). 
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C hapter 4 
Role of Slug transcr iption factor in human mesenchymal stem cells. 
 
 
Silencing of Slug gene expression by siRNA in hMSCs 
The informations derived from experiments on hOBs, led us to investigate whether the 
depletion of a transcription factor such as Slug, had a role in determining the fate of 
uninduced MSC progenitors. Therefore, we blocked Slug endogenous production in 
hMSCs using the same siRNA approach employed for hOBs and depicted in the previous 
chapter. The hMSCs isolated from tiabial plateau (TP) trabecular bone, iliac crest (IC) 
???????????????? ???????s jelly (WJ) umbilical cord, described in chapter 1, were treated 
for 6 days with siRNA/Slug 30 nM. The efficiency of the treatment was tested in all 
hMSCs by quantitative real time RT-PCR (see F igure 1A) which revealed a decrease in 
Slug mRNA expression by about 80% (p<0.05). The efficiency of Slug silencing was also 
validated at protein level by western blot analysis (see F igure 1A). 
Phase contrast microscopy observations suggested that transfected hMSCs slightly reduced 
their proliferation capacity, changed their morphology by becoming rounded in response to 
siRNA/Slug treatment, but remain viable (see F igure 1B).  
To further explore the effects of Slug knockdown on cell function, we performed the 
scratch-wound healing assay. Scratching of the hMSC monolayer triggers a migratory 
event similar to the events that happen in fracture healing. We found that Slug-depleted 
cells had an impaired ability to close the wounded area compared with control and 
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scrambled cells. After 48 hours, gap closure in Slug-depleted hMSCs was significantly 
reduced because migration from the border of the wound was very slow (see F igure 1C).  
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Figure 1. Silencing of Slug gene expression by siSlug in hMSCs. A . hMSCs were transfected with 
siRNA/Slug or a nonrelevant siRNA (scr). Slug expression was determined both at mRNA and protein level, 
and revealed by quantitative RT-PCR and western blot analysis, respectively. RT-PCR results were 
calculated using the ??Ct method, using GAPDH as the housekeeping gene, and WJ-MSCs siRNA/Slug 
transfected sample as the calibrator. Statistical analysis was performed control and a nonrelevant siRNA 
versus siRNA/Slug-silenced cells (* ,o, and ^ for hTP-MSC, hIC-MSC and hWJMSC respectively), as 
described in ?Results? section. On the bottom, representative western blot of siRNA/Slug treated cells shows 
a specific decrease in endogenous protein level. 10 ?g of whole cell lysates were assayed on a 12% SDS-
polyacrylamide gel. The proteins were visualized using Supersignal Femto Substrate (Pierce). Size markers 
are reported (KDa). IP3K was used as loading control. B . Morphological alterations and viability of 
siRNA/Slug transfected cells, determined by double staining assay with Calcein-AM and propidium bromide 
(10X magnification). C . Analysis of hMSCs migration by in vitro scratch assay. hMSCs were transfected 
with 30 nM siRNA/Slug or a nonrelevant siRNA (scr). 72h after silencing treatment, hMSCs monolayers 
were scratch wounded with a pipet tip (0h), and observed over the indicated time periods, 0h, 24h, and 48h 
(4X magnification). Images show that siRNA/Slug treated cells exhibited a reduced capacity to cover the 
scratch area compared to control cells. 
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Effect of Slug siRNA on the expression of specific genes involved in 
osteochondroprogenitors differentiation 
To investigate whether Slug has a specific role in determining the molecular signature of 
hMSCs, we analyzed the effect of Slug knockdown on the expression of transcription 
factors which are required in the control of the differentiation program of 
osteochondroprogenitors. These genes include: i. Runx2, a member of runt family playing 
a pivotal role in osteoblast differentiation decision and hypertrophic chondrocyte 
maturation (Komori., 2009; Kim et al., 1999); ii. Sox9, which is particularly necessary for 
chondrogenic differentiation commitment (Lefebvre., 1998; Bi et al., 1999); iii. Sox5 and 
Sox6 whose main function in chondrocytes is to boost the ability of Sox9 to activate major 
chondrocyte markers (Han et al., 2008); iiii. STAT1 which inhibits chondrocyte 
proliferation and regulates bone development (Xiao et al.,2004; Goldring et al., 2006). 
After Slug silencing, all genes, except Runx2 showed the same modulation that was 
independent of cell type (see F igure 2). Slug-silenced cells always showed an increase in 
Sox9 and Sox5 when compared to the control condition. In particular, this upregulation 
was significant for hTP-MSCs (for Sox9 p=0.035; for Sox5 p=0.027) and hWJ-MSCs (for 
Sox9 p=0.027; for Sox5 p=0.027). On the contrary, Sox6 and STAT1 expression declined 
in all hMSCs treated with siRNA/Slug compared to the control. In particular, 
downregulation of Sox6 was significant for hWJ-MSCs (p=0.027), while downregulation 
of STAT1 was significant for hTP-MSCs (p=0.027) and hIC-MSCs (p=0.043). 
Finally, Runx2 expression did not significantly change after the Slug knockdown, even if 
slightly increased in hIC-MSCs, and decreased in hWJ-MSCs.  
This trend suggests that Slug acts as a negative regulator of Sox9 and Sox5 expression, and 
as a positive regulator of Sox6 and STAT1 genes, in hMSCs. On the contrary, as regards 
Runx2, the role of Slug seems to be influenced by cell type. This is in agreement with data 
previously shown in human primary osteoblasts, demonstrating that the same Slug 
knockdown increased Sox9 expression, but decreased Runx2. This different role of Slug in 
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mature committed osteoblasts and in their undifferentiated progenitors suggests a cell 
stage-specific mechanism of control of Runx2 and osteoblast differentiation by Slug. 
Furthermore the human genomic DNA sequences ?????????? ??? ??? ??????????? ???????? ???
Runx2, Sox9, Sox5, Sox6 and STAT1 were analyzed for the presence of putative Slug 
binding sites (E boxes) (Nieto., 2002) by TFSEARCH predicting transcription factor 
binding sites program (www.cbrc.jp/research/db/TFSEARCH.html). This analysis revealed 
the presence of E boxes in the promoter regions of all five genes (see F igure 2), suggesting 
that they could be potential Slug target genes. 
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Figure 2. Effect of Slug knockdown on the expression of specific genes. On the left, Runx2, Sox9, Sox5, 
Sox6 and STAT1 gene expression after siSlug treatment in hMSCs isolated from tibial plateau (TP) 
??????????? ????? ?????? ?????? ????? ???????????? ????????????s jelly (WJ) umbilical cord. mRNA level was 
revealed by quantitative RT-PCR analysis. RT-PCR results, were calculated using the ??Ct method, and the 
sample with the highest ?Ct as the calibrator for each gene analysis. Statistical analysis was performed 
control versus siSlug-silenced cells (* , o, and ^ for hTP-MSC, hIC-MSC and hWJ-MSC respectively) as 
described in ?Results? section. On the right, schematic representation of Runx2, Sox9, Sox5, Sox6 and 
STAT1 human gene promoters (3000 bp upstream +1 transcription site). Using the TFSEARCH predicting 
transcription factor binding sites program, several potential Slug binding motifs have been identified in the 
promoter regions of all five genes (gray ovals). Sites showing 100% homology with consensus-binding site 
(CAGGTG/CACCTG) are indicated with black ovals. 
RESULTS 
 
157 
 
????????? recruitment of Slug on Runx2 and Sox9 gene promoters 
On the basis of these findings, we tried to dissect the relationship between Slug and some 
of the analyzed genes by investigating in vivo Slug recruitment at specific promoter 
sequences. We focused our attention on the promoter of Runx2 and Sox9 genes, and the 
functionality of their E boxes was analyzed by ChIP (see F igure 3) on six samples of 
hMSCs from the three sources. Occupancy of these E boxes by Slug was compared among 
hMSCs. ChIP data were collectively considered for the presence or absence of PCR signals 
and the different promoter regions containing the E boxes were characterized for their 
high, low or no ability to recruit Slug. The results revealed that Slug can, in vivo, associate 
with multiple sites across Runx2 and Sox9 promoters to a different extent regardless of the 
hMSCs source. 
Considering Runx2 gene, Slug associated with region 2 and 3 to a similar extent, but more 
localized to a discrete region proximal to the transcription start site (region 1). 
Interestingly, the E boxes within region 1 are highly conserved, as revealed by the 
alignment of sequences from rat, mouse and human (see F igure 3A). 
Furthermore, with regard to Slug occupancy of Sox9 promoter, region 2 was the only one 
involved in the interaction, while no chromatin was immunoprecipitated from the region 1 
(see F igure 3B). The alignment of Sox9 sequence promoters from rat, mouse and human 
revealed no significant homology. 
As a whole, these ChIP experiments revealed that both Runx2 and Sox9 are Slug target 
genes in hMSCs, and that the E boxes present in these promoters are differently involved 
in the Slug recruitment. 
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Figure 3. In vivo recruitment of Slug on Runx2 and Sox9 human gene promoters. Protein?DNA 
complexes were in vivo formaldehyde-cross-linked in six samples of hMSC isolated from tibial plateau (TP) 
?????????????????????????????????????????????????? ???????s jelly (WJ) umbilical cord. Chromatin fragments 
were subjected to immunoprecipitation with antibody against Slug. After cross-link reversal, the 
coimmunoprecipitated DNA was amplified by PCR using the primers pairs spanning the reported regions of 
Runx2 and Sox9 promoters. Aliquots of chromatin taken before immunoprecipitation were used as input 
positive controls whereas chromatin eluted from immunoprecipitations lacking antibody were used as no 
antibody controls (NoAb). PCR fragments of all samples analyzed were resolved in 1.5% agarose gels and 
subjected to densitometric analysis for a semi quantitative determination of occupancy of binding sites. High, 
low or no ability to recruit Slug is represented by the extent of the black portion of the square. A 
representative PCR analysis is reported below each investigated region. The relative positions of Slug 
putative binding sites (gray ovals) are indicated. Sites showing 100% homology with consensus-binding site 
(CAGGTG/CACCTG) are indicated with black ovals. The alignment of sequences from rat, mouse and 
human of Runx2 promoter region 1 is reported, showing the highly conserved E boxes.
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DISC USSI O N 
 
 
The complexity of bone cell  functions, appears from several molecular and cellular 
studies, both in terms of differentiation and bone development, and for alterations of this 
tissue in various diseases. The proper bone formation and the maintenance of bone 
homeostasis are regulated by different signaling pathways, known in detail only minimally. 
These signaling pathways, interacting each other, modulate different target genes, which 
play a specific function during differentiation and proliferation of osteoblasts, osteoclasts 
and their precursors. Understanding the mechanisms that control bone formation and 
transcription factors that regulate the expression of specific genes in osteoprogenitors and 
bone mature cells, is the target of much research aimed to develop effective therapeutic 
strategies, in order to solve many pathological conditions as well as osteogenic 
abnormalities, such as critical sized defects, non-union fractures, and vertebral 
interventions. These research make use of experimental strategies and opportune models of 
study in order to transfer as much as possible, the results from the laboratory to the clinic.  
In this context, bone tissue engineering represents a new approach for bone tissue repair 
and regeneration. The regeneration of bone tissue is a multidisciplinary approach that is 
based on the synergistic interaction between human bone cells, various types of scaffolds 
and the concerted action of both positive and negative regulatory factors which control 
osteoblast commitment, differentiation, and functions. In particular, the search for new 
crucial molecules for the commitment of MSCs toward osteogenic lineage and the 
understanding of role that specific transcription factors play in determining osteoblast 
phenotype, are important issues in bone regeneration and repair field. 
 
These considerations have guided the setting of the experiments described in this thesis 
that focused on the study of Slug protein. Through a series of in vitro and in vivo 
experiments, we investigated, for the first time, the expression and role of Slug gene in 
human normal osteoblasts and their mesenchymal precursors, characterizing:  
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- the regulatory elements located in its promoter;  
- the effect of its silencing;  
- its correlation with Wnt pathway and osteogenesis process. 
We started from the consideration that alterations in gene regulation are often associated 
with the onset of various pathological conditions or the difficulty of a cell population to 
react to a tissue trauma. A broad area of molecular biology is aimed, to identify and correct 
such modifications by the recognition of specific binding sequences for transcription 
factors in the genome and the design of new therapeutic molecules, including antisense 
oligonucleotides, decoy molecules, siRNA, antagomir and vectors for gene therapy in an 
attempt to restore the physiological condition.  
With regard to Slug gene, as described in the introduction of this thesis, possible 
alterations in the regulation machinery, which determines Slug absence, have been 
associated with defects in embryonic development (Hemavanthy et al., 2000), while its 
overexpression was found in many types of cancer (Barrallo-Gimeno et al., 2005). To date, 
for what concerns adult bone tissue, Slug, indeed, is considered exclusively a marker of 
malignancy and, consequently, an attractive potential target for therapeutic modulation of 
bone metastasis and osteosarcoma invasiveness (Guo et al., 2007), blocking its expression 
and potentially repressing any detrimental downstream effects. However, there are no data 
about Slug expression and regulation in human normal osteoblasts. Therefore, we started 
investigating in this direction supported by the evidence that: 1. Slug positively affects 
differentiation and migration of osteoblasts from neural crest in the craniofacial 
compartment and 2. the process of fracture repair mimics the embryonic bone development 
where a critical role is played by Slug. 
 
In this study we have demonstrated that the transcription factor Slug:  
- is present at substantial levels in normal human osteoblasts and their mesenchymal 
precursors;  
- is positively correlated with osteogenesis;  
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- is positively regulated by Lef1 and Runx2 osteoblastic transcription factors which are 
directly in vivo recruited in the Slug promoter.  
In particular, our Slug promoter study revealed in a region of approximately 1 Kb upstream 
of the transcription start site, the presence of two putative binding sites for Runx2 and, at 
least, six potential consensus binding sites for the Lef/Tcf family, and not just only one at -
859/-855 position, as recently reported (Saegusa et al., 2009; Hong et al., 2009). We found 
that the sequence regions containing these sites are all involved in the in vivo recruitment 
of Runx2 and Lef/Tcf factors, including Lef1, Tcf-1 and Tcf-4, in human normal 
osteoblasts. On the contrary, the research of other groups focused on cancer experimental 
models demonstrated, for example, the ability of Tcf binding site at -859/-855, to recruit 
Tcf-4 in SW480 human colon cancer (Hong et al., 2009), but not in Hec251 endometrial 
cancer cell line (Saegusa et al., 2009) where, Slug expression seems ??????????????-catenin 
without the involvement of Lef/Tcf factors. Other studies in animal experimental models 
provide evidence that Slug promoter in Xenopus and mouse is directly activated by ?-
catenin/Tcf complexes through the binding sequences (Sakai et al., 2005; Vallin et al., 
2001), and that Slug promoter activity may be inhibited by dominant negative Tcf 
(Conacci-Sorrell et al., 2003). Therefore, combined with these reports, our results 
strengthen the hypothesis that, directly or indirectly, Slug and Lef1 are strictly correlated in 
many cellular events, including osteoblast differentiation, mediated by Wnt/?-catenin 
signalling.  
 
A relationship between Slug and Wnt signalling was also confirmed by our experiments 
with SB216763?? ?? ????????? ????? ??? ????????? ?-catenin levels suppressing GSK-???
activity. Interestingly, SB216763-treated osteoblasts showed a significative Slug gene 
expression increase. This finding correlates positively Slug with osteoblast function, being 
?-catenin largely investigated in association with osteogenesis process. It is largely 
????????? ????? ?-catenin Lef/Tcf transcription factor family cooperate to promote the 
expression of several genes through the recruitment of other factors to form a 
transcriptionally active complex (Nusse., 1999; Case et al., 2008). In the bone context Lef1 
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is reported to have an important role in osteoblast maturation for its ability in the 
regulation of expression of genes involved in the stimulation of bone formation, such as 
Runx2 and Col11a1 (Gaur et al., 2005; Kahler et al., 2008). In addition, an age- and 
gender- dependent role for Lef1 in regulating bone formation in vivo has recently been 
described (Noh et al., 2009). The discovery that Slug expression is upregulated during 
osteogenesis, is positively correlated with the expression of Runx2 and Lef1, and its 
regulation is under the control of Runx2 and Lef1, corroborates the proved function of 
Runx2 in bone tissue and the role of Lef/Tcf transcription factors in osteoblasts. Therefore, 
our results highlight the mechanisms by which Lef1 may affect maturation and 
differentiation of these cells, suggesting a new role of Slug. 
 
Slug knockdown experiments were particularly informative in support of this hypothesis, 
and the suppression of Slug mediated by siRNA increases Runx2 expression, weakens 
Wnt/?-catenin signaling, decreases ALP activity, as well as osteoblast mineralization, 
osteopontin, osteocalcin, and Col1a1, demonstrating that Slug may be considered a novel 
osteogenic factor. It is important to underline that the specificity of the Slug silencing 
effects is attested also by the expression of Rankl which is suppressed by Wnt signaling in 
osteoblasts (Spencer et al., 2006) and is enhanced in response to Slug knockdown, further 
supporting the link between Slug and Wnt. 
 
The investigation of the link between Slug and another important osteoblast marker, the 
CXCL12 chemokine, has allowed us to highlight a potential dual action level of Slug as 
modulator of gene expression. Unexpectely, Slug-silenced osteoblasts showed an increase 
of CXCL12 mRNA but a decrease of CXCL12 protein. CXCL12, together with its receptor 
CXCR4, has recently been suggested to be involved in the bone remodeling process 
(Ponomaryov et al., 2000; Dominici et al., 2009; Otsuro et al., 2008), in the recruitment of 
MSCs to the fracture site during skeletal repair (Kitaori et al., 2009); also it is highly 
expressed and secreted by regenerating/proliferating osteoblasts after irradiation in mouse 
models (Dominici et al., 2009). Although a recent partial characterization of the gene 
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promoter suggested that both the constitutive and induced expression of CXCL12 is finely 
regulated at transcriptional level (Garcia-Moruja et al., 2005; Calonge et al., 2010), the 
molecular mechanisms involved in directing the correct levels of this chemokine remain 
unclear. In our study, we found that Slug knockdown in hOBs induced a consistent 
decrease of CXCL12 protein even if the corresponding mRNA increased. One explanation 
for this apparent discrepancy found for mRNA and protein expression of CXCL12 in Slug-
silenced cells may be the presence of numerous potential Slug targets in the cell and, 
consequently, the wide spectrum of effects generated by its silencing. Therefore, our 
findings suggest possible different roles for Slug and consequently at least two different 
main effects of Slug knockdown: a) Slug may act as a repressor of CXCL12 gene 
transcription and its silencing removes the negative control by increasing CXCL12 mRNA 
levels, b) Slug may have an indirect positive impact on components of specific pathways 
correlated with expression, stability secretion and activity of CXCL12 and its silencing 
results in a decrease in CXCL12 protein. The first hypothesis, supported by the fact that 
Slug is specifically recruited to CXCL12 promoter in vivo as shown by chromatin 
immunoprecipitation analysis, suggests that high levels of CXCL12 mRNA are not 
sufficient to assure high levels of CXCL12 protein. Therefore, we may conclude that the 
amount of CXCL12 protein depends on several factors and mechanisms including Slug-
mediated events. Nevertheless, since the remarkable final phenotypic effect mediated by 
Slug silencing is the decrease in CXCL12 protein expression and secretion, it may be 
concluded that the presence of Slug is required for CXCL12 protein expression: this 
support the hypothesis that both proteins are crucial for osteoblast phenotype and 
strengthen the critical role of Slug in osteoblasts as we have propose. This is the first study 
where the relationship between CXCL12 and Slug is analyzed in a bone cellular context. In 
agreement with our observations, the potential strict correlation between CXCL12 
signaling and Slug activity has been shown in experimental models that can be related to 
bone. For example, CXCL12 and Slug are both involved in neural crest cell (NCC) 
migration. Recent evidence suggests that both knockdown and an over-expression of 
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CXCL12 and its receptor leads to migration and important craniofacial defects for 
patterning the craniofacial skeleton (Olesnicky Killian et al., 2009). 
 
Another important evidence from our results on Slug silenced cells has opened a possible 
new scenario about Slug function. This concerns the effect of Slug silencing on Sox9 
expression. We observed that Slug silencing potentiates the expression of Sox9 both in 
hOBs and in undifferentiated chondrocytes. This is particularly interesting in the context of 
maturation and differentiation of these cells because Sox9 is an indispensable factor for 
chondrogenic development (Akyama et al., 2004; Komori., 2009), activating cartilage-
specific genes, but acts also as a transcriptional repressor for osteoblast differentiation 
(Zhou et al., 2006), interacting with Runx2 and repressing its function. Therefore, our 
findings may suggest not only that Slug is required for supporting osteogenic maturation, 
but also that Slug suppression may have a potential pro-chondrogenic effect. Thus, Slug 
could affect phenotypical changes in response to alteration of its expression levels favoring 
the dominance of Runx2 function over Sox9 or vice versa. This is in agreement with 
several observations demonstrating that, in order to achieve differentiation towards a 
desired lineage, it is important to direct the stem cell differentiation with correct levels of 
transcription factors (Soltanoff et al., 2009; Davis and Zur Nieden, 2008).  
In this context, the concept of manipulating specific transcription factors is creating great 
interest. Overexpression or depletion of transcription factors, including Runx2, Osterix, 
Sox9, Twist1, NFATc1, Foxo1, Sp1, HIF-1 c/EBP, and Rex-1, was recently performed in 
MSCs (Lin et al., 2006; Miraoui et al., 2010; Tominaga et al., 2009; Deng et al., 2008; 
Wan et al., 2010; Bhandari et al., 2010). This approach is largely based on the knowledge 
of the molecular networks implicated in osteogenic differentiation, and, at the same time, it 
allows the identification of the role of a specific 
transcription factors in mediating the fate and maturation of hMSCs. These considerations 
are part of a wider field of observations including those sustaining that the level of 
modulation of several osteoblastic genes may differ depending on culture conditions and 
source from which the cells are taken (Mosna et al., 2010; Hsieh et al., 2010; Noel et al., 
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2008; Mannello et al., 2007; da Silva Meirelles et al., 2008). This may have significant 
implications for cell-based bone tissue regeneration, particularly when much evidence in 
literature suggests that the basal expression levels of specific genes in uninduced MSCs 
may have a crucial role in this scenario (Karsenty., 2008; Marie., 2008; Satija et al., 2007). 
To corroborate this hypothesis and further Slug knowledge, we performed a series of 
experiments with hMSCs isolated from tibial plateau (TP) trabecular bone, iliac crest (IC) 
bone marrow ???? ???????? jelly (WJ) umbilical cord opportunely selected. 
Because we had the opportunity to have a large number of WJ samples, it was possible 
design a series of experiments ad hoc to discriminate among different WJ-MSC samples 
those will have a positive outcome towards osteoblastic differentiation.  Comparing the 
presence of ALP and Runx2 osteoblastic markers with different obstetric parameters, 
?????????????????????????????????????????????????????????????????????? ?????????????????????
and mode of delivery), we found, in fact, that the highest degree of osteoblastic potential 
has been shown by WJ-MSCs with Runx2 transcription factor high basal levels, selected 
from umbilical cords of the heaviest term babies. In addition, our results suggest that it is 
preferred to recruit the samples from full term ???????????????????????????????????????????
age. 
Therefore, even if further evaluation is required, our hypothesis is that our findings may 
help in selecting the optimal umbilical cord donors and in collecting high potential 
?????????? ?????-derived osteoprogenitors efficiently. The analysis of the basal level of 
Runx2 and ALP activity could allow to quickly test an high number of mesenchymal 
precursors cultured in vitro and select the more suitable to potentially use for bone tissue 
engineering application.  
 
Harking to experiments performed in hTP-MSCs, IC-MSCs and WJ-MSCs, we 
demonstrated that the cell response to a same in vitro microenvironment may be different. 
Firstly, we found that hMSCs isolated from the three sources possess similar surface 
marker profiles, but the basal expression levels of transcription factors which control 
differentiation program of osteochondroprogenitors, such as Runx2, Sox9, Sox5, Sox6, 
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STAT1 and Slug, are different. In particular, hWJ-MSCs showed the lowest expression 
levels of Runx2, Sox9, STAT1 and Slug. Furthermore, investigations of the osteogenic 
potential of hMSCs isolated from the three sources highlighted that osteogenically induced 
hWJ-MSCs showed the characteristic staining of bone-like nodules beginning from day 7, 
whereas the same signs of mineralization were evident in hTP- and hIC-MSCs only from 
day 14. Nevertheless, hWJ-MSCs were not able to reach at day 21 the level of 
mineralization that we found in the other hMSCs. These data indicate that there is a 
variability in the extent of osteogenic differentiation among the analyzed hMSCs. This is 
confirmed by the fact that Runx2 expression showed a trend to decrease in hTP-MSCs, 
remained constant in hIC-MSCs, but increased in hWJ-MSCs after 21 days in osteogenic 
medium. It is, in fact, well established that, during bone development, Runx2 induces 
osteoblast differentiation and increases the number of immature osteoblasts, which form 
immature bone, whereas Runx2 expression has to be downregulated for differentiation into 
mature osteoblasts, which form mature bone (Komori., 2010; Maruyama et al., 2007). On 
the contrary, hWJ-????? ?????? ??? ???? ?????? ?? ????????? ????-?????? differentiation, 
quickly respond to osteogenic medium. This is in accordance with many other previously 
reported features of umbilical cord-derived stem cells (Hsieh et al., 2010; Moretti et al., 
2010; Troyer and Weiss, 2008).  
We may speculate that, thanks to the ease of accessibility, lack of ethical concerns, and 
abundant cell number, hWJ-MSCs may be a particularly promising cell population, 
supporting new concepts in cellular therapy. These cells appear to possess the proper stage 
of development that makes them preferable candidates when a bone regeneration under 
endogenous factors control is required. In many cases, in order to promote tissue 
integration, it is, in fact, critical that the pre-differentiated osteogenic progenitors to be 
implanted are able not only to differentiate, but also to interact with the endogenous 
microenviroment and respond to local differentiation signals in vivo. This capability can be 
carried on by cells that have not completely reached the terminal differentiation, such as 
the hWJ-MSCs here described. Conversely, it is conceivable that tibial plateau or iliac 
crest, from which we obtained the other hMSCs, are already committed compartments 
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containing stem cells with a higher maturation stage and particularly prone to form mature 
bone. Probably, these kind of cells are to be preferred when large bone defects have to be 
repaired.  
Another important issue that bone tissue regeneration and repair through therapeutic use of 
cells have to take into account, is that the achievement of pre-differentiated osteogenic 
progenitors requires the employment of induction media containing exogenous 
recombinant growth factors, fetal bovine serum, hormones and other reagents whose 
effects on long-term in vivo differentiation are not known, and which may be potentially 
negative by transmitting infectious agents and triggering an immune response. Therefore, 
in the light of these considerations, it is interesting to investigate the possibility that the 
change in the levels of specific gene transcription can replace the standard method of 
induction to differentiation. In this regard and in order to further investigate the properties 
of the hTP-MSCs, hIC-MSCs and hWJ-MSCs, another aspect we considered in this thesis 
has been the possibility to affect the behaviour of hMSCs by using gene silencing approach 
without exposing cells to induction media. In particular, the informations derived from 
experiments on hOBs, led us to investigate whether the depletion of a transcription factor 
such as Slug, had a role in determining the fate of uninduced MSC progenitors. Our results 
obtained from RT-PCR analysis depicted a complex scenario where all Slug-silenced 
hMSCs from the three sources showed generally a higher expression of Sox9 and Sox5, 
and a lower expression of Sox6 and STAT1 in comparison with control cells. This suggests 
that Slug acts as a negative regulator of Sox9 and Sox5 expression, and as a positive 
regulator of Sox6 and STAT1 genes. Sox5, Sox6 and Sox9 constitute the so-called SOX 
trio and are essential factors for the development of embryonic cartilage, and are mainly 
associated with the commitment of undifferentiated MSCs into chondrocytes (Ikeda et al., 
2004). In particular, Sox9 is the first essential transcription factor for chondrocyte 
differentiation (Lefebvre., 1998; Bi et al., 1999). Sox 5 and Sox6 are indicated as 
downstream genes of Sox9 in chondrocytes, but are not absolutely necessary for 
chondrocyte differentiation even if they strongly potentiate Sox9 activity (Han et al., 2008; 
Ikeda et al., 2004). Recent studies in MSCs have demonstrated that SOX trio family 
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members may be differently regulated. For example, BMP-2, which was reported to 
control chondrogenic differentiation, increased Sox6 and Sox9, but not Sox5 mRNA 
expression (Fernandez-Lloris et al., 2003). As a whole, our results strengthen the evidence 
that a specific factor may differently affect SOX trio regulation, suggesting also a novel 
role for Slug transcription factor. In future studies, we will determine whether Slug acts 
directly on Sox5 and Sox6 promoters or the up-regulation of Sox5 by Slug gene silencing 
was mediated by Sox9.  
Another interesting finding after Slug silencing is STAT1 downregulation. This result 
demonstrates the specificity of knockdown treatment and suggests that STAT1 expression 
is positively regulated by Slug. Accordingly, in chondrogenesis, STAT1 acts downstream 
in relation to Slug and, as Slug, negatively regulates the proliferation of 
chondroprogenitors (Goldring, 2006). Conversely, a recent study demonstrates that STAT1 
is a negative regulator for osteoblast differentiation, and suggests that inhibition of STAT1 
activity may be beneficial for skeletal fracture treatment (Tajima et al., 2010).  
As a whole, these findings support the hypothesis that 1. modulating the expression of one 
or more specific transcription factors a preferential selection of osteo- or chondro- 
precursors may be obtained; and 2. although the mechanisms of this process are currently 
unknown, nevertheless it seems that they are dependent on experimental models and 
developmental stages of the cells. Therefore, to clarify the role of specific transcription 
factors in osteochondroprogenitors and bone mature cells, and to understand the possible 
discrepancies between the data collected so far, further investigations are required. These 
observations are consistent with the results obtained regarding Runx2 in Slug-silenced 
hMSCs. In fact, concerning Runx2, the role of Slug seems to be influenced by cell type. 
We found that, after Slug knockdown, Runx2 expression did not significantly change. This 
can be explained by the evidence that Runx2 has a broader spectrum of phenotype control 
of a cell in comparison with SOX trio or STAT1. In fact, in addition to its role in 
osteoblast differentiation, Runx2 also promotes chondrocyte maturation (Kim et al., 1999; 
Goldring., 2006). This confirms that, for certain genes, including Runx2, their 
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susceptibility to be modulated in expression levels depends on gene function, and is strictly 
correlated with heterogeneity and properties of MSC population. 
 
Based on findings obtained, Slug might represent a new regulation factor required for 
human osteoblast differentiation and maturation, although further studies are required to 
elucidate its regulation and its role in MSCs fate determination. This is can properly done 
with appropriate manipulation of gene expression and using three?dimentional culture 
conditions which, overall,  might affect cell behaviour leading to significant improvement 
in the efficiency of tissue engineering and enhancing the therapeutic value of stem 
cells/osteoprogenitors for the restoration of bone defects. 
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C O N C L USI O NS A ND F U T UR E W O R K  
 
 
 
The experimental approach and data described in this thesis take place in a very broad 
view that regards the understanding of the molecular mechanisms of osteogenesis process, 
and the development of alternative strategies to induce efficient differentiation of hMSCs 
in bone and cartilage tissue engineering and repair. 
Summarizing, the development of effective cellular-based therapies for regenerative 
medicine is based on the achievement of several objectives: 
- Development of new strategies to select most potential cells donors/sites could be 
helpful in expanding and obtaining larger cell population, overcoming the problem 
connected to the small number of stem cells in adult tissue stem cell niche; 
- In vitro manipulation of hMSCs could allow the control of their self-renewal, 
proliferation, and senescence. On the other hand, strategies to prevent and avoid 
hMSCs transformation have to be developed, in order to ensure safe use in short 
and long term therapies with these cells; 
- Development of multicompartimental biomaterial systems for the realization of 
????????-?????????????????????????????????????????????????????????????les, such 
as nutrients, growth factors and pre-differentiating agents promoting the biological 
response to bone and cartilage tissue engineering applications; 
- Appropriate manipulation of gene expression to modificate cell characteristics, 
improving the efficiency of tissue engineering and enhancing the therapeutic value 
of stem cells/osteochondroprogenitors for the restoration of bone defects. 
 
All these efforts and increasing knowledge around human osteochondroprogenitors and 
mature cells through basic research experiments will be of considerable clinical 
significance, especially in terms of developing novel mechanisms of achieving tissue 
regeneration. 
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In particular, in these years, much attention has been paid to discovery the pathways and 
factors implicated in the regulation of hMSCs differentiation process. At present, a great 
number of experimental strategies are addressed to investigate the role of epigenetic 
mechanisms and key transcription factors implicated in the control of stem cell properties, 
as well as in the chondrogenic or osteoblast committed status, in order to identify potential 
therapeutic molecules. In bone tissue context, much research are based on the targeting of 
hMSCs with constructs that cause permanent expression of transcription factors (e.g., 
Satb2, Hoxa2, Runx2, osterix, APC/?-catenin/LefTcf-1) pertaining to osteoblastogenesis 
and/or overexpression of miR- (e.g., miR-29b) upregulated in osteoblasts, or the use of 
miR- antagonists, in stable and inducible viral mono- or polycistronic constructs, that 
target miR- species (e.g., miR-125b, MiR-133, and miR-135a) downregulated in 
osteoblasts. 
Regarding the work of this thesis, we may conclude that our results have identified Slug as 
a new osteogenic factor suggesting that it may be considered a novel therapeutic target for 
bone tissue engineering. Slug suppression, in fact, might have a therapeutic value in 
diseases that involve the formation of ectopic bone such as osteopetrosis and ankylosing 
spondylitis or in pathologies that require chondrocytes differentiation such as 
osteoarthritis. 
Nevertheless, further investigations have to be performed in order to determine the role of 
other transcription factors that take part in Slug regulation and function in hMSCs, and to 
identify the biological phenomena affected by Slug knockdown. 
For these purposes, the molecular aspects of our future work will be based on these main 
objectives: 
- the identification of new potential transcription factors involved in Slug gene 
expression regulation; 
- the identification of new Slug target genes; 
- understanding of Slug function in mesenchymal stem cells commitment, by Slug 
stably-inducible knocked down cells which we are now creating with lentiviral 
systems: 
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- the identification of new osteoblast-specific proteins correlated with Wnt signaling, 
during hMSCs osteoblastogenesis. 
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Evaluation of chemokine and cytokine profiles in osteoblast progenitors
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Abstract
We have used cytokine protein array to analyze the secretion of cytokines from an osteoblastic clone derived from human umbilical cord
blood mesenchymal stem cells (MSCs) cultured in an osteogenic differentiation medium. The analysis demonstrated the unexpected ability
of osteoblast committed cells and their early progenitors to produce significant amounts of a range of soluble immune mediators without in vitro
exposure to clinically relevant bacterial pathogens. The cells were expanded and their osteogenic potential analyzed over 45 days of culture was
revealed by the expression of osteoblast-specific markers (alkaline phosphatase and Runx2), and by matrix mineralization. Over this culture
period, the cells secreted particularly high levels of IL-8, MCP-1 and VEGF, but did not express IL-2, IL-7, IL-17, eotaxin, G-CSF and
IFN-g. These findings should encourage the use of human umbilical cord blood as a potential stem cells source for bone regeneration.
! 2007 International Federation for Cell Biology. Published by Elsevier Ltd. All rights reserved.
Keywords: Osteoblasts; Mesenchymal stem cells; Cytokines; Chemokines; Bio-plex analysis
1. Introduction
There is evidence that umbilical cord blood (UCB) can be
used not only as an alternative source for hematopoietic cells,
but also for mesenchymal stem cells (MSCs). These cells are
of interest because they can differentiate into osteogenic,
chondrogenic, adipogenic, myogenic and neuronal lineages
under controlled in vitro conditions (Kang et al., 2006; Rogers
and Casper, 2004; Erices et al., 2000). However, the frequency
of non-hematopoietic precursors in UCB is low and our evi-
dence, together with several other observations (Kang et al.,
2006; Rogers and Casper, 2004; Erices et al., 2000; Chang
et al., 2006; Gang et al., 2004; Rosada et al., 2003), suggests
that their isolation, growth, expansion and differentiation are
difficult. Concerning the development of bone-forming osteo-
blastic cells from MSCs, several morphologic, biochemical
and molecular techniques for the identification and character-
ization of osteogenic commitment are now available. These in-
clude the identification of expression of bone-related markers,
such as Runx2, type I collagen, alkaline phosphatase, osteo-
pontin, osteonectin, osteocalcin (Rosada et al., 2003; Bieback
et al., 2004; Hutson et al., 2005), and the sites of mineraliza-
tion through von Kossa-positive bone nodules analysis (Erices
et al., 2000).
Accumulating evidence indicates that both bone-forming
osteoblastic cells (OBs) and osteoclasts (OCs), the unique
bone resorptive cells, may release and respond to chemokines
(Kim et al., 2005; Dimitriou et al., 2005; Liu and Hwang,
Abbreviations: OBs, osteoblasts; MSC, mesenchymal stem cell; UCB,
umbilical cord blood; DMEM, Dulbecco’s modified Eagle’s medium; FBS,
fetal bovine serum.
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2005; Takayanagi, 2007). However, little is known regarding
which chemokines or corresponding receptors play important
roles in the development and function of bone cells under nor-
mal or pathological conditions. To date, the investigation of
cytokines and chemokines production by cells from bone tis-
sue has been restricted to inflammatory conditions with a dys-
regulated bone remodeling, including bacterial infections and
osteoarthritis (Wright and Friedland, 2002; Marriott et al.,
2005; Abramson and Yazici, 2006). On the contrary, we are in-
terested in understanding whether the secretion of OBs precur-
sors from MSC soluble factors can promote the induction of
osteogenesis and OB clonal expansion. This information is
of great interest from both the theoretical and practical point
of view, since it may be exploited to improve osteogenic
cell culture medium and facilitate isolation procedures to-
gether with expansion efficacy.
2. Materials and methods
2.1. Isolation of mononuclear umbilical cord blood cells
UCB cells were separated into a Hystopaque-1077 (Sigma) and mononu-
clear cells were washed, suspended in culture medium (D-MEM High-glucose
containing 10% FBS) (Euroclone) at a concentration of 1 ! 106 cells/cm2.
Cultures were maintained at 37 "C in a humidified atmosphere, 5% CO2 in
air, with a change of culture medium every 7 days. UCB derived mesenchymal
stem cells (UCB-derived MSCs) were cultured in osteogenic medium consist-
ing in DMEM High-glucose supplemented with 10% FBS, 10 mM b-glycero-
phophate, 0.1 mM dexamethasone and 50 mM ascorbate up to 45 days. In the
committed cells, the osteogenic medium was changed every three days. Oste-
ogenic differentiation was evaluated by alkaline phosphatase (ALP) staining,
calcium deposition and immunocytochemistry analysis.
For alkaline phophatase staining, prefixed mono-layered cells were incu-
bated at room temperature in a solution containing naphthol AS-BI phosphate
and freshly prepared fast blue BB salt buffered at pH 9.5 with 2-amino-2-
methyl-1,3-propanediol (Alkaline Phosphatase Leukocyte kit, Sigma). The
presence of sites of ALP activity appeared as blue cytoplasmatic staining.
The extent of mineralized matrix in the plates was determined by Alizarin
Red S staining (Sigma). Briefly, cells were fixed in 70% ethanol for 1 h at
room temperature, washed with PBS, stained with 40 mM AR-S (pH 4.2)
for 10 min at room temperature, washed five times with deionized water and
incubated in PBS for 15 min to eliminate non-specific staining. The stained
matrix was observed at different magnification using a Leitz microscope.
Immunocytochemistry analysis was performed employing the streptavidin-
biotin method using Ultraystain Polyvalent-HRP Immunostaining Kit (Ylem).
Cells grown in chamber slides were fixed in cold 100% methanol, and permea-
bilized with 0.2% (vol/vol) Triton X-100 (Sigma) in TBS (Tris-buffered sa-
line). Cells were incubated in 3% H2O2 and the endogenous peroxidase was
blocked with Super Block reagent. A polyclonal antibody for Runx2 (clone
M-70, rabbit anti-human, 1:1000 dilutiondSanta Cruz Biotec), was applied
and incubated at 4 "C overnight. Cells were then incubated at room tempera-
ture with anti-polyvalent Biotinylated Antibody. After rinsing in TBS, Strep-
tavidin HRP was applied, and followed by the addition of Substrate-
chromogen mix (AEC Cromogeno kit-Ylem). After washing, cells were
mounted in glycerol/PBS 9:1 and observed using a Leitz microscope.
2.2. Bio-Plex analysis
UCB-derived MSCs secretion samples were collected at different days
(Fig. 1) and were assayed in duplicate. Concentrations of IL-1b, IL-1RA,
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15,
IL-17, Eotaxin, FGF-basic, G-CSF, GM-CSF, IFN-g, IP-10, MCP-1, MIP-1a,
MIP-1b, RANTES, PDGF, VEGF and TNF-a were simultaneously evaluated us-
ing commercially available multiplex bead-based sandwich immunoassay kits
(Human 27-plex, Bio-Rad Laboratories). Assays were performed following
the manufacturer’s instructions. Briefly, 27 distinct sets of fluorescently dyed
beads loaded with capture monoclonal antibodies specific for each cytokine
to be tested, were used. Secretion samples (50 ml/well) or standards (50 ml/
well) were incubated with 50 ml of pre-mixed bead sets into the wells of
a pre-wet 96 well microtitre plate. After incubation and washing, 25 ml of fluo-
rescent detection antibody mixture were added for 30 min and then the sam-
ples were washed and resuspended in assay buffer. High standard curves for
each soluble factor were used, ranging from 2.00 to 32,000.00 pg/ml and
the minimum detectable dose was <10 pg/ml. The formation of different sand-
wich immunocomplexes on distinct bead sets was measured and quantified us-
ing the Bio-Plex Protein Array System (Bio-Rad Laboratories). A 50 ml
volume was sampled from each well and the fluorescent signal of a minimum
of 100 beads per region (chemokine/cytokine) was evaluated and recorded.
Values presenting a coefficient of variation beyond 10% were discarded before
the final data analysis.
All values were normalized with respect to total protein amount of each
secretion sample. The protein recovery was determined with Bradford method.
2.3. Data analysis and statistics
Data were analysed using the Bio-Plex Manager software version 3.0 (Bio-
Rad Laboratories). Standard levels between 80 and 120% of the expected
values were considered to be accurate and were used. In general, at least 5
standards were accepted and used to establish standard curves following
a 5-parameter logistic regression model (5PL). Samples concentrations were
immediately interpolated from the standard curves. Values were expressed
as pg/ml and presented as mean # SD.
3. Results
3.1. Isolation and differentiation of an osteogenic clone
from hUCB
We are routinely generating heterogeneous adherent cells
from the mononuclear fraction of human UCB under exposure
to osteogenic medium. The osteogenic potential of MSCs and
the progression of osteogenesis are considerably variable and,
as also reported by other researchers, spindle-shaped MSCs
yield varies with the age and the condition of the donor
(Chang et al., 2006; Gang et al., 2004; Rosada et al., 2003).
In order to characterize OBs and their progenitor cells
throughout the period of clonal expansion in vitro in respect
of their chemokines secretion, the levels of 27 cytokines
were simultaneously measured using the multiplex Bio-Plex
technology (Vignali, 2000). The soluble factors analyzed in-
clude those belonging to the inflammatory panel (GM-CSF,
IL-1b, IL-1RA, IL-6, IL-8 and TNFa), the chemokine panel
(eotaxin, IP-10, MCP-1, MIP-1a, MIP-1b, RANTES), the
Th1/Th2 panel (IFN-g, IL-2, IL-4, IL-5, IL-9, IL-10), the cy-
tokine II panel (IL-7, IL-12p70, IL-13, IL-15, IL-17) and
VEGF (Vascular Endothelial Growth Factor), b-FGF (basic Fi-
broblast Growth Factor), G-CSF (Granulocyte Colony Stimu-
lating Factor) and PDGF-BB growth factors.
We chose to consider a cellular clone that was expanded
from mesenchymal-like cells isolated from the Ficoll layer
of an UCB sample (a 28 year old donor at the 39th gestational
week) and plated in a 24 multi-well plate. This clone was
spontaneously selected in one well out of 24 after 14 days of
osteogenic culture medium exposure. This behaviour was ob-
served in the majority (10 out of 11) of samples subjected to
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the same procedure. The clone was able to proliferate actively
for another 7 days up to confluence, when it was expanded and
replated in a 6 multi-well plate for the biological analysis. The
initial adherent fibroblastoid morphology changed to a cuboi-
dal shape during the osteogenic medium exposure that ex-
tended to 45 days (Fig. 1).
Time-dependent differentiation of the foci from MSCs to
OBs was demonstrated by immunocytochemical analysis of
ALP and Runx2 osteogenic markers levels (Fig. 1) and stain-
ing the secreted calcified matrices with alizarin red (Fig. 2).
Approximately 80e90% of these osteogenic-medium treated
cells were differentiated into OBs and were homogeneous
for the OB-like phenotype evaluation.
The osteogenic potential greatly increased during the pro-
cess of expansion, suggesting that UCB-derived MSCs effec-
tively differentiated into OBs. It should be emphasised that
Runx2 is a transcription factor critical for commitment to an
osteogenic lineage (Komori, 2002; Lambertini et al., 2007),
and therefore its increase is a marker of OB differentiation.
In contrast, the cells used as controls and derived from mesen-
chymal-like cells isolated from the same UCB sample were
unable to differentiate in OBs and survived only up to
10th day, even when cultured in osteogenic medium. Overall
the data reported in Figs. 1 and 2 suggest that we can consider
these cells homogeneous for the OB like phenotype starting
from day 14.
3.2. Cytokine and growth factor profile
At the various time-points corresponding to days 10, 14, 18
and 22, the adherent cells were subjected to Bio-Plex analysis.
The secretion profile (Table 1) was compared with that obtained
from mesenchymal-like cells immediately before the beginning
of the differentiation process (C, control cells) cultured in osteo-
genicmediumup to10th day,withoutALPexpression andunable
to differentiate in OBs. IL-2, IL-7, IL-17, eotaxin, G-CSF and
IFN-g were undetectable both in induced OBs and the control
cells. IL-1RA and PDGF were undetectable in induced OBs but
detectable at appreciable levels in control cells. Low levels of
IL-1b, IL-2, IL-4, IL-5, IL-13, IL-15, RANTES and MIP-1a,
were detected. Appreciable levels (from 153.32 to 1518 pg/ml)
of IL-6, IL-9, IL-10, L-12(p70), FGF-basic, GM-CSF, IP-10,
Alizarin Red
1 10 14 18 22 28 36 45
days
Bio-Plex
ALP
Runx2
Runx2
14d 45d
ALP
14d 45d
MONONUCLEAR CELLS FROM UCB
CELLS WITH FIBROBLASTOID MESENCHYMAL-LIKE MORPHOLOGY 
+ osteogenic medium
14 days in DMEM/10% FCS
ISOLATION OF SPINDLE-SHAPED FIBROBLASTOID CELLS
CONTROL CELLS
(surviving up to 10
th
 day)
OSTEOBLAST-LIKE CELLS CLONE
ns Ab ns Ab
Fig. 1. Schematic representation of the experimental strategy for the analysis of osteoblastic differentiation potential of a cellular clone expanded from mesen-
chymal-like cells isolated from UCB. Cells were exposed to differentiation medium and subjected to the indicated analysis at the reported days. ALP staining
for Alkaline Phosphatase activity and immunocytochemical analysis for determination of Runx2 expression levels with specific anti Runx2 antibody were per-
formed. ns ¼ staining with non-specific antibody.
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MIP-1b and TNFa were detected in induced OBs cells. Particu-
larly high levels (from 1160 to 7163 pg/ml) were detected for
IL-8, MCP-1 and VEGF. In the control cells, the levels of IL-8
andMCP-1were high, the levels of IL-10, IL-12(p70), FGF-basic
and GM-CSF low, IL-6, and VEGF undetectable and very low,
respectively. Considering that IL-1 beta is the most important
factor that induces the MSCs to produce IL-6 (Le and Vilcek,
1989), the very low levels of IL-1 beta in our control cells is con-
sistent with the lack of IL-6.
It is important to note that the control cells used in this
study e even if ALP negative e cannot be considered plurip-
otent MSCs, since they grew for 7 days in osteogenic medium.
In agreement with this observation, their cytokines profile dif-
fers from that reported by Liu and Hwang (2005) who, using
pluripotent cord blood-derived mesenchymal stem cells, dem-
onstrated that IL-6, IL-8, TIMP-1 and TIMP-2 were the most
abundant interleukins expressed.
3.3. Time-dependent decrease of IL-6, MCP-1 and MIP-1b
Interestingly, IL-6, MCP-1 and MIP-1b levels decreased
significatively during the OB differentiation process. IL-6 is
a multifunctional cytokine that has important physiological ef-
fects on a wide range of functions, such as promoting B cell
differentiation, T cell activation, and inducing acute phase pro-
teins (Akira et al., 1993). As for bone metabolism, IL-6 has
been shown to stimulate bone resorption and promote OCs for-
mation (Le and Vilcek, 1989; Kwan Tat et al., 2004). Another
important chemokine, monocyte chemoattractant protein-1
(MCP-1), is produced by OBs in initiating inflammation in
progressive bone destruction (Kim et al., 2006). It is an imme-
diate early stress responsive chemokine involved in OCs
fusion and osseous inflammation. In particular, it has been re-
ported that OBs were the principal cells expressing MCP-1 in
inflamed bone (Rahimi et al., 1995). With regard to macro-
phage inflammatory protein 1b (MIP-1b), its role in the devel-
opment of lytic bone lesions and in the suppression of bone
formation, in particular in multiple myeloma has been demon-
strated by Hashimoto et al. (2004).
Therefore, together these observations suggest that de-
creases in IL-6, MCP-1 and MIP-1b expression correlates
with osteoblastic trait and may be proposed as putative osteo-
genic marker.
3.4. Time-dependent increase of IL-10, IL-12, FGF-basic
and VEGF
Unlike IL-6, MCP-1 and MIP-1b, the levels of some solu-
ble factors including IL-10, IL-12, FGF-basic and especially
VEGF increased during differentiation to osteogenic lineage,
with a comparable profile peaking at 18 day (Table 1). The
levels of these factors were very low in control cells. There-
fore, we assume that these molecules may play a potential os-
teogenic role. In fact, IL-10 and IL-12 are two cytokines that
inhibit OCs formation (Xu et al., 1995; Kitaura et al., 2002).
The skeleton is also an important target tissue for FGFs since
these factors are involved in bone development, growth, re-
modeling, and repair (Hurley et al., 2001). In particular,
FGF basic is produced by cultured OBs as a constituent of
the bone matrix, stimulates proliferation of OBs and can in-
crease the amount of bone formation (Ornitz and Marie,
2002; Tang et al., 2007). With regard to VEGF, it is well
known that bone formation is closely related to the formation
of blood vessels (Tang et al., 2007), and that OBs produce this
Fig. 2. Osteoblastic cell differentiation analysis. Osteogenic differentiation was also assessed by Alizarin Red staining that showed the presence of matrix
mineralization.
323L. Penolazzi et al. / Cell Biology International 32 (2008) 320e325
factor maximally at the late phase of osteogenic differentia-
tion, when extracellular matrix is mineralized (Harada et al.,
1995). Of the various angiogenic factors, VEGF is perhaps
the most critical driver of vascular formation during osteogen-
esis (Hu et al., 2003). Several studies have also shown that
VEGF stimulates the proliferation, migration and differentia-
tion of OBs (Mayer et al., 2005; Decker et al., 2000).
4. Discussion
During ‘‘in vitro’’ osteogenic differentiation from UCB
mesenchimal cells several cytokines, chemokines and growth
factors are produced in different ways. Reduction of IL-6,
MCP-1 and MIP-1b levels occurred as osteoblastic differentia-
tion procedes. In contrast, increase of IL-10, IL-12, FGF-basic
and VEGF was observed in association with high expression of
OB markers.
Regarding IL-8, its levels are particularly high both in the
MSC control and OB committed cells, with an oscillatory pro-
file during all the cell culture period. IL-8 assumes a contradic-
tory role; nevertheless it can be considered an immediate early
stress-responsive chemotactic cytokine important for the acti-
vation and chemotaxis of neutrophils and macrophages. It was
also shown that OBs produce IL-8, with the secretion being
regulated by different hormones and cytokines (Dovio et al.,
2004). Even if IL-8, together with other inflammatory media-
tors, seems to be correlated with chronic inflammatory rheu-
matic diseases, including osteoarthritis and rheumatoid
arthritis (Sarkar and Fisher, 2006), our data nevertheless do
not allow us to suggest a functional role for IL-8 in OB
differentiation.
In conclusion, our data confirm that human MSCs from
UCB are promising tools for bone regeneration. In addition,
the experiments here reported demonstrated the surprising
ability of osteoblasts and their early progenitors to produce
significant amounts of an array of soluble immune mediators
without in vitro exposure to clinically relevant bacterial path-
ogens. Therefore, decrease of IL-6, MCP-1 and MIP-1b levels,
and increase of IL-10, IL-12, FGF-basic and VEGF should be
considered markers of OB differentiation. Future studies based
on the current data will look at the functional role of the spe-
cific cytokines or chemokines in different stages of the OB
differentiation and in the cross-talk with osteoblasts and oste-
oclasts. Therefore, our results can be useful both for elucidat-
ing biochemical properties of osteoblast progenitors and
facilitating the development of novel therapeutic tools for
both bone-forming and bone loss diseases.
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Abstract The larynx is a secondary sex organ, and the
hormone dependence of laryngeal carcinomas is considered
an interesting matter of speculation. However, while
tumors of other secondary sex organs, including the pros-
tate, breast, and endometrium, have been recognized as hor-
mone-dependent cancers, the laryngeal carcinomas are still
subject to controversy. In this study, samples from 15
laryngeal carcinomas obtained at the time of surgery were
assayed for speciWc estrogen alpha, progesterone, and
androgen receptor expression, both at mRNA and protein
levels. Detectable levels of speciWc estrogen and progester-
one receptors, 53.3 and 73.3%, respectively, were found in
the tumors. This positive detection by immunohistochemi-
cal analysis was higher in tumors than in normal mucosa
adjacent to the tumor areas and was correlated with the
absence of metastatic lymph nodes. No androgen receptor
protein was detected in any sample analyzed, even if quan-
titative RT-PCR revealed high mRNA levels speciWc for
this receptor. A strict correspondence between protein and
mRNA hormone receptor levels was not found. This is in
agreement with the transcriptional and protein synthesis
mechanisms, and it is also compatible with the complex lar-
ynx tumorigenesis.
Keywords Estrogen receptor · Progesterone receptor · 
Androgen receptor · Larynx carcinoma · 
Quantitative RT-PCR
Introduction
Larynx cancer in Europe accounts for 2–5% of all cancers
with about 45,900 new cases in 2006: 42,100 men and
3,800 women. It still represents the second most frequent
neoplasm of the respiratory apparatus, secondary to pulmo-
nary carcinoma. Its incidence has increased in the last few
decades, and its peak incidence occurs among people in
their sixties and seventies. Major risk factors for the devel-
opment of this tumor are tobacco and alcohol consumption.
Relative 5-year survival is about 63% but prognosis varies
depending on the anatomical site (glottic cancer has a better
prognosis) and the stage. Nearly 95% of all larynx cancers
are squamous cell carcinomas.
This cancer has a male to female sex ratio of 11:1 in
Europe, one of the highest among all cancer sites [1, 2]. It
should be noted that the diVerence in susceptibility to lar-
ynx cancer based on gender has remained unchanged
through the years in spite of the increasing tobacco and
alcohol consumption among women [3–5].
The larynx is considered a secondary sexual organ. It is
inXuenced by sexual hormones, not only during puberty but
also during adulthood as it is subject to laryngeal epithelial
layer modiWcations, cartilage metaplasia, and morphostruc-
tural changes [1, 5–7]. These considerations, in association
with the peculiar epidemiological connotations, imply that
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endocrine factors can be involved in the carcinogenesis
process, in particular the receptor status for sex hormones
including estrogen, androgen, and progesterone receptors
[7]. Even though a number of researchers have provided
evidence in the last 20 years that sex hormone receptors are
expressed in laryngeal carcinomas, the presently performed
overall studies about the presence and the functional role of
these receptors are, nevertheless, controversial.
In order to contribute to the gathered information about
this issue, we present a perspective study on 15 patients
with larynx cancer. The expression of estrogen receptor
alpha (ER!), progesterone receptor (PR), and androgen
receptor (AR) was analyzed at both protein and mRNA lev-
els by immunocytochemistry and quantitative RT-PCR,
respectively. The data obtained from neoplastic tissues
were compared with those obtained from normal mucosa
adjacent to the tumor areas. In addition, a correlation
between the expression levels of these receptors and lymph
node status was performed.
Materials and methods
Tissue specimens
Laryngeal cancer tissues were collected from 15 patients
according to protocols approved by the Committee of Eth-
ics in Research of the University. Surgical samples were
collected from laryngeal tumor tissue and control regions
(normal laryngeal tissue) of the same patient. Every sample
was immediately divided into two parts. One part was Wxed
in 4–8% buVered formaldehyde and subjected to immuno-
histochemical analysis. The other part was immediately fro-
zen in liquid nitrogen for RNA analysis.
The clinical data of the patients are reported in Tables 1
and 2.
Quantitative RT-PCR
Total RNA from fragments (0.5 mm) of laryngeal tumor
and its normal counterpart tissue of the same patient was
extracted using Total RNA Isolation System (Promega).
Two micrograms of the total RNA was then used for dou-
ble-stranded cDNA synthesis. It was reverse transcribed
with the ImProm-II RT System (Promega). The mRNA of
target genes was quantiWed by real-time PCR using ABI
Prism 7700 system and the following TaqMan probes
(Applied Biosystems): 
5! FAM-ATGATGAAAGGTGGGATACGAAAAG-
TAMRA 3! for ER!
5! FAM-ATCATTGCCAGGTTTTCGAAACTTA-
TAMRA 3! for PR
5! FAM-GGATGACTCTGGGAGCCCGGAAGCT-
TAMRA 3! for AR.
PCR was performed in a Wnal volume of 25 !l. After a
10 min pre-incubation at 95°C, runs corresponded to 40
cycles of 15 s at 95°C (denaturation) and 1 min at 60°C
(annealing/elongation). The mRNA levels of target genes
were corrected for GAPDH mRNA levels (reference gene)
and normalized to a calibrator sample as previously
described [8].
Immunohistochemistry
Staining for ER! (clone 6F11, Ventana) and PR (clone
1A6, Ventana) was done on paraYn-embedded sections;
immunohistochemical procedures were done with an auto-
matic immunostaining device (Ventana XT Medical Sys-
tem, Tucson, AZ) and Ventana Kits (Strasbourg, France).
Immunohistochemistry of AR was performed as follows:
sections of paraYn-tissues were deparaVinized and
microwaved for antigen retrieval in Tris–EDTA–citrate pH
7.8. Subsequently, sections were incubated with mouse
Table 1 Clinical data of SCC of the larynx patients
Number of patients 15
Age [mean § SD, range (years)] 64.1 § 11.8 (34–77)
Sex (M/F) 14/1
T stage
1 0/15 (0%)
2 8/15 (53.3%)
3 7/15 (46.7%)
4 0/15 (0%)
N stage
0 10/15 (66.7%)
+ 5/15 (33.3%)
M stage
0 15/15 (100%)
+ 0/15 (0%)
Grade
1 3/15 (20%)
2 7/15 (46.7%)
3 4/15 (26.7%)
Table 2 Tumor localization
One site
Supraglottic 8/15 (53.3%)
Transglottic 2/15 (13.3%)
Two sites
Cord–ventricular 2/15 (13.3%)
Glottic–hypoglottic 3/15 (20%)
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monoclonal primary antibody (AR clone AR411, DIA-
PATH), ready to use, at room temperature. Kit EN-VISION
(DAKO) was then used for the detection of primary anti-
body. Staining was completed by incubation with 3,3!-
diaminobenzidine as chromogen. The sections were coun-
terstained with ematossilin for 2 min and washed again in
PBS 1£ (5 min).
Immunostaining was quantiWed with a Computerized
Image Analysis System (Eureka-Menarini), and only can-
cer cells with distinct nuclear immunostaining for ER!, PR,
and AR were recorded as positive.
The speciWcity of immunolabeling was veriWed in all
experiments by controls in which the speciWc primary anti-
body was omitted.
Results
Characterization of the patients
A series of 15 patients was selected (14 men and one
woman, average age 64 years, range 34–77 years). Thirteen
patients were aVected by primary laryngeal carcinoma
while two were aVected by recurrent laryngeal carcinoma
(Wrst treated by radiotherapy). The patients were selected so
that we had access to suYcient tumor material for histopa-
thological and biochemical analysis. Ten patients under-
went a total laryngectomy and Wve a partial laryngectomy.
Thirteen neck dissections were also performed.
Histological diagnosis of all analyzed samples was squa-
mous cell carcinoma (SCC), predominantly of Grade 2
(moderately diVerentiated tumor) as reported in Table 1.
Four subgroups (Table 2) were deWned on the basis of tis-
sue localization: about half of the cases were in the supra-
glottic area.
Sex hormone receptor expression
All paraYn-embedded tumors and their normal counter-
parts were tested for the presence of ER!, PR, and AR by
immunocytochemical analysis. In all tumors and all normal
tissues, we did not detect any speciWc nuclear positive
staining for AR. On the contrary, ER! and PR proteins
were detected at substantial levels. Immunohistochemistry
demonstrated a particular nuclear ER! and PR positivity
(Fig. 1), although cytoplasmic reaction was also detected at
a lower frequency. Notably, the normal counterparts of
SCC, obtained during surgery at the periphery of the resec-
tions, showed less sex hormone receptor reactivity by
immunocytochemical analysis than the tumorous tissue. In
fact, as reported in Table 3, the frequency of ER! and PR
expression were higher in tumors compared to normal
mucosa adjacent to the tumor areas (53.3 vs. 26.7%, and
73.3 vs. 60%, respectively).
Fig. 1 Immunohistochemistry analysis of ER!, PR (D, E, F), and AR
(G, H, I) steroid hormone receptors. A sample with predominant
expression of ER! and PR in the tumor cells is shown. A, D Normal
areas; B, E tumorous areas. No expression of AR is seen in any ana-
lyzed samples. In G a tumorous area is reported. The positive control
tissue (prostate carcinoma) shows extensive immunostaining for AR
(H). Original magniWcations: £20 and £40. Control experiments car-
ried out with omission of the primary antibody are also reported (C, F,
I negative staining controls) 
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The results of protein expression were then correlated
with the levels of mRNA for ER!, PR, and AR. Quantita-
tive real time RT-PCR analysis was performed on the
mRNA extracted from samples of fresh frozen normal and
neoplastic tissues by using the TaqMan probes speciWc for
ER!, PR, and AR transcripts as reported in the “Materials
and methods” section. The sensitivity of the method was
such that a very high percentage of transcription was
detected in all cases, particularly for ER! and AR
(Table 4). As expected, this indicates that a portion of
mRNA is not translated into the corresponding protein.
Concerning AR, the presence of such elevated mRNA lev-
els without corresponding protein detection is very surpris-
ing. The same results were obtained in all Wve of the
repeated experiments, and this is probably due to the
altered characteristics of the tumor microenvironment that
escape the normal control mechanisms of many molecular
events.
In addition, as reported in Table 4, it is of note that in all
three cases there were no signiWcant diVerences at the tran-
scription levels between tumors and their normal counter-
parts (see a representative plot in Fig. 2), suggesting that in
the normal cells surrounding the tumor area, a tumorous
behavior may be recognized at molecular levels.
When hormone receptor positivity was correlated with
lymph node status, a signiWcant correlation was detected
between pN0 status and the expression of ER! and PR pro-
teins (Fig. 3). In fact, in the ER!-positive or PR-positive
cancer groups, the pN0 status was overrepresented.
Discussion
Currently, prognostic evaluation regarding head and neck
squamous cell carcinomas is based mainly on tumor site,
clinical stage (including lymph node involvement and the
presence of distant metastasis), and histopathologic grade.
Considering that laryngeal cancer has diVerent epidemio-
Table 3 Sex hormone receptor status of SCC of the larynx (% protein) Table 4 Sex hormone receptor status of SCC of the larynx (% mRNA)
Fig. 2 Example of RT-PCR ampliWcation plot monitored in real time. The threshold cycle (Ct) is the Wrst cycle with detectable Xuorescence in
relation to an internal standard
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logical connotations between men and women (like inci-
dence and clinical presentation and features), several
studies since 1980 have analyzed the role of sex hormone
receptors in the complex process of larynx tumorogenesis.
Nevertheless, as previously reported, there is still no con-
sensus about the presence and the functional role of these
receptors in larynx carcinomas.
Schuller et al. [9] reported the evidence of low concen-
tration levels of androgen and estro-progesterone receptors
in laryngeal neoplasms, concluding that larynx cancer may
not be considered a hormone-dependent neoplasm. In con-
trast with this study, Mattox et al. [10] have found positiv-
ity for androgens in 91% of the laryngeal neoplastic
specimens examined from 23 patients, also recovering high
hormonal levels in the lymph node metastases. Moreover,
ten patients with advanced disease have been treated with
Xutamide, a powerful anti-androgenic, without satisfactory
results [10]. Virolainen et al. [11] demonstrated the pres-
ence of androgen receptors in 31% of the evaluated laryn-
geal tumoral samples, estrogen receptors in 69%, and
progesterone receptors in 53% of the cases without substan-
tial diVerences between the sexes. Inconclusive results were
obtained by Ferguson et al. [12] in 1987 using immunohis-
tochemical analysis and by Vecerina-Volic et al. [13] in the
same year, who described high androgen receptor levels
represented in women correlated to male receptor levels in
laryngeal cancer. Also, Toral et al. [14] considered larynx
as an androgen target organ and correlated the larynx carci-
nomas to the loss of androgen receptors. In 1989, Berg
et al. [15] supported the hypothesis of a possible hormonal
therapy in the ENT district, describing the presence of pro-
gesterone receptors in laryngeal cancers as having similar
characteristics to those identiWed in breast cancer. Other
evidence supporting the presence and functionality of ste-
roid hormone receptors, and in agreement with our results,
comes from the inhibitory eVect of antiestrogens on the
growth of squamous-cell carcinoma cell lines from head
and neck cancers [16, 17]. This suggests that antihormones
such as tamoxifen may have a therapeutic role in laryngeal
cancer expressing ER and PR [16, 17]. On the contrary,
other research groups obtained the opposite results. Ogret-
menoglu and Ayas [18] in 1998 were unable to recognize
the clinical importance of estrogen expression in larynx
carcinoma. In a more recent paper, Hagedorn and Nerlich
[19] have associated the immunohistochemical technique to
immunoenzymatic (the EIA) analysis evaluating ER, PR,
and AR expression in normal and neoplastic specimens
coming from patients aVected by larynx carcinoma, demon-
strating a complete lack of sex hormone receptors in their
analysis. All of these controversial results indicate that
growth and diVerentiation of head and neck squamous cell
carcinomas are regulated by several factors and receptors
and that a useful unique predictor of tumor aggressiveness
has not yet been demonstrated. Nevertheless, the presence
of estrogen receptors in a high proportion of laryngeal car-
cinoma cells suggests that hormonal therapy may be a use-
ful adjunctive therapy in selected patients with cancer of
the larynx. Therefore, it becomes imperative for the diag-
nostic histopathologist to test routinely for the presence of
steroid hormone receptors on tumor tissues received in the
laboratory. In addition, the employment of quantitative
methods, such as those described here, may contribute to
the understanding of the molecular mechanisms that sustain
a speciWc larynx cancer phenotype.
Fig. 3 Correlation between 
ER! and PR protein expression 
and lymph node status
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The data obtained from our experiments show speciWc
staining for ER alpha and PR but not for AR, even if high
levels of mRNA for AR were detected. This ER! and PR
positivity was signiWcantly associated with the absence of
lymph node metastasis. Taken together, the experiments
suggest that ER! and PR could mediate estrogen- and pro-
gesterone-dependent changes during tumor progression in
the larynx, and that their eVects may anticipate or replace
the action of AR, probably acting in combination with
other factors. It is important to emphasize that several
investigators employing high-throughput technologies
have suggested that speciWc factors including E-cadherin,
focal adhesion kinase (FAK), p53 protein, Ki-67 antigen,
stomatin-like protein 2, VEGF, PTTG, stratiWn, S100 cal-
cium-binding protein A9, p21-ARC, stathmin, and eno-
lase may play a critical role in the biology of head and
neck squamous cell carcinomas [20–25] and may improve
our ability to predict the clinical course of these tumors.
These new Wndings will certainly help to increase our
understanding of the role of sex hormones in the begin-
ning and in the progression of the larynx tumor by analyz-
ing possible unexplored crosstalk between diVerent
signaling pathways.
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ERa and AP-1 Interact In Vivo
With a Specific Sequence of the F
Promoter of the Human ERa Gene
in Osteoblasts
ELISABETTA LAMBERTINI, ELISA TAVANTI, ELENA TORREGGIANI, LETIZIA PENOLAZZI,
ROBERTO GAMBARI, AND ROBERTA PIVA*
Department of Biochemistry and Molecular Biology, Molecular Biology Section, University of Ferrara, Ferrara, Italy
Estrogen-responsive genes often have an estrogen response element (ERE) positioned next to activator protein-1 (AP-1) binding sites.
Considering that the interaction between ERE and AP-1 elements has been described for the modulation of bone-specific genes, we
investigated the 17-b-estradiol responsiveness and the role of these cis-elements present in the F promoter of the human estrogen
receptor alpha (ERa) gene. The F promoter, containing the sequence analyzed here, is one of the multiple promoters of the human ERa
gene and is the only active promoter in bone tissue. Through electrophoretic mobility shift (EMSA), chromatin immunoprecipitation
(ChIP), and re-ChIP assays, we investigated the binding of ERa and four members of the AP-1 family (c-Jun, c-fos, Fra-2, and ATF2) to a
region located approximately 800 bp upstream of the transcriptional start site of exon F of the human ERa gene in SaOS-2 osteoblast-like
cells. Reporter gene assay experiments in combination with DNA binding assays demonstrated that F promoter activity is under the
control of upstream cis-acting elements which are recognized by specific combinations of ERa, c-Jun, c-fos, and ATF2 homo- and
heterodimers. Moreover, ChIP and re-ChIP experiments showed that these nuclear factors bind the F promoter in vivo with a
simultaneous occupancy stimulated by 17-b-estradiol. Taken together, our findings support a model in which ERa/AP-1 complexes
modulate F promoter activity under conditions of 17-b-estradiol stimulation.
J. Cell. Physiol. 216: 101–110, 2008. ! 2008 Wiley-Liss, Inc.
In bone metabolism, estrogen hormone is essential for
sustaining bone mineral density in both males and females
(Compston, 2001); accordingly, several 17-b-estradiol-induced
effects on gene expression in bone cells have been described
(Syed and Khosla, 2005). The 17-b-estradiol-mediated effects
are achieved through the two isoforms of estrogen receptors,
alpha and beta (ERa and ERb) (Nilsson et al., 2001), whose
expression levels are important in determining cell responses.
In particular, a clear clinical role has been established for the
ERa isoform, which is specifically involved in the regulation of
factors associated with bone formation (Bodine et al., 1998).
Therefore, studies on the regulation of the expression of the
ERa gene are of great interest from the theoretical aswell as the
practical points of view. The transcription of the ERa gene has
been reported as very complex. In fact, seven distinct promoter
regions are dispersed within a more than 150 Kb sequence
upstream of the þ1 transcription initiation site (Kos et al.,
2002). With regard to bone, we and others recently
demonstrated that ERa transcription is only directed by the
distal F promoter, located at "117140 (Denger et al., 2001a;
Lambertini et al., 2003). The activity of the F promoter seems to
be autoregulated by ERa (Denger et al., 2001b), even though
specific evidence for a direct role of 17-b-estradiol in the
regulation of its receptor is not fully provided.
It is well known that ERa can directly bind estrogen response
elements (EREs) in the promoters of estrogen-regulated genes
through a well described genomic mechanism involving specific
molecular interactions (Klinge, 2001; Nilsson et al., 2001;
Gruber et al., 2004). The consensus ERE is an inverted repeat of
the sequence AGGTCA, separated by three base pairs. Its
natural occurrence is rare, and many endogenous estrogen
responsive genes contain non-palindromic EREs, imperfect
EREs, or half-sites, in which unpaired AGGTCA sites are
present (Hall et al., 2002; Tang et al., 2004). In addition to direct
binding to specific EREs, ERamay transactivate target genes by
interacting with other transcriptional factors (TFs) such as Sp1
(Safe, 2001), AP-1 (Petz andNardulli, 2000; Cheung et al., 2005;
Shur et al., 2007) and NF-kappa B (Kalaitzidis and Gilmore,
2005). Both processes result in the recruitment of coactivators
and components of the RNA polymerase II transcription
initiation complex that modulates target gene transcription in a
cell type- and DNA context-dependent manner (Petz and
Nardulli, 2000; Hall et al., 2002; McKenna and O’Malley, 2002).
The AP-1 complex is one of the best characterized targets of
non-classically acting ERa and regulates multiple genes in
different tissues, including ovalbumin, collagenase, IGF-1, and
MMP-13 (Kushner et al., 2000; Lu et al., 2006). In particular,
a large number of ‘‘in vitro’’ and ‘‘in vivo’’ studies have
This article includes Supplementary Material available from the
authors upon request or via the Internet at http://
www.interscience.wiley.com/jpages/0021-9541/suppmat.
Abbreviations: AP1, activator protein 1; ChIP, chromatin
immunoprecipitation; EMSA, electrophoretic mobility shift assay;
ER, estrogen receptor; ERE, estrogen receptor element; Luc,
luciferase; a-MEM, a-minimal essential medium.
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demonstrated that AP-1 proteins have important roles as key
regulators of bone development (Karsenty andWagner, 2002).
The F promoter sequence analyzed here extends from
!117,884 to !117,140 bp and contains an ERE half-site
(50-GGTCA-30) and potential binding sites for a number of TFs
including several AP-1motifs. It has been reported that this ERE
half-site binds ERa and confers transcriptional activation to a
heterologous promoter (Denger et al., 2001b), but a direct
interaction of ERa with this regulatory element has not been
described. Considering that the interaction between ERE and
AP-1 elements has also been described for the modulation of
bone-specific genes (McCabe et al., 1995; Schultz et al., 2005;
Wagner and Eferl, 2005; Lu et al., 2006), we investigated the
possibility that 17-b-estradiol responsiveness of the F
promoter may also be mediated by indirect action of ERa
through AP-1.
Here we used electrophoretic mobility-shift assays (EMSA)
with nuclear extracts and recombinant proteins to test in
particular the binding ability of anAP-1 site located near the ERE
half site, and the ERE half site overlapping with an AP-1 half site.
The ‘‘in vivo’’ dynamic status of these factors binding the
F promoter was also examined using a chromatin
immunoprecipitation (ChIP) assay and re-ChIP assays. Our
results suggest that the functional cooperation between ERa
and AP-1 proteins, including c-jun, c-fos and ATF-2, is estrogen-
dependent and may contribute to the modulation of F
promoter activity and, consequently, the expression of the ERa
gene in different cells in vivo. Therefore, this study extends our
knowledge of the transcriptional regulation of the human ERa
gene in osteoblasts in addition to implicating for the first time
CREB-AP1 protein complexes in F promoter activity.
Materials and Methods
Plasmid constructions
All promoter fragments were cloned in the promoterless
pGL3-Basic vector (Promega, Madison,WI) upstream of the firefly
luciferase (LUC) reporter gene. First, an 862 bp sequence
(!117,884/!117,014) was cloned as a BglII/MluI fragment obtained
by PCR on human genomic DNA using the following 50 and
30 primers, respectively (the restriction endonuclease recognition
sequences are indicated in lower case): 50-
cgacgcgtACCTACTGCATAAACCACACC-30 (forward) and
50-gaagatctTTGAAGAGAAGATTATCACTC-30 (reverse). The
resulting PCR product was digestedwithMluI and BglII and inserted
into a pGL3-Basic LUC reporter vector, digested at the same sites.
This initial fragment was used to generate the 411 (!117,426/
!117,014) truncation construct using an internal HindIII site. The
272 deletion fragment was generated by PCR using the
oligonucleotide cgacgcgtAAGCAAGGCCAC as the 50 primer and
the same 30 primer thatwas used for the 862 construct production.
The 180 deletion fragment was generated by PCR using the
oligonucleotide cgacgcgtTTCCTAATTTCATGGTCA as the
50 primer and the same 30 primer that was used for the 862
construct production.
The E/779 fragment was generated by PCR using the
oligonucleotide cgacgcgtTAATATTCATGCATAAGAA as the
50 primer and the oligonucleotide
gaagatctGCTTGGAACCTTAGAA as the 30 primer.
Cell cultures and transient transfections
SaOS-2 and MCF-7 cells were maintained in a-minimal essential
medium (a-MEM) (Sigma–Aldrich, St. Louis, MO) supplemented
with 10% FBS (CELBIO EuroClone, Milan, Italy) in a humidified
incubator at 378Cwith 5% CO2. For transfection experiments, the
cells were plated in 24-well plates, were maintained in phenol-red
free a-MEMþ 10% charcoal stripped FBS, and were transiently
transfected using Lipofectamine reagent (Invitrogen, Carlsbad,CA)
with 1 mg of promoter constructs in and out of the presence of
10 nM 17-b-estradiol. Following overnight incubation, the medium
was removed and fresh medium was added. After another 24 h,
cells were harvested, lysed, and assayed for luciferase activity.
The LUC activity was normalized by total protein content and by
b-galactosidase values resulting from cotransfection of 0.25 mg
of pCMV-Sport-bgal (Invitrogen). b-galactosidase activity was
measured by using Beta-Glo Assay System (Promega).
RT-PCR analysis
For mRNA analysis, all cellular RNA was extracted using
Total RNA Isolation System (Promega). Two micrograms of the
total RNA were reverse transcribed with the ImProm-II
RT System (Promega). mRNA for ERa was quantified by
Real-time PCR using TaqMan probe: 50 FAM-ATGATGAAA-
GGTGGGATACGAAAAG-TAMRA 30 and the ABI Prism 7700
system (Applied Biosystems). After a 100 pre-incubation at 958C,
runs corresponded to 40 cycles of 1500 at 958C (denaturation) and
10 at 608C (annealing/elongation). ThemRNA levels of target genes
were corrected for GAPDH mRNA levels.
Electrophoretic mobility shift assays
(EMSA) and supershift assays
Nuclear extracts were prepared as previously described (Dignam
et al., 1983). Double-stranded oligonucleotides were end-labeled
with (g 32P) ATP and T4 polynucleotide kinase. For gel shift assay
10 mg of nuclear proteins were preincubated for 50 at room
temperature with 1.2 mg of non-specific competitor DNA poly
(dI-dC)-(dI-dC) (Pharmacia Corporation, Bridgewater, NJ) and
then 10,000 cpm of labeled oligonucleotides were added and
incubated for another 300 at room temperature. For the
competition experiments, a 25, 50, 100, and 250-fold excess of
unlabeled oligonucleotideswas incubatedwith the nuclear extracts
for 150 at room temperature and then incubated with the
appropriate
32P-labeled DNA probe. For supershift experiments, nuclear
extracts were preincubated for 150 at RT with 4 mg of antibodies
against ERa, c-jun, c-fos or ATF-2 (Santa Cruz Biotechnology,
Santa Cruz, CA) prior to their 300 incubation with the labeled
oligonucleotides at room temperature. In the experiments with
purified proteins, 300 ng of ERa c-jun, c-fos, or ATF-2 were added
to the reaction mixture for 150 at 258C. Reactions were run on 6%
polyacrylamide gels and electrophoresed at 150 V for 2 h in 0.5#
TBE buffer. Gels were then dried and exposed to film at !808C.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was carried out using the ChIP kit from Upstate
Biotechnology, Inc. (Lake Placid, NY) as previously described
(Penolazzi et al., in press). The cells were cross-linked with 1%
formaldehyde for 10 min at 378C, washed in ice-cold PBS and
resuspended in SDS lysis buffer for 100 on ice. Samples were
sonicated, diluted 10-fold in dilution buffer supplemented with
protease inhibitors, and precleared with 80 ml of DNA-coated
protein A-agarose; the supernatant was used directly for
immunoprecipitation with 5 mg of anti-ERa, c-jun, c-fos, ATF-2 or
Fra-2 (Santa Cruz Biotechnology) overnight at 48C.
Immunocomplexes weremixedwith 80ml of DNA-coated protein
A-agarose followed by incubation for 1 h at 48C. Beads were
collected and sequentially washed five times with 1 ml each of the
following buffers: low salt wash buffer (0.1% SDS,1% Triton X-100,
2 mM EDTA, 20 mM Tris–HCl pH 8.1, 150 mM NaCl), high salt
wash buffer (0.1% SDS,1%TritonX-100, 2mMEDTA, 20mMTris–
HCl pH 8.1, 500 mM NaCl), LiCl wash buffer (0.25 mM LiCl, 1%
IGEPAL-CA630, 1%deoxycholic acid, 1mMEDTA, 10mMTris-pH
8.1) and TE buffer. The immunocomplexes were eluted two times
by adding a 250 ml aliquot of a freshly prepared 1% SDS, 0.1 M
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NaHCO3 solution, and the cross-linking reactions were reversed
by incubation at 658C for 4 h. Further, the samples were digested
with proteinase K (10 mg/ml) at 428C for 1 h, DNAwas purified by
Qiaquick Spin Columns (Qiagen, Inc., Germantown, MD). For PCR
analysis, aliquots of chromatin prior to immunoprecipitation
were saved (input). Nested PCR was performed to analyze the
presence of DNA precipitated by specific antibodies. Two primers
were used to detect the DNA segment located at !117,254/
!117,040 that encompasses the AP-1(1) and the ERE half site
within the F promoter (Fw (50-TGAGATTTTCCAATCCTAGT-30)
and Rev (50-ACTGTCTTCTTATGCTATAGAA-30)).
Each PCR reaction was performed with 2 ml of the bound DNA
fraction or 1 ml of the input. The PCR was performed as follows:
preincubation at 958C for 10 min, 30 cycles of 10 denaturation at
958C, 10 at the optimal annealing temperature (508C), and 1 min at
728C,with one final incubation at 728C for 50. For the re-ChIP assay
the complexes were eluted from the primary immunoprecipitation
by incubation with 10 mM DTT at 378C for 30 min and diluted
1:40 in buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl,
20 mM Tris–HCl, pH 8.1), followed by re-immunoprecipitation
with a different relevant antibody. Subsequent steps of ChIP
reimmunoprecipitations were the same as for the initial
immunoprecipitations. No-antibody control was included in any
experiment.
Statistical analysis
Data are presented as the mean" SEM from at least three
independent experiments. Statistical analysis was performed by
one-way analysis of variance followed by the Student’s t-test.
A P-value <0.05 was considered statistically significant.
Results
The F promoter of the human ERa gene contains
potential binding sites for ERa-mediated autoregulation
It was previously shown that a region located about 1 Kb
upstream of the human ERa exon F retains putative regulatory
elements involved in the control of ERa gene transcription in
osteoblasts (Denger et al., 2001b). In order to better define the
transcriptional activity of this promoter sequence in terms
of 17-b-estradiol responsiveness, we initially performed a
computational dissection of the region spanning from!117,884
to !117,140, based on the search for estrogen responsive
elements (EREs) and for binding sites for transcription factors
including AP-1 (Petz et al., 2002; Garcia-Arencibia et al., 2005)
and Sp1 (Safe, 2001), that are potentially able to interact with
ERa and influence ERa-mediated gene expression. Sequence
analysis, schematically shown in Figure 1A, revealed the
presence of several AP-1 like sites with 6, 5, or 4 of the 7 bases
of the original 50-TGAC/GTCA-30 (Lee et al., 1987). In addition,
the presence of only one Estrogen Responsive Element in the
form of one-half ERE (50-GGTCA-30, at!117,181) and one-half
AP-1 site (50-GTCA-30), (Bergman et al., 2003) was confirmed.
Putative binding sites for Sp1 were not found.
Cell transfection experiments were initially employed to
evaluate 17-b-estradiol responsiveness of the F promoter
context in human osteoblast-like SaOS-2 cells. These cells
display a well-differentiated phenotype with high ALP activity,
low proliferation rate, and substantial ability to form
mineralized nodules (Lin et al., 2004). To this end, we used four
promoter-LUC constructs, including progressive 5’-deletions
of the F promoter sequence (Fig. 1B), previously characterized
in part by our group (Lambertini et al., 2007). As shown in the
graph of Figure 1B, the entire F promoter sequence under
investigation, corresponding to the 862 bp construct, is used by
SaOS-2 but not by ERa-positive MCF-7 breast cancer cells.
Deletion of the region from !117,884 to !117,426 generates
the 411 bp construct (!117,426/!117,014), designed as the
minimal promoter sequence containing the TATA-like motif
localized upstream of the half ERE under investigation. This
construct exhibited a higher level of Luc activity than the full-
length 862 bp construct, whereas further deletions resulting in
TATA less constructs (the 272 bp and the 180 constructs)
completely abolished Luc activity. These results assigned
maximal transcriptional activity to the region between
nucleotides !117,426 and !117,014, indicating that (a) the
!117,426/!117,286 region is required to sustain transcription,
(b) the TATA-like sequence positively mediates the activity of
this promoter, and (c) the deletion of the sequence from
!117,884 to !117,426 removes a negative control region
(Lambertini et al., 2007). Interestingly, all promoter-Luc
constructs except the 180 bp construct significantly increased
their activity after transfection in the presence of 10 nM 17-b-
estradiol for 24 h. This time point corresponds to the major
17-b-estradiol-mediated induction of ERamRNA, asmeasured
by quantitative RT-PCR (see the insert of Fig. 1B). In particular,
although luciferase activity was lower for the 272 bp construct,
fold-inducibility by E2was>5.6, suggesting that the ERE half-site
and AP-1 sites present in the sequence of this construct may be
critical cis-elements. The same E2 treatment had no effects on
the 180 bp construct in which the AP-1 sites upstream of the
ERE half site were deleted and the ERE half site was maintained.
This suggests that the ERE half site alone is not sufficient to
confer 17-b-estradiol responsiveness to the F promoter. As
expected, the same constructs transfected into non osseous
cell lines includingMCF-7 (see Fig. 1B), HeLa, andMDA-MB-231
cells (data not shown) were 17-b-estradiol unresponsive. The
empty pGL3 basic vector showed no induction of reporter
transcription after 17-b-estradiol treatment.
Therefore, these results are compatible with the presence
of functional elements in the F promoter that mediate the
responsiveness to 17-b-estradiol in osteoblasts through an
autoregulatory mechanism that may potentially be exerted by a
combined action of ERE and AP-1 regulatory sequences.
In order to provide further evidence for the importance of
the sequence !117,884/!117,140 of the F promoter in
osteoblasts, its hormone responsiveness with respect to
another regulatory region was analyzed. A promoter-LUC
construct containing a sequence of 779 bp upstream of the E
promoter (!151,786/!151,007) (Kos et al., 2002) and with an
ERE half site was transfected into SaOS-2 and MCF7 cells, and,
as reported in the insert of Figure 1B, it did not show any LUC
activity or any response to 17-b-estradiol.
ERa and AP-1 are recruited to the F promoter ‘‘in vivo’’
The role of these putative cis elements was then investigated
analyzing the ‘‘in vivo’’ assembly of ERa and AP-1 family
members on the F promoter by chromatin
immunoprecipitation (ChIP) assay following 17-b-estradiol
treatment of SaOS-2 cells (Fig. 2).
The experiments were assessed every 150 for 900 to
determine the order and timing of complex recruitment and to
check for their presence after 24 h of 17-b-estradiol treatment.
After cross-linking with formaldehyde, nuclear extracts were
obtained from the cells and sonicated to fragment the
chromatin. Equal amounts of the same chromatin preparation
were incubated with specific antibodies against ERa, c-Jun,
c-fos, Fos-related antigen 2 (Fra-2), and activating transcription
factor-2 (ATF-2) factors. These components of the AP-1 family
were chosen because it is well documented that they are
expressed in differentiated osteoblasts and have a significant
effect on the developing or remodeling skeleton (McCabe et al.,
1995; Wagner and Eferl, 2005). After immunoprecipitation,
DNA eluted from the beads was used as a template to generate
a 214 bp-F promoter specific PCR product. As shown in
Figure 2A, in the absence of 17-b-estradiol (time 0), the
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recruitment of transcription factors appeared low. After 17-b-
estradiol treatment, ERa displayed an oscillating promoter
occupancy, peaking at 30 and 60 min and then showing a
decreasing level for the remainder of the time course. Within
150 following the addition of 17-b-estradiol, promoter
occupancy peaked when ATF-2 recruitment was analyzed.
Together with ERa, ATF-2 represents the factor most engaged
on the sequence under investigation, whereas Fra-2 does not
appear to be associated with the F promoter at any time of the
treatment. The recruitment of c-Jun and c-fos was present at
lower levels, peaking at 24 h and 15 min, respectively.
As a control, genomic DNA not subjected to
immunoprecipitation was amplified (input). As expected, no
amplification was obtained in the samples collected with beads
alone (NoAb).
These results support the conclusion that ERa andmembers
of theAP-1 family, particularly ATF-2, interact ‘‘in vivo’’ with the
F promoter region; this might involve the sequence containing
the overlapping half ERE and theAP-1 half site and theAP-1 sites
in osteoblastic SaOS-2 cells.
An additional test for the functionality of the F promoter
in the chromatin context of SaOS-2 cells was performed by
re-ChIP experiments in response to 0, 15, 30, 45, 60, 90 min,
and 24 h treatment with 17-b-estradiol. Initial rounds of
immunoprecipitation were performed with the ERa antibody,
and then the precipitated material was challenged further with
antibodies against c-jun, c-fos, ATF-2, and Fra-2. This approach
was undertaken to enrich for chromatin templates that were
associated with both ERa and AP-1 factor partner proteins at
the same time. As shown in Figure 2B, all signals appeared
stronger, and therewas rather constant and rapid association of
ERa with c-jun, c-fos, and ATF-2, even if the DNA protein
interactions presented individual profiles for the different
transcription factors.
Fig. 1. A,B:Functionality of theFpromoterof thehumanERagene.A:Schematic representationof theFpromoter regionbetweennucleotides
!117,884 and!117,140. The nucleotides are numbered relative to themain transcription start site (R1). By using theTransfac database, several
AP-1 like sites with 6, 5 (70–86% homology), or 4 (60% homology) of 7 bases of the original 5(-TGAC/GTCA-3( were identified. In addition, one
estrogen responsive element in the form of half ERE (5(-GGTCA-3(), one half AP-1 site (5(-GTCA-3() and a TATA-like element were identified.
Capital lettermeansexonF.B:PromoteractivityofdeletionconstructsoftheFpromoteroftheERagene.SaOS-2andMCF7cellsweretransiently
transfectedwith theFpromoter-luciferase (LUC)constructs (862, 411, 272, and180respectively) reportedon the left, in thepresence (R) andnot
(!)of10nM17-b-estradiol (E2) for24h.Thepositionsofpotential transcriptionfactorbindingsitesarereported.ThepositionofAP-1(1) ispointed
out.Reporter luciferaseactivitywas assayed48hafter transfection.Theresultswerenormalizedwithprotein concentrationandb-gal activity for
transfection efficiency and represented as the average of five independent experiments performed in duplicate. The data are expressed as the
meanW standard errors and indicated as fold inductions over the promoterless pGL3 Basic vector. Asterisk (M) indicates statistically significant
differencesbetweenthetransfectants indicated inthefigure(P<0.05).ThelevelofERagenetranscription inSaOS-2cells isalsoreported.Thecells
wereculturedinthepresenceof10nME2for24h(R)orremaineduntreated(!).ThecDNAobtainedfromtotalRNAwassubjectedtoquantitative
TaqMan RT-PCR for ERa transcript analysis. The expression levels were normalized on the basis of GAPDH expression and results of the
experiments are reported as relative mRNA expression levels. Results are representative of three independent experiments carried out in
triplicate;DDCtmethodwasusedtocomparegeneexpressiondata; standarderrorof themean(SEM)wascalculated. Inthe insert totheright, the
promoter activity of theE/779 construct of theEpromoter (Kos et al., 2002) of theERa gene is reported. SaOS-2 andMCF7 cellswere transiently
transfectedwith the E promoter-luciferase (LUC) construct (!151,786/!151,007), in the presence (R) or not (!) of 10 nM17-b-estradiol (E2) for
24 h.
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Analysis by EMSA of DNA-protein interactions
at AP-1 and ERE half sites as a whole
To delineate the promoter elements involved in the binding ‘‘in
vivo’’ with ERa and AP-1 factors and the mediating of the
regulatory effect of 17-b-estradiol, electrophoretic mobility-
shift assays (EMSA) were carried out with various 32P-labeled
oligonucleotides (see Table 1). The labeled oligonucleotides
had been incubated with nuclear extracts from 17-b-estradiol-
treated SaOS-2 cells or ERa, c-jun, c-fos, and ATF-2 purified
recombinant proteins and the corresponding specific
antibodies. The data obtained from promoter activity analysis
and experiments performed with oligonucleotides covering
other AP-1 like sites present in the F promoter (see Fig. 1A of
Supplemental Data), led us to focus our analysis on
the sequence around the ERE half site and on the AP-1(1)
site strictly associated to it (see panel A of Fig. 3 for
oligonucleotide localization).
Initially, we used the AP-1/ERE half site oligonucleotide as a
probe, which consisted of the sequence between nucleotides
!117,215 and !117,159. As shown in Figure 3B, specific band
shifts were obtained, generating five major DNA/protein
complexes. Interestingly, the band c2 strongly decreased when
antibodies against c-Fos and ATF-2 were added to the binding
reactions, suggesting that these transcription factors were
present in complex c2. On the contrary, in these experimental
conditions, bands were not depleted by the addition of ERa and
c-Jun antibodies. This lack of activity of MoAbs might be
ascribed to the presence of highly structured heterogeneous
complexes masking MoAb-binding sites.
In order to further characterize the sequence containing the
ERE half site, we performed EMSA competition experiments on
a labeled AP-1/ERE half site oligonucleotide using as a
competitor the AP-1(1) and ERE half site shorter
oligonucleotides encompassing the AP-1/ERE half site
sequence. As shown in the insert of Figure 3B, the presence of
25-, 50-, 100-, or 250-fold molar excess of cold AP-1(1)
oligonucleotide did not affect binding ability. On the contrary,
cold ERE half site competitor significantly reduced formation of
Fig. 2. A,B: ‘‘In vivo’’ recruitment of 17-b-estradiol-modulatedERaandAP-1 factors to theFpromoter.Chromatinwasextracted fromSaOS-2
cells plated at a density of 1T106 and treated for indicated time periods with 10 nM 17-b-estradiol. A: ChIP assays using antibodies against ERa,
c-jun, c-fos, ATF-2 and Fra-2 were performed. The association of the F promoter wasmonitored for the seven treatment times. Representative
agarose gels of at least three independent cell treatments are shown.The immunoprecipitateswere subjected toPCRanalysis using primer pairs
spanning theFpromoter from!117,254 to!117,040bp.Aliquotsof chromatin takenprior to immunoprecipitationwereusedas ‘‘Input’’ controls
whereas chromatin eluted from immunoprecipitations lacking antibody were used as ‘‘no antibody’’ controls. B: Re-ChIPs were performed first
with an immuno-precipitation with anti-ERa and second with a precipitation with c-jun, c-fos, ATF-2, and Fra-2 antibodies, as indicated.
Representative agarose gels are shown.
TABLE 1. Oligonucleotide sequences used in EMSA experiments
Oligonucleotide Sequence
AP-1 consensus 5(-ttccggctgactcatcaagcg-30
CRE consensus 50-agctcctagcctgacgtcagagagagagct-30
ERE consensus 50-aattcgtccaaagtcaggtcacagtgacctgatcaaagtt-30
AP-1/ERE half site 50-tttatttttgagttactgcatttcctaatttcatggtcataacagcct-30
ERE half site 50-tgcatttcctaatttcatggtcataacagcct-30
AP-1(1) 50-ttatttttgagttactgcat-30
Oligo 2 50-actgcatttcctaatttcat-30
Oligo 3 50-atttcatggtcataacagcc-30
Oligo 3m 50-atttcatAAtcataacagcc-30
Oligo 4 50-ggtcataacagcctcctgtc-30
JOURNAL OF CELLULAR PHYSIOLOGY
h E R a F P R O M O T E R R E G U L A T I O N I N O S T E O B L A S T S 105
the c1, c2, and c3 complexes, suggesting a prevalent role for the
ERE half sitewith respect to theAP-1(1) sequence in the binding
of proteins to the AP-1/ERE half site.
In addition, to determine whether any of the complexes
binding to the AP-1/ERE half site were osteoblastic-specific, we
compared the EMSA pattern obtained using nuclear extracts
from MCF7 breast cancer cells. As shown in Figure 3B, all
binding activities, in particular c3, c4 and c5, were stronger in
SaOS-2 than in MCF7 cells. In addition, a complex with an
intermediate mobility between c2 and c3 was present in MCF7,
but not in SaOS-2.
To unequivocally characterize the binding abilities of
transcription factors to this AP-1/ERE half site sequence,
we then performed the EMSA assay with recombinant proteins,
alone or in combination. First, purified c-Jun, c-fos, ATF-2 and
ERa available recombinant proteins were confirmed for their
specific efficacy with the oligonucleotides containing high-
affinity AP-1, CRE and ERa binding sites (AP-1, CRE and ERa
consensus, respectively) (Fig. 4A). In addition, a Western Blot
analysis was performed on both nuclear extracts and total
lysates of E2-treated SaOS-2 cells to quantify the presence of
the transcription factors under investigation. With the
exception of Fra2 (which is found mainly in the total extracts),
substantial levels of ERa, c-Jun, c-fos, andATF-2were present in
both fractions (insert of Fig. 4A).
Next, the experiments reported in Figure 4B were
performed. The results showed supershifts with c-Jun and
ATF-2 antibodies implying that c-Jun/c-Jun, c-Jun/ATF-2, and
ATF-2/ATF-2 combinations occur. A supershift with c-fos
antibody is present only in the c-jun/c-fos combination.
Antibody specific for ERa interfered only partially with ERa
recombinant protein binding but completely abolished the
binding when ATF-2 was also added, providing convincing
evidence that ERa/ATF-2 heterodimers form.On the contrary,
the formation of the ERa/c-jun complex seems not to be
involved. It is noteworthy that the failure to demonstrate a
strong direct binding of ERa to DNA is in agreement with the
observations of several other research groups. In fact, because
of the formation of fragile protein–DNA complexes (Porter
et al., 1996; Sun et al., 1998; Weinmann et al., 2001; Petz et al.,
2002), the interaction between ERa and an identified ERE
appears too weak in many cases for detection in EMSA when
using either nuclear extracts, purified ERa, or in vitro translated
ERa as the ERa protein source. The ability of the AP-1/ERE half
Fig. 3. A,B: In vitro analysis of DNA-protein interactions at the AP-1/ERE half site sequence in presence of nuclear extracts. A: Schematic
representationofoligonucleotidesused in thisEMSAanalysis.B:Gel shift experimentswereperformedwithnuclearextracts fromSaOS-2cells in
thepresenceof32PlabeledAP-1/EREhalfsiteoligonucleotide.Protein–DNAcomplexeswereresolvedfromfreeprobethroughnon-denaturing6%
polyacrylamidegels.Arepresentativegel isshown.The32Plabeledoligonucleotidewas incubatedalone(free), incombinationwith10mgofnuclear
extracts (NE) (M), and in the presence of a 100-fold molar excess of specific unlabeled oligonucleotide (cold), respectively. Where indicated,
antibodiesagainstc-jun,c-fos,ATF-2,andERa(SantaCruzBiotechnology)wereincorporatedintothebindingreactions.Thefivemajorcomplexes
formedaremarkedasc1–c5.Totheright,crosscompetitionswith25-,50-,100-,or250-foldmolarexcessofAP-1/EREhalf site,AP-1(1),andEREhalf
site cold oligonucleotides are reported.
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Fig. 4. A,B: In vitro analysis of DNA-protein interactions at the AP-1/ERE half site sequence in the presence of recombinant proteins. A: The
efficiency of recombinant proteins and antibodies was tested onAP-1, CRE, and ERE consensus oligonucleotides.Western blots (WB)were also
performed todetect the expressionof c-jun, c-fos,ATF-2, Fra-2, andERa in nuclear (NE) and total cellular (CE) extracts fromSaOS-2 cells. B:Gel
shift experiments were performed with recombinant c-jun, ATF-2, c-fos, and ERa proteins in the presence of 32P labeled AP-1/ERE half site
oligonucleotide. Protein–DNA complexes were resolved from free probe through non-denaturing 6% polyacrylamide gels. Representative gels
are shown. Where indicated, antibodies against c-jun, c-fos, ATF-2, and ERa (Santa Cruz Biotechnology) were incorporated into the binding
reactions. A simplified model of the favored protein complexes following each EMSA analysis are reported below.
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site sequence to bind different heterodimers was then tested
employing three different recombinant proteins at the same
time in the EMSA reaction. This assay (Fig. 4B right side)
confirmed that the protein complexes bound to the sequence
may be composed of a mixture of dimers and revealed that
c-Jun/c-fos, ATF-2/ATF-2, and ERa/ATF-2 are the preferred
protein combinations. It is noteworthy that when ERa is
present, ATF-2 preferentially forms homodimers or
heterodimers with ERa over c-Jun or c-fos.
Analysis by EMSA of DNA-protein interactions
at individual AP-1 and ERE half sites
When the above experiments with nuclear extracts and
recombinant proteins were performed using the ERE half site
oligonucleotide (see Fig. 5A), fainter DNA protein interactions
were observed, suggesting that the larger sequence (AP-1/ERE
half site) containing multiple cis elements has a greater binding
ability than the shorter sequence. In particular, the shorter
sequence was not able to bind recombinant ATF-2 protein as a
homodimer. Nevertheless, comparable results were obtained
concerning the c-Jun/c-Jun, c-Jun/c-fos, and c-Jun/ATF-2
complexes.
In order to understand the role of single putative cis
elements, additional EMSA were carried out and the four short
oligonucleotides reported in Figure 5B, covering the entire
AP-1/ERE half site, were individually used. As shown in
Figure 5B, we were only able to detect a faint interaction
between the oligonucleotide 3 containing the ERE half site and
the ERa recombinant protein. When mutant oligonucleotide
3 with 2-bp mutations in the ERE half site (3m) was used, no gel
shifted bands were observed, indicating the potential ability of
the 50-GGTCA-30 sequence in the specific recruitment of the
ERa protein. Contrarily, wewere unable to detect any protein-
DNA complexes with the other oligonucleotides, suggesting
that the direct recruitment of AP-1 members and the AP-1-
mediated recruitment of ERa require the AP-1/ERE half site
sequence as well as combined AP-1 sites and the ERE half site.
In addition, it should be noted that the molar ratios of
recombinant proteins were held constant in all EMSA
experiments and that the binding reactions were processed in
parallel. Thus, the differences observed in the binding of
recombinant proteins to the oligoprobes reflected differences
in protein-DNA interactions and could not be attributed to
differences in experimental conditions. Therefore, the overall
data and, in particular, the major intensity of the gel shifted
band detected with the AP-1/ERE half site suggest that while
c-jun, c-fos, ATF2, and ERa may be individually important, it is
only through their combination that they showmaximumDNA
affinity and regulatory effects on promoter activity. These
conclusions are also supported by the analysis of the abilities of
c-jun, c-fos, ATF2, and ERa to bindmutant AP-1(1) and ERE half
sites. In fact, as reported in the Figure 1B of Supplemental Data,
when the AP-1(1) site was mutated from TGAGTTA to
CAAGTAC, ATF2 binding ability drastically decreased,
whereas enhanced ERa bindingwas observed.On the contrary,
when the ERE half site was mutated from GGTCA to AATCA,
ERa binding was abrogated, but ATF2 binding strongly
increased. This confirms a substantial flexibility of the analyzed
sequence and a compensation of protein/protein and protein/
DNA interactions.
Discussion
The primary conclusion of the results reported here is that ERa
and c-jun, c-fos and ATF-2, but not Fra-2 AP-1 factors interact
‘‘in vivo’’ with specific estrogen-responsive regulatory
sequences and AP-1 cis-elements within the F promoter of the
human ERa gene in osteoblast-like SaOS-2 cells. Western
blotting analysis (insert of Fig. 4A) indicates that the lack of Fra2
recruitment to the F promoter is probably due to a cytoplasmic
compartimentalization of this protein in SaOS-2 cells, even
when they are treated with 17-b-estradiol.
The recruitment of ERa and c-jun, c-fos and ATF-2 factors
is oscillatory and is modulated by 17-b-estradiol. These
transcription factors are co-associated with the F promoter
region !117,884/!117,140 in different combinations through
protein/protein and protein/DNA interactions, as suggested by
EMSA experiments with recombinant proteins and variously
sized oligoprobes. Additionally, to advance knowledge of the
transcriptional pathways that regulate the activity of F
promoter and, consequently, the expression of the ERa gene in
bone, these findings provide new details about the ER/AP-1
pathway at target promoters. In particular, we focused on the
sequence !117,214/!117,167 containing the AP-1(1) site and
the ERE half site. We demonstrated that c-jun/c-fos, ATF-2/
ATF-2, and ERa/ATF-2 are the preferred protein–protein
combinations (Fig. 4B) and that the combined contribution
of multiple cis elements, rather than single cis elements alone,
is a key regulatory process of F promoter activity.
In addition, our results are consistent with recent studies
showing that AP-1 family proteins and ERa sometimes form
heterodimers and interact with Estrogen Responsive Elements
located in the promoter, or upstream/downstream of the
promoter of a number of genes, up- or downregulating their
transcription (Weisz and Rosales, 1990; Petz et al., 2002;
Garcia-Arencibia et al., 2005; Cascio et al., 2007). Conversely,
the activity of AP-1 containing promoters may be regulated by
ERa through direct interaction with Jun (Kushner et al., 2000;
Cheung et al., 2005; Jeffy et al., 2005; Lu et al., 2006). For
example, direct interactions between ERa and Jun were
demonstrated for ovalbumin, c-fos, collagenase, IGF-1,
progesterone receptor, and BRCA1 genes (Gaub et al., 1990;
Umayahara et al., 1994; Kushner et al., 2000; Petz and Nardulli,
2000; Jeffy et al., 2005; Cascio et al., 2007). A mechanism has
been also demonstrated through which ERa can regulate gene
transcription through a promoter that lacks canonical ERE, such
as cyclin D1 promoter in which the c-jun/ATF-2/ER complex is
specifically recruited at the CRE-D1 element, mediating 17-b-
estradiol control of the proliferation of target cells (Sabbah
et al., 1999). The ability of ERa to stimulate activation domains
of Jun and ATF-2 was demonstrated (Sabbah et al., 1999;Wang
et al., 2004). In agreement with these considerations, ERa
represents another gene whose expression may be influenced
both by ERa and AP-1. Even if c-jun is considered the most
potent transcriptional activator in the AP-1 protein family, we
nevertheless hypothesize that in the promoter context
analyzed here, its activity can be attenuated by ERa/ATF-2
heterodimerization. In fact, this combination together with
ATF-2/ATF-2 homodimers seems to be particularly strong, as
results from EMSA analysis. However, we do not exclude the
possibility that other ERE-type elements and cooperative
functions of different combinations of DNA binding proteins
contribute to promoter responsiveness in the context of
different and larger promoter fragments of the ERa gene.
The findings presented in this study, together with further
investigations aimed at the elucidation of the ERa/AP-1 pathway
involved in regulating ERa expression, may also have clinical
relevance for bone diseases. The members of the Jun, Fos and
ATF families, as well as ERa are differentially expressed during
osteoblast maturation (McCabe et al., 1995; Wagner and Eferl,
2005). Being at the receiving end of several signal transduction
cascades, AP-1 activity converts different extra- and
intracellular signals, including estrogens, into changes in gene
expression via expression of AP-1 responsive target genes,
integrating estrogens activity and modulating the critical role of
ERa in the regulation of bone cell function (McCabe et al., 1995;
Schultz et al., 2005;Wagner and Eferl, 2005; Lu et al., 2006; Shur
et al., 2007). Therefore, identification of ERa as a target of
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Fig. 5. A,B: In vitro analysis of DNA-protein interactions at individual AP-1 and ERE half sites. A: Gel shift experiments were performed with
nuclear extracts from SaOS-2 cells and with recombinant c-jun, c-fos, ATF2, and ERa proteins in presence of 32P labeled ERE half site
oligonucleotide. Protein–DNA complexes were resolved from free probe through non-denaturing 6% polyacrylamide gels. Representative gels
are shown.The 32P labeledoligonucleotidewas incubated alone (free), in combinationwith 10mgof nuclear extracts (NE) (M), and in presenceof a
100-fold molar excess of specific unlabeled oligonucleotide (cold), respectively.Where indicated, antibodies against c-jun, c-fos, ATF2, and ERa
(Santa Cruz Biotechnology) were incorporated into the binding reactions. The five major complexes formed are marked as c1–c5. B: Gel shift
experiments were performed with recombinant c-jun, c-fos, ATF2 and ERa proteins in the presence of 32P labeled AP-1(1), 2, 3, and 4
oligonucleotides. 3m, mutant oligonucleotide 3 with 2-bp mutations in the ERE half site. The position of the oligoprobes used in this EMSA
is reported above.
JOURNAL OF CELLULAR PHYSIOLOGY
h E R a F P R O M O T E R R E G U L A T I O N I N O S T E O B L A S T S 109
specific AP-1 factors may be very useful for understanding how
these transcription factors control osteoblast differentiation,
in both physiological and pathological conditions, including
osteopenic diseases such as osteoporosis (Compston, 2001;
Deroo and Korach, 2006; Penolazzi et al., in press), and for
facilitating the development of novel therapeutic tools for bone
diseases.
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NATURAL COMPOUNDS AND THEIR ROLE IN APOPTOTIC CELL SIGNALING PATHWAYS
Apoptosis of Human Primary Osteoclasts
Treated with Molecules Targeting
Nuclear Factor-κB
Roberta Piva,a Letizia Penolazzi,a Monica Borgatti,a
Ilaria Lampronti,a Elisabetta Lambertini,a Elena Torreggiani,a
and Roberto Gambaria,b
aBioPharmaNet, Department of Biochemistry and Molecular Biology,
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Osteoclasts (OCs) are involved in several pathologies associated with bone loss, includ-
ing rheumatoid arthritis, osteoporosis, bonemetastasis ofmyeloma, osteosarcoma, and
breast cancer. In this reviewwe determined the effects of natural compounds, including
extracts from medicinal plants, on differentiation and survival of human primary OCs
obtained from peripheral blood. We found that OCs from umbilical cord blood and
peripheral blood behave differently in response to molecules inducing apoptosis in this
experimental system. Apoptosis induced by decoy oligonucleotides was reproducibly
obtained in OCs from peripheral blood but not in OCs derived from cord blood. With
respect to effects of medicinal plants, we found that crude extracts of Emblica officinalis
are able to induce specifically programmed cell death of mature OCs without alter-
ing the process of osteoclastogenesis. E. officinalis specifically increased the expression
levels of Fas, a criticalmember of the apoptotic pathway. Gel shift experiments BioPhar-
maNet demonstrate that E. officinalis extracts specifically compete with the binding of
a transcription factor involved in osteoclastogenesis NF-κB to its specific target DNA se-
quences. Thismight explain the observed effects of E. officinalis on the expression levels
of IL-6, an NF-κB-specific target gene. We suggest the application of natural products as
an alternative tool for therapy applied to bone diseases.
Keywords: osteoclast; rheumatoid arthritis; osteoporosis; apoptosis;medicinal plants;
Emblica officinalis
Introduction
Osteoclasts (OCs) are multinucleated cells
of hematopoietic origin and are the primary
bone-resorbing cells.1–4 OCs are involved in
several pathologies associated with bone loss,
including rheumatoid arthritis, osteoporosis,
bone metastasis of myeloma, osteosarcoma,
and breast cancer. Accordingly, molecules in-
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Biochemistry and Molecular Biology, Via Fossato di Mortara 74,
44100 Ferrara, Italy. Voice: 39-532-424500; fax 39-532-424443.
gam@unife.it
ducing apoptosis of OCs but not in on os-
teoblasts are expected to be of great interest for
therapeutic intervention in pathologies caused
by bone loss.
In this respect, we recently reported5,6 and
reviewed7 the effects of transcription factor de-
coy oligonucleotides on apoptosis of human
OCs. The first decoy molecules were designed
to inhibit nuclear factor (NF)-κB binding5 to a
target sequence, the second to increase estro-
gen receptor-α (ER-α) expression.6 We found
that both decoy molecules are potent inducers
of apoptosis of human OCs and are able to
increase caspase 3 activity and decrease IL-6
Natural Compounds and Their Role in Apoptotic Cell Signaling Pathways: Ann. N.Y. Acad. Sci. 1171: 448–456 (2009).
doi: 10.1111/j.1749-6632.2009.04906.x c© 2009 New York Academy of Sciences.
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Figure 1. Phenotypical and functional characterization of osteoclasts (OCs)/peripheral blood (PB) and
OCs/umbilical cord blood (UCB). (A) Human primary OCs obtained after 21 days of culture from PB or UCB
were immunostained for matrix metallopeptidase 9 and stained for tartrate-resistant acid phosphatase (TRAP)
to enumerate the attached TRAP-positive multinucleated cells. Cells were photographed at a magnification
of 20×. (B) The pit formation ability of osteoclasts obtained from PB or UCB was assayed using culture
dishes that were bottom coated with calcium-phosphate film [Osteoclast Activity Assay Substrate (OAAS),
Oscotect Inc., Seoul, Korea]. Cells were cultured in contact with the OAAS plate and removed with a solution
of 5% sodium hypochlorite on the day 21. Bone resorption activity was measured by direct observation
under phase-contrast microscopy. (C) Oligonucleotide uptake ability of OCs/PB and OCs/UCB. The cells
were incubated for 3 h with 1 µg of fluorescein-labeled 20-mer double-stranded oligonucleotide complexed
with 4 µg of LipofectAMINE (Invitrogen, Carlsbad, CA), washed, and examined under phase-contrast or
fluorescent light, using a fluorescent filter.
expression. In addition, we provided evidence
indicating that these oligonucleotides are active
in vivo in inducing OC apoptosis.8,9 Because
OCs are essential for skeletal development and
remodeling throughout the life of animals and
humans, the described approach is of potential
clinical importance.
From these data two further issues were lack-
ing. The first one was the possible differential
effects of the employed decoy oligonucleotide
OC derived from different histological com-
partments. The second one was to extend the
observation of the induction of apoptosis to
other molecules exhibiting inhibitory effects on
NF-κB activity.
Osteoclasts Derived from Umbilical
Cord Blood Are Less Prone
to Apoptosis than Osteoclasts
from Peripheral Blood
It is well documented that for in vitro analysis
human OCs could be obtained from the pre-
cursors present in peripheral blood (PB) or um-
bilical cord blood (UCB), but there has been no
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Figure 2. Treatment of OCs/PB and OCs/UCB
with specific transcription factor decoys. In presence
of different decoy molecules able to rectuit NF-κB,
NFATc1 or a transcription factor that negatively af-
fects ERα expression (RA4-3′). The on apoptosis of
OCs obtained from PB (A) or UCB (B) was evaluated
after 14 days of culture. Detection of apoptosis was
performed by TdT-mediated dUTP nick end labeling
(TUNEL) assay, after 48 h 1 µg/mL decoy treatment.
OCs/UCB were also treated with 2 and 3 µg/mL
administered every 48 h for 6 days. Brown color
reaction (arrows in the panels) indicates cells that
underwent apoptosis. Cells were photographed
at a magnification of 20×. C, untreated con-
trol OCs; S, OCs treated with unrelated scramble
oligonucleotide.
detailed analysis of how the kind of source may
affect the behavior of these cells. In the present
study we analyzed the behavior of OCs after
transfection with specific transcription factor
decoymolecules AGAINSTNF-κB or NFATc1
(nuclear factor of activated T cell cytoplasmic.
Phenotypical and Functional
Characterization of OCs/PB
and OCs/UCB
PB and UCB-derived mononuclear cells
were set in culture as previously described.10
Briefly, PB was collected from healthy normal
volunteers after informed consent. Full-term
UCB samples (n = 10) were obtained from the
umbilical vein immediately after vaginal deliv-
ery, with the informed consent of the mother
approved by the Ethical Committee of Ferrara
University and S. Anna Hospital. PB and UCB
mononuclear cells (PBMCs and CBMCs)
were plated in 24-well plates or in chamber
slides and then cultured in Dulbecco’s MEM
supplemented with 10% fetal calf serum (FCS),
100 U/mL penicillin, and 10 U/mL strepto-
mycin for 14 days. On day 14 the PB-derived
OCs generated in the presence of 10% fetal
bovine serum (FBS), parathyroid hormone
(PTH) 10−7 mol/L, macrofage colony-
stimulating factor (M-CSF) (25 ng/mL), and
receptor activator of NF-κB ligand (RANKL;
30 ng/mL) were multinucleated tartrate-
resistant acid phosphatase (TRAP)-positive
cells and expressed matrix metallopeptidase 9
(MMP-9) OC-associated antigen, confirming
the cell phenotype at the molecular level (panel
A, Fig. 1).5,6 The same characteristics were
shown by spontaneously generated UCB-
derived OCs. In order to compare the different
activity of OCs from different origins, we tested
their function in terms of bone resorption abil-
ity. As shown in panel B of Figure 1, resorption
lacunae were detected at a comparable level in
OCs from the two groups. These results indi-
cate that the source ofOCs did not affect pit for-
mation capability, confirming the functionality
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Figure 3. Expression of proapoptotic and survival proteins in OCs/PB and OCs/UCB.
Control cells were immunocytochemically analyzed for basal expression of Bim, Bcl2, Bcl-
XL, and survivin. Cells were photographed at a magnification of 20×. Arrowheads indicate
immunopositivity.
of OCs/UCB and OCs/PB. Moreover, the
two types of OCs retain comparable DNA
uptake ability, as shown in a representative
experiment indicated in panel C, Figure 1.
20-Mer fluorescein-labeled double-stranded
oligonucleotides are widely distributed in all
nuclei of OCs/PB and OCs/UCB.
Effect of Transcription Factor Decoy
on OCs/PB and OCs/UCB
Following these preliminary results, we
treated OCs/PB and OCs/UCB with specific
decoy oligonucleotides (ODN) able to remove
NF-κB or NFATc1 transcription factors or in-
crease ER-α expression, and we then ana-
lyzed the level of apoptosis. Apoptotic cells
were detected by the DeadEnd colorimetric
apoptosis detection system (Promega,Madison,
WI), according to the manufacturer’s instruc-
tions. Measurement of apoptosis was calcu-
lated as a percentage of apoptotic nuclei (dark-
brown nuclei) versus total nuclei of multinu-
cleated TRAP-positive cells evaluated in three
independent experiments. Even if they showed
a comparable transfection efficiency, the effect
of the decoy treatment in the OCs/UCB was
quite different from that observed in OCs/PB
(Fig. 2A, B). As shown in Figure 2 (panel
A), OCs/PB were mostly apoptotic because
they were TdT-mediated dUTP nick end label-
ing (TUNEL) positive; in contrast OCs/UCB
did not exhibit features characteristic of pro-
grammed cell death after the same decoy treat-
ment (panel B, Fig. 2).
The Expression of Survival Proteins
in OCs/UCB
To further study the different sensitivity
to apoptotic stimuli, the basal expression of
Bim, Bcl-2, Bcl-XL, and survivin was tested.
Bim is a pro-apoptotic member of the Bcl-
2 family, and it has been recently showed
that regulation of its levels is critical for
controlling OC apoptosis.11 For this kind of
study an immunocytochemistry analysis was
performed employing the streptavidin–biotin
method using an Ultraystain polyvalent-HRP
(horseradish peroxidase) immunostaining kit
(Ylem, Italy).5 As shown in Figure 3, OCs/PB,
but not OCs/UCB, are strongly immunoposi-
tive for Bim. The resistance to apoptosis may be
ascribed to the presence of anti-apoptotic fac-
tors, including Bcl-2, Bcl-XL, and survivin,12–14
for which we observed a strong staining in
OCs/UCB but not in OCs/PB (Fig. 3). There-
fore, our data support the possibility that the
loss of prosurvival Bcl-2 and the presence of
pro-apoptotic Bim might be critical in driv-
ing OC/PB apoptosis and that, conversely,
the presence of Bcl-2, Bcl-XL, and survivin in
OCs/UCB plays a critical role in blocking OC
apoptosis and promoting OC survival.
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Figure 4. Extracts from medicinal plants differentially inhibit molecular interactions be-
tween NF-κB and target DNA sequences. The effects on NF-κB–DNA interactions of the indi-
cated amounts of extracts (µg/binding reaction) from Aegle marmelos, Polyalthia longifolia,
Lagerstroemia speciosa, Vernonia anthelmintica, Emblica officinalis, and Argemone mexi-
cana were studied by electrophoretic mobility shift assay. ∗, free probe; arrows, NF-κB–DNA
complexes.
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Figure 5. Detection of apoptosis by TUNEL assay in human primary osteoclasts. The
presence of apoptotic OCs after treatment with 0.5, 5, and 50 µg/mL of E. officinalis extract
for 60 h is shown. Brown color reaction indicates cells that underwent apoptosis. In the lower
panel, the immunocytochemical analysis of FAS receptor expression levels in human primary
OCs subjected to the same experimental conditions is reported. C, control cells; cells were
photographed at a magnification of 20×.
Inhibitors of NF-κB Activity
from the Natural World:
Emblica officinalis Extracts
Recent results support the concept that
some medicinal plants and natural prod-
ucts derived from them are of great inter-
est in developing therapeutic strategies against
bone disorders, including rheumatoid arthritis
and osteoporosis.15–20 For instance, Yin et al.
demonstrated that water extracts of Dioscorea
spongiosa stimulate osteoblast proliferation, ex-
hibiting at the same time a potent inhibitory
activity on osteoclastogenesis.21 Moreover, fruit
extracts of Psoralea corylifolia22 and Cnidium mon-
nieri23 exhibit osteoblastic proliferation stim-
ulating activity in osteoblast-like UMR106
cells in vitro. Several plant extracts inhibiting
OC differentiation also display strong anti-
inflammatory properties.21–23
Among medicinal plants, Emblica officinalis is
certainly of interest.21–32 This medicinal plant
has played an important medicinal role for
centuries in the Indian system of medicine.
Fruits of E. officinalis are used for the treat-
ment of a number of diseases, such as dyslipi-
demia24 and atherosclerosis,25 as hepatoprotec-
tive,26 antibacterial,27 and anti-inflammatory
agents.28 In many cases E. officinalis has been
shown to be a potent free-radical scavenging
agent, thereby preventing carcinogenesis and
mutagenesis; for this purpose hypotheses to
determine the mechanism of its action have
been suggested.29
In Vitro Effects of E. officinalis
Extracts on NF-κB Transcription
Factor Activity
The transcription factorNF-κB is involved in
inflammation and it plays a critical role in OC
differentiation, regulating the expression of a
large number of OC-specific genes. The ability
of E. officinalis extracts to interfere with NF-κB
binding properties was investigated. E. officinalis
extracts were incubated in the presence of 5 µg
of K562 cell nuclear extracts with an oligonu-
cleotide containing a cis element of the long ter-
minal repeat of HIV-1, representing the DNA
binding site for NF-κB. DNA–protein interac-
tions were then evaluated by electrophoretic
mobility shift assay.
Representative results are shown in Figure 4;
full results are reported by Lampronti et al.33
High inhibitory activity of E. officinalis was
found in comparison was performed with
extracts from Oroxylum indicum, Santalum yasi,
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Cuscuta reflexa, Argemone mexicana, Cassia sophera,
Paederia foetida, Hygrophila auriculata, and Oci-
mum sanctum.33 Extracts showing high activity
on NF-κB interactions were also those derived
from Aegle marmelos, Moringa oleifera, Vernonia an-
thelmintica, Rumex maritimus, Lagerstroemia speciosa,
Hemidesmus indicus, Polyalthia longifolia, Terminalia
arjuna, Saraca asoka, and Aphanamixis polystachya
(Fig. 4).28
E. officinalis Extracts Induce
Osteoclast Apoptosis
A TUNEL test was performed on OCs from
peripheral blood after exposure for up to 60 h
to quantities of 0.5, 5, and 50 µg/mL of E. of-
ficinalis extract. As shown in Figure 5, a low
but significant level of apoptosis (20%) was
induced by 0.5 µg/mL of extract, while at
5 and 50 µg/mL a dramatic increase (50%
and 98%, respectively) in TUNEL-positive nu-
clei was observed. Times of exposure shorter
than 60 h were also tested (24 and 48 h) with-
out obtaining significant differences from un-
treated cells (data not shown). These results
were confirmed by immunocytochemical anal-
ysis of FAS receptor expression. FAS receptor
is a well-known apoptosis-related protein and,
as shown in Figure 5, its expression increased
in OCs treated with E. officinalis extracts at all
three concentrations used.
Conclusions
Induction of apoptosis of OCs could be an
important strategy for not only interfering with
rheumatoid arthritis complications of the bone
skeleton that result in joint destruction but also
preventing and reducing osteoporosis.
In the present review we report data sug-
gesting the use of primary cultures of human
OCs (hOCs) from PB as a good tool to test
the potential use of E. officinalis fruit extracts
in the therapy of human pathologies associated
with bone loss. In fact E. officinalis extracts sig-
nificantly induce apoptosis in hOCs as a result
of specific inhibition of NF-κB activity. In this
context, the possible use of natural products,
including plant extracts and nutriaceuticals, is
under debate.
In addition, our experimental data indicate
that different susceptibility to apoptosis be-
tween OCs differentiated from hematopoietic
precursor cells present in PB and UCB exists.
Because OCs are extensively employed to in-
vestigate cell response to therapies for the treat-
ment of bone loss associated with several dis-
eases, we conclude that the source of potential
OC precursors used for in vitro analysis may
influence the cell response to biological mod-
ifiers. This may be important in future thera-
peutic designs for limiting the number of bone
resorbing cells and for testing the effects of an-
tiresorptive agents.
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Abstract This study aims to define the function of Slug
transcription factor in human normal osteoblasts (hOBs).
To date, Slug is considered exclusively a marker of
malignancy in bone tissue. Here, we identified, for the first
time, a role for Slug in hOBs using a knockdown approach.
We demonstrated that Slug is positively correlated with
osteoblast markers, including Runx2, osteopontin, osteo-
calcin, Collagen type 1, Wnt/b-catenin signaling mediators,
and mineral deposition. At the same time, Slug silencing
potentiates the expression of Sox-9, a factor indispensable
for chondrogenic development. These data, with the find-
ing that Slug is in vivo recruited by the promoters of Runx2
and Sox-9 genes, suggest that, in hOBs, Slug may act both
as positive and negative transcriptional regulator of Runx2
and Sox-9 genes, respectively. In summary, our results
support the hypothesis that Slug functions as a novel reg-
ulator of osteoblast activity and may be considered a new
factor required for osteoblast maturation.
Keywords Human osteoblasts ! Slug ! Wnt signaling !
Runx2 ! Sox-9
Introduction
Osteoblasts, bone producing cells, originate from multi-
potent mesenchymal stem cells and are responsible for the
secretion of the organic extracellular matrix of bone, both
during development and later during the remodeling of
mature bone [1]. Osteoblast differentiation and activity are
regulated by multiple signaling pathways and specific
factors that, by influencing gene expression, cell prolifer-
ation, and migration, control bone mass homeostasis.
Among these factors, Wingless-type proteins (Wnts) and
bone morphogenetic proteins (BMP) drive early events,
while the helix-loop-helix proteins Twist and Id maintain
proliferation [2–5]. Subsequently, transcriptional regula-
tion of osteoblast differentiation, maturation, and activity is
mainly due to key regulators including Runx2, Msx1 and 2,
Osterix, NFAT2, c-fos, c-jun, ATF4, fra-2, jun D, Dlx3 and
5 [5–12]. In recent years, the knowledge of the molecular
mechanisms that drive the function of these factors in the
regulation of bone cell biology has greatly improved;
nevertheless, many aspects have not yet been investigated.
In particular, the intricate cross-talk among the different
pathways is only partially known. In addition, the expres-
sion and function of the previously mentioned factors in
osteoblasts have been extensively analyzed in experimental
animal models, tumor cells, or cellular lines, whereas data
about these molecules in human primary osteoblasts cul-
tures are very scarce.
Accumulated evidence has shown that lymphocyte
enhancer binding factor 1/T cell factor (LEF1/TCF) tran-
scription factors, the nuclear effectors of the Wnt/b-catenin
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signaling pathway, influence osteoblast proliferation,
function, and regeneration, enhancing expression of
Runx2, the master transcription regulator of osteoblasts
[13]. Nevertheless, most downstream bone-specific target
genes of this pathway are only partially known. Among
these, Slug has been recently implicated in osteosarcoma
progression as a Wnt-responsive molecule strongly corre-
lated with a loss of tumor suppressors such as E-cadherin
[14, 15]. We recently demonstrated that Slug gene is also
expressed in normal human osteoblasts, and Lef/Tcf cis
elements present on its promoter act in regulating its
transcription through a direct binding of Lef-1, TCF-1, and
TCF-4 in vivo (submitted manuscript).
Human Slug, also named Snail 2, belongs to the Snail
family of genes encoding zinc-finger transcription factors
[14]. It is expressed at different stages of development in
different tissues, and mediates epithelial–mesenchymal
transition [14–16]. Moreover, Slug is involved in a broad
spectrum of biological functions, such as cell differentia-
tion, cell motility, cell-cycle regulation, and apoptosis [17].
Slug is also expressed in most normal adult human tissues,
but little is known about its potential functions.
In order to identify new potential osteoblast-specific
proteins, in the current study we investigated the role of
Slug in relation to the expression of Wnt/b-catenin sig-
naling mediators and bone-related genes in human mature
osteoblasts (hOBs). For this purpose, we evaluated the
effects of Slug gene knockdown on osteoblast maturation
by using siRNA strategy. In addition, in order to correlate
the expression level of Slug and its activity in regulating
the transcription of genes that are crucial for osteoblast
differentiation, we investigated Slug in vivo occupancy of
the E boxes regulatory sites present in the Runx2 and Sox-9
gene promoters.
Our findings describe an unknown regulatory function of
Slug and provide clear evidence for a pivotal role of Slug in
regulating osteoblast maturation in human.
Materials and methods
Isolation and culture of osteoblasts and chondrocytes
Bone tissues were harvested from different patients
undergoing total knee replacement for osteoarthritis
(mean ± SD age 65 ± 10 years). The study was approved
by the Istituto Ortopedico Rizzoli (Bologna, Italy) ethical
committee and informed consent was obtained from each
patient. Trabecular bone was obtained from the inner
portion of the tibial plateau. Bone chips were removed
from the tibial plateau, collected in a V-glass tube con-
taining 1.5 ml of 1:1 mixture of DMEM/Ham’s F12 K no
calcium (Gibco, Invitrogen, Paisley, Scotland, UK) and
supplemented with antibiotics (100 U/ml penicillin and
100 lg/ml streptomycin), 25 lg/ml ascorbic acid, 4 mM
glutamine (Sigma–Aldrich, St. Louis, MO, USA) and
2 mM calcium chloride (referred to as enzyme medium) as
previously reported [18] and according to the methods
described by Robey and Termine [19].
Primary chondrocytes were obtained from patients with
osteoarthritis undergoing knee arthroplasty. The chondro-
cytes were isolated from minced tissue by sequential
enzymatic digestion as previously described [20].
Immunocytochemistry
A sample of 104 human osteoblasts (at passage 2) were
seeded in 8-well chamber slide and allowed to adhere for
96 h. Human osteoblasts were fixed in 4%PFA for 20 min at
room temperature and then hydrated with TBS 1% BSA for
5 min at room temperature. The slides were incubated with
monoclonal antibodies anti-human -CD45 (Dako Cytoma-
tion, Glostrup, Denmark), -CD146 (Nocastra, Newcastle,
UK), -CD105 (produced from the hybridoma cell line, clone
SH2; ATCC, Rockville, MD), -Runx-2, -osteocalcin, (all
purchased from R&D Systems,Minneapolis, MN), -alkaline
phosphatase, -collagen type 1 (both obtained from DSHB,
Department of Biological Sciences, Iowa city, IA), -bone
sialoprotein, (Fisher Scientific,Pittsburg, PA, USA), -estro-
gen receptor alpha (Upstate Biotechnology, Lake Placid,
NY), and -collagen type 2 (Millipore, 900 Middlesex Tpk
Billerica, USA) for 1 h at room temperature. The slides were
washed three times with TBS 1%BSA and then sequentially
incubated with multilinker biotinilated secondary antibody
and alkaline phosphatase-conjugated streptavidin (Kit Bi-
oGenex, San Ramon, CA, USA) at room temperature for
20 min. The slides were developed using fast red as sub-
strate, counterstained with haematoxylin, mounted with
glycerol jelly, and evaluated in a brightfield microscope.
Negative and isotype matched controls were performed.
Positive cells were manually counted by two evaluators
blinded to marker evaluated. For each well, we randomly
selected 20 fields at high magnification (940). Results were
expressed as the percentage of positive cells on the total
number of cells counted.
Analysis of osteoblast activity
For alkaline phosphatase staining, the Alkaline phospha-
tase (ALP) Leukocyte kit (Sigma) was used. To perform
the test, prefixed mono-layered cells were incubated at
room temperature in a solution containing naphthol AS-BI
phosphate and freshly prepared fast blue BB salt buffered
at pH 9.5 with 2-amino-2-methyl-1,3-propanediol
(AMPD). The presence of sites of ALP activity appeared as
blue cytoplasmatic staining.
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ALP activity was evaluated in hOBs by the hydrolysis of
p-nitrophenylphosphate (PNPP). The enzyme activity,
expressed as lmol/min/lg of protein, was evaluated 6 days
after siRNA/Slug2 treatment. One unit was defined as the
amount of enzyme which hydrolyzed 1 nmol/PNPP per
minute.
The extent of mineralized matrix in the plates was
determined by Alizarin Red S staining (Sigma) in the
cells cultured for up to 21 days in osteogenic medium
consisting in DMEM, high-glucose, supplemented with
10% FBS, 10 mM b-glycerophosphate, 0.1 mM dexa-
methasone, and 50 mM ascorbate. In the committed
cells, the osteogenic medium was changed every 3 days
as well as RNA interference treatment where indicated.
The cells were then fixed in 70% ethanol for 1 h at room
temperature, washed with PBS, stained with 40 mM AR-
S (pH 4.2) for 10 min at room temperature, washed five
times with deionized water, and incubated in PBS for
15 min to eliminate non-specific staining. The stained
matrix was observed at different magnifications using a
Leitz microscope. Matrix mineralization was quantified
by measuring the number and surface of mineralized
nodules using a digital image analyzer (‘‘Quantity one’’
software, Biorad). The surface and the number of all
mineralized nodules were quantified in 2 wells per
condition at day 14 and 21 of culture.
Small interfering RNA (siRNA) transfection
Three sets of Stealth RNAi duplexes and corresponding
Stealth control were synthesized by Invitrogen Life Tech-
nologies (Carlsbad, CA, USA). Stealth RNAi compounds
are 25 mer dsRNA containing proprietary chemical modi-
fications that enhance nuclease stability and reduce off-
target effects.
The following Stealth RNAi sequences were used:
siRNA/Slug1 sense: 50-CCGUAUCUCUAUGAGAGUUA
CUCCA-30, antisense: 50-UGGAGUAACUCUCAUAGA-
GAUACGG-30; siRNA/Slug2 sense: 50-CCCUGGUUGCU
UCAAGGACACAUUA-30, antisense: 50-UAAUGUGUCC
UUGAAGCAACCAGGG-30; siRNA/Slug3 sense: 50-GG
CUCAUCUGCAGACCCAUUCUGAU-30, antisense: 50-A
UCAGAAUGGGUCUGCAGAUGAGCC-30.
The most effective fragments used for targeting human
Slug were siRNA/Slug2.
Twenty-four hours before siRNA transfection, hOBs
were seeded in triplicate at density of 16 9 103/cm2 in
DMEM with 10% FBS. Cells were transfected with 30 nM
siRNA using Lipofectamine RNAiMAX (Invitrogen Life
Technologies) according to the manufacturer’s instruc-
tions. Transfected cells were incubated for 6 days at 37!C
before gene silencing analysis. As a negative control for
the siRNA treatment, Medium GC Stealth RNAi Negative
Control Duplex (Invitrogen) was used. Knockdown of Slug
expression was verified by Real-Time RT-PCR.
Real-time quantitative RT-PCR
Cells from three wells were harvested and total RNA was
extracted using an RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instruction and
as previously described [21]. Real-time PCR was carried
out using the ABI PRISM 7700 Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA, USA). TaqMan
technology, the Assays-On-Demand kit for human Slug,
Lef-1, b-catenin, Runx2, Sox-9, OPN, OC, Col1a1,
RANKL, and c-myc, were used. The mRNA levels of
target genes were corrected for GAPDH mRNA levels
(endogenous control). All PCR reactions were performed
in triplicate for each sample and were repeated three times.
All experimental data were expressed as the mean ± SEM.
Western blotting
For western blot analysis, the cells were washed twice
with ice-cold PBS and cell lysates were prepared as
previously reported [22]. Then, 10 lg of each sample was
electrophoresed on a 12% SDS-polyacrylamide gel. The
proteins were then transferred onto an Immobilon-P
PVDF membrane (Millipore, Billerica, USA). After
blocking with PBS-0.05% Tween 20 and 5% dried milk,
the membrane was probed with the following antibodies:
Slug (L40C6) from Cells Signaling Technology (Danvers,
CA, USA), Runx2 (sc-10758) and Sox-9 (sc-20095), from
Santa Cruz Biotechnology (Santa Cruz, CA, USA), Lef-1
(L7901) from Sigma Aldrich, IP3 K (06-195), and Active-
b-Catenin (05-665) from Upstate Biotechnology (Lake
Placid, NY).
After washing with PBS-Tween, the membranes were
incubated with peroxidase-conjugated anti-rabbit antibody
(1:50000) or anti-mouse (1:2000) (Dako, Glostrup, Den-
mark) in 5% non-fat milk. Immunocomplexes were
detected using Supersignal West Femto Substrate (Pierce,
Rockford, IL, USA). Anti-IP(3)K was used to confirm
equal protein loading.
Osteocalcin assay
Osteocalcin secretion was measured in cell culture super-
natants collected from osteoblasts plated in 24-well dishes
and cultured with D-MEM, 10% FCS in presence or in
absence of 30 nM siRNA/Slug2 for 6 days. Prior to mea-
surements, the media were collected, centrifuged at 1,300g
for 5 min, and tested by using a human osteocalcin enzyme-
linked immunosorbent assay (ELISA) kit, according to
manufacturer’s instructions (DRG Diagnostics, Germany).
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Osteocalcin levels were corrected with total protein content
and expressed as nanograms per micrograms of cell protein
and each treatment was performed in duplicate.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was carried out as previously described
[21] using the standard protocol supplied by Upstate Bio-
technology with their ChIP assay reagents.
The cells were cross-linked with 1% formaldehyde for
10 min at 37!C, washed in ice-cold PBS, and suspended in
SDS lysis buffer for 10 min on ice. Samples were soni-
cated, diluted 10-fold in dilution buffer supplemented with
protease inhibitors, and precleared with 80 ll of DNA-
coated protein A-agarose; the supernatant was used directly
for immunoprecipitation with 5 lg of anti- Slug, (sc-
10436) (Santa Cruz Biotechnology), overnight at 4!C.
Immunocomplexes were mixed with 80 ll of DNA-coated
protein A-agarose followed by incubation for 1 h at 4!C.
Beads were collected and sequentially washed 5 times with
1 ml each of the following buffers: low salt wash buffer
(0.1% SDS,1% Triton X-100, 2 mM EDTA, 20 mM Tris–
HCl pH 8.1, 150 mM NaCl), high salt wash buffer (0.1%
SDS,1% Triton X-100, 2 mM EDTA, 20 mM Tris–HCl
pH-8.1, 500 mM NaCl), LiCl wash buffer (0.25 mM LiCl,
1% IGEPAL-CA630, 1% deoxycholic acid, 1 mM EDTA,
10 mM Tris-pH 8.1), and TE buffer. The immunocom-
plexes were eluted two times by adding a 250-ll aliquot of
a freshly prepared solution of 1% SDS, 0.1 M NaHCO3
and the cross-linking reactions were reversed by incubation
at 65!C for 4 h. Further, the samples were digested with
proteinase K (10 mg/ml) at 42!C for 1 h, DNA was
recovered by phenol/chloroform extractions, ethanol pre-
cipitated using 1 ll of 20 mg/ml glycogen as the carrier,
and suspended in sterile water. For PCR analysis, aliquots
of chromatin before immunoprecipitation were saved
(input). PCR was performed to analyze the presence of
DNA precipitated by Slug-specific antibody, and by using
specific primers (Table 1) to amplify fragments of the
Runx2 and Sox-9 gene promoters.
Each PCR reaction was performed with 5 ll of the
bound DNA fraction or 2 ll of the input. The PCR was
performed as follows: preincubation at 95!C for 5 min, 30
cycles of 1 min denaturation at 95!C, 1 min annealing at
62!C, and 1 min at 72!C, with one final incubation at 72!C
for 5 min. No-antibody control was included in each
experiment.
Statistical analysis
Data are presented as the mean ± SEM from at least three
independent experiments. Statistical analysis was per-
formed by one-way analysis of variance and the Student’s t
test. A P value \0.05 was considered statistically
significant.
Results
Phenotypical characterization and osteogenic potential
of human osteoblasts
Human primary osteoblast cultures (hOBs) were generated
from bone chips removed from the tibial plateau as pre-
viously described [18] and as reported in ‘‘Materials and
methods’’. We first analyzed a panel of nine phenotypic
markers in cells at the second passage in culture. All
osteoblasts were highly positive for the typical osteogenic
markers, including Runx2, collagen type 1 (Col1a1), bone
sialoprotein (BSP), and osteocalcin (OC), and weakly
positive to ALP. In addition, the cells were positive for
estrogen receptor alpha (ERa), a protein that is known to be
associated to osteoblast differentiation. The samples were
negative for a typical hematopoietic marker (CD45), only
partially positive for a mesenchymal marker such as
CD146, and positive for CD105. After this analysis, the
cells that we used may be considered mature osteoblasts
because they express low levels of CD146 and ALP, and
high levels of CD105, as previously reported [18]. The
percentage of positive cells for the markers analyzed by
immunocytochemistry in five hOB samples is shown in
Table 1, and the immunocytochemical staining of a rep-
resentative sample is reported in Fig. 1a. These
immunocytochemical data have also been confirmed by
FACS analysis (data not shown). Next, the cells were
characterized for their osteogenic capacity. All hOBs
exhibited an evident extracellular matrix mineralization
after 21 days of culture under osteogenic conditions (a
representative sample is shown in Fig. 1b).
Table 1 Immunocytochemical analysis of human primary osteo-
blasts (hOBs)
Markers Percentage of positive cells
hOB1 hOB2 hOB3 hOB4 hOB5
CD45 Negative Negative Negative Negative Negative
ALP 5 15 15 12 15
CD146 2 2 4 2 4
CD105 100 100 100 100 100
Col1a1 50 60 60 60 60
Runx2 80 80 80 80 80
BSP 100 100 100 100 100
OC 60 80 90 100 80
ER-a 100 100 100 100 100
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Slug knockdown and Wnt signaling
We firstly confirmed by western blot analysis on whole cell
extracts (Fig. 2a) that all hOB samples express Slug protein
at comparable levels, approximately the same that were
found in Slug-positive MDA-MB-231 breast cancer cells
[23]. Then, to test whether Slug expression may be corre-
lated with osteoblast phenotype, we used a Slug
Fig. 1 Phenotypical characterization of hOBs. Five hOB samples
were subjected to immunocytochemical analysis for ALP, CD146,
BSP, OC, CD105, Col1a1, Runx2, and ER-a phenotypical markers. a
The staining showed the local expression of the markers analyzed in a
representative sample (920 magnification). b The formation of
extracellular matrix by cells treated with b-glycerophosphate, ascor-
bic acid, and dexamethasone. Mineral formation was examined by
Alizarin Red S staining. The deposition of calcium salts was observed
in osteogenic cultures at day 21
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knockdown approach using siRNA. For this purpose, three
siRNAs against Slug were designed, siRNA/Slug1, siRNA/
Slug2, and siRNA/Slug3, in order to down-regulate Slug
expression. Transfection of hOBs and osteosarcoma SaOS2
cell line with these siRNAs resulted in the down-regulation
of Slug transcript by 30% (siRNA/Slug1 and siRNA/Slug3)
or 80% (siRNA/Slug2) (electronic supplementary material,
Fig. 1). Therefore, we blocked Slug endogenous produc-
tion treating the cells for 6 days with siRNA/Slug2 30 nM
and obtaining a strong inhibition of Slug mRNA and pro-
tein, as revealed by quantitative RT-PCR and western blot,
respectively (Fig. 2b).
In order to establish a role of Slug in osteoblasts, we
analyzed the effects of Slug silencing on the expression of
mediators of a central pathway in bone metabolism, such as
Wnt signaling.
As shown in Fig. 3a, Slug knockdown significantly
reduced the protein levels of two important Wnt mediators,
Lef-1 and b-catenin, in all the analyzed samples. Attempts
to detect a corresponding reduction of mRNA expression
level of Lef-1 and b-catenin met with variable success, and
we found approximately the same Lef-1 and b-catenin
mRNA levels both in siRNA-transfected cells and in con-
trol cells (data not shown). This suggests that, for what
concerns these two genes, the regulation mediated by Slug
silencing is mainly at the protein level that is independent
of mRNA. Therefore, we hypothesized that the levels of
Slug may interfere with Wnt signaling modulating the
levels of Lef-1 and b-catenin, and that Slug may conse-
quently act by controlling the expression of specific genes
in osteoblasts.
In order to strengthen this hypothesis, the expression of
downstream target genes of canonical Wnt signaling such
as Runx2, Sox-9, osteocalcin, RANKL, and c-myc were
examined in Slug silenced cells. As shown in Fig. 3b, the
expression of Runx2, the master transcription regulator of
osteoblasts previously identified as a Lef-1/b-catenin target
gene [13], was markedly decreased in Slug silenced cells
compared to untreated osteoblasts. On the contrary, Slug
knockdown induced expression of Sox-9, a factor indis-
pensable for chondrogenic development [24], in four out
five samples. In this case, the effects of Slug silencing were
Fig. 2 Silencing of Slug gene
expression by siRNA/Slug2 in
hOBs. a Western blot analysis
of endogenous Slug expression
in hOBs. 10 lg of whole cell
lysates from five hOBs samples
were assayed on a 12% SDS-
polyacrylamide gel. The
proteins were visualized using
Supersignal Femto Substrate
(Pierce). Size markers are
reported (KDa). IP3 K was used
as a loading control. Positive
and negative controls for Slug
band (Slug-positive MDA-MB-
231 breast cancer cells, and
Slug-negative MCF7 breast
cancer cells, respectively) are
shown. b hOBs were transfected
with siRNA/Slug2 or a non-
relevant siRNA (scr). Slug
expression was determined both
at mRNA and protein level, and
revealed by quantitative RT-
PCR and western blot analysis,
respectively. RT-PCR results,
after correction to GAPDH
content, are expressed as
siRNA/Slug2 over control ratio.
Results represent
means ± SEM of five hOBs
samples (**P\ 0.01). At the
bottom, representative western
blot of siRNA/Slug2 treated
cells shows a specific decrease
of endogenous Slug protein
level
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both at mRNA and protein level. Accordingly, in four out
five samples, the amount of secreted osteocalcin, which is a
marker of late osteoblast differentiation positively modu-
lated by Wnt signaling [25], was significantly reduced by
Slug knockdown (Fig. 3c), as well as the expression of c-
myc which is induced in response of activation of Wnt
signaling [26] (Fig. 3d). On the contrary, mRNA levels of
the receptor activator of NFkB ligand (RANKL), the
expression of which is repressed by Wnt signaling [27],
was significantly increased in the siRNA/Slug2 hOBs-
treated samples (Fig. 3e). As a whole, these results suggest
that Slug knockdown affects Wnt signaling and conse-
quently its downstream target genes in human osteoblasts.
Slug interacts in vivo with the promoters of Runx2
and Sox-9
Investigations were then performed to address whether
Slug may be directly involved in the control of specific
gene transcription in hOBs. For this purpose, the promoters
of Runx2 and Sox-9 were chosen for chromatin immuno-
precipitation (ChIP) analysis. At first, we searched putative
Slug binding sites, named E boxes [28], in the promoter
regions of human Runx2 and Sox-9 genes by using a
program for predicting transcription factor binding sites
(TFSEARCH, www.cbrc.jp/research/db/TFSEARCH.html
). As shown in Fig. 4, many E boxes were found in the
promoter of both genes; their functionality was then
investigated, analyzing the in vivo association between
Slug and the promoter sequences by ChIP binding assays
(Fig. 4). To this aim, human primary osteoblasts were
exposed to formaldehyde to cross-link proteins and DNA,
and sonicated to fragment the chromatin. Specific antibody
against Slug was used to immunoprecipitate the protein–
DNA complexes. The presence of the promoter-specific
DNA region before immunoprecipitation was confirmed by
PCR (input). After immunoprecipitation, DNA was
extracted from the beads and used as a template to generate
Fig. 3 Effect of Slug interference on Wnt signaling target genes in
hOBs. After siRNA/Slug2 treatment the expression of bone-related
Wnt target genes was analyzed in five hOB samples. a Western blot
analysis of Lef-1 and active b-catenin protein levels. Size markers are
reported (KDa). IP3 K was used as a loading control. b Runx2 and
Sox-9 expression analysis in siRNA/Slug2 treated cells. mRNA and
protein levels were determined by quantitative RT-PCR and western
blot analysis, respectively. c Osteocalcin, c-myc, and RANKL
expression analysis in siRNA/Slug2 treated cells. Osteocalcin protein
was measured in cell culture supernatants by ELISA. The level of c-
myc and RANKL expression was determined by quantitative RT-
PCR. In all quantitative RT-PCR experiments the results, after
correction to GAPDH content, are expressed as siRNA/Slug2 over
control ratio. Results represent means ± SEM of triplicate determi-
nations (*P\ 0.05, **P\ 0.01)
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specific PCR products spanning the putative Slug binding
sites from -3,000 bp to ?1 bp in the promoter of both
genes. Slug recruitment was assessed at the different pro-
moter regions, as indicated in Fig. 4, by using specific sets
of primers (Table 2). Slug occupancy was detected at the
region 2 and 3 of Runx2 gene (Fig. 4a) and at the region 2
of Sox-9 gene (Fig. 4b).
These ChIP experiments were repeated four times with
identical results and demonstrate that both Runx2 and Sox-
9 are Slug target genes in human osteoblasts.
Slug knockdown inhibits maturation of osteoblasts
and supports differentiation of chondrocytes
Afterwards, the effect of Slug silencing on osteoblast mat-
uration was examined analyzing ALP activity and the
formation of mineralized matrix. As shown in Fig. 5a, there
was a significative decrease of ALP activity after 6 days of
siRNA/Slug2 treatment. Accordingly, Slug silenced cells
showed a reduced mineralization ability; in fact, 14 days
after the initiation of osteoblast induction in osteogenic
Fig. 3 continued
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medium, a reduction up to 86% of mineral deposition was
observed in Slug silenced cells in comparison with non-
silenced cells (Fig. 5b). This decrease in osteoblast matu-
ration was accompanied by a significative decrease of other
correlated markers including Col1a1 and classical Runx2
targets such as osteopontin and osteocalcin (Fig. 5c).
Since we have here demonstrated that Slug knockdown-
induced expression of Sox-9 in hOBs, investigations were
Fig. 4 In vivo recruitment of Slug on Runx2 and Sox-9 gene
promoters. Protein–DNA complexes were formaldehyde-cross-linked
in hOBs in vivo. Chromatin fragments from these cells were subjected
to immunoprecipitation with antibody against Slug. After cross-link
reversal, the coimmunoprecipitated DNA was amplified by PCR
using the primers reported in Table 2, and specific for the indicated
promoter regions. PCR fragments were resolved in 1.5% agarose gels.
Aliquots of chromatin taken before immunoprecipitation were used as
Input positive controls whereas chromatin eluted from
immunoprecipitations lacking antibody were used as no antibody
(NoAb) controls. a The immunoprecipitates were subjected to PCR
analysis using primer pairs spanning the reported regions of Runx2
promoter. b The immunoprecipitates were subjected to PCR analysis
using primer pairs spanning the reported regions of Sox-9 promoter.
The specific molecular weights of PCR fragments are shown in
parentheses. The relative positions of Slug putative binding sites
(striped boxes) are indicated. *Sites showing 100% homology with
consensus-binding site (CAGGTG)
Table 2 PCR primers used for
chromatin immunoprecipitation
assay (ChIP)
Gene Primer sequences Product size (bp)
Runx2 Forward F1:50-ATATCCTTCTGGATGCCAGG-30 167
Reverse R1:50-AAGCACTATTACTGGAGAGGC-30
Forward F2:50-GTTTCAGTGAATGCTAATGTAG-30 290
Reverse R2:50-AAGCGTTCATTTAACATGCAG-30
Forward F3:50-CAAGAGCTTTATTTGCATTGAC-30 282
Reverse R3:50-TTGTCCTCTGTGAGGCCTAT-30
Sox9 Forward F1:50-GATAGTGTCCTCACTTCGCA-30 467
Reverse R1:50-TCCACTCTGGCGGAGTCATG-30
Forward F2:50-CAGCCACCACCATCCAAGTT-30 470
Reverse R2:50-GAAGGGCATTGTGTGTACAG-30
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then performed to evaluate the potential pro-chondrogenic
effect of Slug knockdown in human undifferentiated
chondrocytes at passage 6–8. In these conditions, the cells
express very low level of Collagen type 2 [29]. Slug
mRNA expression was blocked in these cells with the same
approach and effectiveness as in hOBs (Fig. 6a). Runx2
and Sox-9 expression was then tested. As shown in Fig. 6b,
a significative upregulation of both these genes, required
for chondrocyte maturation [30], was found in all analyzed
samples after Slug silencing. This effect was accompanied
by a significant increase of Collagen type 2 evaluated by
immunocytochemistry (Fig. 6c).
These preliminary findings demonstrate that when
endogenous Slug levels are suppressed chondrocytes are
inclined to differentiate, supporting the idea that Slug may
play a critical role as pro-chondrogenic factor.
Discussion
To our knowledge, this is the first study to examine the role
of Slug on normal human primary osteoblasts. Much is
known about the role of Slug during development and its
action in malignant progression [14–17, 31]; nevertheless,
its expression and function in normal adult tissues has not
been elucidated. To date, for what concerns bone tissue,
Slug is considered exclusively a marker of malignancy and,
consequently, an attractive potential target for therapeutic
Fig. 5 Effect of Slug interference on
osteoblast maturation. After siRNA/
Slug2 treatment the cells were
analyzed for the presence of alkaline
phosphatase activity (ALP),
formation of mineralized matrix and
expression of osteoblast maturation
markers. a Alkaline phosphatase
activity was evaluated by PNPP
hydrolysis and ALP Leukocyte kit.
The presence of sites of ALP activity
appeared as blue cytoplasmic
staining as shown in the reported
representative sample (920
magnification). b Mineral formation
was examined by Alizarin Red S
staining in the cells cultured with b-
glycerophosphate, ascorbic acid, and
dexamethasone (osteogenic
medium). The deposition of calcium
salts was observed in osteogenic
cultures at day 14, but not in control
cells (not cultured in osteogenic
medium), and was quantified by
measuring the number and surface of
mineralized nodules using a digital
image analyzer (‘‘Quantity one’’
software, Biorad). The ratio of the
surface to the number of nodules in a
representative hOB sample is
reported. c The expression of
Col1a1, osteopontin (OPN) and
osteocalcin (OC) was determined by
quantitative RT-PCR in the cells
cultured in osteogenic medium. The
results, after correction to GAPDH
content, are expressed as siRNA/
Slug2 over control ratio. Results
represent means ± SEM of triplicate
determinations (*P\ 0.05,
**P\ 0.01)
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modulation of bone metastasis and osteosarcoma inva-
siveness [31], blocking its expression and potentially
repressing any detrimental downstream effects.
However, there are no data about Slug expression and
regulation in human normal osteoblasts. Here, we identified
a role for Slug in normal human osteoblast maturation. Gene
expression analysis showed that Slug is positively correlated
with osteoblast markers, such as Runx2, and Wnt/b-catenin
signaling. A requirement for Slug in osteoblast maturation is
supported by Slug knockdown data. In fact, the suppression
of Slug mediated by siRNA weakens Wnt/b-catenin signal-
ing, decreases ALP activity, as well as osteoblast
mineralization, osteopontin, osteocalcin, and Col1a1, dem-
onstrating that Slug may be considered a novel osteogenic
factor. At the same time, Slug silencing does not reflect a
global suppression of gene expression. In fact, the expression
of RANKL which is suppressed by Wnt signaling in osteo-
blasts [27] was enhanced in response to Slug knockdown.
Furthermore, we observed that Slug silencing potentiates the
expression of Sox-9 both in hOBs and in undifferentiated
chondrocytes. This is particularly interesting in the context
of maturation and differentiation of these cells because Sox-
9 is an indispensable factor for chondrogenic development
[24, 30] activating cartilage-specific genes, but also acts as a
transcriptional repressor for osteoblast differentiation [32]
interacting with Runx2 and repressing its function. There-
fore, our findings suggest that Slug is required for supporting
osteogenic maturation, and its suppression also has a
potential pro-chondrogenic effect. Thus, Slug could affect
phenotypical changes in response to alteration of its
expression levels favoring the dominance of Runx2 function
over Sox-9 or vice versa. This is in agreement with several
observations demonstrating that, in order to achieve differ-
entiation towards a desired lineage, it is important to direct
the stem cell differentiation with correct levels of tran-
scription factors [2, 33]. Additional investigations will be
required to understand if Slug plays a role in cell fate
determination between chondrocytes and osteoblasts that are
derived from common mesenchymal progenitors [34].
Our observation that the Slug gene silencingmay decrease
Runx2 and increase Sox-9 expression in hOBs was further
validated by the in vivo occupancy of the E boxes regulatory
sites present in the Runx2 and Sox-9 gene promoters. This
suggests that Slug may act, at the same time, both as positive
and negative transcriptional regulator of Runx2 and Sox-9
genes, respectively, in human osteoblasts. This supports a
role for Slug in maintaining high levels of Runx2 and low
levels of Sox-9 to promote osteoblast maturation. Never-
theless, further studies will be needed to characterize the
action of Slug on the promoter sequences of these genes, and
to establish whether Slug interacts with other transcription
factors both in osteoblasts and their precursors.
Several observations indicate that Sox-9 and Runx2 are
targets of one of the most crucial signaling for normal
skeletogenesis, Wnt/b-catenin pathway [13, 24, 35–38].
Interestingly, we demonstrated that the levels of b-catenin
and Lef-1 proteins, two important mediators of Wnt/b-
catenin signaling, correlate with Slug expression levels and
significantly decrease in Slug silenced cells. Consistent
with these findings, we have recently shown that Slug gene
expression is positively regulated by Lef-1 which directly
binds to Lef/Tcf cis elements present on its promoter
(submitted manuscript).
Fig. 6 Silencing of Slug gene expression by siRNA/Slug2 in
undifferentiated chondrocytes. a Undifferentiated chondrocytes were
transfected with siRNA/Slug2 or a non-relevant siRNA (scr). Slug
expression was determined at mRNA, and revealed by quantitative
RT-PCR. RT-PCR results, after correction to GAPDH content, are
expressed as siRNA/Slug2 over control ratio. Results represent
means ± SEM of three chondrocytes samples (*P\ 0.05). b Runx2
and Sox-9 expression analysis in siRNA/Slug2 treated cells. mRNA
levels were determined by quantitative RT-PCR analysis. c Collagen
type 2 expression analysis in siRNA/Slug2 treated cells. The presence
of protein was determined by immunocytochemistry and appeared as
violet cytoplasmic staining, as shown in the reported representative
sample (920 magnification)
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Previous studies have established that Wnt/b-catenin sig-
naling events are mediated by the existence of a large
signalosome in which inputs from Wnt signaling, steroid
receptors, BMPs, and kinases converge to induce differenti-
ation of osteoblast precursors [39, 40].However, there are still
many unresolved issues about osteoblast regulation through
these different pathways. In this scenario, Slug might repre-
sent a new regulation factor required for human osteoblast
differentiation and maturation. Recent data indicate that, in
addition to Slug, another member of the zinc-finger Snail
family, Snail1, is involved in bone cell differentiation, but
with opposite effect [41]. In fact, in this study, the authors
demonstrated that Snail1 controls bonemass by repressing the
transcriptionofRunx2andvitaminD receptorgenes inmurine
osteoblasts. This suggests that Snail proteins may be involved
in the complex dinamics of osteoblast differentiation and
maturation processes through different mechanisms. Alter-
natively, it is plausible that the effects of a transcription factor
on the regulation of bone specific genes are different inmurine
and human cells, and depend on different moments of osteo-
blastic maturation. This concept may explain the different
results from another group demonstrating that Snail enhances
expression of osteoblast markers in the MC3T3-E1 cell line
[42]. In this study, in addition toSnail, the authors investigated
the contributionofmanyhelix-loop-helix (HLH) transcription
factors such as Twist proteins that compete with all the Snail
factors for the same E-box motifs on the target genes. In
agreement with several lines of evidence, the authors indicate
that Twist proteins inhibit osteoblast differentiation by inter-
fering with Runx2 function. The evidence that we here
obtained on Slug in human osteoblasts supports the conclu-
sions of this study, revealing that the integrated activities of
negative and positive E-box-related regulatory factors may
control osteoblast differentiation. Therefore, even if the gene
regulatory networks are highly intricate, it is possible that
further characterization of the role of Snail together withHLH
transcriptional regulators in human bone differentiation may
provide new insights into the discovery of new molecular
targets to use in bone repair and engineering [43].
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Abstract
Wharton's jelly from the umbilical cord is a noncontroversial source of mesenchymal stem cells
(WJMSCs) with high plasticity, proliferation rate and ability to differentiate towards multiple
lineages. WJMSCs from different donors have been characterized for their osteogenic potential.
Although there is large evidence of WJMSCs plasticity, recently scientific debate has focused on
MSCs selection, establishing predictable elements to discriminate the cells with most promising
osteoprogenitor cell potential.
In the present study a comparative study between the presence of osteoblastic markers and
different parameters that pertain to both the newborn and the mother was performed. Umbilical
cords were collected after all patients signed the informed consent and local ethical commettee
approved the study. Obstetric parameters, including baby's gender and birth weight, mother's age
at delivery, gestational stage at parturition and mode of delivery were examined. After
characterization and expansion, WJMSCs were analyzed for two osteoblastic markers, alkaline
phosphatase (ALP) activity, and the expression level of RUNX-2 transcription factor, and for their
ability to deposit mineralized matrix after osteogenic induction.
We found that osteoblastic potential was not influenced by baby's gender and mode of delivery.
On the contrary, the highest degree of osteoblastic potential has been shown by WJMSCs with
RUNX-2 high basal levels, selected from umbilical cords of the heaviest term babies.
Even if further evaluation is required, our hypothesis is that our findings may help in selecting the
optimal umbilical cord donors and in collecting high potential Wharton's jelly-derived
osteoprogenitors efficiently.
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Background
The umbilical cord is a noncontroversial source of mesen-
chymal stem cells (MSCs) [1,2]. Recently MSCs isolated
from Wharton's Jelly (WJMSCs), a mucoid connective tis-
sue of the umbilical cord, were shown to have the ability
to differentiate towards multiple lineages, including adi-
pose, bone, and neuronal lineages [3,4].
Work from several laboratories suggests that these cells,
which are very abundant, have potential in therapeutic
and tissue engineering field, and indicates that they may
be successfully collected and stored for both preclinical
work, and banking services [5,6].
It is important to point out that patients who receive
umbilical cord stem cells are at a lower risk of developing
graft versus host disease, than those who receive bone
marrow transplants [7].
Even if there is a considerable debate about MSC plastic-
ity, there are numerous recent reviews and papers on
MSCs describing molecular signals that have been identi-
fied in driving MSC differentiation down osteoblast line-
age, and molecules that are known playing an important
role in achieving the desired cellular response such as
bone morphogenetic proteins (BMP), dexamethasone,
ascorbic acid, and ?-glycerophosphate [8,9]. Bone defect
repair has been one of the first applications of MSCs, and
clinical potential of the use of these cells for bone tissue
repair is now extensively explored [10-13].
Nevertheless, bone tissue engineering applications require
that MSCs must possess certain reproducible characteris-
tics such as maintenance of the differentiated phenotype.
In this scenario, an area of intense research activity, is
devoted to improve human MSC characterization, isola-
tion, and expansion [14-16].
Starting from these considerations, we sought to establish
further elements for selection of the most desirable cell
source for obtaining, inside a WJMSCs collection, the cells
with most promising ability to differentiate into osteob-
lasts.
In the present study five different obstetric parameters,
including baby's gender and birth weight, mother's age at
delivery, gestational stage at parturition and mode of
delivery, were correlated with osteoblastic markers, such
as ALP activity, RUNX-2 expression and with the ability of
WJMSCs to differentiate along osteogenic lineage.
The hypothesis that the correlation among these parame-
ters may help the selection of optimal umbilical cord
donors to collect WJMSCs with most promising osteopro-
genitor cell potential is discussed.
Discussion
Human umbilical cord collection and WJMSCs analysis
Human umbilical cord and umbilical cord blood taken
after delivery of the newborn, from samples that would be
inevitably discarded, have been regarded as an alternative
source for transplantation and therapy because of their
haematopoietic and mesenchymal cell components [14].
The increasing interest in mesenchymal progenitors for
tissue repair widely promoted the characterization of early
predictive parameters for plasticity, inducibility and prac-
tical utility of these cells [10].
As previously reported [17] Wharton's jelly is an ideal and
uncontroversial source for mesenchymal stem cells (WJM-
SCs) due to the simple collection procedure and the high
homogeneity of cell population which is obtained.
In this study, we prepared primary cultures of WJMSCs
from 60 donating subjects whose characteristics are
shown in Table 1. Five obstetric factors, including baby's
gender and birth weight, mother's age at delivery, gesta-
tional stage at parturition and mode of delivery were
examined. By flow cytometric analysis (Figure 1A and 1B)
and double staining with propidium iodide (PI) and Cal-
cein-AM (Figure 1C) before and after cryopreservation, we
demonstrated that all WJMSCs samples showed a compa-
rable mesenchymal property and the same level of viabil-
ity. These characteristics indicate that the quality of the
cells is not influenced by the examined obstetric factors.
In order to assess the effect of these maternal and neonatal
factors on osteoblastic potential of WJMSCs, we focused
on the WJMSCs showing the highest levels of mesenchy-
mal and adhesion markers (CD90/Thy-1, CD29/?-1
integrin, CD44/hyaluronan receptor, and CD105/SH2,
endoglin), but not expressing hematopoietic/endothelial
markers (CD34 and CD45). 20 samples were induced to
osteoblast differentiation (see legend of Figure 2), and the
propensity to differentiate into osteoblasts was demon-
strated through the different ability of the cells to deposit
mineralized matrix. A very high heterogeneity in response
to treatment with osteogenic medium was observed, and
all attempts to detect a correlation between this ability
and one of the examined clinical parameters met not suc-
cess. It is important to underline that heterogeneity in the
behaviour of our WJMSC samples is in agreement with the
data obtained by other researchers [18,19] and suggests
that a great variability is often present after the recover of
these staminal cells.
WJMSCs and osteoblastogenesis
On the basis of these observations, we conducted further
analyses adjusting for two specific markers of osteoblast
differentiation: the activity of Alkaline Phosphatase (ALP)
[20] and the expression levels of Runt-related transcrip-
tion factor 2 (RUNX-2) which increases transcription of
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Table 1: Characteristics of subjects
Sample Mother's age (ys) Weeks of
pregnancy
Mode of delivery Gender Birth weight (Kg)
1 26 29 CS F 1.25
2 31 32 CS M 1.74
3 30 40 CS F 3
4 30 32 CS M 1.9
5 30 32 CS M 1.91
6 37 40 SP F 3.59
7 21 41 SP F 3.75
8 35 40 SP F 3.17
9 33 42 SP M 3.05
10 31 40 SP M 3.69
11 38 38 CS F 3.32
12 38 38 CS F 2.6
13 38 39 SP M 3.45
14 36 40 SP F 3.6
15 29 40 CS F 3.22
16 33 38 SP M 3.7
17 34 38 CS F 3.45
18 35 35 CS M 3.31
19 34 40 SP M 3.21
20 35 40 SP M 3.18
21 32 38 CS F 3.6
22 33 35 CS M 2.41
23 33 35 CS M 2.53
24 40 40 SP F 3.75
25 38 39 SP M 3.36
26 29 37 CS F 3.62
27 29 40 SP M 3.4
28 39 39 CS M 3.62
29 33 40 SP F 3.12
30 32 35 SP F 3.17
31 29 37 CS M 2.14
32 37 39 CS M 3.37
33 20 40 SP F 3.02
34 41 39 CS F 2.73
35 35 37 CS F 2.77
36 34 38 CS F 2.9
37 38 38 SP F 3.05
38 34 40 SP M 3.7
39 32 36 SP M 2.93
40 27 38 SP M 3.1
41 30 34 SP M 2.6
42 31 41 SP F 3.25
43 27 33 CS M 1.915
44 27 33 CS F 2.005
45 26 39 SP M 3.35
46 34 42 CS M 3.51
47 23 37 CS F 2.95
48 30 39 CS M 4.24
49 33 39 CS F 3.3
50 37 39 CS M 2.84
51 33 39 CS M 3.27
52 32 40 CS M 3.9
53 31 37 CS F 1.98
54 35 40 SP M 3.95
55 23 37 SP M 3.11
56 40 38 CS M 2.85
57 37 39 CS F 3.3
58 25 35 CS M 3.57
59 25 35 CS F 2.38
60 27 29 CS M 2.1
The recorded clinical parameters are: mother's age, weeks of pregnancy, mode of delivery, newborn gender and birth weight.
F (female) M (male) CS (caesarian delivery) SP (spontaneous delivery)
Umbilical cords were collected, after mothers' consent and approval of "Ethical commettee of University of Ferrara" and "Ethical commettee of 
Sant'Anna Hospital". The study population consisted of 60 healthy pregnant women voluntary enrolled between February 1, 2008 and March 1, 
2009.
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osteoblast specific genes [17]. As shown in Figure 2A,
focusing on basal levels of ALP and RUNX-2, it has been
possible to demonstrate that these parameters can be pre-
dictive of osteoblastic potential of WJMSCs. In fact, the
samples with high basal levels of RUNX-2 and ALP are
more prone to deposit mineral matrix if compared to
WJMSC with low levels of these two proteins. These obser-
vations suggest that it may be possible to discriminate
among different WJMSC samples those will have a posi-
tive outcome towards osteoblastic differentiation.
Osteoblastogenesis and clinical parameters
In a next step, we analyzed whether the basal levels of
RUNX-2 and ALP correlate with the examined obstetrics
factors (Figure 2B). We found that the infant gender and
mode of delivery didn't significantly correlate (P > 0.05)
with basal RUNX-2 expression and ALP activity. On the
other hand, the age of the mother at delivery, has a signif-
icant impact on the basal ALP activity but doesn't affect
RUNX-2 expression level. Samples collected from mothers
which were <32 years old give origin to WJMSCs with high
Small pieces (2-3 mm2) of cords were processed within 4 hours and cultured in DMEM-LGFigure 1
Small pieces (2-3 mm2) of cords were processed within 4 hours and cultured in DMEM-LG. At ~70-80% conflu-
ence, cells were scraped off by 0.05% trypsin/EDTA (Gibco, Grandisland, USA), and analyzed for expression of mesenchymal 
stem cell surface markers [17], by flow cytometric analysis, as reported (representative experiment) in panel A. The gated cells 
were negative for the hematopoietic line markers CD45 and CD34, partially positive for CD105 and CD44, and positive for 
the mesenchymal stem cells markers CD90 and CD29. B) Schematical distribution of the cell surface parameters of the 60 
samples analyzed. C) Comparison of the cell culture viability before and after thawing of a cryopreserved sample (high and low 
panel, respectively). The viability of WJMSCs analyzed by double staining with propidium iodide (PI) and Calcein-AM (Cellstain 
double staining kit, Sigma Aldrich, St Luis, MO, USA) is indicated. Cells were propidium iodide stained and then analyzed, 
before and after cryopreservation, for their DNA content, by using BD Immunocytometry Systems DNA QC Particles (BD, 
New Jersey, USA). The cytofluorimetric profile was analyzed and the percentage of the cell population distribution in the dif-
ferent phases has been reported.
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After characterization in terms of mesenchymal stem cell surface markers expression and cell viability, the osteogenic differen-tia ion of WJMSCs was assessed in the first- and s cond-passage cultur sFigure 2
After characterization in terms of mesenchymal stem cell surface markers expression and cell viability, the 
osteogenic differentiation of WJMSCs was assessed in the first- and second-passage cultures. Cells were cultured 
for 21 days in Osteogenic Differentiation Medium (Osteogenic BulletKit, PT-3924 & PT-4120, Lonza, Basel, Switzerland) or in 
DMEM-LG as a control. The ability of the cells to become mature osteoblasts was evaluated in terms of mineral matrix depo-
sition assessed by Alizarin Red staining (AR-S, Sigma Aldrich, St Luis, MO, USA). The cells fixed in 70% ethanol for 1 h at room 
temperature, were washed with PBS, stained with 40 mM AR-S (pH 4.2) for 10 min at room temperature, washed five times 
with deionized water and incubated in PBS for 15 min to eliminate non-specific staining. The stained matrix was then observed 
at different magnification using a Leitz microscope. In panel A the mineralization status (+, positive or -, negative) was corre-
lated with the basal level (at day ''0'') of RUNX-2 expression and ALP activity. RUNX-2 expression was examined by quantita-
tive TaqMan (ABI PRISM 7700, Applied Biosystems Inc, Foster City, CA, USA) RT-PCR (Assay-on-demand, Hs00231692_m1). 
The data were normalized on the basis of GAPDH expression and reported as relative mRNA expression levels. ??Ct method 
was used to compare gene expression data. ALP activity was measured by the hydrolysis of p-nitrophenylphosphate (PNPP, 
Sigma Aldrich, St Luis, MO, USA) [22] and one unit was defined as the amount of enzyme which hydrolyzed 1 ?mol/PNPP per 
minute. Cell protein content was determined according to the Lowry method [23]. (* = P < 0.05). B) Relationship between 
molecular and obstetric parameters. Basal levels of RUNX-2 expression and ALP activity were related to mother's age, weeks 
of pregnancy and birth weight in 20 WJMSC samples. C) The 20 samples of panel B were subdived in the two reported sub-
groups: premature birth (subgroup I) and full term birth (subgroup II). All examined molecular and obstetric parameters are 
reported. F (female), M (male), CS (Caesarian delivery), SP (spontaneous delivery). D) The ability to deposit mineralized matrix 
was valuated at the indicated times (0, 14, 21 days) in two representative samples of the two subgroups, by Alizarin red stain-
ing.
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ALP activity. Interestingly, birth weight of the infant was
shown to significatively impact on RUNX-2 basal expres-
sion level which, as reported in Figure 2B, decreases with
the decreasing of the baby's weight. The same relationship
was found for the duration of pregnancy. In fact, it was
found that WJMSCs from babies born before the 37 weeks
of gestation express lower basal level of RUNX-2 than the
full term borns. It is very likely that WJMSCs recovered
from premature birth contain a high number of undiffer-
entiated cells with high plasticity, a condition which is not
actually required for osteoblast differentiation.
As a whole, these findings led us to focus on two parame-
ters, weeks of pregnancy and consequently birth weight of
the baby, and RUNX-2 basal levels, subdividing the col-
lected samples in the two subgroups reported in Figure
2C: subgroup I, premature birth with low levels of RUNX-
2, and subgroup II, full term birth with high levels of
RUNX-2. The ability of the samples belonging to these
two subgroups to complete the event of cellular matura-
tion, that is the deposition of mineralized matrix, was
then compared. Two representative samples of the two
subgroups (Figure 2D) demonstrate that, samples from
subgroup I showed a null mineralization status also after
21 day of cell culture in osteogenic medium, whereas sam-
ples from subgroup II showed a high level of mineraliza-
tion beginning from day 14. These findings suggest that
maximal WJMSCs osteoblastic potential can be obtained
by primary cultures with RUNX-2 high basal levels,
selected from the heaviest term babies.
Another clinical observation that is important to do is that
the cases below 37 weeks of gestation were all treated with
24 mg of bethametasone two hours before delivery. Such
a therapy is routinely given to all the pregnant women
delivering prematurely in order to prevent respiratory dis-
tress syndrome in the newborns. Therefore, a possible
influence of this hormone on stem cells behaviour can be
hypothesized. At this regard it has been recently reported
that glucocorticoids play an essential role in favouring
stem cells differentiation towards adipocyte lineage, thus
inhibiting bone and muscle lineages [21]. Such an influ-
ence appears to be exerted by inducing myostatin, a
potent molecule that regulates muscle development.
Therefore, based on the above evidences a possible
absence of osteoblastogenesis could have been expected
in the samples derived from women delivering prema-
turely. Since we observed a low or null mineralization sta-
tus in WJMSCs from such patients, it could be possible to
point out a correlation between the two events. However,
our analysis showed that this evidence is not always occur-
ing, indicating that the short term high dose of
bethametasone administered wasn't ever effective in
inhibiting bone lineage.
Conclusion
To conclude, we should indicate that the analysis of the
basal level of RUNX-2 and ALP activity may allow a quick
testing of a high number of mesenchymal precursors cul-
tured in vitro and select the more suitable to potentially
use for bone tissue engineering application. In addition,
for the same aim, our results suggest that it is preferred to
recruit the samples from full term borns without paying
attention to mother's age.
Even if further evaluation is required, our hypothesis is
that our findings may help in selecting the optimal umbil-
ical cord donors and in collecting high potential Whar-
ton's jelly-derived osteoprogenitors efficiently.
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SLUG: a new target of lymphoid enhancer factor-1
in human osteoblasts
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Abstract
Background: Lymphoid Enhancer Factor-1 (Lef-1) is a member of a transcription factor family that acts as
downstream mediator of the Wnt/b-catenin signalling pathway which plays a critical role in osteoblast proliferation
and differentiation. In a search for Lef-1 responsive genes in human osteoblasts, we focused on the transcriptional
regulation of the SLUG, a zinc finger transcription factor belonging to the Snail family of developmental proteins.
Although the role of SLUG in epithelial-mesenchymal transition and cell motility during embryogenesis is well
documented, the functions of this factor in most normal adult human tissues are largely unknown. In this study we
investigated SLUG expression in normal human osteoblasts and their mesenchymal precursors, and its possible
correlation with Lef-1 and Wnt/b-catenin signalling.
Results: The experiments were performed on normal human primary osteoblasts obtained from bone fragments,
cultured in osteogenic conditions in presence of Lef-1 expression vector or GSK-3b inhibitor, SB216763. We
demonstrated that the transcription factor SLUG is present in osteoblasts as well as in their mesenchymal
precursors obtained from Wharton’s Jelly of human umbilical cord and induced to osteoblastic differentiation. We
found that SLUG is positively correlated with RUNX2 expression and deposition of mineralized matrix, and is
regulated by Lef-1 and b-catenin. Consistently, Chromatin Immunoprecipitation (ChIP) assay, used to detect the
direct Lef/Tcf factors that are responsible for the promoter activity of SLUG gene, demonstrated that Lef-1, TCF-1
and TCF4 are recruited to the SLUG gene promoter “in vivo“.
Conclusion: These studies provide, for the first time, the evidence that SLUG expression is correlated with
osteogenic commitment, and is positively regulated by Lef-1 signal in normal human osteoblasts. These findings
will help to further understand the regulation of the human SLUG gene and reveal the biological functions of
SLUG in the context of bone tissue.
Background
Lymphoid Enhancer binding Factor-1 (Lef-1) is a
nuclear high mobility group (HMG) protein that med-
iates gene transcription in response to canonical Wnt/b-
catenin signaling pathway [1-3]. Wnt signaling controls
normal and abnormal development in a variety of tis-
sues including skeleton, and accumulated evidence has
shown that Lef-1 influences osteoblast proliferation,
maturation, function, and regeneration both in vitro and
in vivo [4-7]. Nevertheless, the exact mechanism by
which Lef-1 affects osteoblast differentiation is
unknown. In a search for Lef-1 responsive genes in
human osteoblasts, we focused on the transcriptional
regulation of the SLUG gene for the reasons reported
below.
SLUG, also named SNAIL2, is a member of a super-
family of zinc-finger transcription factors that play a
central role in the patterning of vertebrate embryos
[8-10]. It is implicated in the induction of epithelial
mesenchymal transitions (EMT) at specific stages of
normal development and tumor progression, acting as a
transcriptional repressor of genes encoding components
of cell-cell adhesive complexes in the epithelia [11-17].
Several signalling pathways inducing EMT cellular event
and including FGF, WNT, TGF-b, BMP, EGF, HIF,
Notch, PTH, integrins and SCF/c-Kit have been shown
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to converge in SNAIL genes induction, as well reviewed
by Barrallo-Gimeno et al. [18], and as previously
reported [9,10,19].
SLUG and its family members also have important
roles in other processes, including protection of cells
from programmed cell death, regulation of cytoskeletal
elements [18], adipocyte differentiation [20] and migra-
tion of neural crest cells [21,22]. Although the expres-
sion of SLUG has been found in most normal adult
human tissues [23-25], little is known about its potential
functions.
It is important to underline that the vertebrate neural
crest, formed at the border between the neural plate
and the non-neural ectoderm during neurulation, is
able, under SLUG control, to give rise to different cell
types including neurons, glia, facial chondrocytes, osteo-
blasts, and melanocytes [8,26,27]. In addition, craniofa-
cial abnormalities have been observed in association
with cerebral malformations and cutaneous lesions in
some neurocutaneous syndromes, emphasizing an
important inductive role of the neural tube in the devel-
opment of non-neural tissues mediated through neural
crest and differentiating genes such as SLUG and Sox10
[28,29]. Overall, these observations encourage investiga-
tion on SLUG expression and functions in adult cells,
including osteoblasts.
We recently demonstrated, by a knockdown approach,
that SLUG is involved in the differentiation and matura-
tion process of normal human osteoblasts [30]. Never-
theless, so far, no data have been presented on SLUG
regulation in these cells and their precursors. Only one
previous investigation has demonstrated that Wnt sig-
naling regulates SLUG expression, in a tumor model,
such as an osteosarcoma cell line, mediating cancer
invasion [31].
The presence of putative cis elements for Lef-1, in
human SLUG gene promoter has raised the possibility
that Lef-1 may be implicated in the modulation of
SLUG expression as previously demonstrated in other
species such as chick and Xenopus [32,33]. In this study
we demonstrated that SLUG is expressed in both nor-
mal human osteoblasts and their mesenchymal precur-
sors, and that Lef-1 is recruited “in vivo“ to its promoter
acting as a positive transcriptional regulator.
Results
SLUG expression in human osteoblasts and their
mesenchymal precursors
Lef-1 has been shown to play a role in osteoblast differ-
entiation and function. Owing to the relationship
between Lef-1, b-catenin and SLUG recently found in
some epithelial-mesenchymal transition cellular models
[34,35], we hypothesized that Lef-1 and SLUG may also
be correlated in osteoblast lineage cells. To test this idea
SLUG expression was examined during osteoblast differ-
entiation and compared with Lef-1 expression levels.
SLUG mRNA levels were measured in human mesench-
ymal stem cells (hMSCs) obtained from umbilical cord
Wharton’s Jelly and induced towards osteogenesis, as
previously described [36]. RNA was collected after 0, 7,
14, 21, and 28 days in culture and evaluated by quanti-
tative RT-PCR. As shown in Figure 1A, these cells dif-
ferentiate along the osteoblast lineage in osteogenic
medium as confirmed by the positive staining for extra-
cellular calcium deposition. Abundant SLUG mRNA
was detected in the cells at all times tested, and was
induced as the cultures progressed. Lef-1 was less abun-
dant, but significantly increased during the osteogenesis.
RUNX2, a determinant transcription factor for osteo-
blastogenesis [37], was also expressed at all stages, and
was induced as the cultures progressed, confirming that
each time point represented increasingly mature
osteoprogenitors.
In order to confirm that the expression profile that we
found was associated with osteoblast phenotype, SLUG,
Lef-1 and RUNX2 expression levels were measured in
human primary osteoblasts obtained from five bone spe-
cimens (hOBs). All these samples were positive for alka-
line phosphatase (ALP) activity, a well-known osteoblast
differentiation marker, and were able to form minera-
lized nodular structures after 14 days in osteogenic con-
dition (see a representative experiment in the panel of
Figure 1B). As shown in Figure 1B, SLUG, Lef-1 and
RUNX2 were detected in all hOB samples analyzed. The
level of SLUG mRNA in hOBs was also compared with
that found in different osteoblast-like cell lines [Addi-
tional file 1].
To further characterize the potential involvement of
SNAIL family members in osteogenesis, the expression
of SNAIL1 and SNAIL3 was examined in the same set
of experiments. SNAIL1 has been recently reported to
act on the osteoblast population regulating bone cells
differentiation and contributing to bone remodeling in
mice [38]. In agreement with this previous study, we
found that SNAIL1 was expressed at early stages of
osteoblast differentiation and then downregulated for
differentiation to proceed (Figure 1A). In hOB samples
SNAIL1 was expressed at substantial levels (Figure 1B).
The expression of SNAIL3 [39] was detectable at very
low levels in the hMSCs induced towards osteogenesis
(Figure 1A), and at low levels in hOBs (Figure 1B).
SLUG expression is positively modulated by Lef-1
hOBs were then transfected with expression vector con-
taining hLef-1 cDNA (K14-myc-hLEF1) as described in
the Methods section. As shown in Figure 2, SLUG
expression significantly increased in Lef-1 overexpres-
sing cells, both at mRNA and protein level, as
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Figure 1 Detection of SLUG expression by quantitative RT-PCR. The level of SLUG, RUNX2 Lef-1, SNAIL1 and SNAIL3 expression was
examined by quantitative RT-PCR in three hMSC samples cultured up to 28 days in osteogenic medium (A) and in five hOB samples (B). The
cDNA obtained from total RNA was subjected to quantitative TaqMan RT-PCR for SLUG, RUNX2, Lef-1, SNAIL1 and SNAIL3 transcript analysis. The
experiments were carried out in triplicate, the expression levels were normalized on the basis of GAPDH expression and results of the
experiments are reported as relative mRNA expression levels. ∆∆Ct method was used to value the gene expression; standard error of the mean
(SEM) was calculated. The commitment to osteoblastic lineage of hMSCs was evaluated by Alizarin Red staining for extracellular calcium
deposition. The authentic osteoblast phenotype was confirmed in hOBs by staining for alkaline phosphatase (ALP) activity and mineralized matrix
deposition (AR, Alizarin Red staining). * = p < 0.05 (respect to day 0).
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demonstrated by RT-PCR (Figure 2A) and Western blot
analysis (Figure 2B). The significant increase of Lef-1 in
the cells transfected with hLef-1 expression vector was
confirmed by the same Western blot analysis (Figure
2B). As expected, forced expression of Lef-1 increased
Slug expression to higher levels in SaOS-2 osteoblast-
like cells than in hOBs, because of a higher intrinsic
transfection facility of this cell line.
The ability of Lef-1 to activate transcription of SLUG
gene was then tested on the human SLUG promoter
(Figure 3). We chose to focus on an approximately 1 Kb
fragment upstream of the transcription start site in the
SLUG gene since it contains sequences involved in the
regulation of promoter activity mediated by b-catenin
[34]. In addition to the previously identified TCF bind-
ing site at -859/-855 position [34,35], we identified, in
this region, another five potential consensus binding
sites for the Lef/Tcf family by using the programs Tran-
scription Element Search Software TESS for transcrip-
tion factor search and MatInspector 7.4 program (Figure
3A). The sequence was cloned upstream of the Luc
reporter gene in the pGL3basic vector, and the con-
struct, (named 982 bp luc-construct), was assayed after
osteoblast transfections performed with or without Lef-1
expression plasmid. As shown in Figure 3B, transient
transfection with the luciferase reporter 982 bp luc-con-
struct resulted in an increase in luciferase activity rela-
tive to the empty, promoterless pGL3-basic vector,
demonstrating that this DNA fragment contains signifi-
cant promoter activity in hOBs (5-10 fold increase). Co-
transfection with plasmid encoding Lef-1 produced a
significant increase in Luc activity as compared with
cells containing the 982 bp luc-construct reporter plas-
mid. This increase was dramatic in Lef-1 overexpressing
SaOS-2 cells. On the contrary, the same experiments
performed in the non-osseous SLUG-negative MCF7
breast cancer cell line revealed no promoter activity.
As a whole, these data indicate that Lef-1 upregulates
SLUG gene expression in normal human osteoblasts.
Lef-1 is recruited to the SLUG promoter “in vivo”
Next, we investigated whether Lef-1 could, “in vivo“,
physically bind with the human SLUG promoter. Con-
sidering that in addition to Lef-1, among TCF family
members, both TCF-1 and TCF-4 are expressed in
osteoblasts [2], the analysis was addressed to all three
proteins. The binding of transcription factor to the
SLUG promoter was verified by performing in vivo
chromatin immunoprecipitation (ChIP) assays (Figure
3C). To this aim, hOBs were exposed to formaldehyde
to cross-link proteins and DNA, and were sonicated to
fragment the chromatin. Specific antibody against Lef-1,
TCF-1 and TCF-4 were used to immunoprecipitate the
protein-DNA complexes. After immunoprecipitation,
DNA was extracted from the beads and used as a tem-
plate to generate specific PCR products. The presence of
the promoter specific DNA region before immunopreci-
pitation was confirmed by PCR (input). In the SLUG
promoter fragment used for the reporter assay, three
different regions were identified, as depicted in Figure
3A, and analyzed by a set of primers spanning the six
consensus binding sites for the Lef/Tcf family. The
amplified product sizes (bp) were 178 for region 1, 164
for region 2, and 165 for region 3. The results showed
that the promoter region 3, containing the previously
identified TCF binding site at -859/-855 position
[34,35], was significantly immunoprecipitated by Lef-1
and TCF4 antibodies, but that Lef-1 was mostly asso-
ciated with the promoter region 1 and not at all with
the promoter region 2 (Figure 3C). On the contrary, we
found that region 2 was rather occupied by TCF-1 and
TCF-4. Therefore, the observation that the endogenous
SLUG gene expression may be increased by Lef-1 was
further validated by the in vivo occupancy of the Lef/
TCF regulatory sites in the SLUG gene promoter.
Activation of Wnt signaling by GSK-3b inhibitor increases
SLUG promoter activity
It has been demonstrated that b-catenin promotes Lef/
Tcf interaction with target DNA sequence in many cel-
lular contexts. In order to support the role of Lef/Tcf
transcription factors in SLUG expression regulation, we
next investigated whether b-catenin activation was
involved in SLUG expression regulation. We used a
treatment with SB216763 as a model for b-catenin acti-
vation (Figure 4A). This compound binds and specifi-
cally inhibits glycogen synthase kinase GSK-3b. GSK-3b
is a serine/threonine kinase, originally identified as a
kinase that is involved in glucose metabolism, but recent
research has determined that it acts on a wide variety of
substrates, including transcription factors, and is a key
regulator in many signalling pathways [40]. This enzyme
is known to be a key negative regulator of canonical
Wnt/b-catenin and PI3K/Akt signalings [41]; hence, its
inhibition activates Wnt signalling selectively via the b-
catenin/TCF pathway and results in relocation of stabi-
lized b-catenin to the nucleus. As expected, the
SB216763-treated cells transfected with the b-catenin/
Tcf transcription reporter construct -TOPflash reporter
system- showed an increase in TOPflash activity up to
4-fold (Figure 4B). The b-catenin/Tcf transcription
reporter assay was recognised as an important assess-
ment method for evaluation of the Wnt pathway activ-
ity. As TOPflash has three TCF-binding sites, it could
be applied to represent the activation of the Wnt path-
way. In fact, our data showed that SB216763 treatment
positively affected b-catenin expression, as revealed by
Western blot reported in Figure 4C. The dose- and
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Figure 2 Effect of Lef-1 overexpression on SLUG expression in hOBs. The effect of Lef-1 overexpression was examined at mRNA (A) and
protein (B) level. (A) SLUG mRNA was evaluated by quantitative RT-PCR in hOBs and SaOS-2 osteoblast-like cells transfected with 2.5 μg of hLef-
1 (K14-myc-hLEF1) expression plasmid. The cDNA obtained from total RNA was subjected to quantitative TaqMan RT-PCR for SLUG transcript
analysis. The expression levels were normalized on the basis of GAPDH expression and results of the experiments are reported as relative mRNA
expression levels. Results are representative of three independent experiments carried out in triplicate. ∆∆Ct method was used to compare gene
expression data; standard error of the mean (SEM) was calculated. * = p < 0.05. (B) SLUG protein levels were examined by Western blot analysis
in hOBs and SaOS-2 osteoblast-like cells transfected with 2.5 μg of hLef-1 expression plasmid. Whole cell lysates were prepared and 25 μg of
protein run on a 12% SDS-polyacrylamide gel. The proteins were visualized using Supersignal West Femto Substrate (Pierce). The quantitative
presentation of the protein levels were performed by densitometric analysis using Anti-IP(3)K as control. D.U. = densitometric units. This
experiment was repeated three times with similar results. A representative SLUG and Lef-1 Western blot analysis with size markers (KDa) is
reported. * = p < 0.05.
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time-response to SB216763 cell treatment was analyzed
in terms of SLUG mRNA levels in osteoblast-like cell
lines [Additional file 2]. The same analysis demonstrated
that the increase in b-catenin mediated by SB216763
was correlated with a significative increase in SLUG and
RUNX2 expression both at protein (Figure 4C) and
mRNA level (data not shown). Therefore, on the whole,
this suggests that the canonical Wnt signaling positively
affects SLUG expression in normal human osteoblasts
via the b-catenin/TCF pathway because, by potentiating
b-catenin, SLUG expression increases.
Discussion
In this paper we have demonstrated that the transcrip-
tion factor SLUG is present in normal human osteo-
blasts and their mesenchymal precursors. Osteoblasts
are the primary cell type responsible for the bone remo-
deling process, and alterations in this pathway can lead
to osteopenic disorders such as osteoporosis. Therefore,
any new marker or mechanism associated with differen-
tiation of these cells represent very relevant information
for the study of bone biology and bone-related diseases
in general.
We have shown that SLUG expression increases dur-
ing osteogenesis, and is positively regulated by Lef-1, an
osteoblastic transcription factor which we found in vivo
recruited by specific cis elements present in the SLUG
promoter. In the SLUG promoter region of approxi-
mately 1 Kb upstream of the transcription start site, we
found at least six potential consensus binding sites for
the Lef/Tcf family, and not just one only at -859/-855
position, as recently reported [34,35]. We found that the
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Figure 3 Lef-1 affects the activity of human SLUG promoter “in vitro“ and binds it “in vivo“. (A) The SLUG promoter region under
investigation is reported. The positions of putative Lef/Tcf binding sites are enclosed by rectangles and are compared with those recently
investigated by others. Positions of PCR primers used in ChIP experiments are also reported. (B) The DNA construct containing the human SLUG
promoter region was cloned into upstream of the firefly luciferase (LUC) reporter gene. hOBs and SaOS-2 osteoblast-like cells were transfected
with the pGL3-SLUG Luc reporter vector containing the sequence from +1 to -982 of the human SLUG promoter (pGL3-SLUG 982 bp), in the
absence (-) or presence (+) of 2.5 μg of hLef-1 expression plasmid. The results of reporter gene assays were normalized with protein
concentration and b-gal activity for transfection efficiency and the data are represented as ratios of luciferase units to b-galactosidase units.
MCF7 breast cancer cell line was used as negative control. All experiments were performed in triplicate and the average of the ratio of the
reporter activity + SEM is shown. * = p < 0.05. (C) Recruitment of Lef1/TCF transcription factors to the human SLUG promoter is demonstrated
by “in vivo“ chromatin immunoprecipitation (ChIP) binding assays. Soluble chromatin was prepared from hOBs and immunoprecipitated with the
indicated specific antibodies against Lef-1, TCF-1, and TCF-4. The associations of the transcription factors to bound precipitated DNA were
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sequence regions containing these sites are all involved,
even if at different levels, in the in vivo recruitment of
Lef/Tcf factors, including Lef-1, TCF-1 and TCF-4, in
human osteoblasts. The investigations on the only pre-
viously characterized TCF binding site (-859/-855),
demonstrated its ability to recruit TCF-4 in SW480
human colon cancer [35], but not in Hec251 endome-
trial cancer cell line [34] where, on the contrary, SLUG
expression seems to be under transcriptional control of
b-catenin without the binding of Lef/Tcf factors at this
site. Other studies in different experimental models
provide evidence that Xenopus and mouse SLUG pro-
moters are directly activated by b-catenin/TCF com-
plexes through the binding sequences [32,33], and that
SLUG promoter activity may be inhibited by dominant
negative Tcf [42]. Combined with these reports, our
results may lead to the hypothesis that, directly or indir-
ectly, SLUG and Lef-1 are strictly correlated in many
cellular events, including osteoblast differentiation,
mediated by Wnt/b-catenin signalling. In addition, this
is supported by our recent evidence demonstrating the
requirement of SLUG for osteoblast maturation and the
Figure 4 Treatment of hOBs with the glycogen synthase kinase (GSK-3b) inhibitor, SB216763. (A) A scheme of SB216763 action
mechanism is reported (see the text for details). (B) Effect of SB216763 on the TOPflash reporter system. 24 h after transient transfection with
the TOPflash plasmid, the cells were treated (+) or not (-) with SB216763 (10 μM) for 24 h prior to harvest. Luciferase activity was normalized to
b-galactosidase activity in the same sample. The bars represent mean ± SEM. * = p < 0.05. (C) The levels of b-catenin expression, SLUG and
RUNX2 were examined by Western blot in hOBs treated with SB216763 (10 μM) or with the only vehicle (-). The quantitative presentation of the
protein levels was performed by densitometric analysis using Anti-IP(3)K as control. D.U. = densitometric units. A representative Western blot
analysis with size markers (KDa) is reported. * = p < 0.05.
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decrease in Wnt/b-catenin signalling after SLUG knock-
down [30]. This suggests a possible role of SLUG as
effector of Wnt/b-catenin signalling.
Our findings confirm a relationship between SLUG
and Wnt signalling showing that the increase in b-cate-
nin levels, obtained by the suppression of GSK-3b activ-
ity with SB216763 inhibitor, induces a significative
SLUG gene expression increase. b-catenin is known to
associate with the Lef/Tcf transcription factor family
and promote the expression of several genes through
the recruitment of other factors to form a transcription-
ally active complex [43,44]. Lef-1 is reported to have an
important role in osteoblast maturation for its ability in
the regulation of expression of genes involved in the sti-
mulation of bone formation, such as RUNX2 and
Col11a1 [45,46]. In addition, an age- and gender- depen-
dent role for Lef-1 in regulating bone formation in vivo
has recently been described [7]. The discovery that
SLUG expression is upregulated during osteogenesis, is
positively correlated with the expression of RUNX2 and
Lef-1, and is under the control of Lef-1, corroborates
the role of Lef/Tcf transcription factors in osteoblasts
and highlights mechanisms by which Lef-1 may affect
maturation and differentiation of these cells. Our results
further support the hypothesis that SLUG may have a
distinct role in normal human osteoblasts, and may be
positively regulated by activity of canonical Wnt/b-cate-
nin signalling pathway. Therefore, as far as bone tissue
is concerned, SLUG should not be considered exclu-
sively as a marker of malignancy and an attractive target
for therapeutic modulation of bone metastasis and
osteosarcoma invasiveness, as indirectly suggested by
Guo et al. [31].
Considering the widespread expression of SLUG in all
osteoblast samples analyzed, we cannot exclude that
SLUG, which encodes an evolutionarily conserved antia-
poptotic transcription factor, may confer a survival
advantage in osteoblasts, as demonstrated for leukemic
B cell progenitors [47].
In conclusion, although further studies are required to
elucidate whether the two Lef-1 isoforms recently iden-
tified [6] may have distinguishable activities in determin-
ing the proper levels of SLUG expression, our study
clearly shows that b-catenin/Lef-1 signalling is involved
in the regulation of this gene in normal human osteo-
blasts. In addition, other factors may contribute to the
SLUG gene regulation. At present, the relationship
between other cis-regulatory elements in the SLUG pro-
moter and osteoblast-inducing signals is completely
unknown. The most likely candidates for this function
are SLUG and RUNX2, which could associate with the
E boxes and RUNX binding sites present in the promo-
ter. Therefore, further work will be necessary to evaluate
a potential transcription autoregulation and to elucidate
the association between SLUG and RUNX2 expression.
Our hypothesis is that SLUG might represent an inter-
esting molecule for normal skeletogenesis acting inside
the recently proposed [48] large signalosome in which
inputs from Wnt/b-catenin/Lef-1 signalling, steroid
receptors, BMPs, and kinases converge to induce differ-
entiation of osteoblast precursors. With this in mind, we
also speculate that study of the association between
SLUG and some organizers of osteoblastic phenotype
may improve the characterization of the human osteo-
blast differentiation stages. In particular, this may be
relevant in approaches addressed to the discovery of
new molecular targets to use in bone repair and regen-
erative medicine.
Conclusions
In this study we showed that transcription factor SLUG
is expressed in both normal human osteoblasts and
their mesenchymal precursors, and that Lef-1, a media-
tor of the Wnt/b-catenin signalling pathway, is recruited
“in vivo“ to its promoter acting as a positive transcrip-
tional regulator. The relationship between SLUG and
Wnt signalling has been confirmed demonstrating that
increase in b-catenin levels induced a significative SLUG
gene expression increase.
In conclusion, our findings reveal the biological func-
tions of SLUG in the context of bone tissue showing
that it is positively correlated with the osteogenesis, and
highlights mechanisms by which Lef-1 may affect
maturation and differentiation of osteoblasts.
Methods
Construction of reporter plasmid
Promoter region (+1 to -982 bp) of the human SLUG
promoter was amplified by PCR from human genomic
DNA using SLUG F genomic primer as sense primer
and SLUG R genomic primer as antisense primer (Table
1). The PCR product was subcloned upstream of a fire-
fly luciferase (LUC) gene in the promoter-less pGL3-
Basic vector (Promega, Madison, WI) using MluI and
BglII restriction sites, and the presence of the insert was
confirmed by restriction digestion.
Cell culture, plasmids and transient transfection
Human primary osteoblasts were obtained from bone
samples collected during nasal septum surgery, and were
cultured as previously described [49]. Recruitment of
subjects donating osteoblasts was in accordance with
approved procedures, and informed consent was
obtained from each patient. Briefly, the bone was cut into
small pieces which were rinsed and then cultured in
Eagle’s MEM (Sigma Aldrich, St. Louis, MO, USA) sup-
plemented with 20% fetal bovine serum (FBS) (CELBIO
EuroClone, Milan, Italy), 2 mM glutamine, 100 units/ml
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penicillin, 100 μg/ml streptomycin, and 50 μg/ml ascor-
bate at 37°C in a humidified atmosphere of 5% CO2.
After about 5-7 days, outgrowth of bone cells from the
bone chips commenced, and confluency in 9 cm2 dishes
was usually reached after 4-6 weeks. For the studies here
presented, only first passage cells were used.
Mesenchymal stem cells were obtained from Whar-
ton’s Jelly of human umbilical cord after the mothers’
consent and approval of the “Ethical committee of Uni-
versity of Ferrara and S.Anna Hospital “, and character-
ized as previously described [36].
The expression vector for full-length Lef-1 (K14-myc-
hLEF1) was a gift from Elaine Fuchs and Rebecca C.
Lancefield (Howard Hughes Medical Institute, The
Rockfeller University, Lab. of Mammalian Cell Biology
& Development, New York U.S.A.). The TCF reporter
plasmid TOP FLASH was kindly provided by Rolf Kem-
ler (Max Planck Institute, Heidelberg, Germany).
For transient transfection assays, 50000 cells/ml were
seeded in 24 or 6 multiwell plates. After 24 h, cells were
transfected using Lipofectamine reagent (Invitrogen,
Carlsbad, CA) and 0.5 μg of reporter construct where
not specified.
SB216763 was purchased from Sigma (Sigma Aldrich,
St. Louis, MO, USA), and dissolved in DMSO.
Analysis of the osteoblast phenotype
For alkaline phophatase staining, prefixed mono-layered
cells were incubated at room temperature in a solution
containing naphthol AS-BI phosphate and freshly pre-
pared fast blue BB salt buffered at pH 9.5 with 2-amino-
2-methyl-1,3-propanediol (Alkaline Phosphatase Leuko-
cyte kit, Sigma). The presence of sites of ALP activity
appeared as blue cytoplasmatic staining.
The extent of mineralized matrix in the plates was
determined by Alizarin Red S staining (Sigma) in the
cells cultured for up to 35 days in osteogenic medium
consisting in DMEM, high-glucose, supplemented with
10% FBS, 10 mM b-glycerophosphate, 0.1 mM dexa-
methasone and 50 mM ascorbate. In the committed
cells, the osteogenic medium was changed every three
days. The cells were then fixed in 70% ethanol for 1 h at
room temperature, washed with PBS, stained with 40
mM AR-S (pH 4.2) for 10 min. at room temperature,
washed five times with deionized water and incubated in
PBS for 15 min. to eliminate non-specific staining. The
stained matrix was observed at different magnifications
using a Leitz microscope.
Luciferase reporter gene assays
For experiments assessing activation of the SLUG pro-
moter, 1 μg of reporter plasmid was cotransfected with
2.5 μg of expression vectors for Lef1 (K14-myc-hLEF1)
and 0.25 μg of pCMV-Sport-bgal (Invitrogen). The cells
were lysed 48 h after transfection using the reporter
lysis buffer (Promega, Madison, WI). Luciferase and b-
galactosidase activities were determined with luciferase
and Beta-Glo assay systems respectively (Promega,
Madison, WI). Their activities were normalized with
respect to total protein amount.
Real-time RT-PCR analysis
For mRNA analysis total cellular RNA was extracted
using Total RNA Isolation System (Promega) and cDNA
synthesis was performed for 1 h at 42°C using 1 μg of
total RNA as a template and 100 U of reverse transcrip-
tase ImProm-II (Promega) as previously described [49].
The level of mRNA expression was analyzed by quanti-
tative real-time PCR using the ABI Prism 7700 system
(Applied Biosystems) and the following TaqMan MGB
probes: 5’ FAM-ATGATGAAAGGTGGGATAC-
GAAAAG-TAMRA 3’ for SLUG, 5’ FAM-GAACCCA-
GAAGGCACAGACAGAAG-TAMRA 3’ for RUNX2, 5’
FAM-TCTAATCCAGAGTTTACCTTCCAGC-TAMRA
3’ for SNAIL1, 5’FAM-GAGACGCAGAGAGAAAT-
CAATGGTG-TAMRA 3’ for SNAIL3, and 5’ FAM-
CATGTCCAGGTTTTCCCATCATATG-TAMRA 3’ for
Lef-1; GAPDH mRNA was used as an endogenous con-
trol (Applied Biosystems Inc, Foster City, CA, USA) and
quantification was performed using a TaqMan assay.
The mRNA levels of target genes were corrected for
GAPDH mRNA levels. All PCR reactions were per-
formed in triplicate for each sample and were repeated
three times. All experimental data were expressed as the
mean ± SEM.
Western Blot analysis
For Western Blot analysis, the cells were washed twice
with ice-cold PBS and cell lysates were prepared as pre-
viously reported [50]. 25 μg of each sample was then
Table 1 Primers used in this study
Oligo name Primer sequences 5’-3’
Primers for reporter construct
Slug F TGTCAAAAGTGTGAGAGAAT
Slug R CTTGCCAGCGGGTCTGGC
Primers for ChIP
Region 1 F GAGGTTACCTCTCTTGAAAATACT
Region 1 R GGAAGAAAGATCCAATCACA
Region 2 F CCAGGCCAGATCCCAGGAGAGC
Region 2 R GCCTCTGGTGTTAATGAGAGCCTA
Region 3 F TGCCCCCCTTCTCTGCCAGAGTT
Region 3 R TTCCGCGAAGCCAGGGGCAGCG
The sequence and the name of the forward (F) and reverse (R) primers for the
construction of reporter plasmid and for Chromatin immunoprecipitation
(ChIP) are reported.
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electrophoresed on a 12% SDS-polyacrylamide gel. The
proteins were then transferred onto an Immobilon-P
PVDF membrane (Millipore Corporation, 900 Middlesex
Tpk Billerica, USA). After blocking with PBS-0.05%
Tween 20 and 5% dried milk, the membrane was probed
with the following antibodies: SLUG (L40C6) from Cells
Signaling Technology Inc. (Danvers, CA, USA), RUNX2
(sc-10758) from Santa Cruz Biotechnology (Santa Cruz,
CA), Lef-1 (L7901) from Sigma Aldrich (St Luis, MO,
USA), IP3K (06-195) and Active-b-catenin from Upstate
Biotechnology, Inc. (Lake Placid, NY). After washing
with PBS-Tween, the membranes were incubated with
peroxidase-conjugated anti-rabbit antibody (1:50000) or
anti-mouse (1:2000) (Dako, 2600 Glostrup, Denmark) in
5% non-fat milk. Immunocomplexes were detected
using Supersignal West Femto Substrate (Pierce). Anti-
IP(3)K was used to confirm equal protein loading.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was carried out as previously described
[49] using the standard protocol supplied by Upstate
Biotechnology (Lake Placid, NY) with their ChIP assay
reagents.
The cells were cross-linked with 1% formaldehyde for
10 min at 37°C, washed in ice-cold PBS and resuspended
in SDS lysis buffer for 10’ on ice. Samples were sonicated,
diluited 10-fold in diluition buffer supplemented with
protease inhibitors and precleared with 80 μl of DNA-
coated protein A-agarose; the supernatant was used
directly for immunoprecipitation with 5 μg of anti- Lef-1
(sc-8591), TCF-1 (sc-13025) and TCF-4 (sc-13027)
(Santa Cruz Biotec, Ca, USA) overnight at 4°C. Immuno-
complexes were mixed with 80 μl of DNA-coated protein
A-agarose followed by incubation for 1 h at 4°C. Beads
were collected and sequentially washed 5 times with 1 ml
each of the following buffers: low salt wash buffer (0.1%
SDS,1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl
pH 8.1, 150 mM NaCl), high salt wash buffer (0.1%
SDS,1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl
pH-8.1, 500 mM NaCl), LiCl wash buffer (0.25 mM LiCl,
1% IGEPAL-CA630, 1% deoxycholic acid, 1 mM EDTA,
10 mM Tris-pH 8.1) and TE buffer. The immunocom-
plexes were eluted two times by adding a 250 μl aliquot
of a freshly prepared solution of 1% SDS, 0.1 M NaHCO3
and the cross-linking reactions were reversed by incuba-
tion at 65°C for 4 h. Further, the samples were digested
with proteinase K (10 mg/ml) at 42°C for 1 h, DNA was
recovered by phenol/chloroform extractions, ethanol pre-
cipitated using 1 μl of 20 mg/ml glycogen as the carrier,
and resuspended in sterile water. For PCR analysis, ali-
quots of chromatin before immunoprecipitation were
saved (Input). PCR was performed to analyze the pre-
sence of DNA precipitated by specific antibodies by using
the primers reported in Table 1.
Each PCR reaction was performed with 10 μl of the
bound DNA fraction or 2 μl of the input. The PCR was
performed as follows: preincubation at 95°C for 5’, 30
cycles of 1’ denaturation at 95°C, 1’ annealing at 62°C
and 1 min at 72°C, with one final incubation at 72°C for
5’. No-antibody control was included in each
experiment.
Statistical analysis
Data are presented as the mean ± SEM from at least
three independent experiments. Statistical analysis was
performed by one-way analysis of variance and the Stu-
dent’s t-test. A P value < 0.05 was considered statisti-
cally significant.
Additional file 1: Detection of SLUG expression by quantitative RT-
PCR in osteoblastic-like cell lines and hOB samples. The level of
SLUG was examined by quantitative RT-PCR in U2OS, SaOS-2, Hobit,
CAL72 osteoblastic-like cell lines and in eight hOB samples. MCF7 breast
cancer cell line was used as negative control. The cDNA obtained from
total RNA was subjected to quantitative TaqMan RT-PCR for SLUG
transcript analysis. The experiments were carried out in triplicate, the
expression levels were normalized on the basis of GAPDH expression and
results of the experiments are reported as relative mRNA expression
levels. ∆∆Ct method was used to value the gene expression; standard
error of the mean (SEM) was calculated.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2199-11-
13-S1.PPT ]
Additional file 2: Treatment of osteoblastic-like cell lines with the
glycogen synthase kinase (GSK-3b) inhibitor, SB216763. The levels of
SLUG expression was examined by quantitative TaqMan RT-PCR in U2OS,
SaOS-2, Hobit, CAL72 osteoblastic-like cell lines treated with SB216763
(10, 25 and 50 μM) or with the only vehicle (-), up to 3 days.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2199-11-
13-S2.PPT ]
Abbreviations
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related transcription factor 2; ALP: alkaline phosphatase.
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INTRODUCTION
There is currently no ideal approach for the treatment of cran-
iofacial defects. Such defects arise from trauma, injuries,
removal of bone tissue as a result of cancer, and developmen-
tal abnormalities. They often lead to massive destruction of
the facial skeleton (1-4). Tissue engineering, which is based on
the use of a combination of appropriate cells, growth factors,
engineering methods, and suitable carrier scaffolds to improve
or replace biological functions, promises to offer new thera-
peutic chances for the repair of damaged bone (4-6). Bone tissue
engineering currently uses either growth factors on a variety of
carriers or osteogenic cells seeded onto an even larger number
of different materials (4-7). In the craniofacial area, despite a
decade of experimental evaluation, ambiguous results have
been obtained in the reconstruction of bony defects, and a
large number of unresolved questions remain in the head and
neck area (7-17). This is correlated with evidence that surgical
repair of such defects, as well as three-dimensional enlarge-
ment of structures in the facial skeleton are remarkable diffi-
cult and unpredictable. Particularly, complex bony defects are
difficult to reconstruct accurately, and complications in the
area of reconstruction are common. It has been demonstrated
that many unsatisfactory results are correlated with poor cell
survival rate, and inferior bone specific cellular activity after
transplantation has to be considered as reason of occurance
due to premature differentiation and subsequent growth inhi-
bition (18). In addition, the extremely high dosages of growth
factors that are required to successfully regenerate bone in a
clinically relevant dimension is to some extent controversial.
Therefore, because biomolecules, as well as cells, both embry-
onic and adult tissue derived, play a critical role in this field of
research, a multidisciplinary approach is absolutely required
for a successful outcome. 
Based on of these considerations, we investigated the character-
istics of bone cells from the nasal septum in terms of potential
osteogenic activity and experimental models to perform an accu-
rate molecular analysis for detection of new therapeutic targets.
Background: The research addressed to detect new molecular targets in the development of
therapeutic strategies aimed to repair bone tissues. 
The aim of this study was to determine the potential osteogenic activity of bone cells from the
nasal septum and their use to perform accurate molecular analysis from a single sample. 
Methodology: The cells, after nasal septum surgery, were subjected to gene silencing, Reverse
Transcriptase - Polymerase Chain reactions, immunocytochemistry and chromatin immunopre-
cipitation. 
Results: Cells from the nasal septum can give rise to mature osteoblasts that express
osteogenic markers (ALP, Runx2, Slug) and are able to mineralize. We demonstrated that
Runx2, a transcription factor critical in early osteospecific differentiation, interacts in vivo with
the promoter of the SLUG gene, a marker of osteoblast maturation. 
Conclusions: We demonstrated that nasal septum-derived osteoblasts represent an interesting
alternative source for bone forming cells, and a promising material to be utilized in bone cellu-
lar therapy. 
Key words: human primary osteoblasts, nasal septum, chromatin immunoprecipitation, bone
repair
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We demonstrate here that these cells represent an interesting
alternative source for bone forming cells. They can be an ideal,
unique, easily accessible and no controversial source for
osteoblasts, due to the simple collection procedure during
nasal septum surgery once bone tissue is routinely discharged.
The ability to proliferate and to differentiate into mature
osteoblasts at the same time makes the use of these cells par-
ticularly attractive both for the research addressed to new mol-
ecular targets detection, and the development of therapeutic
strategies aimed to repair and replace damaged tissues. In addi-
tion, we demonstrated that, from a single sample, it is possible
to obtain sufficient material to perform several molecular
analyses including gene expression studies by Reverse
Transcriptase - Polymerase Chain Reaction (RT-PCR), DNA-
protein interactions assays by chromatin immunoprecipitation
(ChIP), and immunocytochemical experiments.
MATERIALS AND METHODS
Isolation and culture of osteoblasts
Human craniofacial osteoblast cells were obtained from bone
samples collected during nasal septum surgery. Recruitment of
subjects donating osteoblasts was in accordance with approved
procedures, and informed consent was obtained from each
patient. Bone samples were collected from 81 patients
(30F/51M) that underwent septoplasty surgery, FESS or both
procedures (for 8 cases it was possible to collect osteoblasts
both from septum and ethmoid bone) from June 2006 to
February 2010 at the ENT Department of the University
Hospital of Ferrara. This type of surgery is routinely and
worldwide performed in an ENT Surgery Unit. It usually con-
sists in the exeresis of the lower part of the osseous nasal sep-
tum (this portion has been used in this study). This sampling is
very handily and costless. The average age of patients was 
43 years (range: 22-75). Ten out 81 samples were selected and
dedicated to the studies here presented. Briefly, the bone sam-
ples, about 1 cm2 in size, were cut into small fragments that
were washed several times in phosphate-buffered saline (PBS)
to remove blood cells and debris with a final wash in culture
medium. Fragments were then collected in culture flasks con-
taining 6 ml of 1:1 mixture of DMEM/Ham’s F12 (Sigma
Aldrich, St. Louis, MO, USA) supplemented with 20% fetal
bovine serum (FBS) (CELBIO EuroClone, Milan, Italy), 2 mM
glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin,
and 50 mg/ml ascorbate at 37°C in a humidified atmosphere of
5% CO2. After about 5-7 days, outgrowth of bone cells from
the bone chips commenced, and confluency in 25 cm2 dishes
was usually reached after 3-4 weeks (19). For the studies here
presented, only first and second passage cells were used.
Flow cytometric analysis
The cells from all 10 samples were analysed for expression of
surface marker molecules, by direct immunofluorescent stain-
ing. Briefly, cell pellets were resuspended in PBS and incubat-
ed with fluorescein isothiocyanate (FITC)- or phycoerythrin
(PE)- conjugated mouse anti-human antibodies Stro1, CD45-
PE, and CD90-FITC (DakoCytomation, Dako, Denmark), for
15 min at 4°C. Monoclonal antibodies with no specificity were
used as negative control. Antibody treated cells were then
washed with PBS and spinned down. For each sample, the cell
pellet was resuspended in 400 μl of PBS and the fluorescence
of 20,000 cells was analysed using FACS Scan flow cytometer
(Becton Dickinson, New Jersey, USA) and CellQuest software
(Becton Dickinson European HQ, Erembodegem Aalst,
Belgium). Flow cytometric analysis was repeated three times
for each sample to allow SEM calculation. 
Analysis of the osteoblast phenotype
For alkaline phophatase staining, prefixed mono-layered cells
from all 10 samples were incubated at room temperature in a
solution containing naphthol AS-BI phosphate and freshly pre-
pared fast blue BB salt buffered at pH 9.5 with 2-amino-2-
methyl-1.3-propanediol (Alkaline Phosphatase Leukocyte kit,
Sigma). The presence of sites of ALP activity appeared as blue
cytoplasmatic staining. 
The extent of mineralized matrix in the plates was determined
by Alizarin Red S staining (Sigma) in the cells cultured for up
to 35 days in osteogenic medium consisting in DMEM, high-
glucose, supplemented with 10% FBS, 10 mM b-glycerophos-
phate, 0.1 mM dexamethasone and 50 mM ascorbate. In the
committed cells, the osteogenic medium was changed every 
3 days. The cells were then fixed in 10% formaldehyde for 
15 min at room temperature, washed with deionized water,
stained with 40 mM AR-S (pH 4.2) for 20 min at room temper-
ature, and washed 5 times with deionized water to eliminate
non-specific staining. The stained matrix was observed at dif-
ferent magnifications using a Leitz microscope.
Immunocytochemistry
Immunocytochemistry analysis was performed on all 10 sam-
ples using an ImPRESS Universal Reagent Kit (Vector
Laboratories, Inc. Burlingame, CA, USA). About 104 cells were
seeded in 4-well chamber slides, led to adhere for 48 hrs, fixed
in cold 100% methanol and permeabilised with 0.2% (vol/vol)
Triton X-100 (Sigma Aldrich) in TBS (Tris-buffered saline).
Cells were incubated in 0.3% H2O2 and the endogenous peroxi-
dase was blocked with ready-to-use (2.5%) normal horse block-
ing serum (ImPRESS Reagent Kit, Vector Laboratories).
Afterwards, the primary antibodies, two polyclonal antibodies
against human Runx2 (M-70; 1:100 dilution) and human Slug
(H-140; 1:100 dilution) (Santa Cruz, Biotechnology, CA, USA),
respectively, were applied and incubated at 4°C overnight.
Cells were then incubated at room temperature with
ImmPRESS reagent (ImPRESS Reagent Kit) for 30 min. After
rinsing in TBS, substrate–chromogen mix (ImmPACT DAB,
Vector Laboratories). After washing, cells were mounted in
glycerol/PBS 9:1 and observed using a Leitz microscope.
009693_Torreggiani:et al.  08-10-2010  11:13  Pagina 2
Osteogenic potential of nasal septum cells 3
Small interfering RNA (siRNA) transfection
BLOCK-iT Fluorescent Oligo (Invitrogen, Carlsbad, CA, USA)
was used to assess the transfection efficiency of siRNA. It is a
fluorescein-labelled, double-stranded RNA duplex with the
same length, charge and configuration as standard siRNA. The
sequence of the BLOCK-iT Fluorescent Oligo is not homolo-
gous to any known gene, ensuring against nonspecific cellular
events caused by the introduction of the oligonucleotide into
the cells. Human osteoblasts were seeded under the same
experimental conditions and transfected with 30 nM of
BLOCK-iT Oligo. After 24 hours, images of transfected cells
were recorded using a digital imaging system based on a fluo-
rescence microscope (model Axiovert 200L; Carl Zeiss
MicroImaging, Inc.) equipped with a back-illuminated CCD
camera (Roper Scientific), excitation and emission filterwheels
(Sutter Instrument Company), and piezoelectric motoring of
the z stage (Physik Instrumente, GmbH & Co). The data were
acquired and processed using the MetaFluor analyzing pro-
gram (Universal Imaging Corp).
Stealth RNAi duplexes and corresponding Stealth control were
synthesized by Invitrogen Life Technologies. Stealth RNAi
compounds are 25 mer dsRNA containing proprietary chemi-
cal modifications that enhance nuclease stability and reduce
off-target effects. The previously described siRNA/Slug2 tar-
geting human Slug was used (20). Twenty four hrs before
siRNA transfection, hOBs were seeded in triplicate at a density
of 16 x 103/cm2 in DMEM with 10% FBS. Cells were transfect-
ed with 30 nM siRNA using Lipofectamine RNAiMAX
(Invitrogen Life Technologies) according to the manufacturers’
instructions. Transfected cells were incubated for 6 days at
37°C before gene silencing analysis. As a negative control for
the siRNA treatment, Medium GC Stealth RNAi Negative
Control Duplex (Invitrogen) was used. Knockdown of Slug
expression was verified by Real-Time RT-PCR.
Real-time quantitative RT-PCR
Cells from three wells were harvested and total RNA was
extracted using an RNeasy Mini Kit (Qiagen GMBH, Hilden,
Germany) according to the manufacturer’s instruction and as
previously described (20). Real-time PCR was carried out using
the ABI PRISM 7700 Sequence Detection System (Applied
Biosystems Inc, Foster City, CA, USA), TaqMan technology,
and the Assays-On-Demand kit for human Slug, Runx2, and
BSP. The mRNA levels of target genes were corrected for
GAPDH mRNA levels (endogenous control). All PCR reac-
tions were performed in triplicate for each sample and were
repeated three times. All experimental data were expressed as
the mean ± S.E.M.
Western blotting
For western blot analysis, the cells were washed twice with ice-
cold PBS and cell lysates were prepared as previously reported
(19). Then, 10 μg of each sample was electrophoresed through a
12% SDS-polyacrylamide gel. The proteins were then trans-
ferred onto an Immobilon-P PVDF membrane (Millipore,
Billerica, MA, USA). After blocking with PBS - 0.05% Tween
20 and 5% dried milk, the membrane was probed with the fol-
lowing antibodies: Slug (L40C6) from Cells Signaling
Technology (Danvers, CA, USA), and IP3 K (06-195) from
Upstate Biotechnology (Lake Placid, NY, USA). After washing
with PBS-Tween, the membranes were incubated with peroxi-
dase-conjugated anti-rabbit antibody (1:50000) or anti-mouse
(1:2000) (Dako) in 5% non-fat milk. Immunocomplexes were
detected using Supersignal West Femto Substrate (Pierce,
Rockford, IL, USA). Anti-IP(3)K was used to confirm equal
protein loading.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was carried out as previously described using
the standard protocol supplied by Upstate Biotechnology, Inc.
with their ChIP assay reagents (21). The cells were cross-linked
with 1% formaldehyde for 10 min at 37°C, washed in ice-cold
PBS and suspended in SDS lysis buffer for 10 min on ice.
Samples were sonicated, diluted 10-fold in dilution buffer sup-
plemented with protease inhibitors and precleared with 80 ml
of DNA-coated protein A-agarose; the supernatant was used
directly for immunoprecipitation with 5 μg of anti-Runx2, 
(sc-10758) (Santa Cruz Biotec), overnight at 4°C.
Immunocomplexes were mixed with 80 ml of DNA-coated
protein A-agarose followed by incubation for 1 hr at 4°C.
Beads were collected and sequentially washed 5 times with 1
ml each of the following buffers: low salt wash buffer (0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1,
150 mM NaCl), high salt wash buffer (0.1% SDS, 1% Triton X-
100, 2 mM EDTA, 20 mM Tris-HCl pH-8.1, 500 mM NaCl),
LiCl wash buffer (0.25 mM LiCl, 1% IGEPAL-CA630, 1%
deoxycholic acid, 1 mM EDTA, 10 mM Tris-pH 8.1) and TE
buffer. The immunocomplexes were eluted two times by
adding a 250 ml aliquot of a freshly prepared solution of 1%
SDS, 0.1M NaHCO3 and the cross-linking reactions were
reversed by incubation at 65°C for 4h. Further, the samples
were digested with proteinase K (10 mg/ml) at 42°C for 1hr,
DNA was recovered by phenol/chloroform extractions,
ethanol precipitated using 1 ml of 20 mg/ml glycogen as the
carrier, and suspended in sterile water. For PCR analysis,
aliquots of chromatin before immunoprecipitation were saved
(Input). PCR was performed to analyse the presence of DNA
precipitated by Runx2 specific antibody, and by using specific
primers to amplify a fragment of the Slug gene promoter.
Each PCR reaction was performed with 5 !μl of the bound DNA
fraction or 2 μl of the input. The PCR was performed as fol-
lows: preincubation at 95°C for 5 min, 30 cycles of 1 min
denaturation at 95°C, 1 min annealing at 62°C and 1 min at
72°C, with one final incubation at 72°C for 5 min. No-antibody
control was included in each experiment.
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Statistical analysis
Data are presented as the mean ± SEM calculated from at least
three independent experiments performed on material
obtained from all patient analysed. Statistical analysis was
 performed by one-way analysis of variance and the Student’s 
t-test. A p-value < 0.05 was considered statistically significant.
RESULTS
Isolation and characterization of human primary osteoblasts
Human primary osteoblast cultures (hOBs) were generated
from bone chips removed from nasal septum, and were sub-
jected to the experimental procedure schematized in Figure 1.
From a group of 81 patients, 10 samples have been selected for
the analysis here described, essentially based on their ability to
proliferate and differentiate. The appearance of isolated human
osteoblastic cells was examined and we found cell morphology
to be consistent with what has been reported in the literature
(Figure 1) (22). It was observed that immediately following isola-
tion, there was limited cellular migration from the trabecular
bone chips at day 1. After about 7 days, outgrowth of bone
cells from the bone chips commenced, and confluency in T25
flask was usually reached after 3-4 weeks. The cellular mor-
phology was spindle-shape as well as circular for some
osteoblastic cells. On examination of the cells at day 21, there
was a substantial increase in the number of primary cells that
had migrated from the bone chips, increasingly further away
from the bone chips. 
The immunophenotypical profile of the cells from all 10 sam-
ples was determined by flow cytometric analysis The results
indicate that most of the cells (98.12%) expressed cell surface
marker CD90 (Thy-1) (Figure 2A) that is detected in the early
stage of osteoblast differentiation and declines as osteoblasts
differentiate into osteocytes (23). The hematopoietic marker
CD45 was not detectable on these cells (Figure 2A), indicating
that cells were not contaminated with cells of hematopoietic
origin. In addition, flow cytometry showed that the cells did
not express STRO1 (Figure 2A), suggesting that they are most-
ly mature osteoblasts (24). We then analysed the phenotypic
markers by immunocytochemical staining. The cells from all
10 samples were highly positive for both Runx2, a typical
osteogenic marker, and Slug, a zinc finger transcription factor
involved in epithelial-mesenchymal transition and recently cor-
related with osteoblast maturation (Figure 2B) (20,25). A signifi-
cant component of the bone extracellular matrix, the bone
sialoprotein (BSP), was detected at mRNA level by real time
RT-PCR. These data confirm the level of maturation of the
cells giving a definite indication of their commitment.
Next, the cells were characterized for their osteogenic capacity
in terms of alkaline phosphatase (ALP) activity and mineral
deposition (Figure 2C). The presence of sites of ALP activity
was detected in all samples. In addition, Alizarin Red staining
showed that all samples analysed exhibited an evident extracel-
lular matrix mineralization after 14 days of culture under
osteogenic conditions (a representative sample is shown in
Figure 2C). 
Effect of a specific gene knockdown
To analyse the potential to modify cellular phenotype in con-
sequence of nucleic acid based drug treatments, 4 of the 10
samples were transfected with a double-stranded fluorescent
dye-labeled oligonucleotide and the DNA uptake has been
monitored for increasing length of time (2-24 hrs). After 24 hrs,
the fluorescent molecules were widely distributed into the
nuclei of most of the cells (Figure 3A), and the transfection
efficiency was estimated about 80%. Automated cell culture
observation by using the BioStation CT-LA image analysis sys-
tem confirmed the results (data not shown).
To determine the effect of a specific oligonucleotide treatment,
the cells were then transfected with a siRNA against Slug, a
transcription factor that we previously demonstrated correlated
with osteoblastic phenotype (20). The transfection significantly
decreased the mRNA and protein levels of Slug, compared
with those in cells transfected with scramble siRNA (Figure
3B). Concomitantly, the ability to deposit mineral matrix of the
cells decreased significantly, demonstrating that the cells clear-
ly respond to modulation of their osteoblast phenotype (Figure
3B).
Runx2 interacts “in vivo” with the promoter of SLUG gene
To study the feasibility of other molecular investigations, 4 of
the 10 samples were subjected to chromatin immunoprecipita-
tion (ChIP) analysis, an “in vivo” transcriptional regulation
assay. We set up sufficiently sensitive ChIP conditions to allow
Figure 1. Isolation and use of human primary osteoblasts (hOBs).
Human primary osteoblasts were obtained from bone chips removed
from nasal septum. Bone was cut in small pieces which were rinsed
and then cultured in T25 flask. About 7 days after isolation, outgrowth
of bone cells from bone chips began. As shown in this figure, cells pre-
sent a spindle-shape morphology. Once hOBs reached confluency,
they were used for cellular and molecular analysis.
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the analysis of primary cells. At this purpose, the involvement
of a bone-specific transcription factor, Runx2, in the transcrip-
tional regulation of SLUG, was tested. Using a program for
predicting transcription factor binding sites (TFSEARCH,
www.cbrc.jp/research/db/TFSEARCH.html), two potential cis
elements for Runx2 were found in the promoter of the human
SLUG gene at -537 and -476 (Figure 4). Their functionality was
investigated by ChIP assay, analysing the “in vivo” association
between Runx2 and the SLUG promoter. The cells were
exposed to formaldehyde to cross-link proteins and DNA, and
sonicated to fragment the chromatin. Specific antibody against
Runx2 was used to immunoprecipitate the protein – DNA
complexes, and Runx2 recruitment was assessed by using the
specific set of primers reported in Table 1. The presence of the
promoter specific DNA region before immunoprecipitation
was confirmed by PCR (input). After immunoprecipitation,
DNA was extracted from the beads and used as a template to
generate a specific PCR product spanning the putative Runx2
binding site in the SLUG promoter gene. As shown in Figure
4, we demonstrated that the SLUG gene displays a specific reg-
Figure 2. Phenotypical characterization of human primary osteoblasts
(hOBs). A) The characterization of ten hOBs has been performed by
flow cytometric analysis of CD45, CD90 and STRO-1 phenotypical
markers. Data were expressed as % positive cells ± SEM, repeated
three times for each sample. B) hOBs samples were subjected to
immunocytochemical analysis for Runx2 and Slug phenotypical mark-
ers. A representative sample is shown (X10 magnification). The level
of Runx2 and BSP expression was examined by quantitative RT-PCR
in ten hOB samples. The experiments were carried out in triplicate, the
expression levels were normalized on the basis of GAPDH expression
and results of the experiments are reported as relative mRNA expres-
sion levels. ∆∆Ct method was used to value the gene expression; SEM
was calculated. C) The cells were treated with β-glycerophosphate,
ascorbic acid, and dexamethasone and formation of extracellular
matrix was valuated. Mineral formation was examined by Alizarin
Red-S staining after 14 days of osteogenic induction. The authentic
osteoblast phenotype was confirmed in hOBs by staining for alkaline
phosphatase (ALP) activity. 
Figure 3. Transfection efficiency and effect of Slug knockdown during
osteogenic differentiation. A) Cells were transfected with 30nM of a
double-stranded fluorescent dye-labeled oligonucleotide. The uptake
of oligo fluorescent siRNA was analysed in hOBs by fluorescence
microscopy. Two and 24 hrs after the transfection, cells were washed
and examined under phase contrast (left panels) or fluorescent light
using a fluorescent filter (right panels). B) hOBs were treated for 6 days
with siRNA/Slug2 30 nM or a scramble siRNA as negative control. At
the top, representative western blot of siRNA/Slug2 treated cells
shows a specific decrease of endogenous Slug protein level. Size mark-
ers are reported (KDa). IP3K was used as a loading control. RT-PCR
results, after correction to GAPDH content, are expressed as
siRNA/Slug2 over control ratio. Results represent means ± SEM of 4
hOB samples (*p < 0.05). After siRNA/Slug treatment, the cells cul-
tured in osteogenic medium and analysed for the deposition of calci-
um salts by Alizarin Red-S staining. At day 14, more mineralized nod-
ules were observed in untreated cells respect to silenced cells.
Table 1. PCR primers used for chromatin immunoprecipitation assay
(ChIP).
Regions Primer sequences Product
size (bp)
Region 1 Forward F1: 5’-ATATAGGCTCTCATTAACAC-3’ 218
Reverse R1: 5’-AGTATTTTCAAGAGAGGTAA-3’
Region 2 Forward F2: 5’-GAAATGGAGTGAAAAGCAAG-3’ 175
Reverse R2: 5’-TTGCAGGAGAGAGGAAAATA-3’
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ulatory response in osteoblasts with the recruitment of a bone-
specific transcription factor, Runx2, that is required for termi-
nal differentiation of osteoblasts. As expected, no recruitment
of this bone-specific transcription factor was observed in a
sequence of SLUG promoter, (region 2), lacking of Runx2
binding sites (Figure 4) or in MCF-7 breast cancer cells (data
not shown).
These ChIP experiments strengthen the role of Slug in
osteoblasts showing that it is a Runx2 target gene, and demon-
strate the feasibility of this analysis in human primary
osteoblasts obtained from nasal septum.
DISCUSSION
The tissue engineering supported by cell therapy and scaffolds
with advanced carrier technology for growth factors offers
important opportunity for bone tissue repair and regeneration.
It may be based on different approaches that combine the col-
laboration between surgeons, scientists and engineers.
Because the formation of bone tissue is based mainly on the
action of osteoblasts, these cells are of special relevance (26).
Formation of bone involves a complex pattern of cellular
events initiated by proliferation and differentiation of mes-
enchymal precursor cells into bone-forming cells and finally
resulting in the mineralization of the extracellular matrix.
Therefore, the ultimate aim of skeletal tissue regeneration is
mineral deposition in a scaffold with a pore system for growth
of suitable cells, such stem cells or precursor cells that may be
implanted or seeded into the scaffolds capable of supporting
three-dimensional tissue formation (4-7,18,27,28). Various scaffolds
have already been developed for bone tissue engineering appli-
cations. However, the properties of cellular component are
considered particularly determining factors. 
Reconstructive strategies of the craniofacial district, naso-
orbito-ethmoidal fractures, whether isolated or as a component
of complex facial fractures, are always some of the most chal-
lenging skeletal facial injuries to treat (1-3,8-17,29-32). Regeneration
of bone tissue is also required after frequent maxillary or
mandible reabsorption due to tumour resections or tissue
necrosis. The successful facial plastic surgery approaches and
the development of more appropriate and effective treatments
are based on knowledge of bone biology including cellular and
molecular aspects of bone development, formation and repair.
It is important to underline that several clinical studies on con-
genital defects of nasal septum and the findings on experimen-
tal animals after nasal septum ablation demonstrate that the
septum acts as a growth center thrusting the midface bones
downwards and forwards from the cranial base. 
Therefore, a search for the ideal cells to employ in facial skele-
ton regenerative medicine, brought us to consider the potential
use of bone cells obtained from nasal septum for autologous
reconstruction techniques. In fact, the recovery and propagation
facility of these cells make them both a good alternative to bone
marrow osteogenic progenitors from iliac crest, and qualified
differentiated cells that could be directly applied to the bone
defect in combination with suitable scaffolds. It is important to
underline that the lower part of the osseous nasal septum that
we used in this study is part of the maxilla, and it has been pre-
viously demonstrated that the use of osteoblasts of maxillary
origin is safe (33). We demonstrated in the present study that
cells derived from explants of nasal septum are easy to obtain,
can be grown up in culture, express markers of osteoprogenitor
cells, and are committed towards maturation because do not
express STRO1. In fact, previous studies have shown that the
STRO1 antigen defines a MSC precursor subpopulation, is pre-
sent in osteogenic precursor cells isolated from human bone
marrow, is maintained in immature, pre-osteoblastic phenotype,
and is progressively lost by mature osteoblasts (24).
Under appropriate treatment, the cells can be induced to
osteogenic differentiation giving rise to mature osteoblasts
characterized by the expression of osteogenic markers, and
ability to deposit mineralized matrix. These evidences indicate
that these cells may represent a very promising material to be
utilized in bone cellular therapy.
At the same time, we demonstrated that, from a single sample,
it is possible to obtain a sufficient quantity of cells to perform
several molecular analysis including RT-PCR, ChIP, and
Figure 4. In vivo recruitment of Runx2 transcription factor on human
Slug promoter. The Slug promoter region under investigation is
reported (+1/-1900). The positions of the putative Runx2 consensus
binding sites are enclosed by black diamonds. Recruitment of Runx2
transcription factor to the human Slug promoter is demonstrated by ‘in
vivo’ ChIP binding assays. Protein-DNA complexes were formalde-
hyde-cross-linked in hOBs in vivo. Chromatin fragments from these
cells were subjected to immunoprecipitation with antibody against
Runx2. After cross-link reversal, the coimmunoprecipitated DNA was
amplified by PCR using the reported primers, which positions are indi-
cated with arrows. Region 2, lacking Runx2 binding sites, represents a
negative control of ChIP experiments. PCR fragments were resolved
through 1.5% agarose gels. No Ab represents a negative control. Input
represents a positive control using the starting material (0.2%) prior to
immunoprecipitation. The molecular weights of PCR fragments are
shown in parentheses. M: molecular weight marker.
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immunocytochemical experiments. The information that can
be obtained from the molecular approaches described here are
worthy of interest because biochemical signal cascades that
alter expression of genes or activation of proteins play critical
role in tissue engineering field. Many of these signals, only in
part known, include FGF, WNT, TGF-β, BMP, EGF, HIF,
Notch, PTH, and integrins –mediated pathways, and are corre-
lated with changes in specific activities of bone cells and may
be also considered potential therapeutical targets (25,34). Thus, it
is very important, where feasible, to perform a direct molecular
analysis on the same cells that are then to be used for tissue
engineering.
All together, our findings may be considered a preliminary
statement for clinical applications in the head and neck area
aimed to develop an ex vivo model for induction of ectopic
bone formation using autologous committed precursors cells. 
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CXCL12/CXCR4 chemokine/receptor axis signaling has recently been found to play an important role
in the remodeling of bone tissue, but little is known about the molecular mechanisms that are
involved. The present study shows that CXCL12 is present at high levels both in humanmesenchymal
stem cells (hMSCs) and primary osteoblasts (hOBs). When osteogenesis was induced, CXCL12
expressionwas strictly confined tomineralized nodules. To investigate whatmechanisms contribute
to the maintenance of a correct expression of CXCL12 in bone cellular context, we analyzed the
relationship between CXCL12 and Slug, a transcription factor recently associated with osteoblast
maturation. By gene silencing and chromatin immunoprecipitation assay, we showed that both
proteins are required for themineralization process and CXCL12 is transcriptionally and functionally
regulated by Slug, which is recruited at specific sites to its gene promoter in vivo.
These findings showed for the first time a positive correlation between CXCL12 signaling and Slug
activity, thus corroborating the role of these two proteins in bone cellular context and suggesting a
new potential target for bone tissue repair and regeneration.
© 2010 Elsevier Inc. All rights reserved.
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Introduction
CXCL12, also known as stromal cell-derived factor-1 (SDF-1),
belongs to the CXC chemokine family andwas identified according
to NH2-terminal-cysteine motifs [1,2].
During the last decade, accumulating data have supported the role
of CXCL12/CXCR4 axis signaling in the development, differentiation
andrepair of bone tissue. CXCL12 ismainlyproduced in thebone tissue
by immature OBs lining the bone endosteum, MSCs and endothelial
cells [3,4]. A continuous expression of CXCL12 has also been found in
regenerating bone OBs as well as radioablated bone marrow and
proliferating OBs [3,5,6]. Furthermore, CXCL12 has also been found to
have a regulatory role in theosteogenic differentiationofmurineMSCs
[7].
Collectively, accumulated evidence suggests that constitutive and
induced expression of CXCL12 is tightly regulated in different cells.
Nevertheless, the molecular mechanisms involved in directing the
correct levels of this chemokine remain unclear. Recently, a
functional characterization of the CXCL12 gene promoter has been
performed [8,9] and potential binding sites for transcriptional
regulators includingSp1, AP2,HNF-3, NF-X3, glucocorticoid receptor,
NFAT, c-myb, c/EPBβ and bHLH have been identified. In addition,
several authors have observed a cell-specific inductivity of CXCL12
promoter activity [8] in response to anti-mitotic agents,γ irradiation,
cytokines, cell confluence and transiently hypoxic microenviron-
ments [3,8–11]. The important role of CXCL12/CXCR4 signaling in
tumorigenesis was recently confirmed in another neoplastic context
suchaspancreatic cancer, inwhich theabrogationof CXCR4 inhibited
invasion-related genes and the invasive ability of cancer cells [12].
Moreover, it has been highlighted that CXCL12/CXCR4 signaling
finely modulates craniofacial development and both their knock-
downandover-expression result in cranial neural crest cellmigration
defects and ectopic craniofacial cartilage formation [13].
Transcription factors play a critical role in cell–cell communica-
tion, which occurs in neural crest cell migration and epithelial
mesenchymal transition (EMT) correlated with cancer invasion[12].
Slug, also called Snail2, is a member of a superfamily of zinc-finger
transcription factors that play a central role in the patterning of
vertebrate embryos [14]. Slug is implicated in the inductionof EMTat
specific stages of normal development and tumor progression, by
acting as a transcriptional repressor of the gene-encoding compo-
nents of cell–cell adhesive complexes in the epithelia [14–16]. Slug
and its familymembers have also important roles in other processes,
including the protection of cells from programmed cell death, the
regulation of cytoskeletal elements [17] and the migration of neural
crest cells [18]. We recently showed that Slug is required for OB
maturation, being involved in the transcriptional control of OB-
specific genes including Runx-2, a determinant transcription factor
for osteoblastogenesis [19].
To provide critical new insights into themechanisms underlying
the OB phenotype that might lead to better control of the
differentiation of these cells we studied a possible link between
Slug and the CXCL12 chemokine. By expression analysis, gene
silencing and chromatin immunoprecipitation assays we show, for
the first time, that Slug activity and CXCL12 signaling are two strictly
correlated phenomena in bone cellular context. The presence of Slug
is required for CXCL12 expression and these two proteins are both
co-expressed in the mineralized nodules. Our findings corroborate
the role of Slug and CXCL12 in osteogenesis and may be relevant in
approaches aimed at discovering new molecular targets to use in
bone repair regenerative medicine.
Materials and methods
Isolation and culture of hOBs
HOBs were obtained from trabecular bone located in the inner
portion of the tibial plateau of patients undergoing total knee
replacement. Briefly, bone chips were removed from the tibial
plateau, collected in a V-glass tube containing 1.5 ml of 1:1 mixture
of DMEM/Ham's F12K no calcium (Gibco, Invitrogen Corporation,
Paisley, Scotland, UK) and supplemented with 15% FBS, antibiotics
(100U/mlpenicillin and100 μg/ml streptomycin), 25 μg/ml ascorbic
acid (Sigma, St Louis, MO, USA), 4 mMglutamine (Sigma) according
to the methods previously described [20].
Isolation and culture of hMSCs
HMSCs were isolated from bone marrow iliac crest aspirates using
Ficoll-Hypaque density gradient (1.077 g/ml) (Sigma, St Louis, MO,
USA), as previously reported [21]. Briefly, nucleated cells were
collected at the interface, washed twice, suspended in α-MEM
supplemented with 15% FBS and penicillin G (Sigma), counted and
plated at a concentration of 2×106cell/T150 flask. After 48 h non-
adherent cells were removed and the adherent MSCs expanded in
vitro.
Osteogenesis ofMSCs (N=6)was induced 24 h after seeding, by
incubating cells in α-MEM medium supplemented with 100 μM
ascorbic acid, 2 mM β-glycerophosphate and 100 nM dexametha-
sone (all purchased from Sigma) for 4 weeks and analyzed after 24 h
(day0) andatdays 14, 21 and28. The extentofmineralizedmatrix in
the plates was determined by Alizarin Red S staining (Sigma) as
previously reported [19].
Characterization of hOBs and hMSCs by flow cytometry
Both hOBs (N=10) and hMSCs (N=10) (at passage 2) were fixed
in 4% paraformaldehyde and incubated at 4 °C for 30 min with
5 μg/ml of the following monoclonal antibodies: anti-human-CD3,
-CD34, -CD45 (all purchased from Dako Cytomation, Glostrup,
Denmark), -CD90, -CD146 (Becton Dickinson, Mountain View, CA),
-CD105 (produced from the hybridoma cell line, clone SH2, ATCC,
Rockville, MD), diluted in PBS supplemented with 2% BSA and 0.1%
sodium azide. The cells were washed twice and incubated with
polyclonal rabbit anti-mouse immunoglobulins/FITC conjugate
(DakoCytomation) at 4 °C for 30 min. After two final washes, the
cells were analyzed using a FACStar plus Cytometer (Becton
Dickinson). For isotype control, FITC-coupled non-specific mouse
IgG was substituted for the primary antibody. Alkaline phospha-
tase activitywas analyzed using alkaline phosphatase leukocyte kit
(Sigma) as previously described [19].
Real-time RT-PCR
hOBs (N=14) and hMSCs (N=13) were harvested from three
wells and total RNA was extracted using an RNeasy Mini Kit
(Qiagen GMBH, Hilden, GM) according to the manufacturer's
instructions and as previously described [22]. Real-time PCR was
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carried out using the ABI PRISM 7700 Sequence Detection System
(Applied Biosystems Inc, Foster City, CA, USA). TaqMan technol-
ogy, the Assays-On-Demand kit for human Slug and CXCL12 were
used. The mRNA levels of target genes were corrected for GAPDH
mRNA levels (endogenous control). All PCR reactions were
performed in triplicate for each sample and were repeated three
times. All experimental data were expressed as the mean±s.e.m.
CD11 positive cells were also evaluated for CXCL12 expression
as cells expressing low level of CXCL12 in physiological conditions.
Secretion of CXCL12 chemokine
Supernatants frombothosteogenic-inducedhMSCs (at days 0, 14, 21
and 28) and hOBs (N=10) (after 24 h of culture) were collected.
CXCL12 production was evaluated by a specific immunoassay
standardized in our laboratory using antibody pairs matched for
CXCL12 (R&D Systems, Minneapolis, MN, USA). Sensitivity of the
assay was 15 pg/ml. Data were expressed as measured pg/
mlCXCL12/μg of total proteins±s.e.m.
Immunocytochemical analysis of CXCL12 chemokine
For immunocytochemical analysis of osteogenic-induced hMSCs (at
days 0, 14 and 28) the cells werewashed twicewith PBS and fixed in
4% paraformaldehyde (PFA) for 30 min at room temperature. Cells
were then incubated with anti-human-CXCL12 (R&D Systems) or
-Slug (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at room
temperature for 1 h, washed twice with TRIS buffered saline (TBS)
pH 7.2 and then incubatedwith undiluted affinity purified goat anti-
mouse immunoglobulins conjugated with alkaline phosphatase
labeled polymer (Envision kit, Dako, Glostrup, Denmark) or goat
anti-rabbit-HRP (DakoCytomation) at room temperature for 30 min.
An alkaline phosphatase reaction using new fucsin as a substrate or a
peroxidase reaction using 3,3' diaminobenzidine as substrate was
performed. Negative staining control experiments were performed
either by omitting the primary antibody or using a control isotype-
matched antibody. Slides were counterstained with haematoxylin
and evaluated in a brightfield microscope.
Small interfering RNA (siRNA) transfection
Three sets of Stealth RNAi duplexes and corresponding Stealth
control were synthesized by Invitrogen Life Technologies (Carls-
bad, CA, USA). Stealth RNAi compounds were 25 mer dsRNA
containing proprietary chemical modifications that enhance
nuclease stability and reduce off-target effects.
The following Stealth RNAi sequences were used:
siRNA/Slug1 sense: 5'-CCGUAUCUCUAUGAGAGUUACUCCA-3';
antisense: 5'-UGGAGUAACUCUCAUAGAGAUACGG-3';
siRNA/Slug2 sense: 5'-CCCUGGUUGCUUCAAGGACACAUUA-3';
antisense: 5'-UAAUGUGUCCUUGAAGCAACCAGGG-3';
siRNA/Slug3 sense: 5'-GGCUCAUCUGCAGACCCAUUCUGAU-3';
antisense: 5'-AUCAGAAUGGGUCUGCAGAUGAGCC-3'.
As previously found [19], the most effective fragments used for
targeting human Slug were siRNA/Slug2.
Twenty-four hours before siRNA transfection, hOBs (N=9) were
seeded in triplicate at a density of 16 × 103/cm2 in DMEM with 10%
FBS. The cellswere transfectedwith30nMsiRNAusing Lipofectamine
RNAiMAX(InvitrogenLife Technologies, Carlsbad, CA,USA) according
to the manufacturer's instructions. Transfected cells were incubated
for 6 days at 37 °Cbefore gene silencing analysis. As anegative control
for the siRNA treatment, Medium GC Stealth RNAi Negative Control
Duplex (Invitrogen) was used. Knockdown of Slug expression was
verified by real-time RT-PCR.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was carried out as previously described [22] using
the standard protocol supplied by Upstate Biotechnology, Inc.
(Lake Placid, NY) with their ChIP assay reagents. The hOBs (N=3)
and hMSCs (N=3) were cross-linked with 1% formaldehyde for
10 min at 37 °C, washed in ice-cold PBS and suspended in SDS lysis
buffer for 10 min on ice. Sampleswere sonicated, diluted 10-fold in
dilution buffer supplemented with protease inhibitors and
precleared with 80 μl of DNA-coated protein A-agarose; the
supernatant was used directly for immunoprecipitation with 5 μg
of anti- Slug (Santa Cruz Biotechnology, CA, USA), overnight at
4 °C. Immunocomplexes were mixed with 80 μl of DNA-coated
protein A-agarose followed by incubation for 1 h at 4 °C. The beads
were collected and sequentially washed five times with 1 ml each
of the following buffers: low salt wash buffer (0.1% SDS,1% Triton
X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM NaCl), high
salt wash buffer (0.1% SDS,1% Triton X-100, 2 mM EDTA, 20 mM
Tris-HCl pH-8.1, 500 mMNaCl), LiCl wash buffer (0.25 mM LiCl, 1%
IGEPAL-CA630, 1% deoxycholic acid, 1 mM EDTA, 10 mM Tris-pH
8.1) and TE buffer. The immunocomplexes were eluted two times
by adding a 250 μl aliquot of a freshly prepared solution of 1% SDS,
0.1 M NaHCO3 and the cross-linking reactions were reversed by
incubation at 65 °C for 4 h. Then, the samples were digested with
proteinase K (10 mg/ml) at 42 °C for 1 h, DNA was recovered by
phenol/chloroform extractions, ethanol precipitated using 1 μl of
20 mg/ml glycogen as the carrier, and suspended in sterile water.
For PCR analysis, aliquots of chromatin before immunoprecipita-
tion were saved (Input). PCR was performed to analyze the
presence of DNA precipitated by Slug specific antibody. Specific
primers to amplify fragments of the CXCL12 gene promoter were:
Region 1 (243 bp fragment):
Forward F1: 5'-TACAGGCGAGGAAACTGAGGCT-3'
Reverse R1: 5'-GGACTGAATGAGAACCAATGAA-3'
Region 2 (292 bp fragment):
Forward F2: 5'-ATGCGTAATTACTTATGCTTAGC-3'
Reverse R2: 5'-TCAGGTGGGCAGCTGGACCTA-3'
Each PCR reaction was performed with 5 μl of the bound DNA
fraction or 2 μl of the input. The PCR was performed as follows: pre-
incubation at 95 °C for 5 min, 30 cycles of 1 min denaturation at 95 °C,
1 min annealing at 62 °C and 1 min at 72 °C, with one final incubation
at 72 °C for 5 min. No-antibody control was included in each
experiment.
Statistical analysis
Statistical analysis was performed using the non-parametric tests
(Wilcoxon matched-pair test and Friedman ANOVA and Kendall's
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concordance non-parametric test) to evaluate if there was any
tendency to increase or decrease along the time points analyzed. The
Mann–Whitney U test was also used for comparing non-matched
group of data. All values were expressed as themean±s.e.m. of five
different experiments. The analyses were performed using CSS
Statistica Statistical Software (Statsoft Inc., Tulsa, OK, USA). Values of
p<0.05 were considered significant.
Results
hMSC and hOB characterization
To characterize all samples used in this study, a panel of seven
phenotypic markers were first analyzed in isolated hMSCs and
hOBs. As shown in Fig. 1A, flow cytometric analysis showed that
both hMSCs and hOBs were negative for typical hematopoietic
markers such as CD3, CD34, CD45, whereas they were highly
positive to CD90 and CD105. Interestingly, approximately 75% of
hMSCs were positive to CD146, whereas hOBs were negative, as
also described by other authors [23]. Moreover, alkaline phospha-
tase activity was found, as expected, both in hMSCs and in hOBs, at
different levels (Fig. 1B). The osteogenic potential of hMSCs was
then tested by inducing the cells to differentiate along the
osteoblast lineage in osteogenic medium and demonstrating the
positive staining for extracellular calcium deposition at days 14
and 28 (Fig. 1C).
CXCL12 chemokine expression in hMSCs and hOBs
CXCL12 chemokine expression analysis was then performed on
hMSCs and hOBs both at mRNA and protein level. The analysis was
performed both in the cells at the uninduced basal condition, and in
hMSCs induced to differentiate along the osteoblast lineage up to
28 days. As shown in Fig. 2A, we found high levels of CXCL12mRNA
in uninduced hMSCs and hOBs cells, whereas the exposure to
osteogenic medium downregulated the expression of CXCL12
mRNA, producing a significant decrease of CXCL12 transcript at day
14 (p<0.05). The level of CXCL12 mRNA detected at day 14
remained unchanged during osteogenesis up to day 28, and, was
always higher than that found in physiological conditions in CD11b
+cells (% GAPDH=0.0446 ±0.012) (data not shown). Fig. 2B
showed that the level of CXCL12 secretion in the hMSCs induced to
osteogenesis decreased, as determined by ELISA performed in cell
supernatants. This analysis revealed that CXCL12 protein levels
were consistently higher in uninduced versus induced hMSCs in
agreement with results from mRNA analysis. However, it is
interesting to note that the CXCL12 secretion continued to decrease
during osteogenesis even if CXCL12 transcript levels remained
unchanged throughout the time course relative to osteogenesis
induction (from day 14 to day 28). This suggests that different
mechanisms are required to determine the level of CXCL12
expression at mRNA and protein level. Furthermore, intracellular
CXCL12 expressionduring osteogenic induction (fromdays 0 to 28)
also generally decreased, as found by immunocytochemical
analysis (Fig. 2C). Interestingly, the same analysis revealed that
CXCL12 expression at day 28 was strictly confined to mineralized
nodules (Fig. 2C), thus suggesting a potential role of this chemokine
in cells destined to become osteoblasts. Concerning the CXCR4
receptor, we found that its expression was not modulated during
osteogenic differentiation (data not shown).
Slug knockdown and CXCL12 expression
To provide additional evidence for the role of CXCL12 in the bone
cellular context, we correlated the expression of this chemokine
with Slug, a transcription factor that we recently showed to be
required for osteoblast maturation [19]. As shown in Fig. 3A, Slug
mRNA, analyzed by quantitative RT-PCR, increased during the
process of osteogenic differentiation of hMSCs,was highly expressed
in mature hOBs. This was confirmed also at protein level by
immunocytochemical analysis, thus showing that the positive signal
increased during osteogenic differentiation of hMSCs, both in the
single cells and in the mineralized nodules (Fig. 3B).
A possible role for Slug in regulating CXCL12 expression was
tested by knocking down the expression of Slug with a siRNA
approach inhOBs.Weblocked the endogenous productionof Slug by
treating hOBs for 6 days with a previously tested siRNA against Slug
[19] and obtained a strong inhibition of Slug mRNA and protein, as
revealed by quantitative RT-PCR and western blot analysis,
Fig. 1 – Characterization of hMSCs and hOBs. (A) Flow cytometry
analysis of CD3, CD34, CD45, CD90, CD105, CD146. Data were
expressed as % positive cells±s.e.m. (B) Cytochemical activity of
alkaline phosphatase in hMSCs and hOBs. Scale bar=25 μm.
(C) Alizarin red S staining of osteogenic-induced hMSCs at day 14
and day 28.
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respectively (Fig. 4). In addition, as previously shown [19], Slug
knockdown produced a decrease in mineralized matrix deposition
(Fig. 4B). We chose hOBs as an experimental model because of their
high CXCL12 and Slug contents, and their more homogeneous
phenotype in comparisonwith that presentedbyhMSCs. As reported
in Fig. 4C, Slug-silenced cells showed an increase in CXCL12 mRNA.
Nevertheless, when CXCL12 was investigated at protein level, Slug-
silenced cells showed a strong decrease of CXCL12 intracellular
content, as demonstrated by immunocytochemical analysis
(Fig. 4D). In addition, Slug-silenced cells released significantly
lower levels of CXCL12 in comparison with control cells, as
demonstrated by ELISA analysis (control cells: mean±SE 936.61±
261.01; Slug-silenced cells: mean±SE 703±228.24) (Fig. 4E).
The absence of correlation betweenmRNA and protein levels of
CXCL12 in Slug-silenced cells is in agreementwith that observed in
the MSCs induced to osteogenesis (see Fig. 2) and suggests that
Slug is differently involved in determining CXCL12 expression at
mRNA and protein level.
Fig. 2 – CXCL12 expression in osteogenic-induced hMSCs and hOBs. (A) Analysis of CXCL12 mRNA expression in both
osteogenic-induced hMSCs (from day 0 to day 28) and hOBs. Data were expressed as % GAPDH±s.e.m. °p<0.05 hMSCs day 0 versus
hOBs, *p<0.05 hMSCs day 28 versus hOBs. (B) CXCL12 protein secreted levels in both osteogenic-induced hMSCs (from day 0 to day
28) and in hOBs. Data were expressed as pg/ml CXCL12/μg protein±s.e.m. *p<0.05 hMSCs day 28 versus hOBs.
(C). Immunocytochemical analysis of CXCL12 on osteogenic-induced hMSCs at days 0, 14, 28. Magnification, 4× and 10×.
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Slug interacts in vivo with the promoter of the CXCL12 gene
We then tested whether Slug participated directly in the control of
CXCL12 gene transcription in hOBs. For this purpose, chromatin
immunoprecipitation (ChIP) analysis was performed on the promot-
er of the CXCL12 gene. Using a program for predicting transcription
factor binding sites (TFSEARCH, www.cbrc.jp/research/db/
TFSEARCH.html), we found in the promoter of human CXCL12 gene
two consensus sequences for Slug (5'-CANNTG-3'), at −509, and
−1877 together with other non-canonical Slug binding sites,
partially in agreement with those recently determined by Calonge
et al. [9] (Fig. 5). We focused on the consensus E boxes at−509 and
−1877. Their functionality was assessed by ChIP assay, by analyzing
the in vivo association between Slug and the promoter sequences
containing these two E boxes. hOBs and hMSCs were exposed to
formaldehyde to cross-link proteins and DNA, and sonicated to
fragment the chromatin. Specific antibody against Slug was used to
immunoprecipitate the protein–DNA complexes, and Slug recruit-
mentwasassessed at the twodifferentpromoter regionsbyusing the
specific sets of primers as reported in Fig. 5. The presence of the
promoter specific DNA region before immunoprecipitation was
confirmed by PCR (input). After immunoprecipitation, DNA was
extracted from the beads and used as a template to generate specific
PCR products spanning the putative Slug binding sites from
−2000 bp to +1 bp in the CXCL12 gene promoter. Slug occupancy
wasdetected in regions 1and2 inhOBs andonly in region2 inhMSCs,
thus suggesting a possible different role of these cis elements and
different regulatory function of Slug in hOBs and hMSCs. These ChIP
experiments show that CXCL12 is a novel Slug target gene in vivo.
Discussion
The role of CXCL12/CXCR4 chemokine/receptor signaling axis has
been elucidated in many cellular contexts [8]. Concerning bone
tissue, it has recently been suggested that this signaling is involved in
the remodeling process [3,5,6], has a critical role in the recruitment
of MSCs to the fracture site during skeletal repair [24], and is highly
expressed and secreted by regenerating/proliferating osteoblasts
after irradiation in mouse models [5]. Although a recent partial
characterization of the gene promoter suggested that both the
constitutive and induced expression of CXCL12 is finely regulated at
transcriptional level [8,9], the molecular mechanisms involved in
directing the correct levels of this chemokine remain unclear.
This study shows that CXCL12 is present at high levels both in
hMSCs and hOBs uninduced basal condition. In agreement with
previous studies [7,25,26], the expression of this chemokine is
generally downregulated in hMSCs induced to differentiate toward
the osteoblastic lineage, but mineralized nodules show a strong
immunostaining for CXCL12, thus suggesting a potential role for this
chemokine in cells destined to becomeosteoblasts. In fact, also recent
reports [5,24], using in vivo models, demonstrated an elevated
expressionof this chemokine in active proliferatingosteoblasts lining
the bone trabeculae, so corroborating its role in functional activity of
these cells. To investigate what mechanisms contribute to the
maintenance of a correct balance of CXCL12 in bone cellular context,
we analyzed for the first time the relationship between CXCL12 and
Slug, a transcription factor recently associated with osteoblast
maturation [19]. Interestingly,we found that Slug is highly expressed
in the mineralized nodules and is specifically recruited to CXCL12
gene promoter in vivo, as shown by chromatin immunoprecipitation
assays. These findings, suggesting an involvement of Slug and
Fig. 3 – Slug expression in osteogenic-induced hMSCs and hOBs.
(A) Evaluation of Slug mRNA expression in osteogenic-induced
hMSCs (at days 0 and 28) and in hOBs. Data were expressed as %
GAPDH±s.e.m. *p<0.05 hMSCs day 28 versus hOBs.
(B) Immunocytochemical analysis of Slug on osteogenic-induced
hMSCs at days 0, 14, 28. Magnification, 4× and 10×.
Fig. 4 – Evaluation of Slug knockdown effect. (A) siRNA efficiency evaluation on Slug gene and protein knockdown. hOBs were
transfected with siRNA against Slug or a non-relevant siRNA (scr). Slug expression was determined both at protein andmRNA level,
and revealed by western blot and quantitative RT-PCR analysis, respectively. RT-PCR results, after correction to GAPDH content, are
expressed as siRNA/Slug over control ratio. Results represent means±SEM of nine hOBs samples. (B) Alizarin Red S staining of
osteogenic-induced hMSCs both in control (−) and in siRNA/Slug2 silenced (+) hOBs. (C) Evaluation of Slug and CXCL12 mRNA
expression both in control (−) and in siRNA/Slug2 silenced (+) hOBs. Data were expressed as relative mRNA expression levels
(% GAPDH)±s.e.m. *p<0.05. (D) Immunocytochemical analysis of CXCL12 in control (−) and in siRNA/Slug2 silenced (+) hOBs.
Scale bar=25 μm. (E) CXCL12 protein secreted levels in control (−) and in siRNA/Slug2 silenced (+) hOBs. Data were expressed as
pg/ml CXCL12/μg protein±s.e.m. *p<0.05.
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CXCL12 in mineralized matrix deposition, were confirmed by Slug
silencing experiments performed in hOBs, since they express both
proteins at high level.
For this reason, it is important to underline that mature OBs are
committed cells representing the last cellular stage before terminally
differentiated osteocytes. In line with other authors [23,27] hOBs,
compared to MSCs, expressed a low percentage of CD146, which is a
typical marker of self-renewing, clonogenic osteoprogenitor cells in
the bonemarrow, and a low expression of alkaline phosphatase, thus
confirming the different stage of maturation of these cells. In fact,
hOBs have a peculiar gene expression profile, which is different from
that shown by MSCs induced to differentiate towards OBs [28]. In
addition, it has been shown [28] that cytokine expression is
influenced by the osteogenic compartment of MSCs and defines the
response to in vitro stimulatory treatment. Therefore, it is not
surprising that OBs expressed higher mRNA and protein levels for
CXCL12 than MSCs.
We found that Slug knockdown in hOBs induced a consistent
decrease of CXCL12 protein even if the corresponding mRNA
increased. One explanation for this apparent discrepancy found for
mRNA and protein expression of CXCL12 in Slug-silenced cells may
be the presence of numerous potential Slug targets in the cell and,
consequently, the wide spectrum of effects generated by its
silencing. Therefore, our findings suggest possible different roles
for Slug and consequently at least two different main effects of Slug
knockdown: a) Slug may act as a repressor of CXCL12 gene
transcription and its silencing removes the negative control by
increasing CXCL12 mRNA levels, b) Slug may have an indirect
positive impact on components of specific pathways correlatedwith
expression, stability secretion and activity of CXCL12 and its
silencing results in a decrease in CXCL12 protein. Therefore, our
data suggest that high levels of CXCL12 mRNA are not sufficient to
assure high levels of CXCL12protein level that is evidently correlated
with other factors andmechanisms including Slug-mediated events.
Nevertheless, since the remarkable final phenotypic effect mediated
by Slug silencing is the decrease in CXCL12 protein expression and
secretion, it may be concluded that the presence of Slug is required
for CXCL12 protein expression, thus supporting the hypothesis that
both proteins are crucial for osteoblast phenotype.
The analysis of this large and complexhypothesis spectrum is not
the object of our study and remains to be explored in the future;
however, the evidence that Slug suppression and consequent
CXCL12 decrease induced a dramatic phenotypical change in hOBs
witha lossof theirmineralization ability, indicates thatboth Slugand
CXCL12 are required for the osteoblastic phenotype.
It is important to underline that the potential strict correlation
between CXCL12 signaling and Slug activity has been shown in other
experimentalmodels that canbe related tobone. For example, CXCL12
and Slug are both involved in neural crest cell (NCC) migration. NCCs
aremultipotent cells thatmigrate alongdefinedpathways throughout
the embryo in a Slug-dependent manner, giving rise to many diverse
cell types including craniofacial skeletal elements [13]. It is well
known that aberrant migration of NCCs results in a wide variety of
congenital birth defects including craniofacial skeletal abnormalities
[13].Moreover, recent evidence suggests that bothknockdownandan
over-expression of CXCL12 and its receptor leads to migration and
Fig. 5 – Slug binds human CXCL12 promoter in vivo. The CXCL12 promoter region under investigation is shown (+1/−2000). The
positions of the putative Slug consensus binding sites are enclosed by black diamonds and are compared with those recently
investigated by others [9]; non-canonical binding sites (hatched diamonds) are included. The arrows indicate the positions of PCR
primers used in chromatin immunoprecipitation (ChIP) experiments. Recruitment of Slug transcription factor to the human
CXCL12 promoter is shown by in vivo ChIP binding assays. Soluble chromatin was prepared from hOBs and hMSCs and
immunoprecipitated with the specific antibody against Slug. The association of the transcription factor on the regions 1 and 2 of the
human CXCL12 promoter was analyzed by PCR generating the reported DNA fragments. No Ab represents a negative control. Input
represents a positive control using the starting material (0.2%) prior to immunoprecipitation. Representative agarose gels are
shown. M: molecular weight marker.
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important craniofacial defects for patterning the craniofacial skeleton
[13]. Further evidence for the need for a correct balance of CXCL12
signaling and the correlation between Slug and CXCL12 comes from a
recent paper demonstrating that elevated CXCL12 and CXCR4
expression was correlated to advanced cancer stage and metastasis
[29,30]. Interestingly, in CXCR4-silenced pancreatic cancer cells Slug
expression is inhibited [12].
Other factors and mechanisms may surely contribute to CXCL12
gene regulation. At present, the relationship between other cis-
regulatory elements in the CXCL12 promoter and hOBs-inducing
signals is completely unknown. The most likely candidates for this
function are bone-related transcription factors Lef-1 and Runx2
whose putative binding sites are present in the CXCL12 gene
promoter.
In conclusion, although further studies are required to
elucidate in detail the exact function of Slug in regulating
CXCL12/CXCR4 axis, not only in osteoblasts but also during the
osteogenic differentiation of their mesenchymal precursors, our
study clearly shows that Slug activity and CXCL12 signaling are
two strictly correlated phenomena in bone cellular context, and
may be relevant in approaches aimed at discovering new
molecular targets to use in bone repair regenerative medicine.
Our hypothesis is that Slug together with CXCL12 might be one of
the components of the recently proposed [31] large signalosome in
which inputs from Wnt/β-catenin/Lef-1 signaling, steroid recep-
tors, BMPs, and kinases converge to induce osteoblast differenti-
ation and maturation.
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Introduction
?????????????????????????????????????????????????????????????
??????????????????????????? ?????????? ?????????? ????????????
??????????????????????????????????????????????????????? ?????????-
?????????????????????????????????????????????????????????????
?????????? ?????????????????? ??????????? ????????? ?????????
????????????????????????????? ???????? ????????????????? ????
????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
??????????????
?????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????-
?????????????????????????????????????????????????????????? ????
?????????????????????????????????????????????????????????????
????????????????????????????? ???????????????????????????
???????????????????????????????????????????????????????????
??????????????????????????????????????????????????????? ????
Oct, PPAR-???????????????????????????????????????????????
???????????????????????
????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
???????????? ?????????????? ???? ?????????????????????????-
?????? ?????????????????????????????????? ?????????????????
???????????? ???????????? ?????????????? ????????????? ??????
????????????????????????????????????????????????????????????-
??????????????????????????????????????????????????????????????
????????????????????????????????????????????? ????????????????
??????????????????????????????????????????????????????
the cis?????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????
????????????????????????????????? ?????????????????????????????
??????????????????????????????????????????????????????????????????
???????????????????????????????????????? ????????????????? ????
???????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
?????????????????????????? ???????????????????????????????
????????????????? ?????????????????????????in vivo? ?????
????????????????????????????????????????????????????-
????????? ??????????????????????? (ER?????????????????????????
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??????????????????????????????????????????????????????????????
??????? ??????????? ????????????????????????????????????
??????????????????????????in vivo?????????
Materials and methods
Isolation and culture of osteoblasts. ????? ?????????????
?????????? ????? ???????????????????????????????? ???????????
???????????? ??????????????????? ???????????????????????????
???????????????????? ????????????????????????????????????
???????????????????????????????????????
???????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
????????? ?????????? ????????????? ??????????????????????????
??????????????????? ???????????????? ???????????????????
??????????????????????????????????????????????????????????
?????? ???????
Transient transfections and the luciferase assay. ??????????
????????????????????????????????????????????????????????-
????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????
??????????????????????? ???????????????????????????? ????? ????
???????????????????????????????????????????????????????????
?????????????????????????????????????? ???? ???????? ???????
??????????????????????????? ???????????????????????????????????
??????????????????????????????????????????????????????????
??????????
???? ????????????? ????????????????? ????????????????
????????????????????????????????????????????????????????????-
??????? ?????????????????????????????? ??? ?????????????
????????????? ????????????????? ??????????????????????? ???
??????????????????????? ?????????? ??????????????????
???????????????????? ??????????????? ???????????? ????????????
????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
????????????????????????????????????????????????????????
?????????????????????????? ??????????????????????? ???????????
??????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
??????????????????????????????????????????????????????? ????
???????????????????????????????? ????????
Chromatin immunoprecipitation (ChIP) assay. The ChIP 
?????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
????????????????????? ????????????? ??????????? ??? ??????
??????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
?????????????????????????????????? ?????????????????????????
?????????????????????????????????????????????????????????
????????????????????????????????????????????????????????
??????????????????????????????????????????????????????
??????????????????????????????????????? ????? ??????????????????
????????????????????????????????????????????????????????????
????????? ?????????????????????????????????????????????????
?????????????????????????????????????????????????????
????????????????????????????????????????????????????????
??????????????????????????????????????????????????????
?????? ?????????????????? ????????????????????????????? ??
?????????????????????????????????????????????????????-
?????????????????????????????????????????????????????????????
????????????????????????????????????????? ????????????????
????????????????????????????????????????????????????????????
?????????????????????????? ????????????????????????????????
???? ??????????????????????????????????????????????????????
????????????? ???????? ???????????????????????????????
??????????????????????????????????????? ????????????????????
?????????????????????????????????????????????????????????-
?????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????
????????????????????????????
Electrophoretic mobility shift assay (EMSA). ?????????????????
??????????????????????????????????????????????????????????????
?????????????????????????????????????? ?????????????????
[?-??????????????????????????????????????????????????????
?????????????? ??????????????????????????????????????????????
??????????????????? ?????????? ??? ????? ?????????????????
?????????????????????????????????????????????????????????
??????????????????????????????????????? ????????????????
??? ???????????????????????????????????????? ?????????? ????
?????????????????? ?????????????????????? ????????????????
????????????????????????????????????????????????????????-
???????????? ????????????? ???????????????????????????????? ???
????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
????????????? ?????????????????????????????????? ??? ??????
?????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
????????????????????????????????????????????????????????? ????
????????????????????????????????????????????
Immunocytochemistry. ???????????????????????????????????
????????????????????????????? ????????????????????? ?????
????????????????????????????????????????????????????????
???????????????? ??????????????? ???????????????????????????
??????????????????????????????????? ??????????????????
?????????????????? ?????????? ????????????? ?????????????
??????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????-
?????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????
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???????????????? ?????????????????? ??? ????? ????????????
????????????????????????????????????????????????? ?????????
???????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
??????????????????????????????????????????????????? ???????????
????????????????????? ???????????????????????????????
Mineralization assay. ????????????????????????????????? ???
???????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????
????????????????????????????????????????????????????-
??????????????????????????????????????? ??? ??????????????
???????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????-
???????????????????????????????????????????????????????????
??? ????????????????????????????????????????????????????????
??????????? ?????????? ?????????????????? ?????????????????
???????????????????????????????????????????????????????????????
???????????????????????????? ??????????
Real-time quantitative RT-PCR. ??????????? ??????????
????????????????????????????????????????????????????????-
????????????????????????? ?????????? ?????????????????????????
??????????????????????????????????????????P?????????????????
?????????????????????????????????????????????????????????
?????????????????????????????????????? ??????????????????
??????? ???????????????????????????????????????????????
?????????????????????????????????????????????????????????
??????????? ???????????????????????????????????????????? ??????
???????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????
????????????????????????????????????
Calcium measurements. ?????? ?????????? ???? ????????????
????? ???????????????????????????? ????????????????????
?????? ???????????????????????? ??????????????????????????
????????????????? ??????????????????????????????????
????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
??????????????? ???????????? ??? ???? ????????????????????????
??????????????????? ?????????????????????????????????????
????????????????????????????????????????????????????????????
???? ???????? ??? ???? ???? ???? ????????? ?? ??????????????
?????????????????????????????????????????????????????????
?????????????????????????????????????????????????? ????????
???????????????????????????????????? ??????????????????
?????????????????????????????????? ??????????????????????
?????????????????? ?????????????????????????????????????????
??????? ?????????????????????????? ???????????????? ????
?????????????????? ????????????????????????????????????????
???????????????????????d??????????????????????????????? - R), 
???????d???????????????????????????????????????????? ????
??????????????????????? ????????????????????????????????
?????? ????????????????????????????????
Statistical analysis. ?????????????????????????????????????
??????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????
????????????????????????????????????
Results
Characterization of primary osteoblast cultures. ?????
??????????????? ???????????????? ???????? ????? ???? ???????
???????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????
???????????????????? ?????????????????????????????????????????????
????????????????????????????????????????????????????????? ????
???????????????????????????????????????????????????????????
???????????????????????????????????????????????????????
??????????
NFATc1 binds to the decoy ODN molecule. ???????? ????
???????????????????????????????????????????????????????
???????????????????????? ??????????????? ????? ????????????
???????????????????????????? ????????????????????????????????
????? ??????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
??????????????? ?????? ???????????????????????????????????
?????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????
? ????????????????? ?????????????????
??????????? ??????????????????????????? ???
??????????? ??????????????????????????
??????????? ???????????????????????????? ???
??????????? ?????????????????????????????
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